NZ625745B2 - FGFR antibody drug conjugates (ADCs) and the use thereof - Google Patents
FGFR antibody drug conjugates (ADCs) and the use thereof Download PDFInfo
- Publication number
- NZ625745B2 NZ625745B2 NZ625745A NZ62574512A NZ625745B2 NZ 625745 B2 NZ625745 B2 NZ 625745B2 NZ 625745 A NZ625745 A NZ 625745A NZ 62574512 A NZ62574512 A NZ 62574512A NZ 625745 B2 NZ625745 B2 NZ 625745B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- group
- marks
- hydrogen
- formula
- linkage site
- Prior art date
Links
- 239000000611 antibody drug conjugate Substances 0.000 title description 19
- 108091008116 antibody drug conjugates Proteins 0.000 title description 19
- 108091008101 FGF receptors Proteins 0.000 title description 11
- 102000017175 fibroblast growth factor-activated receptor activity proteins Human genes 0.000 title 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 285
- -1 polyethylene Polymers 0.000 claims abstract description 250
- 102000004965 antibodies Human genes 0.000 claims abstract description 203
- 108090001123 antibodies Proteins 0.000 claims abstract description 203
- 108010081268 Type 2 Fibroblast Growth Factor Receptor Proteins 0.000 claims abstract description 117
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract description 113
- 239000011230 binding agent Substances 0.000 claims abstract description 112
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 94
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims abstract description 82
- 125000004432 carbon atoms Chemical group C* 0.000 claims abstract description 79
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 73
- 230000027455 binding Effects 0.000 claims abstract description 71
- 239000000427 antigen Substances 0.000 claims abstract description 50
- 102000038129 antigens Human genes 0.000 claims abstract description 50
- 108091007172 antigens Proteins 0.000 claims abstract description 50
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 46
- 201000010099 disease Diseases 0.000 claims abstract description 27
- 125000005647 linker group Chemical group 0.000 claims abstract description 18
- 125000001424 substituent group Chemical group 0.000 claims abstract description 14
- 230000003463 hyperproliferative Effects 0.000 claims abstract description 11
- 230000002491 angiogenic Effects 0.000 claims abstract description 8
- 230000000069 prophylaxis Effects 0.000 claims abstract description 8
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims abstract 26
- 239000001257 hydrogen Substances 0.000 claims description 280
- 229910052739 hydrogen Inorganic materials 0.000 claims description 280
- 150000001875 compounds Chemical class 0.000 claims description 200
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 153
- 102100018000 FGFR2 Human genes 0.000 claims description 116
- 239000011780 sodium chloride Substances 0.000 claims description 112
- 150000002431 hydrogen Chemical group 0.000 claims description 111
- 150000003839 salts Chemical class 0.000 claims description 109
- 239000012453 solvate Substances 0.000 claims description 93
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 73
- 239000003814 drug Substances 0.000 claims description 69
- 239000000203 mixture Substances 0.000 claims description 68
- 125000004429 atoms Chemical group 0.000 claims description 66
- 201000011510 cancer Diseases 0.000 claims description 63
- 125000000623 heterocyclic group Chemical group 0.000 claims description 62
- 239000000243 solution Substances 0.000 claims description 50
- 229910052799 carbon Inorganic materials 0.000 claims description 45
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 45
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 44
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 38
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 33
- 125000003143 4-hydroxybenzyl group Chemical group [H]C([*])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 claims description 32
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 32
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 32
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 29
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 26
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 20
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 claims description 19
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 19
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 19
- 125000002950 monocyclic group Chemical group 0.000 claims description 17
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 17
- 125000002619 bicyclic group Chemical group 0.000 claims description 16
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 15
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 14
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 14
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 13
- 229910052760 oxygen Inorganic materials 0.000 claims description 13
- 125000001960 7 membered carbocyclic group Chemical group 0.000 claims description 12
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 12
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 11
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 11
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 claims description 11
- 125000004193 piperazinyl group Chemical group 0.000 claims description 10
- 235000008206 alpha-amino acids Nutrition 0.000 claims description 9
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 9
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 8
- 230000001472 cytotoxic Effects 0.000 claims description 8
- 125000001041 indolyl group Chemical group 0.000 claims description 8
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 5
- PBVAJRFEEOIAGW-UHFFFAOYSA-N 3-[bis(2-carboxyethyl)phosphanyl]propanoic acid;hydrochloride Chemical compound Cl.OC(=O)CCP(CCC(O)=O)CCC(O)=O PBVAJRFEEOIAGW-UHFFFAOYSA-N 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 3
- 150000001371 alpha-amino acids Chemical class 0.000 claims description 3
- 230000001085 cytostatic Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- VHJLVAABSRFDPM-UHFFFAOYSA-N 1,4-dimercaptobutane-2,3-diol Chemical compound SCC(O)C(O)CS VHJLVAABSRFDPM-UHFFFAOYSA-N 0.000 claims description 2
- 239000000824 cytostatic agent Substances 0.000 claims description 2
- 231100000433 cytotoxic Toxicity 0.000 claims description 2
- 239000003638 reducing agent Substances 0.000 claims description 2
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims 16
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- SJZRECIVHVDYJC-UHFFFAOYSA-M 4-hydroxybutyrate Chemical group OCCCC([O-])=O SJZRECIVHVDYJC-UHFFFAOYSA-M 0.000 claims 1
- 230000003000 nontoxic Effects 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 claims 1
- 108010044540 auristatin Proteins 0.000 abstract description 8
- 125000000753 cycloalkyl group Chemical group 0.000 abstract description 3
- 102000027765 FGFR2 Human genes 0.000 abstract description 2
- 239000004698 Polyethylene (PE) Substances 0.000 abstract 2
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 abstract 2
- 229920000573 polyethylene Polymers 0.000 abstract 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 114
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 107
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 98
- 210000004027 cells Anatomy 0.000 description 82
- 239000000543 intermediate Substances 0.000 description 82
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 75
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 71
- 150000002829 nitrogen Chemical group 0.000 description 67
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 48
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 46
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 46
- 238000004128 high performance liquid chromatography Methods 0.000 description 45
- JNWBBCNCSMBKNE-UHFFFAOYSA-N HATU Chemical compound F[P-](F)(F)(F)(F)F.C1=CN=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 JNWBBCNCSMBKNE-UHFFFAOYSA-N 0.000 description 44
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 40
- 230000002829 reduced Effects 0.000 description 35
- 239000011541 reaction mixture Substances 0.000 description 32
- 150000001413 amino acids Chemical class 0.000 description 31
- 239000003480 eluent Substances 0.000 description 30
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 29
- 238000006243 chemical reaction Methods 0.000 description 28
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 27
- ODUCDPQEXGNKDN-UHFFFAOYSA-N Nitroxyl Chemical compound O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 description 26
- 239000002585 base Substances 0.000 description 26
- CSNNHWWHGAXBCP-UHFFFAOYSA-L mgso4 Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 24
- 239000000562 conjugate Substances 0.000 description 23
- 239000012442 inert solvent Substances 0.000 description 23
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 23
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 22
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 22
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical class CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 22
- 239000002253 acid Substances 0.000 description 22
- 238000005859 coupling reaction Methods 0.000 description 22
- 235000001014 amino acid Nutrition 0.000 description 21
- 239000002904 solvent Substances 0.000 description 21
- 239000007858 starting material Substances 0.000 description 21
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 19
- 230000001808 coupling Effects 0.000 description 19
- 238000010168 coupling process Methods 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- 239000012074 organic phase Substances 0.000 description 18
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 17
- 238000002953 preparative HPLC Methods 0.000 description 17
- NPZTUJOABDZTLV-UHFFFAOYSA-N 1,2-dihydrobenzotriazol-4-one Chemical compound O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 16
- 229940079593 drugs Drugs 0.000 description 16
- 235000019253 formic acid Nutrition 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 15
- 150000002500 ions Chemical class 0.000 description 15
- 235000018102 proteins Nutrition 0.000 description 15
- 206010006187 Breast cancer Diseases 0.000 description 14
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 14
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- 230000001681 protective Effects 0.000 description 14
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 14
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 13
- 238000003786 synthesis reaction Methods 0.000 description 13
- 210000001519 tissues Anatomy 0.000 description 13
- 229940021015 I.V. solution additive Amino Acids Drugs 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- 201000009030 carcinoma Diseases 0.000 description 12
- 239000003153 chemical reaction reagent Substances 0.000 description 12
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 12
- 235000019341 magnesium sulphate Nutrition 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 11
- 102000018358 Immunoglobulins Human genes 0.000 description 11
- 108060003951 Immunoglobulins Proteins 0.000 description 11
- BIABKPAXSLKGLN-UHFFFAOYSA-N [dimethylamino(2H-triazolo[4,5-b]pyridin-7-yloxy)methylidene]-dimethylazanium;hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F.CN(C)C(=[N+](C)C)OC1=CC=NC2=C1N=NN2 BIABKPAXSLKGLN-UHFFFAOYSA-N 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
- 230000002194 synthesizing Effects 0.000 description 11
- 238000002560 therapeutic procedure Methods 0.000 description 11
- JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-Dimethylaminophenol Substances CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 10
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 10
- 102000027757 FGF receptors Human genes 0.000 description 10
- 102100007405 FGF7 Human genes 0.000 description 10
- 101700033323 FGF7 Proteins 0.000 description 10
- MFRNYXJJRJQHNW-NARUGQRUSA-N Monomethyl auristatin F Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)C([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-NARUGQRUSA-N 0.000 description 10
- 239000006260 foam Substances 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 10
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 10
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 10
- 108010059074 monomethylauristatin F Proteins 0.000 description 10
- SJRJJKPEHAURKC-UHFFFAOYSA-N n-methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 10
- 230000019491 signal transduction Effects 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 10
- 239000003643 water by type Substances 0.000 description 10
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 9
- 206010017758 Gastric cancer Diseases 0.000 description 9
- 230000000875 corresponding Effects 0.000 description 9
- 239000003446 ligand Substances 0.000 description 9
- SECXISVLQFMRJM-UHFFFAOYSA-N n-methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 9
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 8
- FXHOOIRPVKKKFG-UHFFFAOYSA-N DMA Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 8
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 8
- UAOMVDZJSHZZME-UHFFFAOYSA-N Diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 8
- DASWEROEPLKSEI-UIJRFTGLSA-N Monomethyl auristatin E Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)C1=CC=CC=C1 DASWEROEPLKSEI-UIJRFTGLSA-N 0.000 description 8
- 238000007792 addition Methods 0.000 description 8
- 108010093470 monomethyl auristatin E Proteins 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- GUVUOGQBMYCBQP-UHFFFAOYSA-N DMPU Chemical compound CN1CCCN(C)C1=O GUVUOGQBMYCBQP-UHFFFAOYSA-N 0.000 description 7
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-hydroxy-Succinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 108010045030 monoclonal antibodies Proteins 0.000 description 7
- 102000005614 monoclonal antibodies Human genes 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 150000003254 radicals Chemical class 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
- 235000017557 sodium bicarbonate Nutrition 0.000 description 7
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 7
- 102100014001 ABCB1 Human genes 0.000 description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- 230000035693 Fab Effects 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 231100000777 Toxicophore Toxicity 0.000 description 6
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 description 6
- 239000002246 antineoplastic agent Substances 0.000 description 6
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- 239000003054 catalyst Substances 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 125000005842 heteroatoms Chemical group 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N n-butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- 210000000056 organs Anatomy 0.000 description 6
- OFBQJSOFQDEBGM-UHFFFAOYSA-N pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- SVIHRJIEKRFYDN-UHFFFAOYSA-N propanamide Chemical group [CH2]CC(N)=O SVIHRJIEKRFYDN-UHFFFAOYSA-N 0.000 description 6
- 125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 6
- XBDQKXXYIPTUBI-UHFFFAOYSA-N propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 6
- 201000011549 stomach cancer Diseases 0.000 description 6
- 239000001117 sulphuric acid Chemical class 0.000 description 6
- 235000011149 sulphuric acid Nutrition 0.000 description 6
- 230000004083 survival Effects 0.000 description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N t-BuOH Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 6
- LQLJNIMZZWZZLE-UHFFFAOYSA-N 4-(iminomethylideneamino)-N,N-dimethylpentan-1-amine;hydrochloride Chemical compound Cl.N=C=NC(C)CCCN(C)C LQLJNIMZZWZZLE-UHFFFAOYSA-N 0.000 description 5
- SBZXBUIDTXKZTM-UHFFFAOYSA-N Diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 5
- 102000003972 Fibroblast Growth Factor 7 Human genes 0.000 description 5
- 108090000385 Fibroblast Growth Factor 7 Proteins 0.000 description 5
- 229940022353 Herceptin Drugs 0.000 description 5
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 5
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 5
- 230000003213 activating Effects 0.000 description 5
- 235000019270 ammonium chloride Nutrition 0.000 description 5
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 5
- NNTOJPXOCKCMKR-UHFFFAOYSA-N boron;pyridine Chemical compound [B].C1=CC=NC=C1 NNTOJPXOCKCMKR-UHFFFAOYSA-N 0.000 description 5
- 229960004106 citric acid Drugs 0.000 description 5
- 235000015165 citric acid Nutrition 0.000 description 5
- 235000018417 cysteine Nutrition 0.000 description 5
- XTHFKEDIFFGKHM-UHFFFAOYSA-N dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 150000002170 ethers Chemical class 0.000 description 5
- 238000003818 flash chromatography Methods 0.000 description 5
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 5
- 239000010931 gold Substances 0.000 description 5
- 229910052737 gold Inorganic materials 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 5
- QDHHCQZDFGDHMP-UHFFFAOYSA-N monochloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 5
- 229960000060 monoclonal antibodies Drugs 0.000 description 5
- NQRYJNQNLNOLGT-UHFFFAOYSA-N piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 5
- 230000001603 reducing Effects 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 5
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 229940120638 Avastin Drugs 0.000 description 4
- 229920002574 CR-39 Polymers 0.000 description 4
- MVPPADPHJFYWMZ-UHFFFAOYSA-N Chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 4
- 229920000665 Exon Polymers 0.000 description 4
- 102000018233 Fibroblast growth factor family Human genes 0.000 description 4
- 108050007372 Fibroblast growth factor family Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 4
- 206010025323 Lymphomas Diseases 0.000 description 4
- OKDQKPLMQBXTNH-UHFFFAOYSA-N N,N-dimethyl-2H-pyridin-1-amine Chemical compound CN(C)N1CC=CC=C1 OKDQKPLMQBXTNH-UHFFFAOYSA-N 0.000 description 4
- 229960001592 Paclitaxel Drugs 0.000 description 4
- 208000008443 Pancreatic Carcinoma Diseases 0.000 description 4
- OIGNJSKKLXVSLS-VWUMJDOOSA-N Prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 4
- BEOOHQFXGBMRKU-UHFFFAOYSA-N Sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 4
- 229910052783 alkali metal Inorganic materials 0.000 description 4
- 239000000010 aprotic solvent Substances 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 4
- 108091006028 chimera Proteins 0.000 description 4
- 230000004186 co-expression Effects 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 239000002254 cytotoxic agent Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 229940043279 diisopropylamine Drugs 0.000 description 4
- 238000003379 elimination reaction Methods 0.000 description 4
- 230000029578 entry into host Effects 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000003834 intracellular Effects 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L na2so4 Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 230000002018 overexpression Effects 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 229940002612 prodrugs Drugs 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 238000003259 recombinant expression Methods 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 150000003385 sodium Chemical class 0.000 description 4
- 230000001225 therapeutic Effects 0.000 description 4
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 4
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 4
- NFGXHKASABOEEW-UHFFFAOYSA-N (+)-methoprene Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 3
- ZYJPUMXJBDHSIF-NSHDSACASA-N (2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ZYJPUMXJBDHSIF-NSHDSACASA-N 0.000 description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- 150000007578 6-membered cyclic compounds Chemical class 0.000 description 3
- 208000009956 Adenocarcinoma Diseases 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Carbodicyclohexylimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
- PFKFTWBEEFSNDU-UHFFFAOYSA-N Carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 3
- 108010022830 Cetuximab Proteins 0.000 description 3
- 229960002433 Cysteine Drugs 0.000 description 3
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 3
- 229960004679 Doxorubicin Drugs 0.000 description 3
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 3
- AOJJSUZBOXZQNB-VTZDEGQISA-N EPIRUBICIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 229940082789 Erbitux Drugs 0.000 description 3
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 3
- 102100017996 FGFR1 Human genes 0.000 description 3
- 102100020191 FGFR3 Human genes 0.000 description 3
- 210000003128 Head Anatomy 0.000 description 3
- 108010027440 Immunoconjugates Proteins 0.000 description 3
- 102000018748 Immunoconjugates Human genes 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- 229960004338 Leuprorelin Drugs 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 206010027476 Metastasis Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- RIVIDPPYRINTTH-UHFFFAOYSA-N N-ethylpropan-2-amine Chemical compound CCNC(C)C RIVIDPPYRINTTH-UHFFFAOYSA-N 0.000 description 3
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 229960005190 Phenylalanine Drugs 0.000 description 3
- 229940003641 Rituxan Drugs 0.000 description 3
- 210000003491 Skin Anatomy 0.000 description 3
- KZNICNPSHKQLFF-UHFFFAOYSA-N Succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 3
- 108010010691 Trastuzumab Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 description 3
- 108010081291 Type 1 Fibroblast Growth Factor Receptor Proteins 0.000 description 3
- 108010081267 Type 3 Fibroblast Growth Factor Receptor Proteins 0.000 description 3
- 101710004736 XI-A Proteins 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 201000008275 breast carcinoma Diseases 0.000 description 3
- 229960005395 cetuximab Drugs 0.000 description 3
- 201000011231 colorectal cancer Diseases 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 231100000599 cytotoxic agent Toxicity 0.000 description 3
- 230000013080 embryo development ending in birth or egg hatching Effects 0.000 description 3
- 230000013144 embryo development ending in seed dormancy Effects 0.000 description 3
- 238000003197 gene knockdown Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000000968 intestinal Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 3
- YDTFRJLNMPSCFM-YDALLXLXSA-M levothyroxine sodium anhydrous Chemical compound [Na+].IC1=CC(C[C@H](N)C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 YDTFRJLNMPSCFM-YDALLXLXSA-M 0.000 description 3
- 201000005244 lung non-small cell carcinoma Diseases 0.000 description 3
- 229960003646 lysine Drugs 0.000 description 3
- 235000018977 lysine Nutrition 0.000 description 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 3
- HFGVPVHYMUHFRC-UHFFFAOYSA-N oxazinan-2-ium;chloride Chemical compound Cl.C1CCONC1 HFGVPVHYMUHFRC-UHFFFAOYSA-N 0.000 description 3
- 238000010647 peptide synthesis reaction Methods 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 235000015320 potassium carbonate Nutrition 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 231100000486 side effect Toxicity 0.000 description 3
- BZKBCQXYZZXSCO-UHFFFAOYSA-N sodium hydride Chemical compound [H-].[Na+] BZKBCQXYZZXSCO-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 229960003787 sorafenib Drugs 0.000 description 3
- 201000000498 stomach carcinoma Diseases 0.000 description 3
- 229960002317 succinimide Drugs 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 229930003347 taxol Natural products 0.000 description 3
- 229960000575 trastuzumab Drugs 0.000 description 3
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 2
- OMJKFYKNWZZKTK-POHAHGRESA-N (5Z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide Chemical compound CN(C)N\N=C1/N=CN=C1C(N)=O OMJKFYKNWZZKTK-POHAHGRESA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N (E)-but-2-enedioate;hydron Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
- HPBXBPRTXDLJLS-UHFFFAOYSA-N 2,3-diamino-2-(aminomethyl)propanoic acid Chemical compound NCC(N)(CN)C(O)=O HPBXBPRTXDLJLS-UHFFFAOYSA-N 0.000 description 2
- LGEXGKUJMFHVSY-UHFFFAOYSA-N 2-N,4-N,6-N-trimethyl-1,3,5-triazine-2,4,6-triamine Chemical compound CNC1=NC(NC)=NC(NC)=N1 LGEXGKUJMFHVSY-UHFFFAOYSA-N 0.000 description 2
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 2
- OQUJYCIMUCAYEE-UHFFFAOYSA-N 4-(2,5-dioxopyrrol-1-yl)-2,2-dimethylbutanoic acid Chemical compound OC(=O)C(C)(C)CCN1C(=O)C=CC1=O OQUJYCIMUCAYEE-UHFFFAOYSA-N 0.000 description 2
- NCPQROHLJFARLL-UHFFFAOYSA-N 4-(2,5-dioxopyrrol-1-yl)butanoic acid Chemical compound OC(=O)CCCN1C(=O)C=CC1=O NCPQROHLJFARLL-UHFFFAOYSA-N 0.000 description 2
- HFEKDTCAMMOLQP-RRKCRQDMSA-N 5-fluorodeoxyuridine monophosphate Chemical compound O1[C@H](COP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C(F)=C1 HFEKDTCAMMOLQP-RRKCRQDMSA-N 0.000 description 2
- 150000007579 7-membered cyclic compounds Chemical class 0.000 description 2
- OFCNXPDARWKPPY-UHFFFAOYSA-N Allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 2
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N Altretamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 2
- JKOQGQFVAUAYPM-UHFFFAOYSA-N Amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 description 2
- 229960003437 Aminoglutethimide Drugs 0.000 description 2
- ROBVIMPUHSLWNV-UHFFFAOYSA-N Aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 2
- 206010059512 Apoptosis Diseases 0.000 description 2
- 229960002756 Azacitidine Drugs 0.000 description 2
- 229960002170 Azathioprine Drugs 0.000 description 2
- 210000003719 B-Lymphocytes Anatomy 0.000 description 2
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Belustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N Benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- AGEZXYOZHKGVCM-UHFFFAOYSA-N Benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
- 108010005144 Bevacizumab Proteins 0.000 description 2
- 229960001561 Bleomycin Drugs 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 2
- FVLVBPDQNARYJU-KYZUINATSA-N CHEMBL1967746 Chemical compound C[C@H]1CC[C@H](NC(=O)N(CCCl)N=O)CC1 FVLVBPDQNARYJU-KYZUINATSA-N 0.000 description 2
- 101700008564 CHIC2 Proteins 0.000 description 2
- DEQANNDTNATYII-WKXAURAUSA-N C[C@@H](O)[C@H](CO)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)CC2=CC=CC=C2)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC2=CNC3=C2C=CC=C3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 Chemical compound C[C@@H](O)[C@H](CO)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)CC2=CC=CC=C2)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC2=CNC3=C2C=CC=C3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 DEQANNDTNATYII-WKXAURAUSA-N 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L Caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N Carbon tetrachloride Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 229960004562 Carboplatin Drugs 0.000 description 2
- 210000000170 Cell Membrane Anatomy 0.000 description 2
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N Chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 2
- 229960004630 Chlorambucil Drugs 0.000 description 2
- 229960001701 Chloroform Drugs 0.000 description 2
- 208000006990 Cholangiocarcinoma Diseases 0.000 description 2
- 230000037250 Clearance Effects 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 229960004397 Cyclophosphamide Drugs 0.000 description 2
- 229960000684 Cytarabine Drugs 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytosar Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- 229960000640 Dactinomycin Drugs 0.000 description 2
- 108010092160 Dactinomycin Proteins 0.000 description 2
- 229960000975 Daunorubicin Drugs 0.000 description 2
- BMKDZUISNHGIBY-ZETCQYMHSA-N Dexrazoxane Chemical compound C([C@H](C)N1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-ZETCQYMHSA-N 0.000 description 2
- 229960000605 Dexrazoxane Drugs 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N Di-tert-butyl dicarbonate Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Didronel Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N Diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 229960001904 EPIRUBICIN Drugs 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 229940088598 Enzyme Drugs 0.000 description 2
- BFPYWIDHMRZLRN-SLHNCBLASA-N Etivex Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 2
- 229960005420 Etoposide Drugs 0.000 description 2
- 101710003421 FGF Proteins 0.000 description 2
- 101700075612 FGFR4 Proteins 0.000 description 2
- 102100020189 FGFR4 Human genes 0.000 description 2
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N Floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 2
- 229960000961 Floxuridine Drugs 0.000 description 2
- RFHAOTPXVQNOHP-UHFFFAOYSA-N Fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 2
- IRXSLJNXXZKURP-UHFFFAOYSA-N Fluorenylmethyloxycarbonyl chloride Chemical compound C1=CC=C2C(COC(=O)Cl)C3=CC=CC=C3C2=C1 IRXSLJNXXZKURP-UHFFFAOYSA-N 0.000 description 2
- YLRFCQOZQXIBAB-RBZZARIASA-N Fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 2
- 229960001751 Fluoxymesterone Drugs 0.000 description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
- MFWNKCLOYSRHCJ-BTTYYORXSA-N Granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 description 2
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical class C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 206010073071 Hepatocellular carcinoma Diseases 0.000 description 2
- 206010020243 Hodgkin's disease Diseases 0.000 description 2
- 201000006743 Hodgkin's lymphoma Diseases 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- 229960000908 Idarubicin Drugs 0.000 description 2
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin hydrochloride Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 2
- 229960001101 Ifosfamide Drugs 0.000 description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N Ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
- 102000004851 Immunoglobulin G Human genes 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 2
- 206010024324 Leukaemias Diseases 0.000 description 2
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levotetramisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N MeOtBu Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- 229960004296 Megestrol Acetate Drugs 0.000 description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N Melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
- 229960004635 Mesna Drugs 0.000 description 2
- VHRSUDSXCMQTMA-PJHHCJLFSA-N Methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 2
- 229960004857 Mitomycin Drugs 0.000 description 2
- 229960000350 Mitotane Drugs 0.000 description 2
- 229960001156 Mitoxantrone Drugs 0.000 description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N Mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Nitrumon Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
- 229960002700 Octreotide Drugs 0.000 description 2
- 210000001672 Ovary Anatomy 0.000 description 2
- 229960002340 Pentostatin Drugs 0.000 description 2
- FPVKHBSQESCIEP-JQCXWYLXSA-N Pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N Perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 108091000081 Phosphotransferases Proteins 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N Pilopine HS Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N Prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001253 Protein Kinases Human genes 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108010070144 Single-Chain Antibodies Proteins 0.000 description 2
- 102000005632 Single-Chain Antibodies Human genes 0.000 description 2
- 210000002784 Stomach Anatomy 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 229960001603 Tamoxifen Drugs 0.000 description 2
- 229960001712 Testosterone Propionate Drugs 0.000 description 2
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 2
- FOCVUCIESVLUNU-UHFFFAOYSA-N ThioTEPA Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 2
- 229960005454 Thioguanine Drugs 0.000 description 2
- 229960001196 Thiotepa Drugs 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 210000001685 Thyroid Gland Anatomy 0.000 description 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N Topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 2
- XFCLJVABOIYOMF-QPLCGJKRSA-N Toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 2
- 102000004338 Transferrin Human genes 0.000 description 2
- 108090000901 Transferrin Proteins 0.000 description 2
- NMUSYJAQQFHJEW-KVTDHHQDSA-N U-18,496 Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 2
- DRTQHJPVMGBUCF-UCVXFZOQSA-N Uridine Natural products O[C@H]1[C@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UCVXFZOQSA-N 0.000 description 2
- 229940045145 Uridine Drugs 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 102100015249 VEGFA Human genes 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 229960004528 Vincristine Drugs 0.000 description 2
- 229960004355 Vindesine Drugs 0.000 description 2
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N [(8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- JKEKMBGUVUKMQB-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium;tetrafluoroborate Chemical compound F[B-](F)(F)F.C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 JKEKMBGUVUKMQB-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 2
- 230000001154 acute Effects 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 229960000473 altretamine Drugs 0.000 description 2
- 230000001028 anti-proliferant Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- DVQHYTBCTGYNNN-UHFFFAOYSA-N azane;cyclobutane-1,1-dicarboxylic acid;platinum Chemical compound N.N.[Pt].OC(=O)C1(C(O)=O)CCC1 DVQHYTBCTGYNNN-UHFFFAOYSA-N 0.000 description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 229960000397 bevacizumab Drugs 0.000 description 2
- 102000024070 binding proteins Human genes 0.000 description 2
- 108091007650 binding proteins Proteins 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229960002092 busulfan Drugs 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 229950005499 carbon tetrachloride Drugs 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000000451 chemical ionisation Methods 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 230000001684 chronic Effects 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 230000035512 clearance Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- ZNEWHQLOPFWXOF-UHFFFAOYSA-N coenzyme M Chemical compound OS(=O)(=O)CCS ZNEWHQLOPFWXOF-UHFFFAOYSA-N 0.000 description 2
- 230000002596 correlated Effects 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- 150000001945 cysteines Chemical class 0.000 description 2
- 108010057085 cytokine receptors Proteins 0.000 description 2
- 229960003901 dacarbazine Drugs 0.000 description 2
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- 229960003668 docetaxel Drugs 0.000 description 2
- 229960004242 dronabinol Drugs 0.000 description 2
- 238000009510 drug design Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 201000003914 endometrial carcinoma Diseases 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 229960002568 ethinylestradiol Drugs 0.000 description 2
- KVXNKFYSHAUJIA-UHFFFAOYSA-M ethoxyethane;acetate Chemical compound CC([O-])=O.CCOCC KVXNKFYSHAUJIA-UHFFFAOYSA-M 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 229960004884 fluconazole Drugs 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 229940052308 general anesthetics Halogenated hydrocarbons Drugs 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 150000008282 halocarbons Chemical class 0.000 description 2
- 239000008079 hexane Substances 0.000 description 2
- 229960002193 histrelin Drugs 0.000 description 2
- HHXHVIJIIXKSOE-QILQGKCVSA-N histrelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC(N=C1)=CN1CC1=CC=CC=C1 HHXHVIJIIXKSOE-QILQGKCVSA-N 0.000 description 2
- 102000008000 human cationic antimicrobial protein CAP 37 Human genes 0.000 description 2
- 108010089633 human cationic antimicrobial protein CAP 37 Proteins 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 229960001330 hydroxycarbamide Drugs 0.000 description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
- VSNHCAURESNICA-UHFFFAOYSA-N hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 2
- 229940027318 hydroxyurea Drugs 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229960002247 lomustine Drugs 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 2
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 2
- 229960001924 melphalan Drugs 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 229960001428 mercaptopurine Drugs 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N n-heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 230000001264 neutralization Effects 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- OZQGLZFAWYKKLQ-UHFFFAOYSA-N oxazinane Chemical compound C1CCONC1 OZQGLZFAWYKKLQ-UHFFFAOYSA-N 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 239000001184 potassium carbonate Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Inorganic materials [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propanol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 238000006268 reductive amination reaction Methods 0.000 description 2
- 229960003440 semustine Drugs 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- AGGHKNBCHLWKHY-UHFFFAOYSA-N sodium;triacetyloxyboron(1-) Chemical compound [Na+].CC(=O)O[B-](OC(C)=O)OC(C)=O AGGHKNBCHLWKHY-UHFFFAOYSA-N 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 201000010814 synostosis Diseases 0.000 description 2
- 231100000057 systemic toxicity Toxicity 0.000 description 2
- 150000003512 tertiary amines Chemical class 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- 229960000303 topotecan Drugs 0.000 description 2
- 239000012581 transferrin Substances 0.000 description 2
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 description 2
- 229960002415 trichloroethylene Drugs 0.000 description 2
- XSTXAVWGXDQKEL-UHFFFAOYSA-N triclene Chemical group ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- HHJUWIANJFBDHT-KOTLKJBCSA-N vindesine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(N)=O)N4C)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 HHJUWIANJFBDHT-KOTLKJBCSA-N 0.000 description 2
- 229960002066 vinorelbine Drugs 0.000 description 2
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 2
- VKMGSWIFEHZQRS-NSHDSACASA-N (1R)-1-(3,4-dichlorophenyl)-2-(propan-2-ylamino)ethanol Chemical compound CC(C)NC[C@H](O)C1=CC=C(Cl)C(Cl)=C1 VKMGSWIFEHZQRS-NSHDSACASA-N 0.000 description 1
- ZROHGHOFXNOHSO-BNTLRKBRSA-L (1R,2R)-cyclohexane-1,2-diamine;oxalate;platinum(2+) Chemical compound [H][N]([C@@H]1CCCC[C@H]1[N]1([H])[H])([H])[Pt]11OC(=O)C(=O)O1 ZROHGHOFXNOHSO-BNTLRKBRSA-L 0.000 description 1
- AKJHMTWEGVYYSE-FXILSDISSA-N (2E,4E,6E,8E)-N-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenamide Chemical compound C=1C=C(O)C=CC=1NC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C AKJHMTWEGVYYSE-FXILSDISSA-N 0.000 description 1
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N (2E,4E,6Z,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 1
- FKHUGQZRBPETJR-RXSRXONKSA-N (2R)-2-[[(4R)-4-[[(2S)-2-[[(2R)-2-[(3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxypropanoyl]amino]propanoyl]amino]-5-amino-5-oxopentanoyl]amino]-6-(octadecanoylamino)hexanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(=O)NCCCC[C@H](C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O FKHUGQZRBPETJR-RXSRXONKSA-N 0.000 description 1
- AZWPQTJXXZLNAC-YFKPBYRVSA-N (2R)-3-methylsulfanyl-2-(methylsulfanylmethylamino)propanoic acid Chemical compound CSCN[C@H](C(O)=O)CSC AZWPQTJXXZLNAC-YFKPBYRVSA-N 0.000 description 1
- WDQLRUYAYXDIFW-RWKIJVEZSA-N (2R,3R,4S,5R,6R)-4-[(2S,3R,4S,5R,6R)-3,5-dihydroxy-4-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 WDQLRUYAYXDIFW-RWKIJVEZSA-N 0.000 description 1
- BWBHIIJKOYBHON-YFKPBYRVSA-N (2S)-2-(2-carboxyethylamino)pentanedioic acid Chemical compound OC(=O)CCN[C@H](C(O)=O)CCC(O)=O BWBHIIJKOYBHON-YFKPBYRVSA-N 0.000 description 1
- BTLHODXEDLCLAD-VKHMYHEASA-N (2S)-2-(carboxymethylamino)butanedioic acid Chemical compound OC(=O)CN[C@H](C(O)=O)CC(O)=O BTLHODXEDLCLAD-VKHMYHEASA-N 0.000 description 1
- VGGGPCQERPFHOB-RDBSUJKOSA-N (2S)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-RDBSUJKOSA-N 0.000 description 1
- CANZBRDGRHNSGZ-NSHDSACASA-N (2S)-3-methyl-2-(phenylmethoxycarbonylamino)butanoic acid Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)OCC1=CC=CC=C1 CANZBRDGRHNSGZ-NSHDSACASA-N 0.000 description 1
- ZBVJFYPGLGEMIN-OYLNGHKZSA-N (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-( Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1.C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 ZBVJFYPGLGEMIN-OYLNGHKZSA-N 0.000 description 1
- RWHUEXWOYVBUCI-ITQXDASVSA-N (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]amino]-3-( Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 description 1
- GJKXGJCSJWBJEZ-XRSSZCMZSA-N (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[(2S)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CNC2=CC=CC=C12 GJKXGJCSJWBJEZ-XRSSZCMZSA-N 0.000 description 1
- CFCUWKMKBJTWLW-BGLFSJPPSA-N (2S,3S)-2-[(2S,4R,5R,6R)-4-[(2S,4R,5R,6R)-4-[(2S,4S,5R,6R)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-3-[(1S,3S,4R)-3,4-dihydroxy-1-methoxy-2-oxopentyl]-6-[(2S,4R,5S,6R)-4-[(2S,4R,5S,6R)-4,5-dih Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BGLFSJPPSA-N 0.000 description 1
- MKBLHFILKIKSQM-ZOWNYOTGSA-N (3S)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one;hydrochloride Chemical compound Cl.CC1=NC=CN1C[C@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 MKBLHFILKIKSQM-ZOWNYOTGSA-N 0.000 description 1
- WXFXWKOGMWSKOV-UHFFFAOYSA-N (4-methoxyphenyl)methyl heptanoate Chemical compound CCCCCCC(=O)OCC1=CC=C(OC)C=C1 WXFXWKOGMWSKOV-UHFFFAOYSA-N 0.000 description 1
- SWXOGPJRIDTIRL-HFQRKYADSA-N (4R,7S,10S,13S,16S,19R)-10-(4-aminobutyl)-N-[(2S)-1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-pent Chemical compound C([C@H]1C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 SWXOGPJRIDTIRL-HFQRKYADSA-N 0.000 description 1
- XOZIUKBZLSUILX-GIQCAXHBSA-N (4S,7R,8S,9S,13Z,16S)-4,8-dihydroxy-5,5,7,9,13-pentamethyl-16-[(E)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-1-oxacyclohexadec-13-ene-2,6-dione Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C(C)=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 XOZIUKBZLSUILX-GIQCAXHBSA-N 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-thiophen-2-yl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N (7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 1
- KMSKQZKKOZQFFG-YXRRJAAWSA-N (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-6-methyl-5-[(2R)-oxan-2-yl]oxyoxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@@H]1CCCCO1 KMSKQZKKOZQFFG-YXRRJAAWSA-N 0.000 description 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N 1,2-ethanediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- HPIVVOQIZYNVJE-UHFFFAOYSA-N 1,2-oxazolidin-2-ium;chloride Chemical compound Cl.C1CNOC1 HPIVVOQIZYNVJE-UHFFFAOYSA-N 0.000 description 1
- ZVNYJIZDIRKMBF-UHFFFAOYSA-N 1-(1,2,3,4-Tetrahydro-2-oxo-6-quinolyl)-4-veratroylpiperazine Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)N1CCN(C=2C=C3CCC(=O)NC3=CC=2)CC1 ZVNYJIZDIRKMBF-UHFFFAOYSA-N 0.000 description 1
- ZCBGPHRSFFMEGR-UHFFFAOYSA-N 1-(2-bromoethyl)pyridin-1-ium;tetrafluoroborate Chemical compound F[B-](F)(F)F.BrCC[N+]1=CC=CC=C1 ZCBGPHRSFFMEGR-UHFFFAOYSA-N 0.000 description 1
- ILFIJKGQCZMPAJ-XVQYKIGZSA-N 1-adamantyl (2S)-2-amino-3-phenylpropanoate;hydrochloride Chemical compound Cl.C([C@H](N)C(=O)OC12CC3CC(CC(C3)C1)C2)C1=CC=CC=C1 ILFIJKGQCZMPAJ-XVQYKIGZSA-N 0.000 description 1
- MDVGOOIANLZFCP-UHFFFAOYSA-N 1-adamantylmethanol Chemical compound C1C(C2)CC3CC2CC1(CO)C3 MDVGOOIANLZFCP-UHFFFAOYSA-N 0.000 description 1
- QWQHZCBCHKIWPH-UCNGESAXSA-N 1-adamantylmethyl (2S)-2-amino-3-phenylpropanoate;hydrochloride Chemical compound Cl.C([C@H](N)C(=O)OCC12CC3CC(CC(C3)C1)C2)C1=CC=CC=C1 QWQHZCBCHKIWPH-UCNGESAXSA-N 0.000 description 1
- IWWCCNVRNHTGLV-UHFFFAOYSA-N 1-phenylcyclopropane-1-carboxylic acid Chemical compound C=1C=CC=CC=1C1(C(=O)O)CC1 IWWCCNVRNHTGLV-UHFFFAOYSA-N 0.000 description 1
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 1
- 108040005185 1-phosphatidylinositol-3-kinase activity proteins Proteins 0.000 description 1
- DOMWKUIIPQCAJU-LJHIYBGHSA-N 17-Hydroxyprogesterone caproate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CCCCC)[C@@]1(C)CC2 DOMWKUIIPQCAJU-LJHIYBGHSA-N 0.000 description 1
- QMVPQBFHUJZJCS-NTKFZFFISA-N 1V8X590XDP Chemical compound O=C1N(NC(CO)CO)C(=O)C(C2=C3[CH]C=C(O)C=C3NC2=C23)=C1C2=C1C=CC(O)=C[C]1N3[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QMVPQBFHUJZJCS-NTKFZFFISA-N 0.000 description 1
- DSXWYWXHYXKFTN-UHFFFAOYSA-N 2,4-diamino-2-(2-aminoethyl)butanoic acid Chemical compound NCCC(N)(C(O)=O)CCN DSXWYWXHYXKFTN-UHFFFAOYSA-N 0.000 description 1
- XIGGORITFVMMTL-UHFFFAOYSA-N 2-(tert-butylamino)-3,3-dimethylbutanoic acid Chemical compound CC(C)(C)NC(C(O)=O)C(C)(C)C XIGGORITFVMMTL-UHFFFAOYSA-N 0.000 description 1
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2S)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 1
- NFEVMRNCAGDLBK-UHFFFAOYSA-N 2-anilino-2-phenylacetic acid Chemical compound C=1C=CC=CC=1C(C(=O)O)NC1=CC=CC=C1 NFEVMRNCAGDLBK-UHFFFAOYSA-N 0.000 description 1
- FEIYMGHYGZJZCP-UHFFFAOYSA-N 2-ethoxyethyl 2H-quinoline-1-carboxylate Chemical compound C1=CC=C2N(C(=O)OCCOCC)CC=CC2=C1 FEIYMGHYGZJZCP-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- FXBOKASTQKMONI-UHFFFAOYSA-N 2-methyl-5-(2-methylphenoxy)benzenesulfonic acid Chemical class CC1=CC=CC=C1OC1=CC=C(C)C(S(O)(=O)=O)=C1 FXBOKASTQKMONI-UHFFFAOYSA-N 0.000 description 1
- LRDFRRGEGBBSRN-UHFFFAOYSA-N 2-methylpropanenitrile Chemical compound CC(C)C#N LRDFRRGEGBBSRN-UHFFFAOYSA-N 0.000 description 1
- UAVMXZQEEDWREU-UHFFFAOYSA-N 2H-benzotriazol-4-yloxy(tripyrrolidin-1-yl)phosphanium;hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F.C1CCCN1[P+](N1CCCC1)(N1CCCC1)OC1=CC=CC2=C1N=NN2 UAVMXZQEEDWREU-UHFFFAOYSA-N 0.000 description 1
- VUGRPJUREUOUIO-UHFFFAOYSA-N 2H-benzotriazol-4-yloxy-tris(dimethylamino)phosphanium;hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F.CN(C)[P+](N(C)C)(N(C)C)OC1=CC=CC2=C1N=NN2 VUGRPJUREUOUIO-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- UZFPOOOQHWICKY-UHFFFAOYSA-N 3-[13-[1-[1-[8,12-bis(2-carboxyethyl)-17-(1-hydroxyethyl)-3,7,13,18-tetramethyl-21,24-dihydroporphyrin-2-yl]ethoxy]ethyl]-18-(2-carboxyethyl)-8-(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(=C(C)C(C=C4N5)=N3)CCC(O)=O)=N2)C)=C(C)C(C(C)O)=C1C=C5C(C)=C4C(C)OC(C)C1=C(N2)C=C(N3)C(C)=C(C(O)C)C3=CC(C(C)=C3CCC(O)=O)=NC3=CC(C(CCC(O)=O)=C3C)=NC3=CC2=C1C UZFPOOOQHWICKY-UHFFFAOYSA-N 0.000 description 1
- KLDLRDSRCMJKGM-UHFFFAOYSA-N 3-[chloro-(2-oxo-1,3-oxazolidin-3-yl)phosphoryl]-1,3-oxazolidin-2-one Chemical compound C1COC(=O)N1P(=O)(Cl)N1CCOC1=O KLDLRDSRCMJKGM-UHFFFAOYSA-N 0.000 description 1
- SRTTVKQAAQUNAL-UHFFFAOYSA-N 4-(2,5-dioxopyrrol-1-yl)-2,2-dimethylbutanehydrazide;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.NNC(=O)C(C)(C)CCN1C(=O)C=CC1=O SRTTVKQAAQUNAL-UHFFFAOYSA-N 0.000 description 1
- CVPKXUOVXWAIBK-UHFFFAOYSA-N 4-(2,5-dioxopyrrol-1-yl)-N-[2-(methylamino)ethyl]butanamide;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CNCCNC(=O)CCCN1C(=O)C=CC1=O CVPKXUOVXWAIBK-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- SBEOMMHBZTWQLR-UHFFFAOYSA-N 4-azaniumyl-2,2-dimethylbutanoate Chemical compound OC(=O)C(C)(C)CCN SBEOMMHBZTWQLR-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N 5-hydroxylysine Chemical compound NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- KZDJMMNFSFCDQK-UHFFFAOYSA-N 6-(2,5-dioxopyrrol-1-yl)-N'-methylhexanehydrazide;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CNNC(=O)CCCCCN1C(=O)C=CC1=O KZDJMMNFSFCDQK-UHFFFAOYSA-N 0.000 description 1
- WOJKKJKETHYEAC-UHFFFAOYSA-N 6-(2,5-dioxopyrrol-1-yl)hexanoic acid Chemical compound OC(=O)CCCCCN1C(=O)C=CC1=O WOJKKJKETHYEAC-UHFFFAOYSA-N 0.000 description 1
- PLHJCIYEEKOWNM-HHHXNRCGSA-N 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one Chemical compound CN1C=NC=C1[C@](N)(C=1C=C2C(C=3C=C(Cl)C=CC=3)=CC(=O)N(C)C2=CC=1)C1=CC=C(Cl)C=C1 PLHJCIYEEKOWNM-HHHXNRCGSA-N 0.000 description 1
- 102100002706 ABCG2 Human genes 0.000 description 1
- 101700040074 ABCG2 Proteins 0.000 description 1
- 108060005293 AGA Proteins 0.000 description 1
- VJZITPJGSQKZMX-XDPRQOKASA-N AMRUBICIN Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC=C4C(=O)C=3C(O)=C21)(N)C(=O)C)[C@H]1C[C@H](O)[C@H](O)CO1 VJZITPJGSQKZMX-XDPRQOKASA-N 0.000 description 1
- 102100004323 ASPG Human genes 0.000 description 1
- 206010000496 Acne Diseases 0.000 description 1
- 229940099550 Actimmune Drugs 0.000 description 1
- 229960001456 Adenosine Triphosphate Drugs 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 1
- 229940009456 Adriamycin Drugs 0.000 description 1
- JZMHCANOTJFLQJ-IEQBYLOXSA-A Affinitac Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)CO)[C@@H](OP([S-])(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)C1 JZMHCANOTJFLQJ-IEQBYLOXSA-A 0.000 description 1
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 1
- 229960004343 Alendronic acid Drugs 0.000 description 1
- 229940062334 Aloprim Drugs 0.000 description 1
- 229940014175 Aloxi Drugs 0.000 description 1
- 229960001097 Amifostine Drugs 0.000 description 1
- 229960003896 Aminopterin Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N Anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 206010002943 Apert's syndrome Diseases 0.000 description 1
- ATALOFNDEOCMKK-OITMNORJSA-N Aprepitant Chemical compound O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC1=NNC(=O)N1 ATALOFNDEOCMKK-OITMNORJSA-N 0.000 description 1
- 229920002395 Aptamer Polymers 0.000 description 1
- 229940115115 Aranesp Drugs 0.000 description 1
- UVJYAKBJSGRTHA-ZCRGAIPPSA-N Arglabin Chemical compound C1C[C@H]2C(=C)C(=O)O[C@@H]2[C@@H]2C(C)=CC[C@]32O[C@]31C UVJYAKBJSGRTHA-ZCRGAIPPSA-N 0.000 description 1
- 229940087620 Aromasin Drugs 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 210000003567 Ascitic Fluid Anatomy 0.000 description 1
- GJMNAFGEUJBOCE-MEQIQULJSA-N Asoprisnil Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@]([C@]3(C2)C)(COC)OC)=CC=C(\C=N\O)C=C1 GJMNAFGEUJBOCE-MEQIQULJSA-N 0.000 description 1
- 229950003620 Asoprisnil Drugs 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 229960001230 Asparagine Drugs 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- MOTJMGVDPWRKOC-QPVYNBJUSA-N Atrasentan Chemical compound C1([C@H]2[C@@H]([C@H](CN2CC(=O)N(CCCC)CCCC)C=2C=C3OCOC3=CC=2)C(O)=O)=CC=C(OC)C=C1 MOTJMGVDPWRKOC-QPVYNBJUSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N Benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 108010071919 Bispecific Antibodies Proteins 0.000 description 1
- 210000000601 Blood Cells Anatomy 0.000 description 1
- 206010061590 Blood disease Diseases 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N Bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 229940098773 Bovine Serum Albumin Drugs 0.000 description 1
- 108091003117 Bovine Serum Albumin Proteins 0.000 description 1
- 210000000133 Brain Stem Anatomy 0.000 description 1
- 210000000481 Breast Anatomy 0.000 description 1
- 108010013795 Brentuximab Vedotin Proteins 0.000 description 1
- 229960000455 Brentuximab vedotin Drugs 0.000 description 1
- WOVKYSAHUYNSMH-RRKCRQDMSA-N Bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
- 206010006417 Bronchial carcinoma Diseases 0.000 description 1
- 208000003362 Bronchogenic Carcinoma Diseases 0.000 description 1
- 229950004398 Broxuridine Drugs 0.000 description 1
- 208000009899 Burkitt Lymphoma Diseases 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical group CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- LYJIDHHPYRKVNT-UHFFFAOYSA-N C(C)C1=C(C=CC=C1)[N+]=1OC=CC=1 Chemical compound C(C)C1=C(C=CC=C1)[N+]=1OC=CC=1 LYJIDHHPYRKVNT-UHFFFAOYSA-N 0.000 description 1
- PUDHBTGHUJUUFI-PURAGXGVSA-N CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)NC(=O)[C@@H](N)CC1=CC=C2C=CC=CC2=C1 Chemical compound CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)NC(=O)[C@@H](N)CC1=CC=C2C=CC=CC2=C1 PUDHBTGHUJUUFI-PURAGXGVSA-N 0.000 description 1
- JEWJRMKHSMTXPP-WZHZPDAFSA-L CHEBI:25291 Chemical compound C([C@]1(C)[C@H]([C@@H]2[C@]3(C)[N+]4=C([C@H]([C@]3(C)CC(N)=O)CCC(N)=O)C(=C3[N+]5=C([C@H]([C@]3(C)CC(N)=O)CCC(N)=O)C=C3[N+]6=C([C@H](C3(C)C)CCC(N)=O)C(=C1N2[Co-3]6541C)C)C)CC(N)=O)CC(=O)NC[C@@H](C)OP([O-])(=O)O[C@@H]([C@H]2O)[C@@H](CO)O[C@@H]2N2C(C=C(C)C(C)=C3)=C3[N+]1=C2 JEWJRMKHSMTXPP-WZHZPDAFSA-L 0.000 description 1
- 229950007258 CRISNATOL Drugs 0.000 description 1
- 102100006400 CSF2 Human genes 0.000 description 1
- 102100006435 CSF3 Human genes 0.000 description 1
- 229960004015 Calcitonin Drugs 0.000 description 1
- 102400000113 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 229940112129 Campath Drugs 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229960004117 Capecitabine Drugs 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- 102000008646 Carbonic Anhydrase IX Human genes 0.000 description 1
- 108010088013 Carbonic Anhydrase IX Proteins 0.000 description 1
- 229940097647 Casodex Drugs 0.000 description 1
- 229940047495 Celebrex Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N Celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 229950001357 Celmoleukin Drugs 0.000 description 1
- 210000003169 Central Nervous System Anatomy 0.000 description 1
- 210000003679 Cervix Uteri Anatomy 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N Chlormethine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- VSIOEDUREKENGE-UHFFFAOYSA-M Cl(=O)(=O)(=O)[O-].C(C)(C)(C)[N+]=1OC=CC1C Chemical compound Cl(=O)(=O)(=O)[O-].C(C)(C)(C)[N+]=1OC=CC1C VSIOEDUREKENGE-UHFFFAOYSA-M 0.000 description 1
- 229960002286 Clodronic Acid Drugs 0.000 description 1
- ACSIXWWBWUQEHA-UHFFFAOYSA-N Clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 1
- JYGXADMDTFJGBT-VWUMJDOOSA-N Cortisol Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 1
- SBRXTSOCZITGQG-UHFFFAOYSA-N Crisnatol Chemical compound C1=CC=C2C(CNC(CO)(CO)C)=CC3=C(C=CC=C4)C4=CC=C3C2=C1 SBRXTSOCZITGQG-UHFFFAOYSA-N 0.000 description 1
- 229960000978 Cyproterone Acetate Drugs 0.000 description 1
- UWFYSQMTEOIJJG-FDTZYFLXSA-N Cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 1
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N DMSO dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 229940026692 Decadron Drugs 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N Decitabine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- 229940005558 Delestrogen Drugs 0.000 description 1
- 229940003382 Depo-Medrol Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960004833 Dexamethasone phosphate Drugs 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N Diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N Diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- 229940063123 Diflucan Drugs 0.000 description 1
- CYQFCXCEBYINGO-DLBZAZTESA-N Dronabinol Natural products C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@H]21 CYQFCXCEBYINGO-DLBZAZTESA-N 0.000 description 1
- JWJOTENAMICLJG-QWBYCMEYSA-N Dutasteride Chemical compound O=C([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)N[C@@H]4CC3)C)CC[C@@]21C)NC1=CC(C(F)(F)F)=CC=C1C(F)(F)F JWJOTENAMICLJG-QWBYCMEYSA-N 0.000 description 1
- 206010013883 Dwarfism Diseases 0.000 description 1
- 102100010782 EGFR Human genes 0.000 description 1
- 229940110715 ENZYMES FOR TREATMENT OF WOUNDS AND ULCERS Drugs 0.000 description 1
- 102100016662 ERBB2 Human genes 0.000 description 1
- 101700025368 ERBB2 Proteins 0.000 description 1
- 229950001287 Edotecarin Drugs 0.000 description 1
- 230000035695 Efflux Effects 0.000 description 1
- VLCYCQAOQCDTCN-UHFFFAOYSA-N Eflornithine Chemical compound NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 description 1
- 229940053594 Eligard Drugs 0.000 description 1
- 229940053603 Elitek Drugs 0.000 description 1
- 229940087477 Ellence Drugs 0.000 description 1
- 229940108890 Emend Drugs 0.000 description 1
- 210000003372 Endocrine Glands Anatomy 0.000 description 1
- 210000004696 Endometrium Anatomy 0.000 description 1
- 229940114721 Enzymes FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM Drugs 0.000 description 1
- 229940093738 Enzymes for ALIMENTARY TRACT AND METABOLISM Drugs 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 229940089118 Epogen Drugs 0.000 description 1
- 229950006835 Eptaplatin Drugs 0.000 description 1
- 229960001433 Erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N Erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 229960005309 Estradiol Drugs 0.000 description 1
- HEZNVIYQEUHLNI-UHFFFAOYSA-N Ethiofencarb Chemical compound CCSCC1=CC=CC=C1OC(=O)NC HEZNVIYQEUHLNI-UHFFFAOYSA-N 0.000 description 1
- 229940098617 Ethyol Drugs 0.000 description 1
- 229940009626 Etidronate Drugs 0.000 description 1
- 229960004585 Etidronic Acid Drugs 0.000 description 1
- 229940047887 Etopophos Drugs 0.000 description 1
- 210000003499 Exocrine Glands Anatomy 0.000 description 1
- 210000003414 Extremities Anatomy 0.000 description 1
- 229950011548 FADROZOLE Drugs 0.000 description 1
- CLPFFLWZZBQMAO-UHFFFAOYSA-N Fadrozole Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 description 1
- 229960004177 Filgrastim Drugs 0.000 description 1
- 108010029961 Filgrastim Proteins 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N Finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N Fluorene Chemical compound C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N Flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- OSVMTWJCGUFAOD-KZQROQTASA-N Formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 1
- 229960002258 Fulvestrant Drugs 0.000 description 1
- 229960002598 Fumaric acid Drugs 0.000 description 1
- 210000000232 Gallbladder Anatomy 0.000 description 1
- 229940009600 Gammagard Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N Gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 108010091266 Gemtuzumab Proteins 0.000 description 1
- 229940080856 Gleevec Drugs 0.000 description 1
- 229940084910 Gliadel Drugs 0.000 description 1
- 229960002913 Goserelin Drugs 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- 229960003607 Granisetron Hydrochloride Drugs 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010065430 HER-2 positive breast cancer Diseases 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 208000005209 Hematologic Disease Diseases 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 229960004931 Histamine Dihydrochloride Drugs 0.000 description 1
- PPZMYIBUHIPZOS-UHFFFAOYSA-N Histamine dihydrochloride Chemical compound Cl.Cl.NCCC1=CN=CN1 PPZMYIBUHIPZOS-UHFFFAOYSA-N 0.000 description 1
- 229940088597 Hormone Drugs 0.000 description 1
- 108010064750 Humanized Monoclonal Antibodies Proteins 0.000 description 1
- 102000015434 Humanized Monoclonal Antibodies Human genes 0.000 description 1
- 210000004408 Hybridomas Anatomy 0.000 description 1
- 229940088013 Hycamtin Drugs 0.000 description 1
- QWPPOHNGKGFGJK-UHFFFAOYSA-N Hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 1
- 210000003026 Hypopharynx Anatomy 0.000 description 1
- 102100008763 IFNA2 Human genes 0.000 description 1
- 229960000310 ISOLEUCINE Drugs 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N Imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 108010078049 Interferon alpha-2 Proteins 0.000 description 1
- 102000003996 Interferon beta Human genes 0.000 description 1
- 108090000467 Interferon beta Proteins 0.000 description 1
- 229960001388 Interferon-beta Drugs 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 206010061252 Intraocular melanoma Diseases 0.000 description 1
- 229920002459 Intron Polymers 0.000 description 1
- 229940065638 Intron A Drugs 0.000 description 1
- 229940084651 Iressa Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N Irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N Isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- FABUFPQFXZVHFB-CFWQTKTJSA-N Ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-CFWQTKTJSA-N 0.000 description 1
- 208000007766 Kaposi Sarcoma Diseases 0.000 description 1
- 210000003734 Kidney Anatomy 0.000 description 1
- 210000000244 Kidney Pelvis Anatomy 0.000 description 1
- OGNSCSPNOLGXSM-VKHMYHEASA-N L-2,4-diaminobutyric acid Chemical compound NCC[C@H](N)C(O)=O OGNSCSPNOLGXSM-VKHMYHEASA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-2-aminohexanoic acid zwitterion Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid zwitterion Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline zwitterion Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine zwitterion Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000002138 L01XE21 - Regorafenib Substances 0.000 description 1
- 229960000448 Lactic acid Drugs 0.000 description 1
- 241000282842 Lama glama Species 0.000 description 1
- 210000000867 Larynx Anatomy 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N Letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 229940008250 Leuprolide Drugs 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 229940089022 Leuprolide Acetate Drugs 0.000 description 1
- 229940080161 Levothroid Drugs 0.000 description 1
- 229940080162 Levoxyl Drugs 0.000 description 1
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 1
- 241000408529 Libra Species 0.000 description 1
- 210000000982 Limb Buds Anatomy 0.000 description 1
- 210000000088 Lip Anatomy 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- DHMTURDWPRKSOA-RUZDIDTESA-N Lonafarnib Chemical compound C1CN(C(=O)N)CCC1CC(=O)N1CCC([C@@H]2C3=C(Br)C=C(Cl)C=C3CCC3=CC(Br)=CN=C32)CC1 DHMTURDWPRKSOA-RUZDIDTESA-N 0.000 description 1
- 229950001750 Lonafarnib Drugs 0.000 description 1
- WDRYRZXSPDWGEB-UHFFFAOYSA-N Lonidamine Chemical compound C12=CC=CC=C2C(C(=O)O)=NN1CC1=CC=C(Cl)C=C1Cl WDRYRZXSPDWGEB-UHFFFAOYSA-N 0.000 description 1
- 210000004072 Lung Anatomy 0.000 description 1
- 210000001165 Lymph Nodes Anatomy 0.000 description 1
- 208000003543 Lymphoma, T-Cell, Cutaneous Diseases 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N Malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
- 206010025650 Malignant melanoma Diseases 0.000 description 1
- 229940099262 Marinol Drugs 0.000 description 1
- 229960004961 Mechlorethamine Drugs 0.000 description 1
- 210000004379 Membranes Anatomy 0.000 description 1
- 229940101513 Menest Drugs 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 230000036740 Metabolism Effects 0.000 description 1
- GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 description 1
- 241001237731 Microtia elva Species 0.000 description 1
- DYKFCLLONBREIL-KVUCHLLUSA-N Minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 1
- 229960004023 Minocycline Drugs 0.000 description 1
- VMMKGHQPQIEGSQ-UHFFFAOYSA-N Minodronic acid Chemical compound C1=CC=CN2C(CC(O)(P(O)(O)=O)P(O)(O)=O)=CN=C21 VMMKGHQPQIEGSQ-UHFFFAOYSA-N 0.000 description 1
- 210000000214 Mouth Anatomy 0.000 description 1
- 210000004400 Mucous Membrane Anatomy 0.000 description 1
- 210000003205 Muscles Anatomy 0.000 description 1
- 206010028576 Myeloproliferative disease Diseases 0.000 description 1
- 210000004165 Myocardium Anatomy 0.000 description 1
- BXGTVNLGPMZLAZ-UHFFFAOYSA-N N'-ethylmethanediimine;hydrochloride Chemical compound Cl.CCN=C=N BXGTVNLGPMZLAZ-UHFFFAOYSA-N 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N N-benzyl-1-phenylmethanamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- XCVNDBIXFPGMIW-UHFFFAOYSA-N N-ethylpropan-1-amine Chemical compound CCCNCC XCVNDBIXFPGMIW-UHFFFAOYSA-N 0.000 description 1
- RIWRFSMVIUAEBX-UHFFFAOYSA-N N-methyl-1-phenylmethanamine Chemical compound CNCC1=CC=CC=C1 RIWRFSMVIUAEBX-UHFFFAOYSA-N 0.000 description 1
- PSACHCMMPFMFAJ-UHFFFAOYSA-N NMM N-methylmorpholine Chemical compound CN1CCOCC1.CN1CCOCC1 PSACHCMMPFMFAJ-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 108010021717 Nafarelin Proteins 0.000 description 1
- 229960002333 Nafarelin Drugs 0.000 description 1
- 210000001989 Nasopharynx Anatomy 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 229940071846 Neulasta Drugs 0.000 description 1
- 229940029345 Neupogen Drugs 0.000 description 1
- 229950000891 Nolatrexed Drugs 0.000 description 1
- XHWRWCSCBDLOLM-UHFFFAOYSA-N Nolatrexed Chemical compound CC1=CC=C2NC(N)=NC(=O)C2=C1SC1=CC=NC=C1 XHWRWCSCBDLOLM-UHFFFAOYSA-N 0.000 description 1
- 229940085033 Nolvadex Drugs 0.000 description 1
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 description 1
- 229920001850 Nucleic acid sequence Polymers 0.000 description 1
- WNXNWKGPYOZGSO-UHFFFAOYSA-M O=C1N(C(C=C1)=O)CCC(C(=O)NNC(=O)[O-])(C)C Chemical compound O=C1N(C(C=C1)=O)CCC(C(=O)NNC(=O)[O-])(C)C WNXNWKGPYOZGSO-UHFFFAOYSA-M 0.000 description 1
- AGPYBRBZTGFWON-UHFFFAOYSA-N OC(=O)C(F)(F)F.O=C(OC1=CC=CC=C1)C1CC1 Chemical compound OC(=O)C(F)(F)F.O=C(OC1=CC=CC=C1)C1CC1 AGPYBRBZTGFWON-UHFFFAOYSA-N 0.000 description 1
- 108010016076 Octreotide Proteins 0.000 description 1
- FELGMEQIXOGIFQ-UHFFFAOYSA-N Ondansetron Chemical compound CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-UHFFFAOYSA-N 0.000 description 1
- 229960000770 Ondansetron Hydrochloride Drugs 0.000 description 1
- 229940003515 Orapred Drugs 0.000 description 1
- 229960003104 Ornithine Drugs 0.000 description 1
- 210000003300 Oropharynx Anatomy 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- CPZBLNMUGSZIPR-NVXWUHKLSA-N Palonosetron Chemical compound C1N(CC2)CCC2[C@@H]1N1C(=O)C(C=CC=C2CCC3)=C2[C@H]3C1 CPZBLNMUGSZIPR-NVXWUHKLSA-N 0.000 description 1
- 229940088130 Pamidronate Disodium Drugs 0.000 description 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N Pamidronic acid Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 1
- 210000000496 Pancreas Anatomy 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 210000002990 Parathyroid Glands Anatomy 0.000 description 1
- 241000237988 Patellidae Species 0.000 description 1
- 229940097097 Pediapred Drugs 0.000 description 1
- 210000003899 Penis Anatomy 0.000 description 1
- 201000004014 Pfeiffer syndrome Diseases 0.000 description 1
- DHHVAGZRUROJKS-UHFFFAOYSA-N Phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 1
- 229960002139 Pilocarpine Hydrochloride Drugs 0.000 description 1
- 210000002381 Plasma Anatomy 0.000 description 1
- 229960003171 Plicamycin Drugs 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 229960004293 Porfimer Sodium Drugs 0.000 description 1
- 210000003240 Portal Vein Anatomy 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M Potassium bicarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M Potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N Potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N Procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N Procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229940095574 Propionic acid Drugs 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N Propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- 210000002307 Prostate Anatomy 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- VIAFLMPQBHAMLI-UHFFFAOYSA-N PyBOP Chemical compound F[P-](F)(F)(F)(F)F.C1CCCN1[P+](N1CCCC1)(N1CCCC1)ON1C2=CC=CC=C2N=N1 VIAFLMPQBHAMLI-UHFFFAOYSA-N 0.000 description 1
- 101710037934 QRSL1 Proteins 0.000 description 1
- IKMPWMZBZSAONZ-UHFFFAOYSA-N Quazepam Chemical compound FC1=CC=CC=C1C1=NCC(=S)N(CC(F)(F)F)C2=CC=C(Cl)C=C12 IKMPWMZBZSAONZ-UHFFFAOYSA-N 0.000 description 1
- 229940038850 Rebif Drugs 0.000 description 1
- 108091005674 Receptor kinase Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010038038 Rectal cancer Diseases 0.000 description 1
- 210000000664 Rectum Anatomy 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 108010001645 Rituximab Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229950001403 SIZOFIRAN Drugs 0.000 description 1
- 229940063635 Salagen Drugs 0.000 description 1
- 210000003079 Salivary Glands Anatomy 0.000 description 1
- 229940072272 Sandostatin Drugs 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- LVLLALCJVJNGQQ-ZCPUWASBSA-N Seocalcitol Chemical compound C1(/[C@H]2CC[C@@H]([C@@]2(CCC1)C)[C@H](C)/C=C/C=C/C(O)(CC)CC)=C/C=C1/C[C@H](O)C[C@@H](O)C1=C LVLLALCJVJNGQQ-ZCPUWASBSA-N 0.000 description 1
- 229950009921 Seocalcitol Drugs 0.000 description 1
- 210000002966 Serum Anatomy 0.000 description 1
- 208000002491 Severe Combined Immunodeficiency Diseases 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 229920000519 Sizofiran Polymers 0.000 description 1
- 210000003625 Skull Anatomy 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N Sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229940087854 Solu-Medrol Drugs 0.000 description 1
- 206010041823 Squamous cell carcinoma Diseases 0.000 description 1
- 229960001052 Streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N Streptozotocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229940006509 Strontium-89 Drugs 0.000 description 1
- 102000018075 Subfamily B ATP Binding Cassette Transporter Human genes 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 229940099268 Synthroid Drugs 0.000 description 1
- 108091008153 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N TFA trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N THP Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- DRHKJLXJIQTDTD-OAHLLOKOSA-N Tamsulosine Chemical compound CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 DRHKJLXJIQTDTD-OAHLLOKOSA-N 0.000 description 1
- 229940120982 Tarceva Drugs 0.000 description 1
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 1
- 229960003102 Tasonermin Drugs 0.000 description 1
- 229950001699 Teceleukin Drugs 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temodal Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- 229960001278 Teniposide Drugs 0.000 description 1
- 210000001550 Testis Anatomy 0.000 description 1
- 229940085503 Testred Drugs 0.000 description 1
- 229940033529 Tetrahydrocannabinol Drugs 0.000 description 1
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N Thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 description 1
- 108010078233 Thymalfasin Proteins 0.000 description 1
- 102400000800 Thymosin alpha-1 Human genes 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 229940035626 Thyrotropin Class in ATC Drugs 0.000 description 1
- FVRDYQYEVDDKCR-DBRKOABJSA-N Tiazofurin Chemical compound NC(=O)C1=CSC([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=N1 FVRDYQYEVDDKCR-DBRKOABJSA-N 0.000 description 1
- 229940035295 Ting Drugs 0.000 description 1
- 229950009158 Tipifarnib Drugs 0.000 description 1
- 229950002376 Tirapazamine Drugs 0.000 description 1
- QVMPZNRFXAKISM-UHFFFAOYSA-N Tirapazamine Chemical compound C1=CC=C2[N+]([O-])=NC(=N)N(O)C2=C1 QVMPZNRFXAKISM-UHFFFAOYSA-N 0.000 description 1
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
- 210000000515 Tooth Anatomy 0.000 description 1
- 108010033576 Transferrin Receptors Proteins 0.000 description 1
- 102000007238 Transferrin Receptors Human genes 0.000 description 1
- 229960001727 Tretinoin Drugs 0.000 description 1
- SHGAZHPCJJPHSC-NWVFGJFESA-N Tretinoin Chemical compound OC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NWVFGJFESA-N 0.000 description 1
- GCPXMJHSNVMWNM-UHFFFAOYSA-N Trihydroxyarsenite(Iii) Chemical compound O[As](O)O GCPXMJHSNVMWNM-UHFFFAOYSA-N 0.000 description 1
- KVJXBPDAXMEYOA-CXANFOAXSA-N Trilostane Chemical compound OC1=C(C#N)C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@@]32O[C@@H]31 KVJXBPDAXMEYOA-CXANFOAXSA-N 0.000 description 1
- NOYPYLRCIDNJJB-UHFFFAOYSA-N Trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 1
- 229960001099 Trimetrexate Drugs 0.000 description 1
- 229960000434 Triptorelin Acetate Drugs 0.000 description 1
- 108010050144 Triptorelin Pamoate Proteins 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 229950009811 UBENIMEX Drugs 0.000 description 1
- 210000000626 Ureter Anatomy 0.000 description 1
- 210000003932 Urinary Bladder Anatomy 0.000 description 1
- 210000001635 Urinary Tract Anatomy 0.000 description 1
- 210000004291 Uterus Anatomy 0.000 description 1
- 229940029983 VITAMINS Drugs 0.000 description 1
- 210000001215 Vagina Anatomy 0.000 description 1
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N Valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 description 1
- YJDYDFNKCBANTM-QCWCSKBGSA-N Valspodar Chemical compound C\C=C\C[C@@H](C)C(=O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](C(C)C)NC1=O YJDYDFNKCBANTM-QCWCSKBGSA-N 0.000 description 1
- 229950010938 Valspodar Drugs 0.000 description 1
- 210000003462 Veins Anatomy 0.000 description 1
- YTZALCGQUPRCGW-ZSFNYQMMSA-N Verteporfin Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(CCC(=O)OC)=C(C)C(N3)=C3)=N2)C)=C(C=C)C(C)=C1C=C1C2=CC=C(C(=O)OC)[C@@H](C(=O)OC)[C@@]2(C)C3=N1 YTZALCGQUPRCGW-ZSFNYQMMSA-N 0.000 description 1
- 229960003895 Verteporfin Drugs 0.000 description 1
- 229960003048 Vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229940021016 Vitamin IV solution additives Drugs 0.000 description 1
- 210000003905 Vulva Anatomy 0.000 description 1
- 229940099232 Zinecard Drugs 0.000 description 1
- FYQZGCBXYVWXSP-STTFAQHVSA-N Zinostatin stimalamer Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1OC1C/2=C/C#C[C@H]3O[C@@]3([C@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(C)C=CC2=C(C)C=C(OC)C=C12 FYQZGCBXYVWXSP-STTFAQHVSA-N 0.000 description 1
- 229950009233 Zinostatin stimalamer Drugs 0.000 description 1
- 229940072018 Zofran Drugs 0.000 description 1
- JMUHBNWAORSSBD-WKYWBUFDSA-N [(2R)-3-[2-[[(2S)-2-[[(4R)-4-[[(2S)-2-[[(2R)-2-[(3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxypropanoyl]amino]propanoyl]amino]-5-amino-5-oxopentanoyl]amino]propanoyl]amino]ethoxy-hydroxyphosphoryl]oxy-2-hexadecanoyloxypropyl] hexad Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O JMUHBNWAORSSBD-WKYWBUFDSA-N 0.000 description 1
- YJTVZHOYBAOUTO-URBBEOKESA-N [(2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl octadecyl hydrogen phosphate Chemical compound O[C@H]1[C@H](O)[C@@H](COP(O)(=O)OCCCCCCCCCCCCCCCCCC)O[C@H]1N1C(=O)N=C(N)C=C1 YJTVZHOYBAOUTO-URBBEOKESA-N 0.000 description 1
- XJXKGUZINMNEDK-GPJOBVNKSA-L [(4R,5R)-5-(aminomethyl)-2-propan-2-yl-1,3-dioxolan-4-yl]methanamine;platinum(2+);propanedioate Chemical compound [Pt+2].[O-]C(=O)CC([O-])=O.CC(C)C1O[C@H](CN)[C@@H](CN)O1 XJXKGUZINMNEDK-GPJOBVNKSA-L 0.000 description 1
- GBGVQFJZGHBZMC-UHFFFAOYSA-N [(6-chlorobenzotriazol-1-yl)oxy-(dimethylamino)methylidene]-dimethylazanium;tetrafluoroborate Chemical compound F[B-](F)(F)F.C1=C(Cl)C=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 GBGVQFJZGHBZMC-UHFFFAOYSA-N 0.000 description 1
- CWUYOSYHUNLLRT-UHFFFAOYSA-N [2H-benzotriazol-4-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound CN(C)C(=[N+](C)C)OC1=CC=CC2=C1N=NN2 CWUYOSYHUNLLRT-UHFFFAOYSA-N 0.000 description 1
- SRUIBJVUBBOHHY-UHFFFAOYSA-N [2H-benzotriazol-4-yloxy(dimethylamino)methylidene]-dimethylazanium;hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F.CN(C)C(=[N+](C)C)OC1=CC=CC2=C1N=NN2 SRUIBJVUBBOHHY-UHFFFAOYSA-N 0.000 description 1
- RCXMQNIDOFXYDO-UHFFFAOYSA-N [4,7,10-tris(phosphonomethyl)-1,4,7,10-tetrazacyclododec-1-yl]methylphosphonic acid Chemical compound OP(O)(=O)CN1CCN(CP(O)(O)=O)CCN(CP(O)(O)=O)CCN(CP(O)(O)=O)CC1 RCXMQNIDOFXYDO-UHFFFAOYSA-N 0.000 description 1
- OCOKWVBYZHBHLU-UHFFFAOYSA-N [4-[2-[4-(2-methylpropoxycarbonyloxymethyl)-3,5-dioxopiperazin-1-yl]ethyl]-2,6-dioxopiperazin-1-yl]methyl 2-methylpropyl carbonate Chemical compound C1C(=O)N(COC(=O)OCC(C)C)C(=O)CN1CCN1CC(=O)N(COC(=O)OCC(C)C)C(=O)C1 OCOKWVBYZHBHLU-UHFFFAOYSA-N 0.000 description 1
- CTCBPRXHVPZNHB-VQFZJOCSSA-N [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate;(2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O.C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O CTCBPRXHVPZNHB-VQFZJOCSSA-N 0.000 description 1
- UQYZFNUUOSSNKT-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium;hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F.C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 UQYZFNUUOSSNKT-UHFFFAOYSA-N 0.000 description 1
- RNGXQPRVKWFGJM-UHFFFAOYSA-N [dimethylamino(2H-triazolo[4,5-b]pyridin-7-yloxy)methylidene]-dimethylazanium Chemical compound CN(C)C(=[N+](C)C)OC1=CC=NC2=C1N=NN2 RNGXQPRVKWFGJM-UHFFFAOYSA-N 0.000 description 1
- CZQGINAUZYECAI-UHFFFAOYSA-N [dimethylamino-(2-oxopyridin-1-yl)oxymethylidene]-dimethylazanium;tetrafluoroborate Chemical compound F[B-](F)(F)F.CN(C)C(=[N+](C)C)ON1C=CC=CC1=O CZQGINAUZYECAI-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- HPPONSCISKROOD-OYLNGHKZSA-N acetic acid;(2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-y Chemical compound CC(O)=O.C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 HPPONSCISKROOD-OYLNGHKZSA-N 0.000 description 1
- WJGAPUXHSQQWQF-UHFFFAOYSA-N acetic acid;hydrochloride Chemical compound Cl.CC(O)=O WJGAPUXHSQQWQF-UHFFFAOYSA-N 0.000 description 1
- MNZMECMQTYGSOI-UHFFFAOYSA-N acetic acid;hydron;bromide Chemical compound Br.CC(O)=O MNZMECMQTYGSOI-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 229960001445 alitretinoin Drugs 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 238000010640 amide synthesis reaction Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 229960002550 amrubicin Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003388 anti-hormone Effects 0.000 description 1
- 230000000890 antigenic Effects 0.000 description 1
- 229940019336 antithrombotic Enzymes Drugs 0.000 description 1
- 229960001372 aprepitant Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 229960002594 arsenic trioxide Drugs 0.000 description 1
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 229950010993 atrasentan Drugs 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- TYQYRKDGHAPZRF-INIZCTEOSA-N benzyl (2S)-2-amino-3-(1H-indol-3-yl)propanoate Chemical compound O=C([C@H](CC=1C2=CC=CC=C2NC=1)N)OCC1=CC=CC=C1 TYQYRKDGHAPZRF-INIZCTEOSA-N 0.000 description 1
- FPRSPUHXEPWUBZ-HNNXBMFYSA-N benzyl (2S)-2-amino-3-phenylpropanoate Chemical compound C([C@H](N)C(=O)OCC=1C=CC=CC=1)C1=CC=CC=C1 FPRSPUHXEPWUBZ-HNNXBMFYSA-N 0.000 description 1
- 229960004648 betamethasone acetate Drugs 0.000 description 1
- AKUJBENLRBOFTD-QZIXMDIESA-N betamethasone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(C)=O)(O)[C@@]1(C)C[C@@H]2O AKUJBENLRBOFTD-QZIXMDIESA-N 0.000 description 1
- 229950006991 betamethasone phosphate Drugs 0.000 description 1
- PLCQGRYPOISRTQ-LWCNAHDDSA-L betamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-LWCNAHDDSA-L 0.000 description 1
- 229960005354 betamethasone sodium phosphate Drugs 0.000 description 1
- 229960002938 bexarotene Drugs 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 230000000903 blocking Effects 0.000 description 1
- SGIQRFZMJGZMNT-UHFFFAOYSA-N boron(1-);tetrabutylazanium Chemical compound [B-].CCCC[N+](CCCC)(CCCC)CCCC SGIQRFZMJGZMNT-UHFFFAOYSA-N 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000002490 cerebral Effects 0.000 description 1
- 230000005591 charge neutralization Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000000973 chemotherapeutic Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 230000002860 competitive Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 229950006614 cytarabine ocfosfate Drugs 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 230000001086 cytosolic Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 229960003603 decitabine Drugs 0.000 description 1
- 229960002923 denileukin diftitox Drugs 0.000 description 1
- 108010017271 denileukin diftitox Proteins 0.000 description 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 229960005408 deslorelin Drugs 0.000 description 1
- 125000004989 dicarbonyl group Chemical group 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-O dicyclohexylazanium Chemical class C1CCCCC1[NH2+]C1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-O 0.000 description 1
- ZWWWLCMDTZFSOO-UHFFFAOYSA-N diethoxyphosphorylformonitrile Chemical compound CCOP(=O)(C#N)OCC ZWWWLCMDTZFSOO-UHFFFAOYSA-N 0.000 description 1
- 229960000452 diethylstilbestrol Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000001079 digestive Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide DMF Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 1
- 229950005454 doxifluridine Drugs 0.000 description 1
- 229960004199 dutasteride Drugs 0.000 description 1
- 229960002759 eflornithine Drugs 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002357 endometrial Effects 0.000 description 1
- 230000002255 enzymatic Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 102000017256 epidermal growth factor-activated receptor activity proteins Human genes 0.000 description 1
- 108040009258 epidermal growth factor-activated receptor activity proteins Proteins 0.000 description 1
- 210000002919 epithelial cells Anatomy 0.000 description 1
- 229930013356 epothilones Natural products 0.000 description 1
- 238000010931 ester hydrolysis Methods 0.000 description 1
- IIUMCNJTGSMNRO-VVSKJQCTSA-L estramustine sodium phosphate Chemical compound [Na+].[Na+].ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP([O-])([O-])=O)[C@@H]4[C@@H]3CCC2=C1 IIUMCNJTGSMNRO-VVSKJQCTSA-L 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N ethanolamine Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N ethyl amine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- 229960000752 etoposide phosphate Drugs 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 230000002349 favourable Effects 0.000 description 1
- 229950003662 fenretinide Drugs 0.000 description 1
- 231100000592 few side effect Toxicity 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 229960004421 formestane Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960004783 fotemustine Drugs 0.000 description 1
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229920000370 gamma-poly(glutamate) polymer Polymers 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 229960000578 gemtuzumab Drugs 0.000 description 1
- 230000002068 genetic Effects 0.000 description 1
- 210000002768 hair cell Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940020899 hematological Enzymes Drugs 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 125000004634 hexahydroazepinyl group Chemical group N1(CCCCCC1)* 0.000 description 1
- KJZYNXUDTRRSPN-OUBTZVSYSA-N holmium-166 Chemical compound [166Ho] KJZYNXUDTRRSPN-OUBTZVSYSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-O hydron;1,2-oxazole Chemical class C=1C=[NH+]OC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-O 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-O hydron;urea Chemical class NC([NH3+])=O XSQUKJJJFZCRTK-UHFFFAOYSA-O 0.000 description 1
- 229950000801 hydroxyprogesterone caproate Drugs 0.000 description 1
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 1
- 108010061572 ibritumomab tiuxetan Proteins 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 230000001976 improved Effects 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 125000006301 indolyl methyl group Chemical group 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 201000008893 intraocular retinoblastoma Diseases 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000000155 isotopic Effects 0.000 description 1
- 229960002014 ixabepilone Drugs 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 108010021336 lanreotide Proteins 0.000 description 1
- 229960002437 lanreotide Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 229910052808 lithium carbonate Inorganic materials 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 229960003538 lonidamine Drugs 0.000 description 1
- 230000000527 lymphocytic Effects 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960005321 mecobalamin Drugs 0.000 description 1
- 239000002609 media Substances 0.000 description 1
- 230000001404 mediated Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003340 mental Effects 0.000 description 1
- 230000002503 metabolic Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000035786 metabolism Effects 0.000 description 1
- XOBKSJJDNFUZPF-UHFFFAOYSA-N methoxyethyl Chemical compound CCOC XOBKSJJDNFUZPF-UHFFFAOYSA-N 0.000 description 1
- SWVMLNPDTIFDDY-FVGYRXGTSA-N methyl (2S)-2-amino-3-phenylpropanoate;hydrochloride Chemical compound Cl.COC(=O)[C@@H](N)CC1=CC=CC=C1 SWVMLNPDTIFDDY-FVGYRXGTSA-N 0.000 description 1
- LLAZQXZGAVBLRX-UHFFFAOYSA-N methyl 2,5-dioxopyrrole-1-carboxylate Chemical compound COC(=O)N1C(=O)C=CC1=O LLAZQXZGAVBLRX-UHFFFAOYSA-N 0.000 description 1
- FLQHIIVXMKXKFT-UHFFFAOYSA-N methyl 2-amino-4-oxopentanoate Chemical compound COC(=O)C(N)CC(C)=O FLQHIIVXMKXKFT-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- XGZVLEAZGCUUPH-UHFFFAOYSA-N methylamino(methylimino)methanesulfonic acid Chemical class CNC(=NC)S(O)(=O)=O XGZVLEAZGCUUPH-UHFFFAOYSA-N 0.000 description 1
- 235000007672 methylcobalamin Nutrition 0.000 description 1
- 239000011585 methylcobalamin Substances 0.000 description 1
- 229960005225 mifamurtide Drugs 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229950011129 minodronic acid Drugs 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical class C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N o-xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 229960000435 oblimersen Drugs 0.000 description 1
- MIMNFCVQODTQDP-NDLVEFNKSA-N oblimersen Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(S)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)CO)[C@@H](O)C1 MIMNFCVQODTQDP-NDLVEFNKSA-N 0.000 description 1
- 201000002575 ocular melanoma Diseases 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 201000001539 ovarian carcinoma Diseases 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 238000009116 palliative therapy Methods 0.000 description 1
- 229960002131 palonosetron Drugs 0.000 description 1
- 229960003978 pamidronic acid Drugs 0.000 description 1
- 230000036961 partial Effects 0.000 description 1
- 230000001575 pathological Effects 0.000 description 1
- 229960001744 pegaspargase Drugs 0.000 description 1
- 108010001564 pegaspargase Proteins 0.000 description 1
- 229940083249 peripheral vasodilators Enzymes Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- MNTZZDOKIWMNIM-UHFFFAOYSA-N phenyl cyclopropanecarboxylate Chemical compound C1CC1C(=O)OC1=CC=CC=C1 MNTZZDOKIWMNIM-UHFFFAOYSA-N 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N phosgene Chemical class ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 102000021163 phospholipid binding proteins Human genes 0.000 description 1
- 108091010150 phospholipid binding proteins Proteins 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 150000003018 phosphorus compounds Chemical class 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000865 phosphorylative Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- 229960001221 pirarubicin Drugs 0.000 description 1
- 230000003169 placental Effects 0.000 description 1
- 108091008117 polyclonal antibodies Proteins 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000001120 potassium sulphate Substances 0.000 description 1
- VLYFRFHWUBBLRR-UHFFFAOYSA-L potassium;sodium;carbonate Chemical compound [Na+].[K+].[O-]C([O-])=O VLYFRFHWUBBLRR-UHFFFAOYSA-L 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 229960004694 prednimustine Drugs 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 230000002062 proliferating Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000002797 proteolythic Effects 0.000 description 1
- 201000004681 psoriasis Diseases 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000002685 pulmonary Effects 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 229960001964 quazepam Drugs 0.000 description 1
- 230000003439 radiotherapeutic Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 229960004432 raltitrexed Drugs 0.000 description 1
- 102000027656 receptor tyrosine kinases Human genes 0.000 description 1
- 108091007921 receptor tyrosine kinases Proteins 0.000 description 1
- 230000001172 regenerating Effects 0.000 description 1
- 229960004836 regorafenib Drugs 0.000 description 1
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 201000000582 retinoblastoma Diseases 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- WUAPFZMCVAUBPE-IGMARMGPSA-N rhenium-186 Chemical compound [186Re] WUAPFZMCVAUBPE-IGMARMGPSA-N 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 229950003733 romurtide Drugs 0.000 description 1
- 229960002530 sargramostim Drugs 0.000 description 1
- 108010038379 sargramostim Proteins 0.000 description 1
- 229960005399 satraplatin Drugs 0.000 description 1
- CKNPWBAXEKSCRG-UHFFFAOYSA-J satraplatin Chemical compound CC(=O)O[Pt-2]([NH3+])(Cl)(Cl)(OC(C)=O)[NH2+]C1CCCCC1 CKNPWBAXEKSCRG-UHFFFAOYSA-J 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 101710044770 sll1951 Proteins 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229950010372 sobuzoxane Drugs 0.000 description 1
- YOQDYZUWIQVZSF-UHFFFAOYSA-N sodium borohydride Substances [BH4-].[Na+] YOQDYZUWIQVZSF-UHFFFAOYSA-N 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000001187 sodium carbonate Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- ODGROJYWQXFQOZ-UHFFFAOYSA-N sodium;boron(1-) Chemical compound [B-].[Na+] ODGROJYWQXFQOZ-UHFFFAOYSA-N 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000000392 somatic Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- CIOAGBVUUVVLOB-OUBTZVSYSA-N strontium-89 Chemical compound [89Sr] CIOAGBVUUVVLOB-OUBTZVSYSA-N 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- FQZYTYWMLGAPFJ-OQKDUQJOSA-N tamoxifen citrate Chemical compound [H+].[H+].[H+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 FQZYTYWMLGAPFJ-OQKDUQJOSA-N 0.000 description 1
- 229960002613 tamsulosin Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- LDKDMDVMMCXTMO-LBPRGKRZSA-N tert-butyl N-[(2S)-1-hydroxy-3-phenylpropan-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@H](CO)CC1=CC=CC=C1 LDKDMDVMMCXTMO-LBPRGKRZSA-N 0.000 description 1
- YHLRIQZPTHKMQS-UHFFFAOYSA-N tert-butyl N-[2-(methylamino)ethyl]carbamate;hydron;chloride Chemical compound Cl.CNCCNC(=O)OC(C)(C)C YHLRIQZPTHKMQS-UHFFFAOYSA-N 0.000 description 1
- KKVIDFHPHBYQDP-UHFFFAOYSA-N tert-butyl N-[[4-(2,5-dioxopyrrol-1-yl)-2,2-dimethylbutanoyl]amino]carbamate Chemical compound CC(C)(C)OC(=O)NNC(=O)C(C)(C)CCN1C(=O)C=CC1=O KKVIDFHPHBYQDP-UHFFFAOYSA-N 0.000 description 1
- DKACXUFSLUYRFU-UHFFFAOYSA-N tert-butyl N-aminocarbamate Chemical compound CC(C)(C)OC(=O)NN DKACXUFSLUYRFU-UHFFFAOYSA-N 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran THF Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 125000001166 thiolanyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 229960004231 thymalfasin Drugs 0.000 description 1
- 229960000874 thyrotropin Drugs 0.000 description 1
- 230000001748 thyrotropin Effects 0.000 description 1
- 229960003723 tiazofurine Drugs 0.000 description 1
- 230000030968 tissue homeostasis Effects 0.000 description 1
- 229960005267 tositumomab Drugs 0.000 description 1
- 231100000224 toxic side effect Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002103 transcriptional Effects 0.000 description 1
- 229960001670 trilostane Drugs 0.000 description 1
- 229960000294 triptorelin pamoate Drugs 0.000 description 1
- 108010002164 tyrosine receptor Proteins 0.000 description 1
- 229960000653 valrubicin Drugs 0.000 description 1
- 108010082372 valspodar Proteins 0.000 description 1
- 229960002730 vapreotide Drugs 0.000 description 1
- 229950005577 vesnarinone Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamins Natural products 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
Abstract
Disclosed are antibody-linked auristatin conjugates of the general formula (Ia) which comprise a novel linker, wherein AK is a binder which is an antibody or an antigen-binding antibody fragment that binds to FGFR2, and wherein the linker comprises the group L2 which is a linear C2-C10alkylene-##4 group, or a polyethylene linking group of the formula ##3-CH2-CH2-[O-CH2-CH2-]p-##4; p is a number from 2 to 6; ##3 marks the linkage site on the side with AK; ##4 marks the bond to the nitrogen atom of the auristatin derivative, and wherein the C2-C10alkylene group is optionally substituted by 1 to 4 substituents selected independently of one another from the group consisting of methyl, hydroxyl, and benzyl, or wherein two carbon atoms of the C2-C10alkylene group in 1,2-, 1,3- or 1,4-relation to one another, with inclusion of any carbon atoms situated between them, are optionally bridged to form a cycloalkyl ring or a phenyl ring; for the treatment and/or prophylaxis of hyperproliferative and/or angiogenic diseases. In a preferred embodiment L2 is an unsubstituted pentylene chain linked to AK through a carbonyl group. roup, or a polyethylene linking group of the formula ##3-CH2-CH2-[O-CH2-CH2-]p-##4; p is a number from 2 to 6; ##3 marks the linkage site on the side with AK; ##4 marks the bond to the nitrogen atom of the auristatin derivative, and wherein the C2-C10alkylene group is optionally substituted by 1 to 4 substituents selected independently of one another from the group consisting of methyl, hydroxyl, and benzyl, or wherein two carbon atoms of the C2-C10alkylene group in 1,2-, 1,3- or 1,4-relation to one another, with inclusion of any carbon atoms situated between them, are optionally bridged to form a cycloalkyl ring or a phenyl ring; for the treatment and/or prophylaxis of hyperproliferative and/or angiogenic diseases. In a preferred embodiment L2 is an unsubstituted pentylene chain linked to AK through a carbonyl group.
Description
FGFR antibody drug conjugates (ADCs) and the use thereof
The present application s to new binder-drug ates (ADCs) of N,N-dialkylauristatins
that are directed against the target fibroblast growth factor receptor 2 (FGFR2), to active
metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for
treating and/or preventing illnesses, and also to the use of these ADCs for producing medicaments
for treating and/or preventing illnesses, more ularly roliferative and/or angiogenic
es such as, for example, cancer diseases. Such treatments may be sed as a monotherapy
or else in combination with other medicaments or further therapeutic measures.
Cancer diseases are the consequence of uncontrolled cell growth in a wide variety of tissues. In
many cases the new cells penetrate existing tissue (invasive growth), or they metastase into remote
organs. Cancer diseases occur in a wide variety of organs, and the illnesses often ss in a
tissue-specific manner. The designation “cancer disease” as a generic term therefore describes a
large group of defined diseases of different organs, tissues and cell types.
Early-stage tumours may be able to be removed by al and radiotherapeutic measures.
Metastasized tumours can generally only be given palliative therapy by means of chemotherapeutic
agents. The objective in that case is to achieve the optimum combination of ing quality of
life and prolonging remaining lifetime.
The majority of the chemotherapeutic agents which are presently administered parenterally are
often not target-directed at the tumour tissue or the tumour cells, but instead, as a result of their
systemic administration, are buted non-specifically within the body, hence ing at
locations at which exposure to the drug is undesirable, such as in healthy cells, tissues and organs,
for example. This may lead to ed side-effects and even to serious effects of l toxicity,
which then often greatly limit the therapeutically useful dose range of the drug, or necessitate
complete cessation of medication.
The improved and selective availability of these chemotherapeutic agents in the tumour cell or the
immediately surrounding , and the associated boost in effect, on the one hand, and
minimization of toxic side-effects, on the other hand, have therefore been a focal point for a
number of years in the development of new chemotherapeutic agents. Many attempts have been
made to date to develop efficient methods of introducing the drug into the target cell. Optimizing
the association between drug and intracellular target and minimizing the intercellular distribution
of drug, to adjacent cells, for e, nevertheless continue to constitute a difficult problem.
Monoclonal antibodies, for example, are suitable for the target-directed sing of tumour
tissue and tumour cells. The significance of such antibodies for the clinical treatment of cancer
es has seen a erable general increase in recent years, based on the activity of such
agents as trastuzumab (Herceptin®), mab (Rituxan®), cetuximab (Erbitux®) and bevacizumab
(Avastin ®), which have since been approved for the therapy of individual, specific tumour es
[see e.g. G. P. Adams and L. M. Weiner, Nat. Biotechnol. 23, 1147-1157 (2005)]. Consequently
there has also been a marked increase in interest in so-called immunoconjugates such as, for
example, the aforementioned ADCs, in which an internalizing antibody directed against a tumourassociated
antigen is joined covalently via a linking unit ("linker") to a cytotoxic agent. Following
introduction of the ADC into the tumour cell and subsequent cleavage of the conjugate, either the
cytotoxic agent itself or another metabolite with cytotoxic activity, formed from the cytotoxic
agent, is released within the tumour cell, where it is able to develop its effect directly and
selectively. In this way it would be possible to keep the damage to normal tissue within
significantly closer limits in comparison to a conventional chemotherapy of the cancer disease [see
e.g. J. M. Lambert, Curr. Opin. Pharmacol. 5, 543-549 (2005); A. M. Wu and P. D. Senter, Nat.
Biotechnol. 23, 1137-1146 (2005); P. D. Senter, Curr. Opin. Chem. Biol. 13, 235-244 (2009);
L. Ducry and B. Stump, Bioconjugate Chem. 21, 5-13 (2010)].
Instead of antibodies, it is also possible for binders from the small-molecule drug sphere to be used
as binders which bind ively to a specific target location ("target"), such as to a or, for
example [see e.g. E. Ruoslahti et al., Science 279, 377-380 (1998); D. Karkan et al., PLoS ONE
3 (6), e2469 (June 25, 2008)]. Also known are conjugates of cytotoxic drug and addressing ligand
that exhibit a defined cleavage point between ligand and drug for the release of the drug. A
"predetermined break point" of this kind may exist, for example, within a peptide chain which can
be cleaved selectively at a particular site by a specific enzyme at the location of action [see
e.g. R. A. Firestone and L. A. Telan, US Patent Application US 2002/0147138].
The activity of monoclonal antibodies is demonstrated in various types of cancer. Thus
HERCEPTIN® and x® are used sfully in the treatment of HER2-positive breast
cancer and EGFR-positive colorectal cancer, respectively.
The coupling of xic compounds to dies forms an extended possibility for additionally
improving cancer therapy, since these conjugates allow tumour-specific toxophore lation
and at the same time reduce the systemic toxicity. With respect to activity and nce, clinical
studies with brentuximab vedotin in Hodgkin’s lymphoma and with trastuzumab-DM1 in breast
cancer have yielded highly ing results, which support the development of new antibodies
and new ADCs against other tumour antigens.
Antibody-based y proves to be very powerful in the treatment of various carcinomas,
including solid tumours. Thus, for e Herceptin ® has been deployed sfully in the
treatment of breast cancer, and Rituxan® is powerful in forms of carcinoma associated with the B
cells. At the focal point of the pment of a sful antibody-based therapy is the isolation
of antibodies against cell surface proteins which are expressed preferably on tumour cells.
The fibroblast growth factor receptors are tyrosine receptor kinases (RTK), of which four are
known in mammals (FGFR1, FGFR2, FGFR3, FGFR4). As ligands, 22 human fibroblast growth
factors (FGF) have been identified (Eswarakumar and Schlessinger, Cytokine & Growth Factor
Reviews 2005, 16:139-149; Shimada et al., Proc. Natl. Acad. Sci. USA 2001, 98:6500-6505). The
FGFRs consist of three extracellular immunoglobulin (Ig)-like domains, namely D1-D3, with
domains 2 and 3 being necessary for ligand binding, and also of an individual transmembrane
domain and a cytoplasmic domain, which contains the catalytic centre of the n tyrosine
kinase (a schematic illustration is given in Figure 1).
Schematic illustration of the structure of FGFR2. Alpha (SEQ ID NO: 1) and beta (SEQ ID NO: 2)
splice variants are compared with one another. The illustration shows the three Ig-like domains
(D1, D2 and D3), the transmembrane domain (TM) and the intracellular kinase domain. The
heparin binding site (HBS), the acidic box (AB), and the alternative IIIb/IIIc domains are likewise
ed. The amino terminus is marked by N, the carboxy terminus by C.
The extracellular component additionally harbours the acidic box (AB) and the heparin binding
site (HBS) (see Figure 1). An ant feature of the FGFR family of RTKs is that there are
ent, alternatively d variants in existence. The full-length FGFR is identified as FGFR
alpha (SEQ ID NO: 1), while the isoform, which is missing D1, is identified as FGFR beta (SEQ
ID NO: 2) (Figure 1). An alternative splicing in domain 3 leads to two different variants, namely
FGFR2 IIIb, which is encoded by the exons 7 and 8, and FGFR2 IIIc, which is encoded by the
exons 7 and 9 (Figure 1). The latter splicing influences the ligand binding, leading to the
specificity pattern. FGFR2 IIIc is expressed primarily by mesenchymal cells, and FGFR2 IIIb
essentially by epithelial cells. FGF7 is also known as keratinocyte growth factor (KGF), and binds
only to FGFR2 IIIb, which is therefore also called KGFR. When the FGFs bind to their receptors,
there is subsequent zation and phosphorylation of the FGFRs, and a downstream signalling
via the FRS-GRB2 docking n complex to the RAS-MAPK signal transduction cascade and
the PI3K-AKT signal transduction cascade. The former signal transduction cascade is involved in
cell growth and in cell entiation, while the latter is involved in the survival of the cells and in
the ination of cell fate (Katoh und Katoh, Int. J. Oncol. 2006, 29:163-168).
For correct genesis during embryogenesis, an orchestrated signal transduction of all four
receptors (FGFR1 to FGFR4) and of their splicing variants via the different FGFs is necessary
(Ornitz et al., Genome Biol 2001, 2:3005). In the case of FGFR2, the absence of all FGFR2
variants leads to s in placental and limb bud formation, and therefore leads to fatality at the
E10.5 stage. Specific knock-out of FGFR2 IIIb in the mouse leads likewise to fatality (at P0) in
WO 87716
association with agenesis of the lungs, of the anterior lobe, of the thyroid gland, of the teeth and of
the limbs, whereas disruption of the FGFR2 IIIc variant is survivable, with incidence of retarded
ossification, tional dwarfism and synostosis of the base of the skull (Eswarakumar and
Schlessinger, 2005). Activating mutations of FGFR2 in the germ track lead to severe
malformations during embryogenesis, such as coronal osis and cranial synostosis in the case
of Apert’s syndrome or in the case of Pfeiffer’s syndrome in humans (Robin et al., in Gene
Reviews, NCBI elf Washington, edited by Pagon et al., 1993). In adults, FGFR2 signal
transduction is involved in wound healing, in epithelial repair and in the protection of cells of the
skin and mucous membrane (Braun et al., Phil. Trans. R. Soc. Lond. B 2004, 359:753-757) and in
ration in the event of liver damage (Steiling et al., Oncogene 2003, 0-4388; Böhm,
dissertation, Eidgenössische Technische hule Zürich, 2009). A role of FGFR2 signal
transduction in the ion of EPDC (epicardial derived cells) into the heart following tion
is therefore under discussion because during embryogenesis, FGF10-FGFR2 signal transduction is
necessary for the migration of EPDC into the compact myocardium, a process which is necessary
for the development of the heart Hernández et al., Development 2011:3331-3340; Winter
and De Groot, Cell Mol. Life Sci. 2007, 64:692-703). All of these roles played by FGFR2 are
regenerative in nature, and apparently of essential importance only under non-physiological
conditions, as a result of a disruption in tissue homeostasis. Increased somatic signal transduction
via FGFR2 is involved in various pathological conditions such as acne (Katoh, J. of Invest.
Dermatol. 2009, 129:1861-1867), psoriasis (Finch et al., Am. J. Pathol. 1997, 151:1619-1628; Xu
et al., J. Invest. Dermatol. 2011:131:1521-1529) and cancer (see below).
A number of studies have been published which show a strong association of FGFR2 expression
with an adverse outcome in cancer patients:
The overexpression of FGFR2 and/or KGF is accompanied by expansive growth of stomach
carcinoma and shorter survival of the patients (Matsunobu et al., Int. J. Cancer 2006, 28:307-314;
wa et al., Oncol. Reports 2009, 21:875-880). The overexpression of FGFR2 was detected in
% of all h carcinoma samples examined (Matsunobu et al., Int. J. Cancer 2006,
28:307-314; Toyokawa et al., Oncol. Reports 2009, 21:875-880). Adenocarcinoma (70% of all
stomach carcinomas) is subdivided, additionally, into two different ogical types, namely
stomach cancer of the intestinal type of and of the diffuse type. Interestingly, the first, less
aggressive type is associated with an ted ErbB2 signal pathway, whereas, in the case of the
latter, more aggressive type, aberrations occur in the FGFR2/PI3K signal pathway (Yamashita et
al., Surg. Today 2011, 41:24-38). FGFR2 overexpression occurred in 53% of all samples of
stomach cancer of the e kind (Yamashita et al., Surg. Today 2011, 38). Drawing
together all of the data, HER2 expression and FGFR2 expression appear to occur in two different
patient populations. To some extent possibly, the expression of FGFR2 is the result of a gene
amplification, since amplifications of FGFR2 are found in approximately 7-10% of all primary
stomach carcinomas (Kunii et al., Cancer Res. 2008, 68:232348). Moreover, FGFR2
expression has not only been found in ases, but was in fact even greater in metastases than
in primary tumours (Yamashita et al., Surg. Today 2011, 41:24-38).
In the case of breast cancer, FGFR2 IIIb expression was found in 57% of tumour samples, but
hardly at all in healthy tissue (Tamaru et al. 2004, 84:1460-1471). KGF (FGF7) occurred in 45%
of random samples, generally together with FGFR2 IIIb. The co-expression of FGF7 and its single
receptor FGFR2 IIIb was associated with a significantly reduced number of tic cells within
the primary tumour by comparison with primary breast carcinomas, where neither FGF7 nor
FGFR2 IIIb was expressed (Tamaru et al. 2004, 84:1460-1471). As in the case of stomach cancer,
a gene amplification was found for breast cancer as well, and also in 4% of triply negative breast
carcinomas (TNBC) (Turner et al., Oncogene 2010, 29:2013-2023). In breast cancer, a number of
changes in individual nucleotides (Single Nucleotide Polymorphism, SNP) have been fied
that are associated with an sed risk of breast cancer (Hunter et al., Nature Genetics 2007,
6:870-874). If the SNPs are localized within Intron 2, this leads to a transcriptional upregulation of
FGFR2 (Katoh, Expert Reviews 2010, 10:1375-1379). Interestingly, FGFR1 is upregulated
preferentially in the case of gen receptor (ER) positive breast carcinomas, while FGFR2 is
upregulated in the case of ER-negative breast omas (Katoh, Expert Reviews 2010, 10:1375-
1379).
In the case of pancreatic carcinoma, the overexpression of FGFR2 IIIb and/or FGF7 is heavily
correlated with venal invasion (Cho et al., Am. J. Pathol. 170:1964-1974), with co-expression of
FGFR2 and FGF7 having been found in tumour cells, but ing even more frequently in the
stroma cells which are adjacent to the tumour cells ata et al., Am. J. Pathol. 1998, 3-
222).
In the case of epithelial ovary cancer, 80% of cases showed upregulation of FGRF2 as compared
with normal tissue, and in 70% there was FGF7 in the ascitic fluid (Steele et al., Oncogene
:5878-5887).
The FGFR2 protein was found in all invasive al carcinomas , with strong expression at
the invasive front of the tumours (Kawase et al., Int. J. Oncol. 2010, 36:331-340).
In the case of pulmonary adenocarcinoma, co-expression of FGF7 and FGFR2 occurred in 51.6%
of cases, and is correlated with lower degrees of differentiation, higher rate of proliferation, lymph
node metastasis, and shorter 5-year survival (Yamayoshi et al., J. Pathol. 2004, 204:110-118).
In the case of endometrial carcinoma, activating FGFR2 mutations occur in approximately 16% of
cases (Pollock et al., Oncogene 2007, 26:7158-7162).
In the case of oesophageal cancer (OC), co-expression of FGF7 and FGFR2 in cancer cells was
found in 26% of patients, and was ated with a trend towards a shorter survival time (Yoshino
et al., Int. J. Oncol. 2007, 31:721-728).
In the case of liver cell carcinoma, the expression of FGFR2 was lated 4.7 times more
strongly in poorly differentiated s. This expression is ated with the incidence of portal
vein invasion and lower disease-free survival times (Harimoto et al., Oncology 2010, 78:361-368).
A number of publications, with in vitro and in vivo experimental data, show a causal connection
between altered FGFR2 signal transduction and tumour growth.
Knock-down or inhibition of FGFR2 in cells of h cancer (Takeda et al., Clin. Cancer Res.
2007; 13:3051-3057; Kunii et al., Cancer Res. 2008; 68:2340-2348), breast cancer (Turner et al.,
Oncogene 2010, 29:2013-2023), n cancer (Cole et al., Cancer Biol. Ther. 2010, 10:495-504)
and squamous carcinoma of the head and neck all et al., Clin. Cancer Res. 2011, 17:5016-
5025) led to reduced proliferation or increased apoptosis of the tumour cells. In tumour
xenotransplants as well, knock-down of FGFR2 and inhibition of FGFR2 in tumour cell lines
which press FGFR2 was observed to cause growth inhibition in stomach cancer cell lines
(Takeda et al., Clin. Cancer Res. 2007; 13:3051-3057) and ovarian cancer cell lines (Cole et al.,
Cancer Biol. Ther. 2010, 10:495-504). er, FGF7, which exclusively activates FGFR2,
increases the proliferation of stomach cancer cell lines (Shin et al., J. Cancer Res. Clin. Oncol.
2002, 128:596–602), breast cancer cell lines (Zhang et al., ncer Res. 1998, 18:2541-2546)
and ovarian cancer cell lines (Cole et al., Cancer Biol. Ther. 2010, 10:495-504) in vitro and in
vivo . Furthermore, knock-down of FGFR2 in endometrial c ancer cell lines which contain FGFR2
with activating mutations likewise led to the standstill of the cell cycle and to the induction of cell
death (Byron et al., Cancer Res. 2008, 68:6902-6907).
FGFR2 signal transduction promotes the migration and invasion of stomach cancer cell lines (Shin
et al., J. Cancer Res. Clin. Oncol. 2002, 128:596–602), breast cancer cell lines (Zhang et al.,
Anticancer Res. 1998, 1-2546) and pancreatic cancer cell lines in vitro (Nomura et al., Br. J.
Cancer 2008, 99:305-313; Niu et al., J. Biol. Chem. 2007, 282:6601-6011).
In the case of oesophageal cancer, FGFR2 is the most highly upregulated gene in tumourassociated
fibroblasts. Isolated tumour-associated fibroblasts released a e factor which
promotes the proliferation of oesophageal cancer cells (Zhang et al., hum. Cancer Biol. 2009,
:4017-4022), thereby demonstrating that FGFR2 expressed by stroma cells is also able to
promote tumour progression.
There are only a few reports on anti-FGFR2 antibodies. Fortin et al. (J. Neurosci. 2005, 25: 7470-
7479) describe a blocking anti-FGFR2 antibody. Wei et al. (Hybridoma 2006, 25: 115-124) have
shown antibodies with exclusive specificity for FGFR2 IIIb, which inhibit the KGF-induced cell
proliferation. WO2007/144893 describes inhibiting antibodies which bind FGFR2 and FGFR3. In
WO2010/054265 and in Zhao et al. (Clin. Cancer Res. 2010,16:5750-5758), antibodies which
inhibit FGF binding are described, including for example GAL-FR21 and GAL-FR22. Bai et al.
(Cancer Res. 2010, 0-7639) describe antibodies having specificity for FGFR2 IIIb. R&D
Systems market GFR2 antibodies which have an ty-neutralizing effect in the
cturer’s assays. WO2005/066211 describes dies which are directed against various
cell-surface FGFRs, including FGFR2. WO2009/100105 describes isoform-specific anti-FGFR2
antibodies which can be linked covalently to effector molecules. WO2007/134210 describes
methods for treating colorectal cancer using anti-FGFR2 antibodies or immunoconjugates.
WO2007/144893 describes FGFR2 antibodies with binding ty for further FGFRs, which
block the ligand-dependent and the constitutive ligand-independent FGFR2 receptor tion.
Auristatin E (AE) and monomethylauristatin E (MMAE) are synthetic analogues of the dolastatins,
a specific group of linear pseudopeptides which were originally isolated from marine sources and
which have in some cases very potent cytotoxic activity with respect to tumour cells [for a review
see e.g. G. R. Pettit, Prog. Chem. Org. Nat. Prod. 70, 1-79 (1997); G. R. Pettit et al., Anti-Cancer
Drug Design 10, 529-544 (1995); G. R. Pettit et al., Anti-Cancer Drug Design 13, 243-277
(1998)].
H3C CH H C
3 CH3 OH
O H
H N
R N N
N N
O O CH
CH O CH O O 3
3 3 CH3
3 CH
3 CH
Auristatin E (AE): R = CH3
Monomethylauristatin E (MMAE): R = H
MMAE, however, possesses the disadvantage of a comparatively high systemic toxicity. For
ing tumour selectivity, MMAE is used more particularly in conjunction with enzymatically
cleavable -citrulline linkers in the ADC setting for more ed tumour therapy
[-A2; S. O. Doronina et al., Bioconjugate Chem. 17, 114-124 (2006)]. Following
proteolytic ge, MMAE is released preferably intracellularly from corresponding ADCs.
Monomethylauristatin F (MMAF) is an auristatin derivative having a C-terminal alanine
unit which exhibits only moderate antiproliferative activity in comparison to MMAE. This fact is
very probably attributable to the free carboxyl group, whose ty and charge adversely affect
the capacity of this compound to access cells. In this connection, the methyl ester of MMAF
(MMAF-OMe) has been described, as a l-charged prodrug tive with cell access
capability, which, in comparison to MMAF, has an in vitro cytotoxicity for various carcinoma cell
lines that is increased by a number of orders of magnitude [S. O. Doronina et al., Bioconjugate
Chem. 17, 114-124 (2006)]. It can be d that this effect is brought about by MMAF itself,
which, following uptake of the prodrug into the cells, is rapidly released by intracellular ester
hydrolysis.
H C CH H3C CH
3 3 O
O 3 H
H N
N N O
HN N
O O
CH O CH O O
3 3 CH
3 CH
3 CH 3
Monomethylauristatin F (MMAF): R = H
Monomethylauristatin F methyl ester (MMAF-OMe): R = CH3
However, drug compounds based on simple ester tives are generally subject to the risk of
al instability on account of non-specific ester ysis, independent of the intended site of
action, by means, for example, of esterases that are present in the blood plasma; this non-specific
hydrolysis may significantly restrict the usefulness of such compounds in therapy.
Monomethylauristatin F (MMAF) and also various ester derivatives and amide derivatives thereof
have been disclosed in -A2. Further auristatin analogues with a C-terminal,
amidically substituted phenylalanine unit are described in WO 01/18032-A2. WO 02/088172-A2
and WO 08603-A1 claim MMAF analogues which relate to side-chain modifications of the
phenylalanine, while -A2 claims those in which the carboxyl group of the
alanine has been modified. Auristatin conjugates linked via the C-terminus have been
recently described in WO 17531-A1 [see also S. O. Doronina et al., Bioconjugate Chem.
19, 1960-1963 (2008)].
The problem addressed with the present invention was that of ing new binder-drug
conjugates (ADCs) which, through combination of new N,N-dialkylauristatin tives with
innovative, suitable linkers and binder, exhibit a very attractive activity e, such as, for
example, in terms of their specific tumour effect and/or the reduced potential of the metabolites
formed intracellularly to be a substrate with respect to transporter proteins, and which are therefore
suitable for the treatment and/or prophylaxis of hyperproliferative and/or angiogenic diseases, such
as cancer diseases, for example.
- 9 –
the group -B- L2 -§§ is a linker,
where
WO 87716
where two carbon atoms of the alkanediyl chain in 1,2-, 1,3- or 1,4-relation to one
another, with inclusion of any carbon atoms situated between them, may be
bridged to form a (C3-C6)-cycloalkyl ring or a phenyl ring,
D is a group of the formula
O #3 T1 #3 R5
N or
#3 R3 R4
O , R26 T2
R1 R2
where
#3 marks the linkage site with the nitrogen atom,
R1 is hydrogen or methyl,
R2 is isopropyl, isobutyl, sec-butyl, tert-butyl, phenyl, benzyl, oxyethyl,
4-hydroxybenzyl, 4-hydroxynitrobenzyl, 4-hydroxyaminobenzyl,
1-phenylethyl, diphenylmethyl, dazolylmethyl or 1H-indol
ylmethyl,
R1 and R2 together with the carbon atom to which they are bonded form a
(1S,2R)phenylcyclopropane-1,1-diyl group of the formula
#4 #5
in which
#4 marks the linkage site with the adjacent nitrogen atom,
#5 marks the linkage site with the carbonyl group,
the ring A with the N-O moiety present therein is a mono- or ic, optionally substituted
heterocycle of the formula
O or O
O O
N N N N
#6 , #6 , #6 #6
in which
#6 marks the linkage site with the carbonyl group,
R6 is hydrogen, hydroxy or benzyloxy,
R3 is hydrogen or methyl,
R4 is isopropyl, isobutyl, sec-butyl, utyl, phenyl, , 1-hydroxyethyl,
4-hydroxybenzyl, 4-hydroxynitrobenzyl, 4-hydroxyaminobenzyl,
1-phenylethyl, diphenylmethyl, 1H-imidazolylmethyl or 1H-indol
ylmethyl,
R3 and R4 together with the carbon atom to which they are bonded form a (1S,2R)
phenylcyclopropane-1,1-diyl group of the formula
#7 #8
in which
#7 marks the e site with the adjacent nitrogen atom,
#8 marks the linkage site with the group T1,
T1 is a group of the formula -C(=O)-OR7, -C(=O)-NR8R9, -C(=O)-NH-NH-R10
or -CH2-O-R11,
in which
R7 is hydrogen, methyl, ethyl, n-propyl, tert-butyl, benzyl or
adamantylmethyl,
R8 is hydrogen or methyl,
R9 is hydrogen, methyl, ethyl, n-propyl or benzyl,
R8 and R9 together with the nitrogen atom to which they are bonded form a
4- to 7-membered cycle,
R10 is benzoyl,
R11 is benzyl, which may be substituted in the phenyl group by
methoxycarbonyl or yl,
R5 is hydrogen, methyl or a group of the formula
#9 O #9 S
, ,
#9 R13
#9 #9 or
R12 R12
, N N
in which
#9 marks the linkage site with –CHC(R26)-T2,
R12 is phenyl which may be substituted by methoxycarbonyl, carboxyl
or a group of the a –S(O)2OH,
R13 is phenyl which may be substituted by methoxycarbonyl or
carboxyl,
R26 is en or hydroxy,
T2 is phenyl, benzyl, 1H-indolyl or 1H-indolylmethyl,
R35 is methyl or hydroxy,
(followed by page 13A)
and also their salts, solvates and solvates of the salts.
In a preferred ment
AK is a binder which is an antibody or an antigen-binding antibody fragment that binds to FGFR2.
In another preferred embodiment
G is a carbonyl or a group of the formula
O O HO
#1 #1 #2 O
N H
N #2 H #1 N #2
O ,
OH O
or #1
where
#1 marks the linkage site with the sulphur atom of the binder,
#2 marks the linkage site with the group L1,
L1 is a bond, linear (C1-C10)-alkanediyl, or a group of the formula
##1 ##2
O m or ##1 L1A B1 L1B ##2
where
m is a number from 2 to 6,
## 1 marks the e site with the group G,
##2 marks the linkage site with the group B,
(followed by page 13B)
L1A is linear (C2-C10)-alkanediyl,
B1 is a group of the formula
O O O
##5 ##6 L5 ##6
N N ##5 N N L6
R29 R30 , R31 R32
or S ##6
##5 S
in which
## 5 marks the linkage site with the group L1A,
## 6 marks the linkage site with the group L1B,
L5 is a bond or (C2-C4)-alkanediyl,
L6 is a bond or a group of the formula
R33 HN
HN O
O ##8 or ##8
##7 ##7
R34 O
in which
## 7 marks the linkage site with the carbonyl group,
## 8 marks the linkage site with L1B,
R33 is hydrogen, )-alkylcarbonyl, tert-butyloxycarbonyl, or
benzyloxycarbonyl,
R34 is hydrogen or methyl,
wed by page 13C)
R29 is hydrogen or (C1-C4)-alkyl,
R30 is hydrogen or (C1-C4)-alkyl,
R29 and R30 together with the atoms to which they are bonded form a 5- or
6-membered heterocycle,
R31 is hydrogen or (C1-C4)-alkyl,
R32 is hydrogen or (C1-C4)-alkyl,
R31 and R32 together with the atoms to which they are bonded form a 5- or
6-membered heterocycle,
L1B is linear (C2-C10)-alkanediyl,
where (C2-C10)-alkanediyl is optionally substituted by 1 to 4 substituents selected
independently of one another from the group ting of methyl, hydroxy and benzyl,
where two carbon atoms of the alkanediyl chain in 1,2, 1,3 or 1,4-relation to one
r, with inclusion of any carbon atoms situated between them, are optionally
bridged to form a (C3-C6)-cycloalkyl ring or a phenyl ring,
B is a bond or a group of the formula
(followed by page 13D)
O O O O
* ** L3 ** O **
N N * N N L4 * Q1
R14 R15 R16 R17 O
, , ,
R20 O
* P ** * N **
Q2 * **
O , R18 R19 O , R21 R22 ,
O O R36
O ** ** or
* N * N O **
H *
R23 R24 O R27
, R37 O
where
* marks the linkage site with L1,
** marks the linkage site with L2,
P is O or NH,
L3 is a bond or )-alkanediyl,
L4 is a bond or a group of the formula
R28 HN
HN O
O **** or *** ****
R25 O
in which
(followed by page 13E)
*** marks the linkage site with the carbonyl group,
**** marks the linkage site with L2,
R25 is hydrogen or methyl,
R28 is hydrogen, (C1-C4)-alkylcarbonyl, tert-butyloxycarbonyl, or
benzyloxycarbonyl,
Q1 is a 4- to 7-membered heterocycle,
Q2 is a 3- to 7-membered carbocycle or a 4- to 7-membered heterocycle,
R14 is hydrogen or (C1-C4)-alkyl,
R15 is hydrogen or (C1-C4)-alkyl,
R14 and R15 together with the atoms to which they are bonded form a 5- or 6-
membered cycle,
R16 is hydrogen or (C1-C4)-alkyl,
R17 is hydrogen or (C1-C4)-alkyl,
R16 and R17 together with the atoms to which they are bonded form a 5- or 6-
ed heterocycle,
R18 is hydrogen or (C1-C4)-alkyl,
R19 is hydrogen or the side group of a natural o acid or of its homologues or
isomers,
R20 is hydrogen or (C1-C4)-alkyl,
(followed by page 13F)
R19 and R20 together with the atoms to which they are bonded form a pyrrolidinyl
ring,
R21 is hydrogen or (C1-C4)-alkyl,
R22 is hydrogen or (C1-C4)-alkyl,
R21 and R22 together with the atoms to which they are bonded form a 3- to 7-
membered carbocycle,
R23 is (C1-C4)-alkyl,
R24 is hydrogen or (C1-C4)-alkyl,
R27 is hydrogen or (C1-C4)-alkyl,
R36 is en, (C1-C4)-alkylcarbonyl, tert-butyloxycarbonyl, or benzyloxycarbonyl
R37 is hydrogen or methyl,
R36 and R37 together with the atoms to which they are bonded form a pyrrolidine
ring,
and also their salts, solvates and solvates of the salts.
wed by page 14)
reproduced in the g examples, by using corresponding isotopic modifications of the
tive reagents and/or starting compounds.
Preferred salts in the context of the present invention are physiologically acceptable salts of the
nds of the invention. Also encompassed are salts which gh themselves not suitable
for pharmaceutical applications may nevertheless be used, for example, for isolating or ing
the compounds of the invention.
Physiologically acceptable salts of the compounds of the invention encompass acid addition salts
of mineral acids, carboxylic acids and sulphonic acids, examples being salts of hydrochloric acid,
hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, ethanesulphonic acid,
benzenesulphonic acid, toluenesulphonic acid, naphthalenedisulphonic acid, acetic acid,
oroacetic acid, propionic acid, lactic acid, tartaric acid, malic acid, citric acid, fumaric acid,
maleic acid and benzoic acid.
Physiologically acceptable salts of the compounds of the invention also encompass salts of
customary bases, such as, by way of example and preferably, alkali metal salts (e.g. sodium and
potassium salts), alkaline earth metal salts (e.g. calcium and magnesium salts) and ammonium
salts, d from ammonia or organic amines having 1 to 16 C atoms, such as, by way of
example and preferably, ethylamine, diethylamine, triethylamine, ethyldiisopropylamine,
monoethanolamine, diethanolamine, triethanolamine, dicyclohexylamine, ylaminoethanol,
procaine, dibenzylamine, N-methylpiperidine, N-methylmorpholine, arginine, lysine and 1,2-
ethylenediamine.
Solvates in the context of the invention are those forms of the compounds of the invention that
form a complex in the solid or liquid state through coordination with solvent molecules. es
are one ic form of solvates, in which the coordination takes place with water. Preferred
solvates in the t of the t invention are hydrates.
Furthermore, the present invention also asses prodrugs of the compounds of the invention.
The term “prodrugs” here identifies compounds which may themselves be biologically active or
inactive but are converted during their residence in the body into compounds of the invention (by
metabolism or hydrolysis, for example).
In the context of the present ion the definitions of the substituents, unless otherwise
specified, are as follows:
(C 1-C4)-Alkyl in the context of the invention is a linear or branched alkyl radical having 1 to 4
carbon atoms. By way of example and with preference, the following may be mentioned: methyl,
ethyl, n-propyl, isopropyl, l, isobutyl, 1-methylpropyl and tert -butyl.
Alkanediyl in the context of the invention is a linear, α,ω-divalent alkyl radical having the
ular number of carbon atoms indicated. By way of example and of preference, the following
may be mentioned: methylene, -1,2-diyl (1,2-ethylene), propane-1,3-diyl (1,3-propylene),
butane-1,4-diyl (1,4-butylene), pentane-1,5-diyl entylene), hexane-1,6-diyl (1,6-hexylene),
heptane-1,7-diyl (1,7-hexylene), octane-1,8-diyl (1,8-octylene), nonane-1,9-diyl (1,9-nonylene),
decane-1,10-diyl decylene).
(C 3-C7)-Cycloalkyl and 3- to 7-membered carbocycle respectively in the context of the invention is
a clic, saturated cycloalkyl group having 3 to 7 carbon atoms. By way of example and of
preference, the following may be mentioned: cyclopropyl, cyclobutyl, entyl, cyclohexyl and
cycloheptyl.
The side group of an α-amino acid in the definition of R19 encompasses not only the side groups of
the naturally occurring α-amino acids but also the side groups of homologues and isomers of these
α-amino acids. The α-amino acid here may be in the L or D configuration or else may be present
as a mixture of the L and D forms. Examples that may be given of side groups are as follows:
methyl (alanine), propanyl (valine), yl (norvaline), 2-methylpropanyl (leucine),
1-methylpropanyl (isoleucine), 1-yl (norleucine), tert -butyl (2-tert -butylglycine), phenyl
(2-phenylglycine), benzyl (phenylalanine), p-hydroxybenzyl (tyrosine), indolylmethyl (tryptophan
), imidazolylmethyl (histidine), hydroxymethyl e), 2-hydroxyethyl (homoserine),
1-hydroxyethyl (threonine), mercaptomethyl (cysteine), methylthiomethyl (S-methylcysteine),
2-mercaptoethyl (homocysteine), 2-methylthioethyl (methionine), carbamoylmethyl (asparagine),
2-carbamoylethyl (glutamine), carboxymethyl (aspartic acid), 2-carboxyethyl (glutamic acid),
4-aminobutanyl (lysine), ohydroxybutanyl (hydroxylysine), 3-aminopropanyl
hine), oethyl (2,4-diaminobutyric acid), aminomethyl (2,3-diaminopropionic acid),
3-guanidinopropanyl (arginine), 3-ureidopropanyl (citrulline). Preferred α-amino acid side
groups in the definition of R19 are methyl (alanine), propanyl (valine), ylpropanyl
ne), benzyl (phenylalanine), olylmethyl (histidine), hydroxymethyl (serine),
1-hydroxyethyl (threonine), 4-aminobutanyl e), 3-aminopropanyl (ornithine),
2-aminoethyl (2,4-diaminobutyric acid), aminomethyl (2,3-diaminopropionic acid),
3-guanidinopropanyl (arginine). The L configuration is preferred in each case.
A 4- to 7-membered heterocycle in the context of the invention is a monocyclic, saturated
heterocycle having a total of 4 to 7 ring atoms, which contains one or two ring heteroatoms from
the series N, O, S, SO and/or SO2 and is linked via a ring carbon atom or optionally a ring en
atom. Preference is given to a 5- to 7-membered heterocycle having one or two ring heteroatoms
from the series N, O and/or S, more preferably a 5- or 6-membered heterocycle having one or two
ring heteroatoms from the series N and/or O. By way of example, the following may be mentioned:
azetidinyl, oxetanyl, pyrrolidinyl, pyrazolidinyl, tetrahydrofuranyl, thiolanyl, piperidinyl,
piperazinyl, tetrahydropyranyl, ydrothiopyranyl, linyl, thiomorpholinyl,
hexahydroazepinyl and hexahydro-1,4-diazepinyl. ence is given to pyrrolidinyl, tetrahydrofuranyl
, piperidinyl, piperazinyl, tetrahydropyranyl and morpholinyl.
In the formula of the group which may be represented by A, B, D, G, L1, L2, L4, R1, R2, R3, R4 and R5,
respectively, the end point of the line at which the symbol #6, *, **, #3, #1, #2, ##1, ##2, ##3, ##4, ***,
****, #4, #5, #6, #7, #8 or #9 is located is not a carbon atom or a CH2 group, but instead is part of the
bond to the atom designated in each case, to which the A, B, D, G, L1, L2, L4, R1, R2, R3, R4 or R5 is
bonded.
In the context of the present invention, all radicals which occur multiply have their definition
ndently of one another. If radicals in the compounds of the invention are substituted, the
radicals, unless ise specified, may be substituted one or more times. Substitution by one or
by two cal or different substituent(s) is preferred. ularly preferred is substitution by one
substituent.
In the context of the present invention the terms used, unless otherwise specified, have the
ing definitions:
The term r” is understood in the st sense as a chemical unit which comprises a
covalent bond or a series of atoms that links a binder covalently to a drug. The term “linker” is
understood preferably as a series of atoms in the sense of the t invention that links a binder
covalently to a drug. Furthermore, linkers may be represented, for example, by divalent chemical
units, such as alkyldiyls, aryldiyls, heteroaryldiyls, heterocyclyldiyls, dicarbonyl acid esters,
onyl acid amides.
The term “binder” is understood in the broadest sense as a molecule which binds to a target
molecule which is present on a particular target cell population to be addressed with the binder-
drug conjugate. The term “binder” should be understood in its broadest interpretation and
encompasses, for example, s, proteins which are able to bind particular sugar chains, or
phospholipid-binding proteins. Such binders comprise, for example, high molecular mass proteins
(binding proteins), polypeptides or peptides (binding es), non-peptidic (e.g. aptamers
(US5,270,163) review article by Keefe AD., et al., Nat. Rev. Drug Discov. 2010; 9:537-550), or
vitamins) and all other cell-binding molecules or substances. Binding proteins are, for example,
antibodies and dy fragments or antibody mimetics such as, for example, affibodies,
adnectins, anticalins, DARPins, avimers, nanobodies w articles by Gebauer M. et al., Curr.
Opinion in Chem. Biol. 2009; 13:245-255; Nuttall S.D. et al., Curr. Opinion in Pharmacology
2008; 8:608-617). Binding peptides are, for example, ligands of a ligand-receptor pair, such as
VEGF in the ligand-receptor pair VEGF/KDR, such as transferrin of the ligand-receptor pair
transferrin/transferrin receptor, or cytokines/cytokine receptor, such as TNFalpha in the ligand
or pair TNFalpha/TNFalpha receptor.
The term “epitope” as used herein encompasses any determinants of a protein that are able to bind
specifically to an immunoglobulin or T-cell receptor. Such determinants commonly consist of
chemically active surface arrangements of molecules, such as amino acids, carbohydrates or a
ation thereof, for example, which commonly have a specific dimensional structure
and also defined charge properties. Two antibodies bind to the same epitope if it is shown in a
competitive g assay format that the first antibody es with the second antibody.
Binding assays of this kind are known to the d person.
A “target molecule” is understood in the st sense to be a molecule which is present in the
target cell population, and may be a protein (e.g. a receptor of a growth factor) or a non-peptidic
molecule (e.g. a sugar or phospholipid). Preferably it is a receptor or an antigen.
The term “extracellular” target molecule describes a target molecule which is attached to the cell
and which is located on the outside of a cell or the part of a target molecule which is located on the
outside of a cell, i.e. a binder may bind to an intact cell at its extracellular target molecule. An
extracellular target molecule may be anchored in the cell membrane or may be part of the cell
membrane. The skilled person knows of methods for identifying extracellular target molecules.
For proteins this may be done via determination of the transmembrane domain(s) and the
orientation of the protein in the membrane. This data is generally recorded in protein databases
(e.g. SwissProt).
The term “cancer target molecule” describes a target molecule which is multiply present on one or
more cancer cell types in comparison to non-cancer cells of the same tissue type. The cancer target
molecule is ably present selectively on one or more cancer cell types in comparison to non-
cancer cells of the same tissue type, with “selectively” describing an at least twofold accumulation
on cancer cells in ison to non-cancer cells of the same tissue type (a “selective cancer target
molecule”). The use of cancer target molecules allows selective therapy of cancer cells with the
conjugates of the invention.
The binder may be linked via a bond to the linker. The g of the binder may take place by
means of a heteroatom of the binder. Inventive heteroatoms of the binder that may be used for
linking are sulphur (in one embodiment via a sulphhydryl group of the binder), oxygen (in
accordance with the invention by means of a carboxyl or hydroxy group of the binder) and
nitrogen (in one embodiment via a primary or ary amine group or amide group of the
binder). These heteroatoms may be present in the natural binder or may be introduced by means of
methods of chemistry or molecular biology. In accordance with the invention, the linking of the
binder to the toxophore has little influence over the binding activity of the binder to the target
molecule. In a red embodiment the linking has no influence on the binding activity of the
binder to the target molecule.
The term “antibody” is understood in accordance with the present invention in its broadest sense
and encompasses immunoglobulin molecules, examples being intact or modified monoclonal
antibodies, polyclonal antibodies or multispecific antibodies (e.g. bispecific antibodies). An
immunoglobulin molecule preferably comprises a molecule having four polypeptide chains, two
heavy chains (H chains) and two light chains (L chains), which are linked typically by disulphide
bridges. Each heavy chain comprises a le domain of the heavy chain (abbreviated to VH)
and a constant domain of the heavy chain. The constant domain of the heavy chain may
encompass, for example, three domains CH1, CH2 and CH3. Each light chain comprises a variable
domain (abbreviated to VL) and a nt domain. The constant domain of the light chain
comprises one domain (abbreviated to CL). The VH and VL domains may be further subdivided
into regions having hypervariability, also called complementarity-determining s viated
to CDR), and regions having a low sequence ility ework region”, abbreviated to FR).
Each VH and VL region is typically composed of three CDRs and up to four FRs. For example, in
the following order from the amino terminus to the carboxy us: FR1, CDR1, FR2, CDR2,
FR3, CDR3, FR4. An antibody may be obtained from any species suitable for the antibody, such
as, for example, rabbit, llama, camel, mouse or rat. In one embodiment the antibody is of human or
murine origin. An antibody may for example be human, humanized or chimeric.
The term lonal” antibody identifies antibodies which have been obtained from a population
of ntially neous antibodies, i.e. individual antibodies of the population are identical
except for naturally ing mutations which may occur in small numbers. Monoclonal
dies recognize a single antigenic binding site with a high specificity. The term “monoclonal
antibody” does not refer to a particular production method.
The term “intact” antibody refers to antibodies which comprise not only an antigen-binding
domain but also the constant domain of the light and heavy chain. The constant domain may be a
naturally occurring , or a variant thereof in which a plurality of amino acid positions have
been altered.
The term “modified ” antibody refers to intact antibodies which have been fused with another
polypeptide or protein, not originating from an antibody, via the amino terminus or carboxyl
terminus thereof, by means of a covalent bond (e.g. a peptide linkage). rmore, dies
may be modified by introducing reactive cysteines at defined locations, in order to facilitate
coupling to a toxophore (see Junutula et al. Nat Biotechnol. 2008 Aug;26(8):925-32).
2012/075277
The term “human” dy identifies antibodies which can be obtained from a human being or are
synthetic human antibodies. A etic” human antibody is an antibody which in parts or as a
whole is obtainable from tic sequences in silico which are based on the analysis of human
antibody sequences. A human antibody may be encoded, for example, by a nucleic acid which has
been isolated from a library of antibody sequences which are of human . One example of
such antibodies can be found in Söderlind et al., Nature Biotech. 2000, 18:853-856.
The term “humanized” or “chimeric” antibody describes antibodies which consist of a non-human
and of a human sequence component. In these antibodies, part of the sequences of the human
immunoglobulin (recipient) is replaced by sequence components of a non-human immunoglobulin
(donor). In many cases the donor is a murine immunoglobulin. With humanized antibodies, amino
acids of the CDR in the ent are replaced by amino acids of the donor. In some cases, amino
acids of the framework as well are replaced by corresponding amino acids of the donor. In some
cases the humanized antibody contains amino acids which were present neither in the ent nor
in the donor and which were inserted during the optimization of the antibody. In the case of
chimeric antibodies, the le domains of the donor immunoglobulin are fused with the constant
regions of a human antibody.
The term complementarity-determining region (CDR) as used here refers to those amino acids in a
variable antibody domain that are necessary for binding to the n. Every variable region
typically has three CDR regions, identified as CDR1, CDR2 and CDR3. Each CDR region may
comprise amino acids according to the definition of Kabat and/or amino acids of a hypervariable
loop, defined according to Chotia. The tion according to Kabat encompasses, for example,
the region of approximately amino acid position 24 – 34 (CDR1), 50 – 56 (CDR2) and 89 – 97
(CDR3) of the variable light chain and 31 – 35 (CDR1), 50 – 65 (CDR2) and 95 – 102 (CDR3) of
the variable heavy chain (Kabat et al., Sequences of Proteins of Immulological Interest, 5th Ed.
Public Health e, National Institutes of , Bethesda, MD. (1991)). The definition
according to Chotia encompasses, for example, the region of approximately amino acid position
26 – 32 , 50 – 52 (CDR2) and 91 – 96 (CDR3) of the variable light chain and 26 – 32
(CDR1), 53 – 55 (CDR2) and 96 – 101 (CDR3) of the variable heavy chain Chothia and Lesk; J
Mol Biol 196: 901-917 (1987)). In some cases a CDR may comprise amino acids from one CDR
region as defined by Kabat and Chotia.
Depending on the amino acid sequence of the constant domain of the heavy chain, antibodies may
be d into different classes. There are five main classes of intact antibodies: IgA, IgD, IgE,
IgG and IgM, and a number of them may be broken down into further subclasses (isotypes), e.g.
IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2. The constant domains of the heavy chain that correspond
to the different classes are identified as [alpha/α], [delta/δ], [epsilon/ε], [gamma/γ] and [mu/ µ].
Both the three-dimensional structure and the t ure of antibodies are known.
The term ional fragment” or “antigen-binding antibody fragments” of a
dy/immunoglobulin is defined as a fragment of an antibody/immunoglobulin (e.g. the
variable domains of an IgG) which further encompasses the antigen binding domains of the
antibody/immunoglobulin. The “antigen binding domain” of an antibody typically encompasses
one or more hypervariable regions of an antibody, e.g. the CDR, CDR2 and/or CDR3 region.
r, the work” or old” region of an antibody may also play a part with regard to
the binding of the antibody to the antigen. The framework region forms the scaffold for the CDRs.
The antigen-binding domain preferably encompasses at least amino acids 4 to 103 of the variable
light chain and amino acid 5 to 109 of the variable heavy chain, more preferably amino acid 3 to
107 of the le light chain and 4 to 111 of the variable heavy chain, particular preference being
given to the complete variable light and heavy chains, i.e. amino acid 1 – 109 of the VL and 1 to
113 of the VH (numbering according to 8320).
“Functional fragments” or “antigen-binding antibody fragments” of the invention encompass, nonconclusively
, Fab, Fab’, F(ab’)2 and Fv fragments, diabodies, Single Domain Antibodies (DAbs),
linear antibodies, individual chains of antibodies (single-chain Fv, abbreviated to ScFv); and
multispecific antibodies, such as bi and tri-specific antibodies, for example, formed from antibody
nts C. A. K Borrebaeck, editor (1995) Antibody Engineering (Breakthroughs in Molecular
Biology), Oxford University Press; R. Kontermann & S. Duebel, editors (2001) Antibody
Engineering (Springer Laboratory Manual), Springer Verlag). Antibodies other than
“multispecific” or “multifunctional” dies are those having identical binding sites.
Multispecific antibodies may be specific for different epitopes of an antigen or may be specific for
epitopes of more than one antigen (see, for example WO 93/17715; WO 92/08802; WO 60;
WO 92/05793; Tutt, et al., 1991, J. Immunol. 147:60 69; U. S. Pat. Nos. 4,474,893; 4,7 14,68 1;
4,925,648; 920; 5,601,8 19; or Kostelny et al., 1992, J. Immunol. 148: 1547 1553). An
F(ab’) 2 or Fab molecule may be constructed such that the number of intermolecular disulphide
interactions occurring between the Ch1 and the CL domains can be reduced or else completely
prevented.
“Functional fragments” or “antigen-binding antibody fragments” may be fused with another
polypeptide or protein, not originating from an dy, via the amino terminus or carboxyl
terminus thereof, by means of a covalent bond (e.g. a e linkage). Furthermore, antibodies
and antigen-binding fragments may be modified by introducing reactive cysteines at defined
locations, in order to facilitate coupling to a toxophore (see la et al. Nat Biotechnol. 2008
Aug;26(8):925-32).
2012/075277
Polyclonal dies can be prepared by methods known to a person of ordinary skill in the art.
Monoclonal antibodies may be prepared by methods known to a person of ordinary skill in the art
(Köhler and Milstein, Nature, 256, 495-497, 1975). Human and humanized onal antibodies
may be prepared by methods known to a person of ordinary skill in the art (Olsson et al., Meth
Enzymol. 92, 3-16 or Cabilly et al US 567 or Boss et al US 4,816,397).
A person of ordinary skill in the art is aware of diverse methods for preparing human antibodies
and fragments thereof, such as, for example, by means of transgenic mice (N Lonberg and
D Huszar, Int Rev Immunol. 1995;13(1):65-93) or Phage Display Technologies (Clackson et al.,
Nature. 1991 Aug 15;352(6336):624-8). Antibodies of the invention may be obtained from
recombinant antibody libraries consisting for example of the amino acid sequences of a
multiplicity of dies compiled from a large number of healthy volunteers. Antibodies may
also be produced by means of known recombinant DNA technologies. The nucleic acid sequence
of an antibody can be obtained by routine sequencing or is available from publically accessible
databases.
An “isolated” antibody or binder has been purified to remove other constituents of the cell.
Contaminating constituents of a cell which may interfere with a stic or therapeutic use are,
for example, enzymes, hormones, or other peptidic or ptidic constituents of the cell. A
preferred antibody or binder is one which has been purified to an extent of more than 95%, relative
to the antibody or binder mined for example by Lowry method, UV-Vis spectroscopy or by
SDS ary gel electrophoresis). Furthermore an antibody which has been ed to such an
extent that it is possible to determine at least 15 amino acids of the amino terminus or of an
al amino acid sequence, or which has been purified to homogeneity, the homogeneity being
determined by SDS-PAGE under reducing or non-reducing conditions (detection may be
determined by means of Coomassie Blau staining or preferably by silver tion). However, an
antibody is normally prepared by one or more purification steps.
The term “specific binding” or “binds specifically” refers to an antibody or binder which binds to a
predetermined antigen/target le. Specific binding of an antibody or binder typically
describes an antibody or binder having an affinity of at least 10-7 M, with the antibody or binder
having an at least two times higher affinity for the ermined antigen/target molecule than for
a non-specific n/target molecule (e.g. bovine serum albumin, or casein) which is not the
ermined antigen/target molecule or a closely related antigen/target molecule.
Antibodies which are specific t a cancer cell antigen can be prepared by a person of ordinary
skill in the art by means of methods with which he or she is familiar (such as recombinant
expression, for example) or may be acquired commercially (as for example from Merck KGaA,
Germany). Examples of known commercially available antibodies in cancer therapy are Erbitux®
(cetuximab, Merck KGaA), Avastin® (bevacizumab, Roche) and Herceptin® (trastuzumab,
Genentech). Trastuzumab is a recombinant humanized monoclonal antibody of the IgG1kappa type
which in a cell-based assay (Kd = 5 nM) binds the ellular domains of the human epidermal
growth receptor with high affinity. The antibody is produced inantly in CHO cells.
A preferred subject of the invention are binder-drug ates of the general formula (Ia) in
which
n is a number from 1 to 50,
AK is AK1 or AK2
where
AK1 is a binder which binds FGFR2 and is bonded via a sulphur atom of the binder to
the group G,
AK2 is a binder which binds FGFR2 and is bonded via a nitrogen atom of the binder to
the group G,
G when AK = AK1, is a group of the formula
O O HO
#1 #1 #2 O
N H
N #2 H #1 N #2
O ,
OH O
or #1
O
where
#1 marks the linkage site with the sulphur atom of the binder,
#2 marks the linkage site with the group L1,
when AK = AK2, is carbonyl,
L1 is a bond, linear (C1-C10)-alkanediyl, a group of the formula
##1 ##2
O m or ##1 L1A B1 L1B ##2
where
m is a number from 2 to 6,
## 1 marks the linkage site with the group G,
##2 marks the linkage site with the group B,
L1A is linear (C2-C10)-alkanediyl,
B1 is a group of the formula
O O O
##5 ##6 L5 ##6
N N ##5 N N L6
R29 R30 , R31 R32
or S ##6
##5 S
in which
## 5 marks the linkage site with the group L1A,
## 6 marks the e site with the group L1B,
L5 is a bond or (C2-C4)-alkanediyl,
L6 is a bond or a group of the formula
R33 HN
HN O
O ##8 or ##8
##7 ##7
R34 O
in which
## 7 marks the e site with the carbonyl group,
## 8 marks the linkage site with L1B ,
R33 is hydrogen, (C1-C4)-alkylcarbonyl, tert-butyloxycarbonyl or
benzyloxycarbonyl,
R34 is hydrogen or methyl,
R29 is hydrogen or (C1-C4)-alkyl,
R30 is hydrogen or (C1-C4)-alkyl,
R29 and R30 together with the atoms to which they are bonded form a 5- or 6-
membered heterocycle,
R31 is hydrogen or (C1-C4)-alkyl,
R32 is hydrogen or (C1-C4)-alkyl,
R31 and R32 together with the atoms to which they are bonded form a 5- or 6-
membered heterocycle,
L1B is linear 0 )-alkanediyl,
where (C1-C10 )-alkanediyl may be substituted by 1 to 4 substituents selected
independently of one another from the group consisting of , hydroxy and
benzyl,
where two carbon atoms of the diyl chain in 1,2, 1,3 or 1,4-relation to one
another, with inclusion of any carbon atoms situated between them, may be
bridged to form a (C3-C6)-cycloalkyl ring or a phenyl ring,
B is a bond or a group of the formula
O O O O
* ** L3 ** O **
N N * N N L4 * Q1
R14 R15 R16 R17 O
, , ,
R20 O
* P ** * N **
Q2 * **
O , R18 R19 O , R21 R22 ,
O O R36
O ** ** or
N * N O **
H *
R23 R24 O R27
, R37 O
where
* marks the linkage site with L1,
** marks the linkage site with L2,
P is O or NH,
L3 is a bond or (C2-C4)-alkanediyl,
L4 is a bond or a group of the formula
R28 HN
HN O
O **** or *** ****
R25 O
in which
*** marks the linkage site with the carbonyl group,
**** marks the linkage site with L2,
R25 is en or methyl,
R28 is en, (C1-C4)-alkylcarbonyl, utyloxycarbonyl or
benzyloxycarbonyl,
Q1 is a 4- to 7-membered heterocycle,
Q2 is a 3- to 7-membered carbocycle or a 4- to 7-membered heterocycle,
R14 is hydrogen or (C1-C4)-alkyl,
R15 is hydrogen or (C1-C4)-alkyl,
R14 and R15 together with the atoms to which they are bonded form a 5- or 6-membered
heterocycle,
R16 is hydrogen or (C1-C4)-alkyl,
R17 is hydrogen or (C1-C4)-alkyl,
R16 and R17 together with the atoms to which they are bonded form a 5- or 6-membered
cycle,
R18 is hydrogen or (C1-C4)-alkyl,
R19 is hydrogen or the side group of a natural α-amino acid or of its homologues or
isomers,
R20 is hydrogen or )-alkyl,
R19 and R20 together with the atoms to which they are bonded form a pyrrolidinyl ring,
R21 is hydrogen or (C1-C4)-alkyl,
R22 is hydrogen or (C1-C4)-alkyl,
R21 and R22 together with the atoms to which they are bonded form a 3- to 7-membered
carbocycle,
R23 is (C1-C4)-alkyl,
R24 is hydrogen or (C1-C4)-alkyl,
R27 is hydrogen or (C1-C4)-alkyl,
R36 is hydrogen, (C1-C4)-alkylcarbonyl, tert-butyloxycarbonyl or benzyloxycarbonyl,
R37 is en or methyl,
R36 and R37 together with the atoms to which they are bonded form a
idine ring,
L2 is linear (C2-C10)-alkanediyl or is a group of the formula
##3 ##4
O p
where
p is a number from 2 to 6,
## 3 marks the linkage site with the group B,
##4 marks the linkage site with the nitrogen atom,
where (C2-C10)-alkanediyl may be substituted by 1 to 4 substituents selected independently
of one another from the group consisting of methyl, hydroxy and benzyl,
where two carbon atoms of the alkanediyl chain in 1,2, 1,3 or 1,4-relation to one another,
with inclusion of any carbon atoms situated between them, may be d to form a
(C3-C6)-cycloalkyl ring or a phenyl ring,
D is a group of the formula
O #3 R5
#3 T1
N or
#3 R3 R4
O , R26 T2
R1 R2
in which
#3 marks the e site with the nitrogen atom,
R1 is hydrogen or methyl,
R2 is isopropyl, isobutyl, sec-butyl, tert-butyl, phenyl, benzyl, 1-hydroxyethyl, 4-
ybenzyl, 4-hydroxynitrobenzyl, 4-hydroxyaminobenzyl, 1-phenylethyl
, diphenylmethyl, 1H-imidazolylmethyl or 1H-indolylmethyl,
R1 and R2 together with the carbon atom to which they are bonded form a )
phenylcyclopropane-1,1-diyl group of the formula
#4 #5
in which
#4 marks the linkage site with the adjacent nitrogen atom,
#5 marks the linkage site with the carbonyl group,
the ring A with the N-O moiety present therein is a mono- or bicyclic, optionally
substituted heterocycle of the formula
O O O or
N N N N
#6 , #6 , #6 #6
in which
#6 marks the linkage site with the yl group,
R6 is hydrogen, hydroxy or benzyloxy,
R3 is hydrogen or methyl,
R4 is isopropyl, isobutyl, sec-butyl, utyl, phenyl, benzyl, 1-hydroxyethyl, 4-
hydroxybenzyl, 4-hydroxynitrobenzyl, 4-hydroxyaminobenzyl, ylethyl
, diphenylmethyl, 1H-imidazolylmethyl or 1H-indolylmethyl,
R3 and R4 together with the carbon atom to which they are bonded form a (1S,2R)
phenylcyclopropane-1,1-diyl group of the formula
#7 #8
in which
#7 marks the linkage site with the adjacent nitrogen atom,
#8 marks the linkage site with the group T1,
T1 is a group of the formula -C(=O)-OR7, -C(=O)-NR8R9, -C(=O)-NH-NH-R10 or
-CH2-O-R11,
in which
R7 is hydrogen, methyl, ethyl, n-propyl, tert-butyl, benzyl or
adamantylmethyl,
R8 is hydrogen or methyl,
R9 is hydrogen, , ethyl, n-propyl or benzyl,
or
R8 and R9 together with the en atom to which they are bonded
form a 4- to ered heterocycle,
R10 is benzoyl,
R11 is benzyl, which may be substituted in the phenyl group by
methoxycarbonyl or carboxyl,
R5 is hydrogen, methyl or a group of the formula
#9 O #9 S
, ,
#9 R13
#9 #9 or
R12 R12
, N N
in which
#9 marks the linkage site with –CHC(R26)-T2,
R12 is phenyl which may be substituted by methoxycarbonyl, yl or a
group of the formula –S(O)2OH,
R13 is phenyl which may be substituted by methoxycarbonyl or carboxyl,
R26 is hydrogen or hydroxy,
T2 is phenyl, benzyl, 1H-indolyl or 1H-indolylmethyl,
R35 is methyl or hydroxy,
and also their salts, solvates and solvates of the salts.
Preferred subject of the invention are binder-drug conjugates of the general formula (Ia) in which
n is a number from 1 to 20,
AK is AK1 or AK2
where
AK1 is a binder which binds FGFR2 and is bonded via the sulphur atom of a ne
residue of the binder to the group G,
AK2 is a binder which binds FGFR2 and is bonded via the NH side group of a lysine
residue of the binder to the group G,
G when AK = AK1, is a group of the formula
N #2
in which
#1 marks the linkage site with the cysteine e of the binder,
#2 marks the linkage site with the group L1,
or
when AK = AK2, is carbonyl,
L1 is a bond, linear (C2-C6)-alkanediyl, a group of the formula
##1 ##2
O m or ##1 L1A B1 L1B ##2
where
m is a number from 2 to 6,
## 1 marks the linkage site with the group G,
##2 marks the linkage site with the group B,
L1A is linear (C2-C6)-alkanediyl,
B1 is a group of the formula
O O O
##5 ##6 L5 ##6
N N ##5 N N L6
R29 R30 , R31 R32
or S ##6
##5 S
in which
## 5 marks the linkage site with the group L1A,
## 6 marks the linkage site with the group L1B,
L5 is a bond,
L6 is a bond or a group of the formula
R33 HN
HN O
O ##8 or ##8
##7 ##7
R34 O
in which
## 7 marks the linkage site with the carbonyl group,
## 8 marks the linkage site with L1B,
R33 is hydrogen, carbonyl or tert-butyloxycarbonyl,
R34 is hydrogen or methyl,
R29 is hydrogen,
R30 is hydrogen,
R31 is hydrogen or methyl,
R32 is hydrogen or methyl,
L1B is linear (C2-C6)-alkanediyl,
and
where (C2-C6)-alkanediyl may be substituted by 1 or 2 methyl substituents,
B is a bond or a group of the a
O O O O
* ** L3 ** O **
N N * N N L4 * Q1
R14 R15 R16 R17 O
, , ,
R20 O O
* N ** **
* ** O
N * N
H H
R18 R19 O , R21 R22 , R23 R24 O
O R36
** or
* N O **
R37 O
where
* marks the linkage site with L1,
** marks the linkage site with L2,
L3 is a bond or ethane-1,2-diyl,
L4 is a bond or a group of the formula
R28 HN
HN O
O **** or *** ****
R25 O
in which
*** marks the linkage site with the carbonyl group,
**** marks the linkage site with L2,
R25 is hydrogen or methyl,
R28 is en, methylcarbonyl or tert-butyloxycarbonyl,
Q1 is a 4- to 7-membered heterocycle,
R14 is hydrogen,
R15 is hydrogen,
R16 is hydrogen or ,
R17 is hydrogen or methyl,
R16 and R17 together with the atoms to which they are bonded form a piperazinyl ring,
R18 is hydrogen,
R19 is hydrogen, methyl, propanyl , ylpropanyl or 1-methylpropanyl,
R20 is hydrogen or methyl,
R19 and R20 together with the atoms to which they are bonded form a pyrrolidinyl ring,
R21 is hydrogen or methyl,
R22 is hydrogen or methyl,
R21 and R22 together with the atoms to which they are bonded form a cyclopropyl ring,
R23 is methyl,
R24 is hydrogen or methyl,
R27 is hydrogen,
R36 is hydrogen, methylcarbonyl or tert-butyloxycarbonyl,
R37 is hydrogen or methyl,
R36 and R37 together with the atoms to which they are bonded form a pyrrolidine ring,
L2 is linear (C2-C6)-alkanediyl or is a group of the formula
##3 ##4
O p
where
p is a number from 2 to 6,
## 3 marks the linkage site with the group B,
##4 marks the e site with the en atom,
where (C2-C10)-alkanediyl may be substituted by 1 or 2 methyl substituents,
D is a group of the formula
O #3 R5
#3 T1
N or
#3 R3 R4
O , R26 T2
R1 R2
where
2012/075277
#3 marks the linkage site with the nitrogen atom,
R1 is hydrogen,
R2 is oxyethyl, benzyl, 4-hydroxybenzyl, 1-phenylethyl or 1H-indolylmethyl,
R1 and R2 together with the carbon atom to which they are bonded form a (1S,2R)
phenylcyclopropane-1,1-diyl group of the formula
#4 #5
in which
#4 marks the linkage site with the adjacent nitrogen atom,
#5 marks the linkage site with the carbonyl group,
the ring A with the N-O moiety present therein is a mono- or bicyclic, optionally
tuted heterocycle of the formula
O O or O
N N N N
#6 , #6 , #6 #6
in which
#6 marks the linkage site with the carbonyl group,
R6 is hydrogen, hydroxy or benzyloxy,
R3 is hydrogen,
R4 is 1-hydroxyethyl, benzyl, 4-hydroxybenzyl, 1-phenylethyl or 1H-indolylmethyl,
R3 and R4 together with the carbon atom to which they are bonded form a (1S,2R)
phenylcyclopropane-1,1-diyl group of the formula
#7 #8
in which
#7 marks the linkage site with the adjacent en atom,
#8 marks the linkage site with the group T1,
T1 is a group of the formula -C(=O)-OR7, -NR8R9, -C(=O)-NH-NH-R10 or
-CH2-O-R11,
in which
R7 is hydrogen, methyl, ethyl, n-propyl, tert-butyl, benzyl or
adamantylmethyl,
R8 is hydrogen or methyl,
R9 is en, methyl, ethyl, n-propyl or benzyl,
R8 and R9 together with the nitrogen atom to which they are bonded form a
4- to 7-membered heterocycle,
R10 is benzoyl,
R11 is , which may be substituted in the phenyl group by
ycarbonyl or carboxyl,
R5 is hydrogen, methyl or a group of the formula
#9 O #9 S
, ,
#9 R13
#9 #9 or
R12 R12
, N N
in which
#9 marks the linkage site with –CHC(R26)-T2,
R12 is phenyl which may be substituted by methoxycarbonyl, carboxyl or a
group of the formula –S(O)2OH,
R13 is phenyl which may be substituted by methoxycarbonyl or carboxyl,
R26 is hydrogen or hydroxy,
T2 is phenyl, benzyl, 1H-indolyl or 1H-indolylmethyl,
R35 is methyl or hydroxy,
and also their salts, solvates and solvates of the salts.
Preferred subject matter of the invention are -drug conjugates of the general formula (Ia), in
which
n is a number from 1 to 10,
AK is AK1 or AK2
where
AK1 is a binder which binds FGFR2 and is bonded via the sulphur atom of a cysteine
residue of the binder to the group G,
AK2 is a binder which binds FGFR2 and is bonded via the NH side group of a lysine
residue of the binder to the group G,
G when AK = AK1, is a group of the formula
N #2
in which
#1 marks the linkage site with the cysteine residue of the binder,
#2 marks the linkage site with the group L1,
when AK = AK2, is carbonyl,
L1 is a bond, linear (C2-C6)-alkanediyl, a group of the a
##1 ##2
O m
where
m is a number 2 or 3,
## 1 marks the linkage site with the group G,
##2 marks the linkage site with the group B,
where (C2-C6)-alkanediyl may be substituted by 1 or 2 methyl substituents,
B is a bond or a group of the formula
O O O
L3 ** O **
* N N L4 * Q1
R16 R17
, O ,
O O
* ** or O **
N * N
H H
R21 R22 R23 R24 O
where
* marks the linkage site with L1,
** marks the linkage site with L2,
L3 is a bond or ethane-1,2-diyl,
L4 is a bond or a group of the formula
R28 HN
HN O
O **** or *** ****
R25 O
in which
*** marks the linkage site with the carbonyl group,
**** marks the linkage site with L2,
R25 is methyl,
R28 is en, methylcarbonyl or tert-butyloxycarbonyl,
Q1 is piperidine-1,4-diyl,
R16 is hydrogen or methyl,
R17 is hydrogen or methyl,
2012/075277
R16 and R17 together with the atoms to which they are bonded form a piperazinyl ring,
R21 is hydrogen or methyl,
R22 is hydrogen or ,
or
R21 and R22 together with the atoms to which they are bonded form a cyclopropyl ring,
R23 is methyl,
R24 is hydrogen,
L2 is linear (C2-C6)-alkanediyl or is a group of the formula
##3 ##4
O p
where
p is a number from 2 to 6,
## 3 marks the linkage site with the group B,
##4 marks the linkage site with the nitrogen atom,
D is a group of the formula
O #3 T1 #3 R5
N or
#3 R3 R4
O ,
R1 R2
where
#3 marks the linkage site with the nitrogen atom,
R1 is hydrogen,
R2 is 1-hydroxyethyl, benzyl, 4-hydroxybenzyl, 1-phenylethyl or 1H-indolylmethyl,
2012/075277
R1 and R2 together with the carbon atom to which they are bonded form a (1S,2R)
phenylcyclopropane-1,1-diyl group of the formula
#4 #5
in which
#4 marks the linkage site with the adjacent nitrogen atom,
#5 marks the linkage site with the carbonyl group,
the ring A with the N-O moiety present n is a mono- or bicyclic, optionally
substituted heterocycle of the formula
O O O or O
N N N N
#6 , #6 , #6 #6
in which
#6 marks the linkage site with the carbonyl group,
R6 is hydrogen, hydroxy or benzyloxy,
R3 is hydrogen,
R4 is benzyl, 4-hydroxybenzyl, ylethyl or 1H-indolylmethyl,
R3 and R4 together with the carbon atom to which they are bonded form a (1S,2R)
phenylcyclopropane-1,1-diyl group of the formula
WO 87716
#7 #8
in which
#7 marks the linkage site with the adjacent nitrogen atom,
#8 marks the linkage site with the group T1,
T1 is a group of the formula -C(=O)-OR7, -C(=O)-NR8R9 or -CH2-O-R11,
in which
R7 is hydrogen, methyl, ethyl, n-propyl, tert-butyl, benzyl or
tylmethyl,
R8 is hydrogen or methyl,
R9 is hydrogen, methyl, ethyl, n-propyl or benzyl,
R11 is , which may be substituted in the phenyl group by
methoxycarbonyl or carboxyl,
R5 is hydrogen, methyl or a group of the formula
#9 R13
#9 #9 or
R12 R12
, N N
in which
#9 marks the linkage site with –CHCH2phenyl,
R12 is phenyl which may be substituted by methoxycarbonyl, carboxyl
or a group of the formula –S(O)2OH,
R13 is phenyl which may be substituted by methoxycarbonyl or
carboxyl,
R35 is methyl or hydroxy,
and also their salts, es and solvates of the salts.
Preferred subject matter of the present invention are -drug conjugates of the general formula
(Ia), in which
n is a number from 1 to 10,
AK is AK2,
where
AK2 is a binder which binds FGFR2 and is bonded via the NH side group of a lysine
residue of the binder to the group G,
G is carbonyl,
L1 is a bond,
B is a bond,
L2 is linear (C3-C6)-alkanediyl or is a group of the formula
##3 ##4
O p
where
p is a number 2 or 3,
## 3 marks the linkage site with the group B,
##4 marks the linkage site with the nitrogen atom,
D is a group of the formula
O #3 T1
N or
#3 R3 R4
R1 R2
where
#3 marks the linkage site with the nitrogen atom,
R1 is hydrogen,
R2 is benzyl, 4-hydroxybenzyl or olylmethyl,
R1 and R2 er with the carbon atom to which they are bonded form a (1S,2R)
phenylcyclopropane-1,1-diyl group of the formula
#4 #5
in which
#4 marks the linkage site with the adjacent nitrogen atom,
#5 marks the linkage site with the carbonyl group,
the ring A with the N-O moiety present therein is a mono- or ic, optionally
substituted heterocycle of the formula
in which
#6 marks the linkage site with the carbonyl group,
R3 is hydrogen,
R4 is benzyl, 4-hydroxybenzyl or 1H-indolylmethyl,
R3 and R4 together with the carbon atom to which they are bonded form a (1S,2R)
phenylcyclopropane-1,1-diyl group of the formula
#7 #8
in which
#7 marks the linkage site with the adjacent nitrogen atom,
#8 marks the e site with the group T1,
T1 is a group of the a -C(=O)-OR7 or -C(=O)-NR8R9
in which
R7 is hydrogen, methyl, ethyl, n-propyl, tert-butyl, benzyl or
adamantylmethyl,
R8 is hydrogen,
R9 is hydrogen or benzyl,
R35 is methyl,
and also their salts, solvates and es of the salts.
Preferred subject matter of the invention are binder-drug conjugates of the general formula (Ia), in
which
n is a number from 1 to 10,
AK is AK1,
where
AK1 is a binder which binds FGFR2 and is bonded via the sulphur atom of a cysteine
residue of the binder to the group G,
G is a group of the formula
N #2
where
#1 marks the linkage site with the cysteine residue of the binder,
#2 marks the linkage site with the group L1,
L1 is a bond, linear (C3-C5)-alkanediyl or a group of the formula
##1 ##2
O m
where
m is a number 2 or 3,
## 1 marks the linkage site with the group G,
##2 marks the linkage site with the group B,
where (C3-C5)-alkanediyl may be substituted by 1 or 2 methyl substituents,
B is a bond or a group of the a
O O
L3 **
* N N L4
R16 R17
where
* marks the linkage site with L1,
** marks the linkage site with L2,
L3 is a bond or ethane-1,2-diyl,
L4 is a bond or a group of the formula
O ****
R25 O
in which
*** marks the linkage site with the yl group,
**** marks the e site with L2,
R25 is methyl,
R28 is hydrogen, methylcarbonyl or tert-butyloxycarbonyl,
R16 is hydrogen or methyl,
R17 is hydrogen or methyl,
R16 and R17 together with the atoms to which they are bonded form a piperazinyl ring,
L2 is linear (C3-C5)-alkanediyl or is a group of the formula
##3 ##4
O p
where
p is a number 2 or 3,
## 3 marks the linkage site with the group B,
##4 marks the linkage site with the nitrogen atom,
D is a group of the formula
O #3 T1
N or
#3 R3 R4
R1 R2
where
#3 marks the linkage site with the en atom,
R1 is hydrogen,
R2 is benzyl, oxybenzyl or 1H-indolylmethyl,
R1 and R2 together with the carbon atom to which they are bonded form a (1S,2R)
phenylcyclopropane-1,1-diyl group of the formula
#4 #5
in which
#4 marks the linkage site with the adjacent nitrogen atom,
#5 marks the linkage site with the carbonyl group,
the ring A with the N-O moiety present therein is a mono- or bicyclic, optionally
substituted heterocycle of the formula
in which
#6 marks the linkage site with the carbonyl group,
R3 is hydrogen,
R4 is benzyl, 4-hydroxybenzyl or 1H-indolylmethyl,
R3 and R4 together with the carbon atom to which they are bonded form a (1S,2R)
phenylcyclopropane-1,1-diyl group of the formula
#7 #8
in which
#7 marks the linkage site with the adjacent nitrogen atom,
#8 marks the linkage site with the group T1,
T1 is a group of the formula -C(=O)-OR7 or -C(=O)-NR8R9,
in which
R7 is en, methyl, ethyl, n-propyl, tert-butyl, benzyl or
adamantylmethyl,
R8 is hydrogen,
R9 is hydrogen or benzyl,
R35 is ,
and also their salts, solvates and solvates of the salts.
Additionally preferably ed by the present invention is a binder-drug conjugate as bed
above, where the binder comprises the amino acid sequence of the variable light and heavy chains
of the antibody M048-D01-hIgG1-b, reproduced in SEQ ID NO: 14 (Vl) and SEQ ID NO: 13 (Vh),
the amino acid ce of the light and heavy chain of the antibody M048-D01-hIgG1-b
reproduced in SEQ ID NO: 9 (light chain) and SEQ ID NO: 10 (heavy chain).
Additionally provided by the present invention are compounds of the formula (XXXa)
O H C R35 H C
3 CH
3 3
Cys O H
H N
N N D
N L1 B L2 N N
O O
CH O CH O O
3 3 CH
H CH CH
O C 3
3 3
(XXXa),
in which
Cys is a cysteine residue which is bonded via the sulphur atom of the side chain to a carbon
atom of the succinimide,
L1 is a bond, linear (C1-C10)-alkanediyl, a group of the formula
##1 ##2
O m or ##1 L1A B1 L1B ##2
where
m is a number from 2 to 6,
## 1 marks the linkage site with the group G,
##2 marks the e site with the group B,
L1A is linear (C2-C10)-alkanediyl,
B1 is a group of the formula
O O O
##5 ##6 L5 ##6
N N or ##5 N N L6
R29 R30 R31 R32
in which
## 5 marks the linkage site with the group L1A,
2012/075277
## 6 marks the linkage site with the group L1B ,
L5 is a bond or (C2-C4)-alkanediyl,
L6 is a bond,
R29 is hydrogen or (C1-C4)-alkyl,
R30 is hydrogen or (C1-C4)-alkyl,
R29 and R30 together with the atoms to which they are bonded form a 5- or 6-
membered cycle,
R31 is hydrogen or (C1-C4)-alkyl,
R32 is hydrogen or (C1-C4)-alkyl,
R31 and R32 together with the atoms to which they are bonded form a 5- or 6-
membered heterocycle,
L1B is linear (C2-C10 )-alkanediyl,
and
where (C1-C10 )-alkanediyl may be substituted by 1 to 4 substituents selected independently
of one another from the group consisting of , hydroxy and benzyl,
where two carbon atoms of the alkanediyl chain in 1,2, 1,3 or 1,4-relation to one r,
with inclusion of any carbon atoms situated between them, may be bridged to form a (C3-
C6)-cycloalkyl ring or a phenyl ring,
B is a bond or a group of the formula
2012/075277
O O O
* ** L3 **
N N * N N L4
R14 R15 R16 R17
, ,
O O
O ** **
* Q1 or * N
O R27
where
* marks the linkage site with L1,
** marks the linkage site with L2,
P is O or NH,
L3 is a bond or (C2-C4)-alkanediyl,
L4 is a bond,
Q1 is a 4- to 7-membered heterocycle,
Q2 is a 3- to 7-membered carbocycle or a 4- to 7-membered heterocycle,
R14 is en or (C1-C4)-alkyl,
R15 is hydrogen or (C1-C4)-alkyl,
R14 and R15 together with the atoms to which they are bonded form a 5- or 6-membered
heterocycle,
R16 is hydrogen or (C1-C4)-alkyl,
R17 is hydrogen or (C1-C4)-alkyl,
R16 and R17 together with the atoms to which they are bonded form a 5- or 6-membered
heterocycle,
R18 is hydrogen or (C1-C4)-alkyl,
R19 is hydrogen or the side group of a natural α-amino acid or of its gues or
isomers,
R20 is hydrogen or (C1-C4)-alkyl,
or
R19 and R20 together with the atoms to which they are bonded form a pyrrolidinyl ring,
R21 is hydrogen or (C1-C4)-alkyl,
R22 is hydrogen or (C1-C4)-alkyl,
R21 and R22 together with the atoms to which they are bonded form a 3- to 7-membered
carbocycle,
R23 is (C1-C4)-alkyl,
R24 is hydrogen or (C1-C4)-alkyl,
R27 is hydrogen or (C1-C4)-alkyl,
L2 is linear (C2-C10)-alkanediyl or is a group of the a
##3 ##4
O p
where
p is a number from 2 to 6,
## 3 marks the linkage site with the group B,
##4 marks the linkage site with the nitrogen atom,
where (C2-C10)-alkanediyl may be substituted by 1 to 4 tuents selected ndently
of one another from the group consisting of methyl, hydroxy and benzyl,
where two carbon atoms of the alkanediyl chain in 1,2, 1,3 or 1,4-relation to one another,
with inclusion of any carbon atoms situated between them, may be bridged to form a (C3-
C6)-cycloalkyl ring or a phenyl ring,
D is a group of the formula
O T1 #3 R5
N or
#3 R3 R4
O , R26 T2
R1 R2
where
#3 marks the linkage site with the nitrogen atom,
R1 is hydrogen or methyl,
R2 is isopropyl, isobutyl, sec-butyl, utyl, phenyl, benzyl, 1-hydroxyethyl, 4-
hydroxybenzyl, 4-hydroxynitrobenzyl, 4-hydroxyaminobenzyl, 1-phenylethyl
, diphenylmethyl, 1H-imidazolylmethyl or 1H-indolylmethyl,
R1 and R2 together with the carbon atom to which they are bonded form a )
phenylcyclopropane-1,1-diyl group of the formula
#4 #5
in which
#4 marks the linkage site with the adjacent nitrogen atom,
#5 marks the e site with the carbonyl group,
the ring A with the N-O moiety present therein is a mono- or bicyclic, optionally
substituted cycle of the formula
O O O or
N N N N
#6 , #6 , #6 #6
in which
#6 marks the linkage site with the carbonyl group,
R6 is hydrogen, hydroxy or benzyloxy,
R3 is hydrogen or methyl,
R4 is isopropyl, isobutyl, sec-butyl, tert-butyl, phenyl, benzyl, oxyethyl, 4-
hydroxybenzyl, oxynitrobenzyl, 4-hydroxyaminobenzyl, 1-phenylethyl
, diphenylmethyl, 1H-imidazolylmethyl or 1H-indolylmethyl,
R3 and R4 together with the carbon atom to which they are bonded form a (1S,2R)
phenylcyclopropane-1,1-diyl group of the formula
#7 #8
in which
#7 marks the e site with the adjacent nitrogen atom,
#8 marks the linkage site with the group T1,
T1 is a group of the formula -C(=O)-OR7, -C(=O)-NR8R9, -C(=O)-NH-NH-R10 or
-CH2-O-R11,
in which
R7 is hydrogen, methyl, ethyl, n-propyl, tert-butyl, benzyl or
adamantylmethyl,
R8 is hydrogen or ,
R9 is hydrogen, methyl, ethyl, n-propyl or benzyl,
R8 and R9 together with the nitrogen atom to which they are bonded form a 4-
to 7-membered heterocycle,
R10 is benzoyl,
R11 is benzyl, which may be substituted in the phenyl group by
methoxycarbonyl or carboxyl,
R5 is en, methyl or a group of the formula
#9 O #9 S
, ,
#9 R13
#9 #9 or
R12 R12
, N N
in which
#9 marks the linkage site with –CHC(R26)-T2,
R12 is phenyl which may be substituted by ycarbonyl, carboxyl or a
group of the a –S(O)2OH,
R13 is phenyl which may be substituted by methoxycarbonyl or carboxyl,
R26 is hydrogen or hydroxy,
T2 is phenyl, benzyl, 1H-indolyl or 1H-indolylmethyl,
R35 is methyl or hydroxy,
2012/075277
and also their salts, solvates and solvates of the salts.
Preferred in the context of the present ion are additionally also compounds of the formula
(XXXa) in which
Cys is a cysteine residue which is bonded via the sulphur atom of the side chain via a carbon
atom of the succinimide,
L1 is a bond, linear (C2-C6)-alkanediyl, a group of the formula
##1 ##2
O m or ##1 L1A B1 L1B ##2
where
m is a number 2 or 3,
## 1 marks the linkage site with the group G,
##2 marks the linkage site with the group B,
L1A is linear (C2-C6)-alkanediyl,
B1 is a group of the formula
O O O
##5 ##6 L5 ##6
N N or ##5 N N L6
R29 R30 R31 R32
in which
## 5 marks the linkage site with the group L1A,
## 6 marks the linkage site with the group L1B,
L5 is a bond,
L6 is a bond,
R29 is hydrogen,
R30 is hydrogen,
R31 is hydrogen or methyl,
R32 is hydrogen or methyl,
L1B is linear (C2-C6)-alkanediyl,
where (C2-C6)-alkanediyl may be substituted by 1 or 2 methyl substituents,
B is a bond or a group of the formula
O O O
* ** L3 **
N N * N N L4
R14 R15 R16 R17
O **
or * N
R23 R24 O
where
* marks the linkage site with L1,
** marks the linkage site with L2,
L3 is a bond or -1,2-diyl,
L4 is a bond,
R14 is en,
R15 is hydrogen,
R16 is hydrogen or methyl,
R17 is hydrogen or methyl,
R16 and R17 together with the atoms to which they are bonded form piperazinyl ring,
WO 87716
R23 is methyl,
R24 is hydrogen or methyl,
L2 is linear (C2-C6)-alkanediyl or is a group of the a
##3 ##4
O p
where
p is a number 2 or 3,
## 3 marks the linkage site with the group B,
##4 marks the linkage site with the nitrogen atom,
D is a group of the formula
O #3 T1 #3 R5
N or
#3 R3 R4
O ,
R1 R2
where
#3 marks the linkage site with the nitrogen atom,
R1 is hydrogen,
R2 is 1-hydroxyethyl, benzyl, 4-hydroxybenzyl, 1-phenylethyl or 1H-indolylmethyl,
or
R1 and R2 together with the carbon atom to which they are bonded form a (1S,2R)
phenylcyclopropane-1,1-diyl group of the formula
#4 #5
in which
#4 marks the linkage site with the adjacent nitrogen atom,
#5 marks the linkage site with the carbonyl group,
the ring A with the N-O moiety present therein is a mono- or bicyclic, ally
substituted heterocycle of the formula
O O O or
N N N N
#6 , #6 , #6 #6
in which
#6 marks the linkage site with the carbonyl group,
R6 is hydrogen, hydroxy or benzyloxy,
R3 is hydrogen,
R4 is 1-hydroxyethyl, benzyl, 4-hydroxybenzyl, 1-phenylethyl or olylmethyl,
R3 and R4 together with the carbon atom to which they are bonded form a (1S,2R)
phenylcyclopropane-1,1-diyl group of the formula
2012/075277
#7 #8
in which
#7 marks the linkage site with the adjacent nitrogen atom,
#8 marks the linkage site with the group T1,
T1 is a group of the formula -C(=O)-OR7, -C(=O)-NR8R9, -C(=O)-NH-NH-R10 or
-CH2-O-R11,
in which
R7 is hydrogen, methyl, ethyl, n-propyl, tert-butyl, benzyl or
adamantylmethyl,
R8 is hydrogen or ,
R9 is hydrogen, methyl, ethyl, n-propyl or ,
R8 and R9 together with the nitrogen atom to which they are bonded form a 4- to 7-
membered heterocycle,
R10 is benzoyl,
R11 is benzyl which may be substituted in the phenyl group by
methoxycarbonyl or carboxyl,
R5 is hydrogen, methyl or a group of the formula
#9 R13
#9 #9 or
R12 R12
, N N
in which
#9 marks the linkage site with –CHCH2phenyl,
R12 is phenyl which may be tuted by methoxycarbonyl, carboxyl or a
group of the formula –S(O)2OH,
R13 is phenyl which may be substituted by methoxycarbonyl or carboxyl,
R35 is methyl or hydroxy,
and also their salts, solvates and solvates of the salts.
Particularly preferred in the context of the present invention are additionally also compounds of
the formula (XXXa) in which
Cys is a cysteine residue which is bonded via the sulphur atom of the side chain via a carbon
atom of the succinimide,
L1 is a bond or linear (C2-C6)-alkanediyl,
B is a bond or a group of the formula
O O
L3 **
* N N L4
R16 R17
where
* marks the linkage site with L1,
** marks the e site with L2,
L3 is a bond,
L4 is a bond,
R16 is hydrogen or methyl,
R17 is hydrogen or ,
L2 is linear (C2-C6)-alkanediyl or is a group of the formula
##3 ##4
O p
where
p is a number 2 or 3,
## 3 marks the linkage site with the group B,
##4 marks the linkage site with the nitrogen atom,
D is a group of the formula
O #3 T1
N or
#3 R3 R4
R1 R2
where
#3 marks the linkage site with the nitrogen atom,
R1 is en,
R2 is benzyl or 1H-indolylmethyl,
or
R1 and R2 together with the carbon atom to which they are bonded form a )
phenylcyclopropane-1,1-diyl group of the formula
#4 #5
in which
#4 marks the linkage site with the adjacent nitrogen atom,
#5 marks the linkage site with the carbonyl group,
the ring A with the N-O moiety present therein is a mono- or bicyclic, optionally
substituted heterocycle of the formula
2012/075277
in which
#6 marks the linkage site with the carbonyl group,
R3 is hydrogen,
R4 is benzyl, 4-hydroxybenzyl or 1H-indolylmethyl,
R3 and R4 together with the carbon atom to which they are bonded form a (1S,2R)
phenylcyclopropane-1,1-diyl group of the formula
#7 #8
in which
#7 marks the linkage site with the adjacent nitrogen atom,
#8 marks the linkage site with the group T1,
T1 is a group of the formula -C(=O)-OR7 or -C(=O)-NR8R9,
in which
R7 is hydrogen,
R8 is hydrogen,
R9 is en,
R35 is methyl,
and also their salts, solvates and solvates of the salts.
The present invention additionally provides compounds of the a (XXXI)
HO NH
O 3
O H C R35 H C
3 CH
3 O 3 H
N H N
H N N D
L1 B L2 N N
O O
CH O CH O O CH
3 3 3
H C CH CH
3 3
(XXXI),
in which
L1 is a bond, linear (C1-C10)-alkanediyl, a group of the formula
##1 ##2
O m or ##1 L1A B1 L1B ##2
where
m is a number from 2 to 6,
## 1 marks the linkage site with the group G,
##2 marks the linkage site with the group B,
L1A is linear (C2-C10)-alkanediyl,
B1 is a group of the formula
O O O
##5 ##6 L5 ##6
N N or ##5 N N L6
R29 R30 R31 R32
in which
## 5 marks the linkage site with the group L1A,
## 6 marks the linkage site with the group L1B,
L5 is a bond or (C2-C4)-alkanediyl,
L6 is a bond,
R29 is hydrogen or (C1-C4)-alkyl,
R30 is hydrogen or (C1-C4)-alkyl,
R29 and R30 together with the atoms to which they are bonded form a 5- or 6-
membered heterocycle,
R31 is hydrogen or (C1-C4)-alkyl,
R32 is hydrogen or (C1-C4)-alkyl,
R31 and R32 together with the atoms to which they are bonded form a 5- or 6-
ed heterocycle,
L1B is linear (C2-C10 )-alkanediyl,
where (C1-C10 )-alkanediyl may be substituted by 1 to 4 substituents selected independently
of one another from the group consisting of methyl, hydroxy and ,
where two carbon atoms of the alkanediyl chain in 1,2, 1,3 or 1,4-relation to one another,
with inclusion of any carbon atoms situated between them, may be d to form a (C3-
C6)-cycloalkyl ring or a phenyl ring,
B is a bond or a group of the formula
WO 87716
O R20
O ** * P ** * N **
* Q1 Q2
, O , R18 R19 O ,
* **
N **
H or * N
R21 R22
where
* marks the linkage site with L1,
** marks the linkage site with L2,
P is O or NH,
Q1 is a 4- to 7-membered heterocycle,
Q2 is a 3- to 7-membered carbocycle or a 4- to 7-membered heterocycle,
R18 is hydrogen or (C1-C4)-alkyl,
R19 is hydrogen or the side group of a natural α-amino acid or of its homologues or
isomers,
R20 is hydrogen or (C1-C4)-alkyl,
R19 and R20 er with the atoms to which they are bonded form a pyrrolidinyl ring,
R21 is hydrogen or (C1-C4)-alkyl,
R22 is en or (C1-C4)-alkyl,
R21 and R22 together with the atoms to which they are bonded form a 3- to 7-membered
carbocycle,
R27 is hydrogen or (C1-C4)-alkyl,
L2 is linear (C2-C10)-alkanediyl or is a group of the formula
##3 ##4
O p
where
p is a number from 2 to 6,
## 3 marks the linkage site with the group B,
##4 marks the linkage site with the nitrogen atom,
where 0)-alkanediyl may be substituted by 1 to 4 substituents selected ndently
of one another from the group consisting of methyl, hydroxy and benzyl,
where two carbon atoms of the alkanediyl chain in 1,2, 1,3 or 1,4-relation to one another,
with inclusion of any carbon atoms situated between them, may be bridged to form a
(C3-C6)-cycloalkyl ring or a phenyl ring,
D is a group of the formula
O #3 T1 #3 R5
N or
#3 R3 R4
O , R26 T2
R1 R2
in which
#3 marks the linkage site with the nitrogen atom,
R1 is hydrogen or methyl,
R2 is isopropyl, isobutyl, sec-butyl, tert-butyl, phenyl, benzyl, 1-hydroxyethyl,
4-hydroxybenzyl, 4-hydroxynitrobenzyl, 4-hydroxyaminobenzyl, yl-
ethyl, ylmethyl, 1H-imidazolylmethyl or 1H-indolylmethyl,
2012/075277
R1 and R2 together with the carbon atom to which they are bonded form a (1S,2R)
phenylcyclopropane-1,1-diyl group of the formula
#4 #5
in which
#4 marks the linkage site with the adjacent nitrogen atom,
#5 marks the linkage site with the carbonyl group,
the ring A with the N-O moiety present therein is a mono- or ic, optionally
substituted heterocycle of the formula
O O O or
N N N N
#6 , #6 , #6 #6
in which
#6 marks the linkage site with the yl group,
R6 is hydrogen, y or benzyloxy,
R3 is hydrogen or methyl,
R4 is isopropyl, isobutyl, sec-butyl, tert-butyl, phenyl, benzyl, 1-hydroxyethyl,
4-hydroxybenzyl, 4-hydroxynitrobenzyl, 4-hydroxyaminobenzyl, 1-phenylethyl
, diphenylmethyl, 1H-imidazolylmethyl or 1H-indolylmethyl,
R3 and R4 together with the carbon atom to which they are bonded form a (1S,2R)
phenylcyclopropane-1,1-diyl group of the formula
#7 #8
in which
#7 marks the linkage site with the adjacent nitrogen atom,
#8 marks the linkage site with the group T1,
T1 is a group of the formula -C(=O)-OR7, -C(=O)-NR8R9, -C(=O)-NH-NH-R10 or
-CH2-O-R11,
in which
R7 is hydrogen, methyl, ethyl, n-propyl, tert-butyl, benzyl or
adamantylmethyl,
R8 is hydrogen or ,
R9 is hydrogen, methyl, ethyl, n-propyl or benzyl,
R8 and R9 together with the nitrogen atom to which they are bonded form a 4-
to ered heterocycle,
R10 is benzoyl,
R11 is benzyl, which may be tuted in the phenyl group by
methoxycarbonyl or carboxyl,
R5 is hydrogen, methyl or a group of the formula
WO 87716
#9 O #9 S
, ,
#9 R13
#9 #9 or
R12 R12
, N N
in which
#9 marks the linkage site with –CHC(R26)-T2,
R12 is phenyl which may be substituted by methoxycarbonyl, carboxyl or a
group of the formula –S(O)2OH,
R13 is phenyl which may be substituted by methoxycarbonyl or carboxyl,
R26 is hydrogen or hydroxy,
T2 is phenyl, benzyl, 1H-indolyl or 1H-indolylmethyl,
R35 is methyl or hydroxy,
and also their salts, solvates and solvates of the salts.
Preferred in the context of the present ion are also compounds of the formula (XXXI) in
which
L1 is a bond, linear (C2-C6)-alkanediyl or a group of the formula
##1 ##2
O m
where
m is a number 2 or 3,
## 1 marks the linkage site with the group G,
##2 marks the linkage site with the group B,
where (C2-C6)-alkanediyl may be substituted by 1 or 2 methyl substituents,
B is a bond or a group of the formula
H R20
N **
* N **
* , R18 R19 O ,
O O
* ** or **
N * N
R21 R22 R27
where
* marks the linkage site with L1,
** marks the linkage site with L2,
R18 is hydrogen,
R19 is methyl, yl, 2-methylpropanyl or 1-methylpropanyl,
R20 is hydrogen or (C1-C4)-alkyl,
R19 and R20 together with the atoms to which they are bonded form a pyrrolidinyl ring,
R21 is hydrogen or methyl,
R22 is hydrogen or methyl,
R21 and R22 together with the atoms to which they are bonded form a cyclopropyl ring,
R27 is hydrogen or methyl,
L2 is linear )-alkanediyl or is a group of the formula
##3 ##4
O p
where
p is a number 2 or 3,
## 3 marks the e site with the group B,
##4 marks the linkage site with the nitrogen atom,
where (C2-C10)-alkanediyl may be substituted by 1 or 2 methyl substituents,
where two carbon atoms of the alkanediyl chain in 1,4-relation to one another, with
inclusion of any carbon atoms situated n them, may be bridged to form a phenyl
ring,
D is a group of the formula
O #3 T1 #3 R5
N or
#3 R3 R4
O ,
R1 R2
in which
#3 marks the linkage site with the nitrogen atom,
R1 is hydrogen,
R2 is 1-hydroxyethyl, benzyl, 4-hydroxybenzyl, 1-phenylethyl or 1H-indolylmethyl,
R1 and R2 together with the carbon atom to which they are bonded form a (1S,2R)
phenylcyclopropane-1,1-diyl group of the formula
#4 #5
in which
#4 marks the linkage site with the nt nitrogen atom,
#5 marks the linkage site with the carbonyl group,
the ring A with the N-O moiety present therein is a mono- or bicyclic, optionally
substituted heterocycle of the formula
O O O or
N N N N
#6 , #6 , #6 #6
in which
#6 marks the linkage site with the yl group,
R6 is hydrogen, hydroxy or benzyloxy,
R3 is hydrogen,
R4 is 1-hydroxyethyl, benzyl, 4-hydroxybenzyl, 1-phenylethyl or 1H-indolylmethyl,
R3 and R4 together with the carbon atom to which they are bonded form a )
phenylcyclopropan-1,1-diyl group of the formula
#7 #8
in which
#7 marks the linkage site with the adjacent nitrogen atom,
#8 marks the linkage site with the group T1,
T1 is a group of the formula -C(=O)-OR7, -C(=O)-NR8R9, -C(=O)-NH-NH-R10 or
-CH2-O-R11,
in which
R7 is hydrogen, methyl, ethyl, n-propyl, utyl, benzyl or
tylmethyl,
R8 is hydrogen or methyl,
R9 is hydrogen, methyl, ethyl, n-propyl or benzyl,
R8 and R9 together with the nitrogen atom to which they are bonded form a 4-
to 7-membered heterocycle,
R10 is l,
R11 is benzyl, which may be substituted in the phenyl group by
methoxycarbonyl or carboxyl,
R5 is hydrogen, methyl or a group of the formula
#9 R13
#9 #9 or
R12 R12
, N N
in which
#9 marks the linkage site with –CHCH2phenyl,
R12 is phenyl which may be substituted by methoxycarbonyl, carboxyl or a
group of the formula –S(O)2OH,
R13 is phenyl which may be substituted by methoxycarbonyl or carboxyl,
R35 is methyl or hydroxy,
and also their salts, solvates and solvates of the salts.
Particularly preferred in the context of the present ion are also compounds of the formula
(XXXI) in which
L1 is a bond,
B is a bond,
L2 is linear (C2-C6)-alkanediyl or is a group of the formula
##3 ##4
O p
where
p is a number 2 or 3,
## 3 marks the linkage site with the group B,
##4 marks the linkage site with the nitrogen atom,
D is a group of the formula
O #3 T1
N or
#3 R3 R4
R1 R2
where
#3 marks the linkage site with the nitrogen atom,
R1 is hydrogen,
R2 is benzyl, 4-hydroxybenzyl or olylmethyl,
R1 and R2 together with the carbon atom to which they are bonded form a
(1S,2R)phenylcyclopropane-1,1-diyl group of the formula
#4 #5
in which
#4 marks the e site with the adjacent nitrogen atom,
#5 marks the linkage site with the yl group,
the ring A with the N-O moiety present therein is a mono- or ic,
optionally substituted heterocycle of the formula
in which
#6 marks the linkage site with the carbonyl group,
R6 is hydrogen, hydroxy or benzyloxy,
R3 is hydrogen,
R4 is benzyl, 4-hydroxybenzyl or 1H-indolylmethyl,
R3 and R4 together with the carbon atom to which they are bonded form a
(1S,2R)phenylcyclopropane-1,1-diyl group of the formula
#7 #8
in which
#7 marks the linkage site with the adjacent nitrogen atom,
#8 marks the linkage site with the group T1,
T1 is a group of the formula -C(=O)-OR7 or -C(=O)-NR8R9,
in which
2012/075277
R7 is hydrogen,
R8 is hydrogen,
R9 is hydrogen,
R35 is methyl,
and also their salts, solvates and solvates of the salts.
Preferred in the context of the present invention are also compounds of the formula (Ia), in which
AK is AK1
where
AK1 is an antibody or an antigen-binding dy fragment which binds to FGFR2 and
is bonded via the sulphur atom of a cysteine residue of the binder to the group G,
G is a group of the formula
N #2
where
#1 marks the linkage site with the cysteine residue of the binder,
#2 marks the linkage site with the group L1,
n, L1, B, L2, D and R35 have the definitions ted above,
and also their salts, solvates and solvates of the salts.
Preferred in the context of the present invention are also compounds of the formula (Ia), in which
AK is AK2
where
AK2 is an antibody or an n-binding antibody fragment which binds to FGFR2 and
is bonded via the NH side group of a lysine residue of the binder to the group G,
G is carbonyl,
n, L1, B, L2, D and R35 have the definitions indicated above,
and also their salts, solvates and solvates of the salts.
Preference in the context of the present invention is also given to compounds of the formula (Ia),
in which
AK is AK1
where
AK1 is a binder which binds FGFR2, and which is bonded via the sulphur atom of a
cysteine residue of the binder to the group G,
G is a group of the formula
N #2
where
#1 marks the linkage site with the cysteine residue of the binder,
#2 marks the linkage site with the group L1,
n, L1, B, L2, D and R35 have the definitions ted above,
and also their salts, solvates and solvates of the salts.
Preference in the context of the present invention is also given to nds of the formula (Ia),
in which
AK is AK2
where
AK2 is an a binder which binds FGFR2 and which is bonded via the NH side group of a
lysine residue of the binder to the group G,
G is carbonyl,
n, L1, B, L2, D and R35 have the definitions indicated above,
and also their salts, solvates and es of the salts.
Preference in the context of the present invention is also given to compounds of the general
formula (Ia), in which
AK is AK2
where
AK2 is a binder which binds FGFR2 and which is bonded via the NH side group of a
lysine residue of the binder to the group G,
G is carbonyl,
L1 is a bond,
B is a bond,
L2 is linear (C3-C6)-alkanediyl or is a group of the formula
##3 ##4
O p
where
p is a number 2 or 3,
##3 marks the e site with the group B,
##4 marks the linkage site with the nitrogen atom,
n, D and R35 have the definitions indicated above,
and also their salts, solvates and solvates of the salts.
Preference in the context of the present invention is also given to compounds of the general
formula (Ia), in which
AK is AK1
where
AK1 is a binder which binds FGFR2 and which is attached via the sulphur atom of a
cysteine residue of the binder to the group G,
G is a group of the formula
N #2
where
#1 marks the e site with the cysteine residue of the binder,
#2 marks the linkage site with the group L1,
L1 is a bond, linear )-alkanediyl or a group of the formula
##1 ##2
O m
where
m is a number 2 or 3,
##1 marks the linkage site with the group G,
##2 marks the linkage site with the group B,
where (C3-C5)-alkanediyl may be substituted by 1 or 2 methyl substituents,
B is a bond or a group of the formula
O O
L3 **
* N N L4
R16 R17
where
* marks the linkage site with L1,
** marks the linkage site with L2,
L3 is a bond or ethane-1,2-diyl,
L4 is a bond or a group of the formula
O ****
R25 O
in which
*** marks the linkage site with the yl group,
**** marks the linkage site with L2,
R25 is methyl,
R28 is hydrogen, methylcarbonyl or tert-butyloxycarbonyl,
R16 is hydrogen or methyl,
R17 is hydrogen or methyl,
or
R16 and R17 together with the atoms to which they are bonded form a zinyl ring,
L2 is linear (C3-C5)-alkanediyl or is a group of the formula
##3 ##4
O p
where
p is a number 2 or 3,
##3 marks the linkage site with the group B,
##4 marks the linkage site with the nitrogen atom,
n, D and R35 have the definitions indicated above,
and also their salts, solvates and solvates of the salts.
Preferred in the t of the present invention are also compounds of the formula (Ia), (XXXa)
and (XXXI), in which
L1 is a bond,
B is a bond,
L2 is linear (C3-C6)-alkanediyl or is a group of the formula
##3 ##4
O p
where
p is a number 2 or 3,
##3 marks the linkage site with the group B,
##4 marks the linkage site with the nitrogen atom,
n, AK, Cys, G, D and R35 have the definitions indicated above,
and also their salts, solvates and solvates of the salts.
Preferred in the t of the present invention are also compounds of the formula (Ia), in which
L1 is linear 0)-alkanediyl or a group of the formula
##1 ##2
O m
where
m is a number from 2 to 6,
##1 marks the linkage site with the group G,
##2 marks the linkage site with the group B,
where (C1-C10)-alkanediyl may be substituted by 1 to 4 substituents ed ndently
of one another from the group consisting of methyl, hydroxyl and benzyl,
B is a bond or a group of the formula
O O O
L3 ** O **
* N N L4 * Q1
R16 R17 O
, ,
O R36
O **
* N or O **
H *
R23 R24 O R37 O
where
* marks the linkage site with L1,
** marks the linkage site with L2,
L3 is a bond or (C2-C4)-alkanediyl,
L4 is a group of the formula
R28 HN
HN O
O **** or *** ****
R25 O
in which
*** marks the linkage site with the carbonyl group,
**** marks the linkage site with L2,
R25 is hydrogen or methyl,
R28 is hydrogen, (C1-C4)-alkylcarbonyl, utyloxycarbonyl or
benzyloxycarbonyl,
Q1 is a 4- to 7-membered cycle,
R16 is hydrogen or (C1-C4)-alkyl,
R17 is hydrogen or (C1-C4)-alkyl,
R16 and R17 together with the atoms to which they are bonded form a 5- or 6-membered
heterocycle,
R23 is (C1-C4)-alkyl,
R24 is hydrogen or (C1-C4)-alkyl,
R36 is hydrogen, (C1-C4)-alkylcarbonyl, utyloxycarbonyl or benzyloxycarbonyl,
R37 is hydrogen or methyl,
R36 and R37 together with the atoms to which they are bonded form a pyrrolidine ring,
L2 is linear (C2-C10)-alkanediyl or is a group of the formula
##3 ##4
O p
where
p is a number from 2 to 6,
##3 marks the linkage site with the group B,
##4 marks the linkage site with the nitrogen atom,
where (C2-C10)-alkanediyl may be substituted by 1 to 4 tuents selected independently
of one another from the group consisting of methyl, hydroxyl and benzyl,
n, AK, G, D and R35 have the tions indicated above,
and also their salts, solvates and solvates of the salts.
Preferred in the context of the present invention are also compounds of the formula (Ia), in which
L1 is linear (C2-C6)-alkanediyl or a group of the formula
##1 ##2
O m
where
m is a number 2 or 3,
##1 marks the linkage site with the group G,
##2 marks the linkage site with the group B,
B is a bond or a group of the formula
O O R36
L3 **
* N N L4 or O **
R16 R17
R37 O
where
* marks the e site with L1,
** marks the linkage site with L2,
L3 is a bond or ethane-1,2-diyl,
L4 is a group of the formula
R28 HN
HN O
O **** or *** ****
R25 O
where
*** marks the linkage site with the carbonyl group,
**** marks the linkage site with L2,
R25 is hydrogen or methyl,
R28 is hydrogen, carbonyl or utyloxycarbonyl,
R16 is hydrogen or methyl,
R17 is hydrogen or methyl,
R16 and R17 together with the atoms to which they are bonded form a piperazinyl ring,
R36 is hydrogen, methylcarbonyl or tert-butyloxycarbonyl,
R37 is hydrogen or methyl,
R36 and R37 together with the atoms to which they are bonded form a pyrrolidine ring,
L2 is linear (C2-C6)-alkanediyl or is a group of the formula
##3 ##4
O p
where
p is a number 2 or 3,
##3 marks the linkage site with the group B,
##4 marks the linkage site with the en atom,
n, AK, G, D and R35 have the definitions indicated above,
and also their salts, solvates and solvates of the salts.
Preferred in the context of the present invention are also compounds of the formula (Ia) and
(XXXa), in which
G is a group of the a
N #2
in which
#1 marks the linkage site with the cysteine residue of the binder,
#2 marks the linkage site with the group L1,
L1 is linear (C3-C5)-alkanediyl or a group of the formula
##1 ##2
O m
in which
m is a number 2 or 3,
##1 marks the linkage site with the group G,
##2 marks the linkage site with the group B,
where (C3-C5)-alkanediyl may be substituted by 1 or 2 methyl substituents,
B is a bond or a group of the formula
O O
L3 **
* N N L4
R16 R17
where
* marks the linkage site with L1,
** marks the linkage site with L2,
L3 is a bond or ethane-1,2-diyl,
L4 is a bond,
L2 is linear (C3-C5)-alkanediyl or is a group of the a
##3 ##4
O p
where
p is a number 2 or 3,
##3 marks the linkage site with the group B,
##4 marks the linkage site with the nitrogen atom,
n, AK1, Cys, D, R16 and R17 have the definitions ted above,
and also their salts, solvates and solvates of the salts.
Preferred in the context of the present invention are also compounds of the formula (Ia), (XXXa)
and (XXXI), in which
D is a group of the formula
O #3 R5
#3 T1
N or
#3 R3 R4
O , R26 T2
R1 R2
where
#3 marks the linkage site with the nitrogen atom,
R1 is hydrogen or methyl,
R2 is pyl, isobutyl, sec-butyl, tert-butyl, phenyl, benzyl, 1-hydroxyethyl,
4-hydroxybenzyl, 4-hydroxynitrobenzyl, 4-hydroxyaminobenzyl, 1-phenyl-
ethyl, diphenylmethyl, 1H-imidazolylmethyl or 1H-indolylmethyl,
R1 and R2 together with the carbon atom to which they are bonded form a (1S,2R)
phenylcyclopropane-1,1-diyl group of the formula
#4 #5
in which
#4 marks the linkage site with the adjacent en atom,
#5 marks the linkage site with the carbonyl group,
the ring A with the N-O moiety present therein is a mono- or bicyclic, optionally
substituted heterocycle of the formula
O O or O
N N N N
#6 , #6 , #6 #6
in which
#6 marks the linkage site with the carbonyl group,
R6 is hydrogen, hydroxy or oxy,
R3 is hydrogen or ,
R4 is isopropyl, isobutyl, sec-butyl, tert-butyl, phenyl, benzyl, 1-hydroxyethyl, 4-
hydroxybenzyl, 4-hydroxynitrobenzyl, 4-hydroxyaminobenzyl, 1-phenylethyl
, diphenylmethyl, 1H-imidazolylmethyl or 1H-indolylmethyl,
R3 and R4 er with the carbon atom to which they are bonded form a (1S,2R)
phenylcyclopropane-1,1-diyl group of the formula
#7 #8
in which
#7 marks the linkage site with the adjacent nitrogen atom,
#8 marks the linkage site with the group T1,
T1 is a group of the formula -C(=O)-OR7, -C(=O)-NR8R9, -NH-NH-R10 or
-CH2-O-R11,
in which
R7 is hydrogen, methyl, ethyl, n-propyl, tert-butyl, benzyl or
adamantylmethyl,
R8 is hydrogen or ,
R9 is hydrogen, methyl, ethyl, n-propyl or benzyl,
R8 and R9 together with the nitrogen atom to which they are bonded form a 4- to 7-
membered heterocycle,
R10 is benzoyl,
R11 is benzyl, which may be substituted in the phenyl group by
ycarbonyl or carboxyl
R5 is hydrogen, methyl or a group of the formula
#9 O #9 S
, ,
#9 R13
#9 #9 or
R12 R12
, N N
in which
#9 marks the linkage site with 26)-T2,
R12 is phenyl which may be substituted by methoxycarbonyl, yl or a
group of the formula –S(O)2OH,
R13 is phenyl which may be tuted by methoxycarbonyl or carboxyl,
R26 is hydrogen,
T2 is phenyl, benzyl, 1H-indolyl or 1H-indolylmethyl,
n, AK, Cys, G, L1, B, L2, D and R35 have the definitions indicated above,
and also their salts, solvates and solvates of the salts.
Preferred in the context of the present invention are also compounds of the formula (Ia), (XXXa)
and (XXXI), in which
D is a group of the formula
R1 R2
where
#3 marks the linkage site with the nitrogen atom,
R1 is hydrogen or methyl,
R2 is isopropyl, isobutyl, sec-butyl, tert-butyl, phenyl, benzyl, 1-hydroxyethyl, 4-
hydroxybenzyl, 4-hydroxynitrobenzyl, 4-hydroxyaminobenzyl, 1-
ethyl, diphenylmethyl, dazolylmethyl or 1H-indolylmethyl,
or
R1 and R2 together with the carbon atom to which they are bonded form a )
phenylcyclopropane-1,1-diyl group of the formula
#4 #5
in which
#4 marks the linkage site with the adjacent nitrogen atom,
#5 marks the linkage site with the carbonyl group,
the ring A with the N-O moiety present n is a mono- or bicyclic, optionally
substituted heterocycle of the formula
O O O or
N N N N
#6 , #6 , #6 #6
in which
#6 marks the linkage site with the carbonyl group,
R6 is hydrogen, hydroxy or benzyloxy,
n, AK, Cys, G, L1, B, L2 and R35 have the definitions indicated above,
and also their salts, solvates and es of the salts.
Preferred in the context of the present invention are also compounds of the formula (Ia), (XXXa)
and (XXXI), in which
D is a group of the formula
R1 R2
where
#3 marks the linkage site with the nitrogen atom,
R1 is hydrogen,
R2 is , 4-hydroxybenzyl, 1-phenylethyl or 1H-indolylmethyl,
or
R1 and R2 together with the carbon atom to which they are bonded form a (1S,2R)
phenylcyclopropane-1,1-diyl group of the formula
#4 #5
in which
#4 marks the linkage site with the nt nitrogen atom,
#5 marks the linkage site with the carbonyl group,
the ring A with the N-O moiety present therein is a mono- or bicyclic, optionally
substituted heterocycle of the formula
WO 87716
in which
#6 marks the linkage site with the carbonyl group,
n, AK, Cys, G, L1, B, L2 and R35 have the definitions indicated above,
and also their salts, solvates and solvates of the salts.
Preferred in the context of the present invention are also compounds of the formula (Ia), (XXXa)
and , in which
R35 is hydroxyl,
and
n, AK, Cys, G, L1, B, L2, D and R35 have the tions indicated above,
and also their salts, solvates and solvates of the salts.
Preferred in the context of the present invention are also compounds of the formula (Ia), (XXXa)
and (XXXI), in which
R35 is methyl,
n, AK, Cys, G, L1, B, L2, D and R35 have the definitions indicated above,
and also their salts, es and solvates of the salts.
A preferred subject of the present invention are binder-drug conjugates of the general formula (Ia)
in which D can have the following structures and * stands for the linkage site with the nitrogen
atom:
or ,
and also their salts, solvates and solvates of the salts.
A preferred t of the present invention are binder-drug conjugates of the l formula (Ia)
in which D has a structure which is disclosed by one of the intermediates of the present invention;
and the linker unit -B-L2-§§ and also all other variables are defined in accordance with the
present invention; and their salts, solvates and solvates of the salts. AK is preferably an anti-
FGFR2 antibody or antigen-binding fragment thereof.
A red subject of the present invention are binder-drug conjugates of the general formula (Ia)
in which the linker-drug unit has a structure which is disclosed by one of the intermediates or
es of the present invention; and their salts, solvates and solvates of the salts. AK is
preferably an anti-FGFR2 antibody or antigen-binding fragment thereof.
A preferred subject of the present invention are binder-drug conjugates of the general formula (Ia)
in which the linker-drug unit has a ure which is disclosed by one of the examples of the
present invention; and their salts, es and solvates of the salts. AK is preferably an anti-
FGFR2 antibody or antigen-binding fragment thereof.
Particularly red subject of the present invention are binder-drug conjugates of the general
a (Ia)
H C R35 H C
3 CH
3 O 3
H N
N N D
AK G L1 B L2 N N
O O
CH O CH3 O O CH
H C CH CH3 3
3 3
(Ia),
in which
n is a number from 1 to 50,
AK is a binder which binds to FGFR2,
the group §-G-L1-B-§§ is a linker,
where
§ marks the linkage site with the group AK and
§§ marks the linkage site with the nitrogen atom,
L2 is linear (C2-C10)-alkanediyl or is a group of the formula
##3 ##4
O p
where
p is a number from 2 to 6,
WO 87716
## 3 marks the linkage site with the group B,
##4 marks the linkage site with the nitrogen atom,
where 0)-alkanediyl may be tuted by 1 to 4 methyl substituents ed
independently of one another from the group consisting of methyl, hydroxyl and benzyl
and
where two carbon atoms of the alkanediyl chain in 1,2, 1,3 or 1,4-relation to one another,
with inclusion of any carbon atoms situated between them, may be bridged to form a
(C3-C6)-cycloalkyl ring or a phenyl ring,
D is a group of the following formula, where * is the linkage site to the nitrogen atom
H
and also their salts, solvates and solvates of the salts.
Particularly preferred subject of the present invention are compounds of the following formula
H C CH H C
3 3 3 CH3 N
O H
H N
AK N N O
N N
O O
O CH3 O CH O O
3 CH3
H C CH CH
3 3 3
where AK is a binder which binds FGFR2, and n is a number from 1 to 10, and also their salts,
solvates and solvates of the salts. It is preferred if the binder is bonded via a NH side group of a
lysine residue to the linker-toxophore unit.
Particularly preferred subject of the present invention are compounds of the following
formula
H C CH H C
3 3 3 CH3 N
O H
H N
AK N N O
N N
O O
O CH3 O CH O O
3 CH3
H C CH CH
3 3 3
where AK is an antibody or an antibody fragment which binds FGFR2, and n is a number from 1
to 10, and also their salts, solvates and solvates of the salts. It is preferred if the antibody or
antibody fragment is bonded via an NH side group of a lysine residue of the antibody or antibody
fragment to the linker-toxophore unit.
Particularly preferred subject of the present invention is the compound of the following a
H C CH H C
3 3 3 CH
3 N
O H
H N
AK N
2A N O
N N
O O
O CH O CH O O
3 3 CH
H C CH CH 3
3 3 3
where AK2A is M048-D01-hIgG1 and n is a number from 1 to 10, and also the salts, solvates and
solvates of the salts thereof.
A further ularly preferred subject of the present ion is the compound of the following
formula
H3C CH H3C
3 CH
O 3 N
H N
AK2B N N O
N N
O O
O CH O CH3 O O
3 CH
H C CH3 CH 3
3 3
where AK2B is M048-D01-hIgG1-b and n is a number from 1 to 10, and also the salts, solvates
and solvates of the salts f.
The definitions of radicals that are indicated individually in the respective combinations and
preferred combinations of radicals are also replaced arbitrarily by radical tions of other
combinations, independently of the respective combinations of radicals that are indicated.
Especially preferred are combinations of two or more of the abovementioned preference ranges.
Further ed by the invention is a s for preparing the compounds of the invention of the
formula (Ia), characterized in that a solution of the binder in PBS buffer
[A] is admixed with a suitable reducing agent, such as, for example, dithiothreitol or tris(2-
carboxyethyl)phosphine hydrochloride, and is uently reacted with a compound of
the formula (IIa)
O H C R35 H C
3 CH
3 O 3
H N
N N D
N L1 B L2 N N
O O
CH3 O CH O O
3 CH
H C CH CH 3
O 3 (IIa),
3 3
in which D, L1, B, L2 and R35 each have the definitions indicated above,
to give a compound of the formula (I-A)
O H C R35 H C
3 CH
3 O 3 H
AK1 H N
N N D
N L1 B L2 N N
O O
CH O CH O O
3 CH
3 CH 3
O H C CH 3
3 3
(Ia-A),
in which n, AK1, D, L1, B, L2 and R35 each have the tions indicated above,
or
[B] is reacted with a compound of formula (IIIa)
H3C R35 H3C
O CH3
O H
O H N
N N D
N L1 B L2 N N
O O
CH O CH O O CH
O 3 3 3
H C CH CH
3 3
(IIIa),
in which D, L1, B, L2 and R35 each have the definitions indicated above,
to give a compound of the formula (Ia-B)
O H C R35 H C
3 CH
3 O 3 H
AK H N
2 N N D
L1 B L2 N N
O O
CH O CH O O
3 3 CH
CH 3
H C CH 3
3 3
(Ia-B),
in which n, AK2, D, L1, B, L2 and R35 each have the definitions indicated above.
Cysteine coupling:
The partial reduction of the antibody and also the subsequent conjugation of the (partially) reduced
antibody with a compound of the a (IIa) takes place in accordance with the methods known
to the skilled person, see e.g. Ducry et. al., Bioconj. Chem. 2010, 21, 5 and references herein,
Klussman et. al., Bioconj. Chem. 2004, 15(4), 765-773. The mild reduction of the antibody is
accomplished preferably by addition of 2-6 equivalents of TCEP to the antibody, which is present
in a suitable buffer solution, preferably phosphate buffer, and by stirring for 30-180 minutes at
temperatures between 15 and 40°C, preferably at RT. This is ed by the ation, by
addition of a solution of a compound of the formula (IIa) in DMSO, acetonitrile or DMF to the
solution of the (partially) reduced antibody in PBS buffer, and subsequent on at a
ature of 0°C to +40°C, more particularly of +10°C to +30°C, for a period of 30 minutes to
6 hours, more particularly 1 to 2 hours.
Lysine ng:
First of all the nds of the formula (IIIa) or comparable activated carboxyl components are
ed by conventional methods of peptide chemistry. They are then taken up in inert solvents
such as DMSO or DMF, for example, and added to the antibody, which is preferably present in
phosphate buffer at a neutral pH. The solution is stirred for 1-16 h at a temperature between 15 and
40°C, preferably RT.
The preparation processes described above are elucidated by way of e using the schemes
below (Scheme 1 and 2):
Scheme 1
H C CH H C
O 3 3 N
O 3 CH
3 H
H H N
N N N O
N N N
H O O
O N O CH O CH O
O 3 O 3
3 H C CH
3 3 CH
O 3
1 H C CH H C
O 3 3 O 3 CH N
3 H
H H N
N N N N O
N N N
H O O
O O CH O CH O O CH
3 C CH 3 3
3 3 CH
[a): 1. AK (antibody), TCEP, PBS buffer, RT; 2. Addition of the ide tive in DMSO,
RT].
Scheme 2
H C CH H C
3 3 CH NH
O O 3 3 H 2
H N
O N N O
N N N
O O
O CH3 O CH O O CH
3 3
O H3C CH
3 CH3
H C CH3 H C
3 3 CH NH
O 3 2
AK H N
2 N N O
N N
O O
O CH O CH3 O O CH3
3 H3C CH
3 CH3
[a): AK (antibody), PBS buffer, RT admix with activated carboxyl derivative of the linker-drug
components].
The compounds of the formula (II) in which L1 and B are a bond can be prepared by subjecting a
compound of the formula (IV)
H C CH H C
3 3 CH
O 3
H N
N N D
HN N
O O
CH O CH O O
3 CH
3 CH 3
H C CH 3 (IV),
3 3
in which D has the definition indicated above,
to reductive amination in an inert solvent with a compound of the formula (V)
PG1 N
L2A H (V),
in which
L2A has the above-defined definition of L2, but is shortened by one carbon atom in the alkyl
chain length,
PG1 is an amino-protective group such as, for example, (9H-fluorenylmethoxy)carbonyl,
tert-butoxycarbonyl or benzyloxycarbonyl,
to give a compound of the formula (VI)
H C CH H C
3 3 CH
O 3
H N
PG1 L2 N N D
N N N
H O O
CH O CH O O CH
3 3 3
H C CH CH
3 (VI),
3 3
in which D, L2 and PG1 have the tion indicated above,
eliminating the tive group PG1 from this compound by methods known to the skilled ,
and reacting the deprotected compound in an inert solvent in the presence of a suitable base with
methyl 2,5-dioxo-2,5-dihydro-1H-pyrrolecarboxylate to give a compound of the formula (II-A)
H C CH3 H C
3 CH
3 3
O O H
H N
L2 N N D
N N N
O O
CH O CH O O
3 3 CH
O H C CH CH3 (II-A),
3 3
in which D and L2 each have the definitions indicated above.
The compounds of the formula (II) in which B is a group of the formula (B1)
* **
N N
R14 R15 (B1),
in which *, **, R14 and R15 each have the conditions indicated above,
can be prepared by eliminating the protective group PG1 from a compound of the formula (VI) by
methods known to the skilled person, and reacting the deprotected compound in an inert solvent in
the presence of a suitable base with a compound of the formula (VII)
O O
N L1 N
O (VII),
in which L1 has the definition indicated above,
to give a compound of the formula (II-B)
H C CH3 H C
3 CH
3 3
O O O H
H N
L1 L2 N N D
N N N N N
H H O O
CH O CH O O CH
3 3 3
O H C CH CH3 (II-B),
3 3
in which D, L1 and L2 each have the tions indicated above.
The compounds of the formula (II) in which B is a group of the formula (B2)
O O
* N N **
R16 R17 (B2),
in which *, **, L3, R16 and R17 each have the ions indicated above can be prepared by
subjecting a compound of the formula (IV)
to reductive ion in an inert solvent with a compound of the a (VIII)
O O
HO L2A H (VIII),
in which
L2A has the above-defined definition of L2, but is ned by one carbon atom in the alkyl
chain length,
to give a compound of the formula (IX)
H C CH H C
3 CH
3 3 O 3 H
H N
HO L2 N N D
N N
O O
O CH O CH O O CH
3 3
H C CH CH 3
3 (IX),
3 3
in which D and L2 have the tions indicated above,
and reacting this compound in an inert solvent in the presence of a suitable coupling reagent and a
suitable base with a compound of the formula (X)
N L1
N L3 NH
H 2
O (X),
in which L1 and L3 each have the definitions indicated above,
to give a compound of the formula (II-C)
H C CH3 H C
3 CH
3 3
O O H
H H H N
L1 N N L2 N N D
N L3 N N
O O
O O CH O CH O O
3 3 CH
O H C CH CH3
3 3
(II-C),
in which D, L1, L2 and L3 each have the tions indicated above.
Compound of the formula (II), in which B is a group of the formula (B3)
O O
L3 **
* N N L4A
R16 R17 (B3),
in which *, **, L3, R16 and R17 each have the conditions indicated above and
L4A is a group of the formula
2 O
O **** or *** ****
R25 O
in which
*** marks the linkage site with the carbonyl group,
**** marks the linkage site with L2,
R25 is hydrogen or methyl,
can be ed by reacting a compound of the formula (IX) in an inert solvent in the presence of a
suitable base and a suitable coupling t with a compound of the formula (XI-A) or (XI-B)
O R25 O
PG2 PG2
O OH O
HN N
PG1 (XI-A) or PG1 (XI-B),
in which R25 and PG1 each have the definitions ted above and
PG2 is a suitable carboxyl-protective group, more particularly benzyl,
to give a compound (XII-A) or (XII-B)
2012/075277
PG1 H3C CH H3C CH3
HN 3 O H
H N
O O L2 N N D
PG2 N N
O O
O R25 O CH O CH O O CH
3 3 3
H C CH CH
3 3
(XII-A)
H C CH H C
3 3 CH
O 3 H
H N
O L2 N N D
N N
PG1 N O O
O CH O CH3 O O CH
H CH CH 3
C 3
3 3
),
in which D, PG1, PG2 and L2 have the definitions indicated above,
eliminating the protective group PG2 from this compound subsequently, by methods known to the
skilled person, and reacting the deprotected compound in an inert solvent in the presence of a
suitable coupling reagent and a suitable base with a compound of the formula (X), and finally,
ating the protective group PG1 from this compound, by methods known to the skilled
person, to give a compound of the formula (II-D-A) or (II-D-B)
H C CH H C
NH 3 3 CH
O 3
2 H
H H N
N O L2 N N D
L3 N N
O O
O NH O R25 O CH O CH O O CH
3 3 3
H C CH CH
O 3 3
(II-D-A),
2012/075277
H C CH H C
3 3 CH
O 3
H N
O L2 N N D
N N
HN O O
O CH O CH O O CH
3 3 3
H C CH CH
3 3
O O
L3 L1 N
O O
(II-D-B),
in which D, L1, L2 and L3 have the definitions indicated above.
Compound of the formula (II), in which B is a group of the formula (B4)
O **
* Q1A
O (B4),
in which *, ** each have the conditions indicated above and
Q1A is an N-linked 4- to 7-membered heterocycle,
can be prepared by reacting a compound of the a (IX) in an inert solvent in the presence of a
suitable base and a suitable coupling reagent with a compound of the formula (XXI)
PG1 (XXI),
in which PG1 and Q1A each have the definitions indicated above,
to give a compound of the formula (XXII)
H C CH H C
3 CH
3 O 3
H N
O L2 N N D
N N
N O O
PG1 O CH O CH O O CH
3 3 3
H C CH CH
3 3
(XXII),
in which PG1, Q1A, D and L2 have the definitions indicated above,
ating the protective group PG1 from this compound, by methods known to the skilled person,
and subsequently reacting the deprotected compound in an inert solvent in the presence of a
suitable coupling reagent and a suitable base with a compound of the formula (XXIII)
N L1
O (XXIII),
in which L1 has the definition ted above,
to give a compound of the formula (II-D)
H3C CH H3C
3 CH3
O H
H N
O O L2 N N D
N N
L1 N Q1A O O
N O CH3 O CH O O
3 CH
H C CH CH 3
O 3 3
O
(II-D),
in which Q1A, D, L1 and L2 have the definitions indicated above.
The compounds of the formula (III), in which L1 and B are a bond can be prepared by reacting a
compound of the a (IX) in an inert solvent in the presence of a suitable coupling t and
a suitable base with N-hydroxysuccinimide to give a compound of the formula (III-A)
H C CH3 H C
3 CH
3 3
O O H
H N
O L2 N N D
N N N
O O
O CH O CH O O CH
3 3 3
O H C CH CH3 (III-A),
3 3
in which D and L2 each have the tions indicated above.
The compounds of the formula (III), in which L1 is a bond and B is a group of the a (B5A)
* P **
O (B5A),
in which *, ** and P each have the definitions indicated above and
Q2A is a 3- to 7-membered carbocycle,
can be prepared by reacting a compound of the formula (IX) in an inert solvent in the ce of a
suitable coupling reagent and a suitable base with a compound of the formula (XIII)
PG2 P H
O Q2A (XIII),
in which P, Q2A and PG2 each have the definitions indicated above,
to give a compound of the formula (XIV)
H C CH3 H C
3 CH
O 3 O 3 H
H N
PG2 P L2 N N D
O Q2A N N
O O
O CH O CH O O
3 3 CH
H C CH CH3 3 (XIV),
3 3
in which D, P, Q2A, L2 and PG2 each have the definitions indicated above,
eliminating the protective group PG2 from this compound by methods known to the skilled person,
and subsequently reacting the deprotected nd in an inert solvent in the presence of a
suitable base with N-hydroxysuccinimide to give a compound of the formula (III-B)
O H C CH3 H C
3 CH
O 3 O 3 H
H N
N P L2 N N D
O Q2A N N
O O
O O CH O CH O O
3 3 CH
CH3 3
H C CH
3 3
(III-B),
in which D, P, Q2A and L2 each have the tions indicated above.
The compounds of the formula (III), in which L1 is a bond and B is a group of the formula (B6)
* N **
R18 R19
O (B6),
in which *, **, R18, R19 and R20 each have the definitions indicated above,
can be prepared by reacting a compound of the formula (IX) in an inert solvent in the presence of a
suitable coupling reagent and a suitable base with a nd of the formula (XV)
O R20
PG2 NH
R18 R19 (XV),
in which R18, R19, R20 and PG2 each have the tions indicated above,
to give a compound of the formula (XVI)
H C CH3 H C
3 CH
O R20 3 O 3 H
H N
PG2 N L2 N N D
O N N
O O
R18 R19 O CH O CH O O
3 CH
3 CH3 3
H C CH (XVI),
3 3
in which D, R18, R19, R20, L2 and PG2 each have the definitions indicated above,
eliminating the protective group PG2 from this compound by s known to the skilled person,
and subsequently reacting the deprotected compound in an inert solvent in the presence of a
suitable coupling reagent and a suitable base with N-hydroxysuccinimide to give a compound of
the formula (III-C)
O H C CH3 H C
3 CH
O R20 3 O 3 H
H N
N N L2 N N D
O N N
O O
O R18 R19 O CH O CH O O CH
3 3
H C CH CH3 3
3 3
(III-C),
in which D, R18, R19, R20 and L2 each have the definitions indicated above.
The nds of the formula (III), in which L1 is a bond and B is a group of the formula (B7)
* **
R21 R22 (B7),
in which *, **, R21 and R22 each have the definitions indicated above,
can be prepared by eliminating the protective group PG1 from a compound of the formula (VI) by
methods known to the skilled person, and reacting the resultant deprotected compound in an inert
solvent in the ce of a le base with a compound of the formula (XVII)
O R21 R22 O
O O
N N
O O
O O (XVII),
in which R21 and R22 each have the definitions ted above,
to give a compound of the formula (III-D)
O H C CH3 H C
3 CH
O O 3 O 3 H
H N
N L2 N N D
O N N N
H O O
O R21 R22 CH O CH O O
3 CH
3 CH3 3
H C CH
3 3
(III-D),
in which D, R21, R22 and L2 each have the definitions indicated above.
The compounds of the formula (III), in which B is a group of the formula (B8)
O **
* N
R23 R24
O (B8),
in which *, **, R23 and R24 each have the definitions indicated above,
can be prepared by ng a compound of the a (IX) in an inert solvent in the presence of a
suitable coupling reagent and a suitable base with a compound of the formula (XVIII)
PG1 OH
R23 R24 (XVIII),
in which R23, R24 and PG1 each have the definitions indicated above,
to give a compound of the formula (XIX)
H C CH3 H C
3 CH
3 O 3 H
H N
PG1 O L2 N N D
N N N
H O O
R23 R24 O CH O CH O O
3 CH
3 3
H C CH CH3 (XIX),
3 3
in which D, R23, R24, L2 and PG1 each have the definitions indicated above,
ating the protective group PG1 from this compound by methods known to the skilled person,
and subsequently reacting the deprotected compound in an inert solvent in the presence of a
suitable coupling reagent and a suitable base with a compound of the formula (XX)
O O
O L1A O
N N
O O
O O (XX),
in which
L1A is linear (C1-C10)-alkanediyl or is a group of the formula
##1 ##2
O m
where
m is a number from 2 to 6,
##1 marks the linkage site with the group G,
##2 marks the linkage site with the group B,
where (C1-C10)-alkanediyl may be substituted by 1 to 4 methyl substituents,
and
where two carbon atoms of the diyl chain in 1,2, 1,3 or 1,4-relation to one another,
with inclusion of any carbon atoms situated between them, may be bridged to form a (C3-
cloalkyl ring or a phenyl ring,
to give a compound of the formula (III-E)
H C CH H C
3 CH
O 3 O 3 H
H N
O L2 N N D
L1A N N N
H O O
R23 R24 O CH O CH3 O O CH3
O O 3
H C CH CH
3 3
O N
(III-E),
in which D, R23, R24, L1A and L2 each have the definitions indicated above.
The compounds of the a (III), in which B is a group of the formula (B5B)
* O **
O (B5B),
in which * and ** each have the definitions indicated above and
Q2B is an N-linked 4- to ered heterocycle,
can be prepared by ng a compound of the formula (IX) in an inert solvent in the presence of a
suitable base and a suitable coupling reagent with a compound of the formula (XXIV)
PG1 (XXIV),
in which PG1 and Q2B each have the definitions indicated above,
to give a compound of the formula (XXV)
H C CH H C
3 CH
3 3 O 3 H
H N
O L2 N N D
N N
N O O
PG1 O CH O CH O O CH3
3 3
H3C CH3 CH
(XXV),
in which PG1, Q2B, D and L2 have the definitions indicated above,
eliminating the protective group PG1 from this compound by methods known to the skilled person,
and subsequently converting the deprotected compound in an inert solvent in the presence of a
suitable base with a compound of the formula (XX) into a compound of the formula (III-F)
H C CH H C
3 CH
3 3 O 3
H N
O L2 N N D
N N
O N Q2B O O
O CH O CH O O
3 CH
3 3
H C CH CH
O L1A 3 3
(III-F),
in which Q2B, D, L1A and L2 have the definitions ted above.
The reactions (IV) + (V) → (VI) and (IV) + (VIII) → (IX) take place in the solvents which are
customary for a reductive amination and are inert under the reaction conditions, optionally in the
presence of an acid and/or of a water-removing agent as catalyst. Such solvents include, for
e, alcohols such as methanol, l, n-propanol, isopropanol, n-butanol or tert-butanol,
ethers such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane or bis(2-methoxyethyl) ether, or
other solvents such as dichloromethane, 1,2-dichloroethane, N,N-dimethylformamide or else water.
It is also possible to use mixtures of these ts. As solvent it is preferred to use a
1,4-dioxane/water mixture, with on of acetic acid or dilute hydrochloric acid as catalyst.
ng agents suitable for this reaction are, in particular, complex borohydrides, such as, for
example, sodium borohydride, sodium cyanoborohydride, sodium triacetoxyborohydride, tetra-
n-butylammonium borohydride or borane-pyridine complex. It is preferred to use sodium
cyanoborohydride or borane-pyridine complex.
The reactions (IV) + (V) → (VI) and (IV) + (VIII) → (IX) take place in l in a temperature
range from 0°C to +120°C, preferably at +50°C to +100°C. The reactions may be carried out under
atmospheric, increased or d pressure (e.g. from 0.5 to 5 bar); it is usual to operate at
atmospheric pressure.
The above-described coupling reactions (IX) + (X) → (II-C), (XII-A) or (XII-B) + (X) → (II-D-A)
or (II-D-B), (IX) + (XIII) → (XIV), (IX) + (XV) → (XVI) and (XXII) + (XXIII) → (II-D) (amide
formation from amine component and carboxylic acid component tively) are carried out by
standard methods of peptide chemistry [see e.g. M. Bodanszky, Principles of Peptide Synthesis,
Springer-Verlag, Berlin, 1993; M. Bodanszky and A. Bodanszky, The Practice of Peptide
Synthesis , Springer-Verlag, Berlin, 1984; H.-D. Jakubke and H. eit, äuren, Peptide,
Proteine , Verlag Chemie, Weinheim, 1982].
Examples of inert solvents for these coupling reactions are ethers such as diethyl ether, diisopropyl
ether, tert -butyl methyl ether, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane or bis(2-
methoxyethyl) ether, arbons such as benzene, toluene, , pentane, hexane, heptane,
cyclohexane or petroleum ons, halogenated hydrocarbons such as romethane,
trichloromethane, tetrachloromethane, 1,2-dichloroethane, trichloroethylene or chlorobenzene, or
dipolar-aprotic solvents such as acetone, methyl ethyl ketone, acetonitrile, ethyl acetate, pyridine,
dimethyl sulphoxide (DMSO), N,N -dimethylformamide (DMF), N,N -dimethylacetamide (DMA),
N,N' -dimethylpropyleneurea (DMPU) or N-methylpyrrolidinone (NMP). It is also le to use
mixtures of such solvents. ence is given to using N,N -dimethylformamide.
Examples of suitable activating/condensing agents for these couplings include carbodiimides such
as N,N' -diethyl-, N,N' -dipropyl-, N,N' -diisopropyl-, N,N' -dicyclohexylcarbodiimide (DCC) or N-(3-
dimethylaminoisopropyl)-N' -ethylcarbodiimide hydrochloride (EDC), phosgene derivatives such
as N,N' -carbonyldiimidazole (CDI) or isobutyl chloroformate, 1,2-oxazolium compounds such as
2-ethylphenyl-1,2-oxazolium 3-sulphate or 2-tert -butylmethylisoxazolium perchlorate,
acylamino compounds such as 2-ethoxyethoxycarbonyl-1,2-dihydroquinoline, phosphorus
compounds such as propanephosphonic ide, diethyl cyanophosphonate, bis(2-oxo
oxazolidinyl)phosphoryl chloride, benzotriazolyloxytris(dimethylamino)phosphonium
hexafluorophosphate or benzotriazolyloxytris(pyrrolidino)phosphonium hexafluorophosphate
(PyBOP), or uronium compounds such as O-(benzotriazolyl)-N,N,N',N' -tetramethyluronium
luoroborate (TBTU), O-(benzotriazolyl)-N,N,N',N' -tetramethyluronium
hexafluorophosphate (HBTU), xo(2H)-pyridyl)-1,1,3,3-tetramethyluronium
tetrafluoroborate (TPTU), O-(7-azabenzotriazolyl)-N,N,N',N' -tetramethyluronium
hexafluorophosphate (HATU) or O-(1 Hchlorobenzotriazolyl)-1,1,3,3-tetramethyluronium-
tetrafluoroborate (TCTU), optionally in ation with further auxiliaries such as 1-
hydroxybenzotriazole (HOBt) or N-hydroxysuccinimide (HOSu), and also, as bases, alkali metal
carbonates, e.g. sodium or potassium carbonate, or tertiary amine bases such as triethylamine,
N-methylmorpholine, N-methylpiperidine, N,N -diisopropylethylamine, pyridine or 4-N,N -
dimethylaminopyridine.
In the context of the present invention, as activating/condensing agents for such coupling
reactions, it is preferred to use N-(3-dimethylaminoisopropyl)-N' -ethylcarbodiimide hydrochloride
(EDC) in combination with 1-hydroxybenzotriazole (HOBt) and N,N-diisopropylethylamine, or
O-(7-azabenzotriazolyl)-N,N,N',N' -tetramethyluronium uorophosphate (HATU) likewise
in conjunction with N,N -diisopropylethylamine.
The coupling ons (IX) + (X) → (II-C), ) or (XII-B) + (X) → (II-D-A) or B), (IX)
+ (XIII) → (XIV) , (IX) + (XV) → (XVI) and (XXII) + (XXIII) → (II-D) are carried out in general
in a temperature range from -20°C to +60°C, preferably at 0°C to +40°C. The reactions may take
place under heric, at increased or at reduced pressure (e.g. from 0.5 to 5 bar); it is usual to
operate under heric pressure.
The esterifications (IX) + (XVIII) → (XII) and (IX) + (XI-A) or (XI-B) → (XII-A) or (XII-B), (IX)
+ (XXIV) → (XXV) and also (IX) + (XXI) → (XXII) take place in analogy to the above-described
amide coupling reactions. These reactions take place preferably in dichloromethane, using N-(3-
dimethylaminoisopropyl)-N' -ethylcarbodiimide hydrochloride (EDC) and 4-dimethylamino-
pyridine at a temperature of +50°C to 100°C under atmospheric re.
The functional groups optionally present in the compounds – such as amino, hydroxyl and
yl groups in particular – may also be present in a temporarily protected form during the
above-described process steps, if useful or ary. In these cases, such protective groups are
introduced and removed in accordance with customary methods known from peptide chemistry
[see, for example, T.W. Greene and P.G.M. Wuts, Protective Groups in Organic Synthesis, Wiley,
New York, 1999; M. Bodanszky and A. zky, The Practice of Peptide Synthesis, Springer-
Verlag, Berlin, 1984]. Where two or more protected groups are present, they can be liberated again
optionally simultaneously in a one-pot reaction, or else liberated again in separate reaction steps.
As an amino-protective group PG1 it is preferred to use tert -butoxycarbonyl (Boc),
benzyloxycarbonyl (Z) or (9H-fluorenylmethoxy)carbonyl (Fmoc); for a hydroxyl or carboxyl
on it is preferred to use tert -butyl or benzyl as protective group PG2. The elimination of a
tert -butyl or tert -butoxycarbonyl group is typically accomplished by treatment with a strong acid,
such as hydrogen chloride, hydrogen bromide or trifluoroacetic acid, in an inert solvent such as
diethyl ether, oxane, dichloromethane or acetic acid; this reaction may optionally also be
carried out without addition of an inert solvent. In the case of benzyl or benzyloxycarbonyl as
protective group, this group is removed preferably by hydrogenolysis in the presence of a suitable
ium catalyst, such as palladium on activated carbon, for e. The (9H-fluoren
oxy)carbonyl group is generally eliminated using a secondary amine base such as
diethylamine or dine.
The reaction (VI) → (II-A) takes place in a t which is inert under the reaction conditions,
such as, for example, ethers such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane or bis(2-
methoxyethyl) ether, alcohols such as methanol, ethanol, isopropanol, n-butanol or tert -butanol, or
dipolar-aprotic solvents such as acetone, methyl ethyl ketone, acetonitrile, ethyl acetate, pyridine,
dimethyl sulphoxide (DMSO), N,N -dimethylformamide (DMF), N,N -dimethylacetamide (DMA),
N,N' -dimethylpropyleneurea (DMPU) or N-methylpyrrolidinone (NMP) or water. It is also possible
to use mixtures of such ts. Preference is given to using a e of 1,4-dioxane and water.
Suitable bases for the reaction (VI) → (II-A) are, for example, alkali metal ates such as
potassium carbonate, sodium carbonate or lithium carbonate, alkali metal hydrogencarbonates such
as sodium or potassium hydrogencarbonate or alkali metal alkoxides such as sodium methoxide,
sodium ethoxide or potassium tert-butoxide. It is preferred to use sodium hydrogencarbonate.
The reaction (VI) → (II-A) takes place in a temperature range from 0°C to +50°C, preferably at
+10°C to +30°C. The reaction may take place under atmospheric, under elevated or under reduced
pressure (e.g. from 0.5 to 5 bar); it is usual to operate under atmospheric pressure.
The reaction (VI) + (VII) → (II-B) takes place in a solvent which is inert under the reaction
conditions, such as, for e, ethers such as ydrofuran, 1,4-dioxane, 1,2-dimethoxyethane
or bis(2-methoxyethyl) ether, alcohols such as methanol, ethanol, isopropanol, n-butanol or tert -
butanol, or r-aprotic solvents such as acetone, methyl ethyl ketone, acetonitrile, ethyl
acetate, pyridine, dimethyl sulphoxide (DMSO), N,N -dimethylformamide (DMF), N,N -
dimethylacetamide (DMA), N,N' -dimethylpropyleneurea (DMPU) or N-methylpyrrolidinone
(NMP) or water. It is also possible to use es of such solvents. Preference is given to using
DMF.
Suitable bases for the on (VI) + (VII) → (II-B) are, for example, ry amine bases such as
triethylamine, N-methylmorpholine, N-methylpiperidine, N,N -diisopropylethylamine, pyridine or
4-N,N -dimethylaminopyridine. Preference is given to using N,N -diisopropylethylamine.
The reaction (VI) + (VII) → (II-B) takes place in a temperature range from 0°C to +50°C,
preferably at +10°C to +30°C. The reaction may take place under atmospheric, under elevated or
under reduced pressure (e.g. from 0.5 to 5 bar); it is usual to operate under atmospheric re.
The reactions (IX) → (III-A), (XIV) → (III-B) and (XVI) → (III-C) and also (VI) + (XVII) → (III-
D), (XIX) + (XX) → (III-E) and (XXV) + (XX) → (III-F) take place in a solvent which is inert
under the reaction conditions. Examples of suitable ts are ethers such as diethyl ether,
diisopropyl ether, tert -butyl methyl ether, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane or
bis(2-methoxyethyl) ether, hydrocarbons such as benzene, toluene, xylene, pentane, hexane,
heptane, cyclohexane or petroleum ons, halogenated hydrocarbons such as dichloromethane,
trichloromethane, tetrachloromethane, 1,2-dichloroethane, trichloroethylene or chlorobenzene, or
dipolar-aprotic solvents such as acetone, methyl ethyl ketone, acetonitrile, ethyl acetate, pyridine,
dimethyl sulphoxide (DMSO), N,N -dimethylformamide (DMF), N,N -dimethylacetamide (DMA),
2012/075277
N,N' hylpropyleneurea (DMPU) or ylpyrrolidinone (NMP). It is also possible to use
mixtures of such solvents. Preference is given to using N,N hylformamide.
Suitable bases for these reactions are, for example, tertiary amines such as triethylamine,
N-methylmorpholine, N-methylpiperidine, N,N propylethylamine, pyridine or 4-N,N -
ylaminopyridine. Preference is given to using N,N -diisopropylethylamine, optionally with
addition of 4-N,N -dimethylaminopyridine.
The reactions (IX) → (III-A), (XIV) → (III-B) and (XVI) → (III-C) and also (VI) + (XVII) → (IIID
) and (XIX) + (XX) → (III-E) take place in a temperature range from 0°C to +50°C, preferably at
+10°C to +30°C. The reaction may take place under atmospheric, under elevated or under reduced
pressure (e.g. from 0.5 to 5 bar); it is usual to operate under atmospheric pressure.
The compounds of the formulae (II) and (III) are sub-quantities of the compounds of the formulae
(IIa) and (IIIa) respectively, where R35 is methyl. The preparation of the compounds (IIa) and (IIIa)
takes place in analogy to the preparation of the compound of the formulae (II) and (III) as
described above.
The above-described processes are illustrated by way of example by the following synthesis
schemes (Scheme 3 to 13, 18):
Scheme 3
H C O
H C CH 3
3 3 CH
3 N
O H
H N
N N O
HN N
O O
CH O CH O O
3 CH
3 3 x TFA
H C CH CH
3 3
1. N H
a) O
2. Pd/C
H C CH H C
3 3 CH
O 3 N
H N
N N O
H N N
2 N
O O
CH O CH O O CH
3 3 3
H C CH CH
3 3
O O
N O
b) CH
H C CH H C
3 3 CH
3 N
O O H
H N
N N O
N N N
O O
CH O CH O O
3 3 CH
H C CH CH 3
O 3
3 3
[a): 1. Water/dioxane, 1N HCl, 100°C; 2. H2, Pd/C, methanol, RT; b): NaHCO3, H2O, dioxane,
RT].
2012/075277
Scheme 4
H C CH H C
3 3 CH
3 NH2
O H
H N
H N N N
2 O
N N
O O
CH3 O CH O O
3 CH3
H C CH CH3
3 3
N O
a) N
O + O
O N
H3C CH3 H C
3 CH3 NH
O H 2
H H N
O N N N O
N N
O O
HN CH O CH3 O O CH
3 3
O H C CH CH
3 3
[a): Diisopropylethylamine, DMF, RT].
2012/075277
Scheme 5
H C CH H C
3 3 CH
O 3 N
H N
N N O
HN N
O O
CH O CH O O CH
3 3 3 x TFA
H C CH CH
3 3
a) HO NaCNBH3
H C CH H C
3 CH
3 3 O 3 N
H N
HO N N O
N N
O O
O CH O CH O O
3 3 CH
H C CH CH
3 3
O NH
b) N
O CH
N H C CH H C O
3 CH
O 3 N
N 3
H N
O N N N O
N N
O O
O CH O CH O O
3 3 CH
H C CH CH
3 3
[a): Water/dioxane, 1N HCl, 100°C; b): HATU, diisopropylamine, DMF, RT].
Scheme 6
H C CH H3C
3 3 CH
3 N
O H
H N
HO N N O
N N
O O
O CH O CH O O
3 CH
3 3
H3C CH3 CH
1. HN
O OH
a) O CH
2. Pd/C
Boc H C CH H C O
HN 3 3 CH N
O 3 H
H N
HO O N N O
N N
O O
O CH O O CH O O CH
3 CH
3 3 CH3 3
H C CH
3 3
1. N NH x HCl
b) O
2. TFA
H C CH H3C O
3 CH
NH2 3 O 3 N
H H N
N O N N O
HN N N
O O
O CH O CH O CH O O
3 CH
O 3 3 3
H C CH CH
3 3
[a): 1. EDCI, DMAP, dichloromethane, RT; 2. H2, methanol, RT ; b): 1. EDCI, HOBt,
ropylamine, DMF, RT; 2. dichloromethane, RT].
Scheme 7
H C CH H3C CH
3 3 3 N
O H
H N
HO N N O
N N
O O
O CH O CH O O
3 3 CH
CH 3
H C CH 3
3 3
1. Z N OH
2. Pd/C
H C CH H C
3 3 CH N
O 3 H
H N
O N N O
N N
O O
HN O CH O CH3 O O CH
3 3
H C CH CH3
3 3
b) O
H C CH H C
3 3 CH
O 3 N
H N
O N N O
N N
O O
O N O CH O CH3 O O CH
3 3
H C CH CH3
3 3
[a): 1. EDCI, DMAP, dichloromethane, RT; 2. H2, ol, RT ; b): HATU, diisopropylamine,
DMF, RT].
WO 87716
Scheme 8
H C CH H C
3 3 CH
O 3 O
H N
HO N N O
N N
O O
O CH O CH O O
3 3 CH
CH 3 H C
H C CH 3 3
3 3
H C CH H C
3 3 CH O
O O 3
H N
O N N O
N N N
O O
O CH O CH O O CH
3 3 3 H C
O H C CH CH
3 3
3 3
[a): EDCI, dichloromethane, RT].
2012/075277
Scheme 9
H C CH H C
3 CH
3 3 3 O
O H
H N
HO N N NH2
N N
O O
O CH O CH3 O O CH
3 3
H C CH CH3
3 3
a) Bn
2. Pd/C
H C CH H C
3 CH
3 3 3 O
O H
H H N
N N N NH2
N N
O O
O O CH O CH3 O O CH
3 3
H C CH CH3
3 3
OH N
H C CH H3C
3 CH
3 O 3 O
H H N
N N N NH2
N N
O O
O O CH O CH O O
3 CH
3 CH 3
O H3C CH3 3
O N
N H
[a): HATU, diisopropylethylamine, DMF, RT; 2. H2, methanol, RT; b): EDCI, DMAP,
dichloromethane, RT].
WO 87716
Scheme 10
H C CH H3C
3 CH
3 3 O
O H
H N
HO N N N
N N H
O O
O CH O CH3 O O CH
3 3
H C CH CH3
3 3
CH O
H3C 3
1. NH2
H3C O
a) CH
2. TFA
H3C CH3 H C
3 CH3 O
O O H
H H N
N N N N
HO N N H
O O
H C O CH O CH O O CH
3 3 3 3
H3C CH3 CH
O H C CH H C
3 CH
3 3 O
O O H
H H N
N N N N N
O N N H
O O
O H C O CH3 O CH O O
3 CH3
H C CH CH
3 3
[a): 1. HATU, diisopropylethylamine, DMF, RT; 2. dichloromethane, RT; b): EDCI, DMAP,
dichloromethane, RT].
2012/075277
Scheme 11
H C CH H C
3 3 CH
3 N
O H
H N
N N O
H N N
2 N
O O
CH O CH O O
3 3 CH
H CH CH 3
C 3
3 3
O O
O O
a) N N
O O
O O
H C CH H C
3 CH N
O O 3 3 O 3
H N
N N O
O N N N
H O O
N CH O CH O O
3 CH
O 3
O H C CH CH 3
3 3
[a): Diisopropylethylamine, DMF, RT].
Scheme 12
H C CH H C
3 3 CH N
O 3 H
H N
HO N N O
N N
O O
O CH O CH O O
3 3 CH
H C CH CH
3 3
H C O O
3 OH
1. H C
3 CH HN
3 CH3
2. TFA
H C CH H C
3 CH
3 3 N
O 3
H N
O N N O
H N N N
2 O O
CH O CH O CH O O CH
3 3 3
H C CH CH 3
3 3
x TFA
O O
O O
b) N N
O O
O O
H C CH H C O
3 3 CH
O 3 N
H N
O N N O
HN N N
O O
CH O CH O CH O O CH
O 3 3 3 3
H C CH CH
3 3
O O
[a): 1. EDCI, DMAP, dichloromethane, RT; 2. romethane, RT; b): diisopropylamine,
DMAP, dichloromethane, RT].
2012/075277
Scheme 13
H C CH H3C
3 CH
3 O 3 N
H N
O N N O
N N
O O
HN O CH O CH O O CH
3 3
H3C CH3 CH 3
O O
O O
a) N N
O O
O O
H C CH H C
3 CH
3 3 N
O H
H N
O N N O
N N
O O
O N O CH O CH3 O O CH
3 3
H C CH CH3
3 3
[a): DMAP, diisopropylamine, dichloromethane, RT].
Scheme 18
H C CH H C O
3 CH
3 3 O 3 N
H N
N N O
HN N x TFA
O O
CH O CH O O
3 3 H C H C
CH 3 3
H C CH 3
3 3
1. H
HN NaCNBH3
a) Z O
2. Pd/C
C CH C O
H H
3 3 CH N
O 3
H N
H N N N
2 O
N N
O O
CH O CH O O
3 3 H C H C
CH 3 3
H C CH 3
3 3
H C CH H C
3 3 CH
3 N
O H
H N
N N O
N N
O O
O NH CH O CH O O
3 3 H C H C
3 3
O H C CH CH
3 3
[a): 1. dioxane, 1N HCl, 100°C; 2. H2, Pd/C, methanol, RT; b): HATU,
diisopropylethylamine, RT].
The compounds of the formula (IV) can be prepared from commercially available amino acid
building blocks or those known from the literature (see, for e, Pettit et al., Synthesis 1996,
719; Shioiri et al., Tetrahedron Lett. 1991, 32, 931; Shioiri et al., Tetrahedron 1993, 49, 1913;
Koga et al., Tetrahedron Lett. 1991, 32, 2395; Vidal et al., Tetrahedron 2004, 60, 9715; Poncet et
al., Tetrahedron 1994, 50, 5345. Pettit et al., J. Org. Chem. 1994, 59, 1796) in analogy to
processes known from the literature, in accordance with customary methods of peptide chemistry,
and as described in the present mental section. The synthesis schemes below (Scheme 14 to
16) illustrate the preparation by way of example.
Scheme 14
OMe OH
H O
O N H N
O O N
O H N
H C O 2 O
3 H C O
a) 3 b)
3 CH H C
3 3 CH
[ a): Hydroxylamine hydrochloride, KOH, MeOH, 0°C → RT; b): BrCH2(CH2)2CH2Br, K2CO3,
acetone, ].
Scheme 15
3 1. H CH
O N 3
H C OH
3 H C
O O
H C CH
O CH 3 3
H N O CH
HN 3 2 3
CH N
3 CH
CH O O CH 2. H2, Pd/C
3 3 CH O O CH
CH 3 3
3 H C CH CH
3 3 3
[a): 1. Diisopropylethylamine, BEP, dichloromethane, -10°C → RT; 2. MeOH].
Scheme 16
H C CH
CH OH
H C 3
H N O CH N
2 3
N 3
CH H C
3 3 O O O
CH O O CH O CH
H C CH 3 CH 3
3 3 3
O O
1. 1. N
H C CH
3 3
FmocH C OH b)
3 a) H N
2 x 2 TFA
CH3 O 2. TFA
2. TFA
H C CH H C
3 3 3 CH
3 N
O H
H N
FmocH C N OH +
3 N O
N N H
O O
CH O CH O O x TFA
3 CH
H C CH 3 CH 3
3 3 3
H C CH H C CH
3 3 3 3 N
O H
H N
N N O
HN N
O O
CH O CH O O
3 H C CH 3 CH
CH 3
3 3 3
[ a): 1. Diisopropylethylamine, BEP, DMF, RT; 2. dichloromethane; b): 1. HATU,
ropylethylamine, DMF, RT; 2. romethane, RT; c): 1. HATU, diisopropylethylamine,
DMF, RT; 2. piperidine, DMF, RT].
The compounds of the formulae (XI), (XIII), (XV), (XVII) and (XXI), including, where
appropriate, chiral or diastereomeric forms thereof, are available commercially or are bed as
such in the literature, or they can be prepared by routes that are obvious to the skilled person, in
analogy to methods published in the literature. Numerous comprehensive instructions and also
literature information on the preparation of the starting materials are also given in the experimental
n, in the section relating to the preparation of the starting compounds and intermediates.
The compounds of the formulae (V), (VII), (VIII), (X), (XVIII), (XX) and (XXIII), including,
where appropriate, chiral or diastereomeric forms f, are known from the literature, or can be
prepared by routes which are obvious to the skilled person, in analogy to methods published in the
literature. Numerous comprehensive instructions and also literature ation on the preparation
of the starting materials are also given in the experimental section, in the section relating to the
preparation of the starting compounds and intermediates.
Alternatively, individual steps of the preparation ce may be d out in a different order
or with other protective group combinations. This approach is illustrated by way of example in the
synthesis schemes below (Scheme 17, 19, 20 and 21).
2012/075277
Scheme 17
H CH O
H N
H C OH
HN 3 N
HN OH
O H C CH
3 3
O O
O O H C CH
3 3
CH CH
3 3
O 3 H C CH H C
3 3 O 3
H N O CH
2 3 H
N CH N OH
CH O O CH N N
H C CH 3 CH
3 3 3 HN O CH O CH O O
3 H C CH 3 CH
3 3 3
3 N
N O
c) O O
x TFA
H C CH H C
3 3 O 3 CH
3 N
H N
N N O
N N
O O
HN O CH O CH O O
3 CH
H C CH 3 CH 3
3 3 3
1. H2
O O
N O
O H C CH H C
3 3 CH N
O 3 3
H N
N N N O
N N
O O
O CH O CH O O
3 CH
H C CH 3 CH 3
3 3 3
[ a): Borane-pyridine complex, acetic acid, MeOH; b): 1. HOBt, EDCI, diisopropylethylamine,
DMF, RT; 2. TFA, dichloromethane, RT; c): HATU, diisopropylethylamine, DMF, RT; d): 1.
Pd/C, MeOH, RT; 2. NaHCO3, dioxane, water].
Scheme 19
H3C CH3
CH 1. CH
3 OH 3
O N
H C H C
3 CH H C
O CH3 O O 3 O 3
3 CH
H N O CH CH 3 H
2 3 N OH
N CH O N N
CH O O CH
3 3 CH O CH O O
H C CH CH a) 3 3
3 H C
3 CH
3 H C CH CH
3 3 CH 3 3 3
N b)
O O
3 CH H C
3 3 CH
O O 3
H O
N N
O N N
O O
CH O CH O O CH
H C 3 CH 3 CH 3
3 CH
CH 3 H C
3 3 3
2. O
H C CH H C
3 O 3 CH NH
3 3 2
H N
N N O
HN N
O O
CH O CH O O
3 H C CH 3 CH
CH 3
3 3 3
[ a): 1. HATU, diisopropylethylamine, DMF, RT; 2. TFA, dichloromethane, RT; 3.
((H3C)3C(C=O))2O, DMF, diisopropylethylamine; b): diisopropylethylamine, BEP, DMF, RT; c):
1. H2, Pd/C (10%), methanol, RT; 2. HATU, diisopropylethylamine, DMF, RT; 3. TFA,
dichloromethane, RT].
Scheme 20
N CH O
H H C OH
HN N
H C CH3 HN OH
O 3
O O
O O H C CH
a) 3 3
CH3 CH
1. 3
O 3 H C CH H C
3 3 O 3
H2N O CH
3 H
N CH3 N OH
CH3 O O CH N N
H3C CH3 CH 3
3 NH CH O CH O O
2 3 H C CH 3 CH
3 3 3
O O 3
N O O O
2. H
3 N OH
O N N
CH O O
c) O H C CH CH
3 3 3
CH3 N
N O d)
O O
x CF3 COOH H
H C O
3 CH
3 N
O O H
H N
N N O
N N
O O
CH O O CH 3
O H C CH CH 3
3 3 3
[a): Borane-pyridine complex, acetic acid, MeOH; b): 1. HOBt, EDCI, diisopropylethylamine,
DMF, RT; 2. TFA, dichloromethane, RT; 3. H2, Pd/C, MeOH, RT c): 1. , dioxane, water;
d): HATU, diisopropylethylamine, DMF, RT].
2012/075277
Scheme 21
H N O CH
2 N 3
CH O O CH
H C CH 3 CH
3 3 3
z O
1. N
H C OH
3 a)
H C CH
3 3
2. H b) CH
2 3
CH CH OH
C 3
3 H N
H C CH H C
3 3 H C
O 3 3 O O O
O CH
H CH 3
O 3
HN N CH
CH O CH O O CH
3 NH
H C CH 3 CH 3 O O
3 3 3 1. N e)
2 x TFA
H c)
2. TFA
O d)
H C CH H C
3 3 O 3 CH
3 N
H N
BnO N OH N O
N N H
+ O O
O CH O CH O O
3 CH
H C CH 3 CH x TFA 3
3 3 3
H C CH H C
3 3 CH
O 3 3 N
H N
HO N N O
N N
O O
O CH O CH O O
3 CH
H C CH 3 CH 3
3 3 3
[a): 1. HOBt, EDCI, diisopropylethylamine, DMF, RT; b) H2, Pd/C, MeOH, RT; c) boranepyridine
complex, acetic acid, MeOH; d) TFA, dichloromethane, RT; e): HATU,
diisopropylethylamine, DMF, RT; f): HATU, diisopropylethylamine, DMF, RT; g) H2, Pd/C,
MeOH, RT].
WO 87716
The FGFR2 cancer target molecule of the binder of the present ion is known to the skilled
person. The full-length FGFR2 is identified as FGFR2 alpha (SEQ ID NO: 1), while the isoform
lacking the D1 domain is identified as FGFR2 beta (SEQ ID NO: 2) (see Figure 1). Alternative
splicing in domain 3 leads to two different variants, namely FGFR2 IIIb, which is encoded by the
exons 7 and 8, and FGFR2 IIIc, which is encoded by the exons 7 and 9 (see Figure 1).
In one embodiment of the ion the binder binds – preferably specifically – to FGFR2. In a
further subject of the invention, the binder binds – preferably specifically – to the extracellular
domain of the target molecule FGFR2 (see Figure 1).
In a further embodiment of the invention, the binder binds – preferably specifically – to one or
more forms of the human FGFR2 polypeptide. In a further subject of the invention, the binder
binds – preferably specifically – to all isoforms and splice variants of FGFR2. In the text below,
the concept of different “forms” of FGFR2 includes, though is not limited to, different isoforms,
different splice variants, different glycoforms or FGFR2 polypeptides which o different
translational and post-translational modifications.
In a r embodiment of the invention, the binder binds - preferably specifically – to the N-
terminal domains of the cancer target molecule FGFR2. In a further t of the invention, the
binder binds – preferably specifically – to the extracellular N-terminal epitope
SLVEDTTLEPE 15 ) of FGFR2 (SEQ ID NO: 23).
In a further embodiment of the invention, the binder also binds – preferably specifically – to the
FGFR2 of different s. The effect of this is that the conjugates of the invention can more
easily, pharmacologically, be investigated in these s. Preferred species are rodents, more
particularly mice or rats, but also dogs, pigs and non-human es.
In one preferred embodiment the binder, after binding to FGFR2 on the target cell, is internalized
by the target cell as a result of the binding. The effect of this is that the binder-drug conjugate,
which may be an immunoconjugate or an ADC, is taken up by the target cell.
In one embodiment the binder is a binding n. In one red embodiment the binder is an
antibody, an antigen-binding antibody fragment, a pecific antibody or an antibody mimetic.
Preferred antibody mimetics are affibodies, adnectins, anticalins, DARPins, avimers, or
nanobodies. Preferred multispecific antibodies are bispecific and cific antibodies.
In one preferred embodiment the binder is an antibody or an antigen-binding antibody fragment,
more preferably an isolated antibody or an isolated antigen-binding antibody fragment.
Preferred antigen-binding antibody fragments are Fab, Fab’, F(ab’)2 and Fv fragments, diabodies,
DAbs, linear antibodies and scFv. Particularly preferred are Fab, ies and scFv.
In one particularly preferred embodiment the binder is an antibody. Particularly preferred are
monoclonal antibodies or antigen-binding antibody fragments thereof. Further particularly
preferred are human, humanized or chimeric antibodies or antigen-binding antibody fragments
thereof.
In one preferred embodiment, the antibody or the antigen-binding fragment comprises the amino
acid sequence of the CDR sequences of the variable light and heavy chain of the antibody M048-
D01-hIgG1.
In a further red embodiment, the dy or the antigen-binding fragment comprises the
amino acid sequence of the CDR sequences of the variable light and heavy chain of the antibody
M048-D01-hIgG1 represented in SEQ ID NO: 15 (H-CDR1), SEQ ID NO: 16 (H-CDR2), SEQ ID
NO: 17 (H-CDR3), SEQ ID NO: 18 (L-CDR1), SEQ ID NO: 19 2) and SEQ ID NO: 20
(L-CDR3).
In a further preferred embodiment, the dy or the antigen-binding fragment comprises the
amino acid sequence of the variable light and heavy chains of the dy M048-D01-hIgG1 or
M048-D01-hIgG1-b.
In a further preferred embodiment, the antibody or the n-binding fragment comprises the
amino acid sequence of the variable light and heavy chains of the antibody M048-D01-hIgG1,
represented in SEQ ID NO: 12 (Vl) and SEQ ID NO: 11 (Vh), or of the variable light and heavy
chains of the antibody 01-hIgG1-b, ented in SEQ ID NO: 14 (Vl) and SEQ ID
NO: 13 (Vh).
In a further particularly preferred embodiment, the antibody or the antigen-binding fragment
comprises the amino acid sequence of the variable light and heavy chain of the antibody M048-
D01- hIgG1-b represented in SEQ ID NO: 14 (Vl) und SEQ ID NO: 13 (Vh).
In a further particularly red embodiment, the antibody comprises the amino acid ce of
the light and heavy chain of the antibody M048-D01-hIgG1-b represented in SEQ ID NO: 9 (light
chain) and SEQ ID NO: 10 (heavy chain).
In a r particularly preferred embodiment, the antibody comprises the amino acid sequence of
the light and heavy chain of the antibody M048-D01-hIgG1 represented in SEQ ID NO: 7 (light
chain) and SEQ ID NO: 8 (heavy chain).
Examples of further FGFR2 antibodies are the GAL-FR21-mIgG1 (SEQ ID NO: 3 and SEQ ID
NO: 4) and GAL-FR22-mIgG2a (SEQ ID NO: 5 and SEQ ID NO: 6) antibodies that are described
in this invention. The two last-mentioned antibodies were constructed on the basis of
WO2010/054265 from the variable regions, described therein, of the light (Vl) and heavy (Vh)
chains of the antibodies GAL-FR21 (SEQ ID NO: 1 and SEQ ID NO: 4 from WO2010/054265)
and GAL-FR22 (SEQ ID NO: 7 and SEQ ID NO: 8 from WO2010/054265), with the variable
regions of GAL-FR21 having been reformatted into an mIgG1 format, while the variable regions of
22 were reformatted into an mIgG2a format.
Antibodies or antigen-binding antibody fragments which bind cancer target molecules may be
prepared by a person of ordinary skill in the art using known processes, such as, for e,
chemical synthesis or recombinant expression. Binders for cancer target molecules may be
ed commercially or may be prepared by a person of ordinary skill in the art using known
processes, such as, for example, al synthesis or recombinant expression. Further processes
for preparing dies or antigen-binding antibody fragments are described in WO2007070538
(see page 22 “Antibodies”). The skilled person knows how processes such as phage display
libraries (e.g. Morphosys HuCAL Gold) can be compiled and used for discovering antibodies or
antigen-binding antibody fragments (see WO2007070538, page 24 ff and Example 1 on page 70,
Example 2 on page 72). Further processes for ing antibodies that use DNA libraries from
B-cells are described for example on page 26 (WO2007070538). Processes for humanizing
antibodies are described on page 30-32 of WO2007070538 and in detail in Queen, et al., Pros.
Natl. Acad. Sci. USA 86:10029-10033, 1989 or in WO90/0786. Furthermore, processes for the
recombinant expression of proteins in general and of antibodies in particular are known to the
skilled person (see, for example, in Berger and Kimrnel (Guide to Molecular Cloning Techniques,
s in Enzymology, Vo1. 152, Academic Press, Inc.); Sambrook, et al., (Molecular g:
A Laboratory , (Second Edition, Cold Spring Harbor Laboratory Press; Cold Spring
Harbor, N.Y.; 1989) Vol. 1-3); Current Protocols in Molecular Biolony, (F.M. l et al.
, Current Protocols, Green Publishing Associates, Inc./John Wiley & Sons, Inc.); Harlow
et al., (MonocIonal Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press
(19881, Paul [Ed.]); Fundamental Immunology, (Lippincott ms & Wilkins (1998)); and
, et al., (Using Antibodies: A tory Manual, Cold Spring Harbor Laboratory Press
(1998)). The skilled person knows the corresponding vectors, promoters and signal peptides which
are necessary for the expression of a protein/antibody. Commonplace processes are also described
in WO2007070538 on pages 41–45. Processes for preparing an IgG1 antibody are described for
e in WO2007070538 in Example 6 on page 74 ff. Processes which allow the determination
of the alization of an antibody after binding to its antigen are known to the skilled person and
are bed for example in WO2007070538 on page 80. The skilled person is able to use the
processes described in WO2007070538 that have been used for preparing carboanhydrase IX (Mn)
antibodies in y for the preparation of antibodies with different target molecule specificity.
Further examples of FGFR2 binders are the single chain Fv antibody fragments PRO-007 (binds
FGFR2 with high affinity) and PRO-001 (binds FGFR3 with high affinity and FGFR2 with low
affinity) described in WO2007144893.
The compounds of the invention s le pharmacological properties and can be used for
the prevention and treatment of diseases in humans and animals.
The binder-drug conjugates (ADCs) of the invention, of the formula (Ia), exhibit a high and
specific cytotoxic activity with regard to tumour cells, as may be shown on the basis of the assays
set out in the present experimental section (Section C). This high and specific cytotoxic activity on
the part of the binder-drug conjugates (ADCs) of the invention, of the formula (Ia), is achieved
h the appropriate combination of the new N,N-dialkylauristatin derivative and binder with
linkers which exhibit not only an enzymatically, hydrolytically or reductively cleavable
predetermined break point, for the release of the toxophores, but also no such predetermined break
point. More ularly, through the use of stable linkers which have no enzymatically,
hydrolytically or ively cleavable predetermined break point for the release of the toxophores,
and which, following uptake of the ADCs into the tumour cell and following complete
intracellular, enzymatic breakdown of the antibody, still remain wholly or partly intact, the activity
is confined very ically to the tumour cell. Compatibility between ADCs and stable linkers
poses, among other things, that the metabolites formed ellularly can be formed with
sufficient efficacy, are able to reach their target and are able there to develop their antiproliferative
activity on the target with sufficient potency, without being carried out of the tumour
cell again hand by transporter proteins. Such a compatibility of the ADCs with a stabile
linker chemistry and with the target in question offers an enlarged therapeutic window (see, e.g.,
L. Ducry, Bionconjugate Chem. 2010, 21-5; A.G. Polson, Cancer Res. 2009, 69, 2358).
More particularly, the binder-drug conjugates of the invention, of the formula (Ia), exhibit a high
and specific cytotoxic activity with respect to tumour cells which express FGFR2. The activity
with respect to tumour cells which do not express FGFR2 is significantly weaker at the same time.
On the basis of this profile of ties, the nds of the invention are therefore suitable to a
particular degree for the treatment of hyperproliferative diseases in humans and in mammals
generally. The nds are able on the one hand to inhibit, block, reduce or lower cell
proliferation and cell division, and on the other hand to se apoptosis.
The hyperproliferative diseases for the treatment of which the compounds of the invention can be
employed include in particular the group of cancer and tumour es. In the context of the
present invention, these are understood as meaning, in ular, the following diseases, but
without being limited to them: y carcinomas and mammary tumours (ductal and lobular
forms, also in situ, triple-negative, egative), tumours of the atory tract (parvicellular
and non-parvicellular oma, bronchial oma), cerebral tumours (e.g. of the brain stem
and of the alamus, astrocytoma, oblastoma, ependymoma and neuro-ectodermal and
pineal tumours), tumours of the digestive organs (oesophagus, carcinomas of the oesophagogastric
junction (=EGJ), stomach (diffuse and intestinal forms), gall bladder, small intestine, large
intestine, rectum), liver tumours (including hepatocellular carcinoma, cholangiocellular carcinoma
and mixed hepatocellular and cholangiocellular carcinoma), tumours of the head and neck region
(larynx, hypopharynx, nasopharynx, oropharynx, lips and oral cavity), skin s (squamous
epithelial carcinoma, Kaposi sarcoma, malignant melanoma, Merkel cell skin cancer and nonmelanomatous
skin cancer), tumours of soft tissue (including soft tissue sarcomas, osteosarcomas,
malignant fibrous histiocytomas, lymphosarcomas and rhabdomyosarcomas), tumours of the eyes
(including intraocular melanoma and retinoblastoma), tumours of the endocrine and exocrine
glands (e.g. thyroid and parathyroid glands, pancreas and salivary gland), tumours of the urinary
tract (tumours of the bladder, penis, kidney, renal pelvis and ureter) and tumours of the
uctive organs (carcinomas of the endometrium, cervix, ovary, vagina, vulva and uterus in
women and omas of the prostate and testicles in men). These also include proliferative blood
diseases in solid form and as circulating blood cells, such as lymphomas, leukaemias and
myeloproliferative diseases, e.g. acute myeloid, acute lymphoblastic, chronic lymphocytic, chronic
myelogenic and hair cell leukaemia, and also orrelated lymphomas, Hodgkin's lymphomas,
dgkin's lymphomas, cutaneous T-cell lymphomas, Burkitt's lymphomas and lymphomas in
the central nervous system.
Preferred hyperproliferative diseases for anti-FGFR2 binder-drug conjugates
Hyperproliferative diseases for the ent of which the compounds of the invention can be
preferably employed are FGFR2-expressing tumours, such as, for example, stomach oma
(intestinal and diffuse types), signet ring oma, especially of diffuse type, oesophageal cancer,
cancer of the oesophagogastric junction (EGJ), breast cancer, cancer of the large intenstine,
colorectal carcinoma, rectal carcinoma, te cancer, kidney cancer, carcinomas of the head and
neck region, pancreatic cancer, liver cancer, cervical carcinoma, ovarian carcinoma, endometrial
carcinoma, more particularly of trioid type, of papillary serous type, or of clear cell
subtype, lung cancer, more particularly non-small-cell lung carcinoma (NSCLC), adenocarcinoma,
us carcinoma and pancreatic carcinoma.
These well-described diseases in humans can also occur with a comparable aetiology in other
mammals and can be treated there with the compounds of the present invention.
In the context of this ion, the term "treatment" or "treat" is used conventionally and means
the care, management and support of a patient with the aim of combatting, shing, attenuating
or relieving a disease or health defect and of ing the living ions which are adversely
affected by this e, such as in the case of a cancer disease.
The present ion thus further provides the use of the compounds of the invention for the
treatment and/or prevention of diseases, in particular the abovementioned es.
The present invention furthermore provides the use of the compounds of the invention for the
preparation of a medicament for the treatment and/or prevention of diseases, in particular the
abovementioned diseases.
The present invention furthermore provides the use of the compounds of the invention in a method
for the treatment and/or prevention of diseases, in particular the abovementioned es.
The present invention furthermore provides a method for the treatment and/or prevention of
diseases, in particular the abovementioned diseases, using an effective amount of at least one of
the compounds of the invention.
The compounds according to the invention can be employed by themselves or, if required, in
combination with one or more other pharmacologically active substances, as long as this
combination does not lead to undesirable and ptable side effects. The present invention
furthermore therefore es medicaments comprising at least one of the compounds of the
invention and one or more further drugs, in particular for the treatment and/or prevention of the
abovementioned diseases.
For e, the compounds of the present invention can be combined with known
antihyperproliferative, cytostatic or cytotoxic nces for the treatment of cancer diseases.
Suitable drugs in the combination which may be mentioned by way of example are as follows:
eukin, alendronic acid, alfaferone, alitretinoin, allopurinol, aloprim, aloxi, altretamine,
aminoglutethimide, amifostine, amrubicin, ine, anastrozole, anzmet, aranesp, arglabin,
arsenic trioxide, aromasin, 5-azacytidine, azathioprine, BCG or CG, bestatin, betamethasone
acetate, betamethasone sodium phosphate, bexarotene, bleomycin sulphate, broxuridine,
bortezomib, busulfan, calcitonin, campath, capecitabine, carboplatin, casodex, ne,
celmoleukin, cerubidin, chlorambucil, cisplatin, cladribin, clodronic acid, cyclophosphamide,
cytarabine, dacarbazine, dactinomycin, daunoxome, decadron, on phosphate, delestrogen,
denileukin diftitox, depomedrol, deslorelin, dexrazoxane, diethylstilbestrol, diflucan, docetaxel,
doxifluridine, doxorubicin, dronabinol, DW-166HC, eligard, elitek, ellence, emend, epirubicin,
n-alfa, epogen, eptaplatin, ergamisol, e, estradiol, estramustine sodium phosphate,
ethinylestradiol, ethyol, etidronic acid, etopophos, etoposide, fadrozole, farstone, filgrastim,
finasteride, fligrastim, floxuridine, fluconazole, fludarabin, 5-fluorodeoxyuridine monophosphate,
-fluorouracil (5-FU), fluoxymesterone, ide, formestane, fosteabine, fotemustine,
fulvestrant, gammagard, gemcitabine, gemtuzumab, gleevec, gliadel, goserelin, granisetron
hydrochloride, histrelin, hycamtin, hydrocortone, erythro-hydroxynonyladenine, hydroxyurea,
ibritumomab tiuxetan, idarubicin, ifosfamide, eron-alpha, interferon-alpha-2, eron-
alpha-2α, interferon-alpha-2β, interferon-alpha-n1, interferon-alpha-n3, interferon-beta, interferongamma-1α
, interleukin-2, intron A, iressa, ecan, kytril, lentinan sulphate, letrozole,
leucovorin, leuprolide, leuprolide acetate, levamisole, levofolic acid calcium salt, levothroid,
levoxyl, lomustine, lonidamine, marinol, mechlorethamine, mecobalamin, medroxyprogesterone
acetate, megestrol acetate, melphalan, menest, 6-mercaptopurine, mesna, methotrexate, metvix,
osine, minocycline, mitomycin C, mitotane, mitoxantrone, modrenal, myocet, atin,
neulasta, a, neupogen, mide, nolvadex, NSC-631570, OCT-43, octreotide,
ondansetron hydrochloride, orapred, oxaliplatin, paclitaxel, pediapred, pegaspargase, s,
pentostatin, picibanil, pilocarpine hydrochloride, pirarubicin, plicamycin, porfimer sodium,
prednimustine, prednisolone, prednisone, in, procarbazine, t, raltitrexed, rebif,
rhenium-186 etidronate, rituximab, roferon-A, romurtide, salagen, sandostatin, sargramostim,
semustine, sizofiran, sobuzoxane, solu-medrol, streptozocin, strontium-89 de, synthroid,
tamoxifen, tamsulosin, tasonermin, tastolactone, taxoter, teceleukin, temozolomide, side,
testosterone propionate, testred, thioguanine, thiotepa, thyrotropin, onic acid, topotecan,
toremifen, tositumomab, tastuzumab, teosulfan, tretinoin, l, trimethylmelamine, trimetrexate,
triptorelin acetate, triptorelin pamoate, UFT, uridine, valrubicin, vesnarinone, vinblastine,
vincristine, vindesine, vinorelbine, virulizin, zinecard, zinostatin-stimalamer, zofran; ABI-007,
acolbifen, actimmune, affinitak, aminopterin, arzoxifen, asoprisnil, tane, atrasentan, n,
BAY 43-9006 (sorafenib), CCI-779, 1, celebrex, cetuximab, crisnatol, cyproterone acetate,
decitabine, DN-101, doxorubicin-MTC, dSLIM, dutasteride, edotecarin, eflornithine, an,
fenretinide, histamine dihydrochloride, histrelin el implant, holmium-166 DOTMP,
onic acid, interferon-gamma, intron-PEG, ixabepilone, keyhole limpet hemocyanine, L-
651582, lanreotide, lasofoxifen, libra, lonafarnib, miproxifen, minodronate, MS-209, liposomal
MTP-PE, MX-6, nafarelin, bicin, neovastat, nolatrexed, oblimersen, onko-TCS, osidem,
paclitaxel polyglutamate, pamidronate disodium, PN-401, QS-21, quazepam, R-1549, raloxifen,
ranpirnas, 13-cis -retic acid, satraplatin, seocalcitol, T-138067, tarceva, exin, thymosinalpha-1
, tiazofurin, tipifarnib, tirapazamine, TLK-286, toremifen, transMID-107R, valspodar,
vapreotide, nib, verteporfin, vinflunin, Z-100, onic acid and combinations of these.
In a preferred embodiment, the compounds of the present invention can be combined with
antihyperproliferative agents, which can be, by way of example – without this list being conclusive
as follows:
aminoglutethimide, L-asparaginase, azathioprine, 5-azacytidine, bleomycin, busulfan, carboplatin,
carmustine, chlorambucil, cisplatin, colaspase, cyclophosphamide, cytarabine, dacarbazine,
dactinomycin, daunorubicin, lstilbestrol, 2',2'-difluorodeoxycytidine, docetaxel, doxorubicin
(adriamycin), epirubicin, epothilone and its derivatives, erythro-hydroxynonyladenin, ethinylestradiol
, etoposide, fludarabin phosphate, 5-fluorodeoxyuridine, 5-fluorodeoxyuridine monophosphate
, rouracil, fluoxymesterone, flutamide, hexamethylmelamine, hydroxyurea,
hydroxyprogesterone caproate, idarubicin, ifosfamide, interferon, irinotecan, orin,
lomustine, rethamine, medroxyprogesterone acetate, megestrol acetate, melphalan,
6-mercaptopurine, mesna, methotrexate, mitomycin C, mitotane, mitoxantrone, paclitaxel,
pentostatin, N-phosphonoacetyl L-aspartate (PALA), ycin, prednisolone, prednisone,
bazine, raloxifen, semustine, ozocin, tamoxifen, teniposide, testosterone propionate,
thioguanine, thiotepa, can, trimethylmelamine, uridine, stine, vincristine, vindesine
and vinorelbine.
The compounds of the invention can also be combined in a very promising manner with biological
therapeutics such as antibodies (e.g. avastin, rituxan, erbitux, herceptin). The nds of the
invention can also achieve positive effects in combination with therapies directed against
angiogenesis, such as, for example, with avastin, ib, recentin, regorafenib, sorafenib or
nib. Combinations with inhibitors of the proteasome and of mTOR and also with
antihormones and steroidal metabolic enzyme inhibitors are likewise particularly suitable because
of their favourable profile of side effects.
Generally, the following aims can be pursued with the combination of compounds of the present
invention with other agents having a cytostatic or cytotoxic action:
• an ed activity in slowing down the growth of a tumour, in reducing its size or even in
its complete elimination compared with treatment with an individual drug;
• the possibility of employing the chemotherapeutics used in a lower dosage than in
monotherapy;
• the possibility of a more tolerable therapy with few side effects compared with individual
administration;
• the possibility of ent of a broader spectrum of tumour diseases;
2012/075277
• the achievement of a higher rate of response to the therapy;
• a longer survival time of the patient compared with present-day standard therapy.
The compounds according to the invention can moreover also be employed in combination with
radiotherapy and/or surgical intervention.
The present invention furthermore provides medicaments which comprise at least one compound
of the invention, conventionally together with one or more inert, xic, ceutically
suitable ents, and the use thereof for the abovementioned purposes.
The compounds of the invention can act ically and/or locally. They can be administered in a
suitable manner for this purpose, such as for example parenterally, possibly by means of
inhalation, or as an implant or stent.
The compounds of the invention can be stered in suitable administration forms for these
administration routes.
Parenteral administration can be effected with bypassing of an absorption step (e.g. intravenously,
intraarterially, intracardially, intraspinally or intralumbally) or with inclusion of an tion (e.g.
intramuscularly, subcutaneously, intracutaneously, percutaneously or intraperitoneally).
Administration forms which are suitable for parenteral administration include injection and
infusion formulations in the form of solutions, suspensions, emulsions or lizates. Parenteral
administration is preferred, in particular intravenous stration.
In general, it has proved advantageous in the case of parenteral administration to administer
amounts of from about 0.001 to 1 mg/kg, preferably about 0.01 to 0.5 mg/kg of body weight to
achieve effective results.
heless it may be necessary to deviate from the amounts mentioned, and in particular
depending on the body weight, administration route, individual behaviour towards the active
nd, nature of the formulation and point of time or interval at which administration takes
place. Thus in some cases it may be sufficient to manage with less than the abovementioned
minimum amount, while in other cases the upper limit mentioned must be exceeded. In the case
where relatively large amounts are administered, it may be advisable to distribute these into several
individual doses over the day.
The following es illustrate the invention. The invention is not d to the examples.
The percentage figures in the following tests and examples are percentages by weight, unless
stated otherwise; parts are parts by weight. Solvent , dilution ratios and concentration data of
liquid/liquid solutions in each case relate to the volume.
A. Examples
Abbreviations and acronyms:
ABCB1 ATP-binding te sub-family B member 1 (synonym for P-gp
and MDR1)
abs. te
ADC antibody-drug-conjugate
Ac acetyl
aq. aqueous, aqueous solution
ATP adenosine triphosphate
BCRP breast cancer resistance n, an efflux transporter
Boc tert -butoxycarbonyl
br. broad (in NMR)
Ex. example
ca . circa , approximately
CAIX carboanhydrase IX
CI chemical ionization (in MS)
d doublet (in NMR)
d day(s)
TLC thin-layer chromatography
DCI direct chemical ionization (in MS)
dd t of a doublet (in NMR)
DMAP 4-N,N -dimethylaminopyridine
DME methoxyethane
DMEM Dulbecco’s modified eagle medium (standardized nutrient medium
for cell culture)
DMF N,N -dimethylformamide
DMSO dimethyl sulphoxide
DPBS, D-PBS, PBS Dulbecco's phosphate-buffered saline solution
PBS = DPBS = D-PBS, pH 7.4, from Sigma, No. D8537
Composition:
0.2 g KCl
0.2 g KH2PO 4 (anhydrous)
8.0 g NaCl
1.15 g Na2HPO 4 (anhydrous)
make up to 1 l with H2O
dt doublet of a triplet (in NMR)
WO 87716
DTT hiothreitol
EDC N' -(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride
EGFR epidermal growth factor receptor
EI electron impact ionization (in MS)
ELISA enzyme-linked immunosorbent assay
eq. equivalent(s)
ESI electrospray ionization (in MS)
ESI-MicroTofq ESI- MicroTofq (name of the mass spectrometer, with Tof = time of
flight and q = quadrupole)
FCS foetal calf serum
FGFR2 fibroblast growth factor or 2
Fmoc (9H-fluorenylmethoxy)carbonyl
sat. saturated
GTP guanosine 5'-triphosphate
h hour(s)
HATU O-(7-azabenzotriazolyl)-N,N,N',N' -tetramethyluronium
hexafluorophosphate
HEPES 4-(2-hydroxyethyl)piperazineethanesulphonic acid
HOAc acetic acid
HOBt 1-hydroxy-1H-benzotriazole e
HOSu N-hydroxysuccinimide
HPLC high-pressure, high-performance liquid chromatography
IC 50 half-maximum inhibitory concentration
i.m. intramuscular, administration into the muscle
i.v. intravenous, administration into the vein
Kato III human tumour cell line
conc. concentrated
LC-MS liquid chromatography-coupled mass spectrometry
LLC-PK1 cells Lewis lung carcinoma pork kidney cell line
L-MDR human MDR1 transfected LLC-PK1 cells
m multiplet (in NMR)
MDA-MB-231 human tumour cell line
MDR1 multidrug ence protein 1
MFM-223 human tumour cell line
min minute(s)
MS mass spectrometry
MTT 3-(4,5-dimethylthiazol yl)-2,5-di phenyl trazolium bromide
NCI-H716 human tumour cell line
NMM N-methylmorpholine
NMP N-methylpyrrolidinone
NMR nuclear magnetic resonance spectrometry
NMRI mouse strain, originating from Naval Medical Research Institute
(NMRI)
Nude mice experimental animals
NSCLC all cell lung cancer (non-parvicellular bronchial carcinoma)
PBS phosphate-buffered saline solution
Pd/C palladium on activated carbon
P-gp P-glycoprotein, a orter protein
PNGaseF enzyme for sugar elimination
quant. quantitative (for yield)
quart quartet (in NMR)
quint quintet (in NMR)
Rf retention index (for TLC)
RT room temperature
Rt retention time (for HPLC)
s singlet (in NMR)
s.c. subcutaneous, administration beneath the skin
SCID mice experimental mice with a severe combined immunodeficiency
SNU-16 human tumour cell line
SUM52-PE human tumour cell line
t t (in NMR)
tert ry
TFA trifluoroacetic acid
THF tetrahydrofuran
UV ultraviolet spectrometry
v/v volume to volume ratio (of a solution)
Z benzyloxycarbonyl
WO 87716
HPLC and LC-MS methods:
Method 1 (LC-MS):
Instrument: Waters Acquity SQD UPLC ; column: Waters Acquity UPLC HSS T3 1.8µ
50 mm x 1 mm; eluent A: 1 l water + 0.25 ml 99% strength formic acid, eluent B: 1 l acetonitrile +
0.25 ml 99% strength formic acid; gradient: 0.0 min 90% A → 1.2 min 5% A → 2.0 min 5% A;
flow rate: 0.40 ml/min; oven: 50°C; UV ion: 210-400 nm.
Method 2 (LC-MS):
Instrument: ass QuattroPremier with Waters UPLC Acquity; column: Thermo il
GOLD 1.9µ 50 mm x 1 mm; eluent A: 1 l water + 0.5 ml 50% strength formic acid, eluent B: 1 l
acetonitrile + 0.5 ml 50% th formic acid; gradient: 0.0 min 90% A → 0.1 min 90% A → 1.5
min 10% A → 2.2 min 10% A; flow rate: 0.33 ml/min; oven: 50°C; UV detection: 210 nm.
Method 3 (LC-MS):
Instrument: Micromass Quattro Micro MS with HPLC Agilent Series 1100; column: Thermo
Hypersil GOLD 3µ 20 mm x 4 mm; eluent A: 1 l water + 0.5 ml 50% strength formic acid, eluent
B: 1 l acetonitrile + 0.5 ml 50% th formic acid; gradient: 0.0 min 100% A → 3.0 min 10% A
→ 4.0 min 10% A → 4.01 min 100% A (flow rate 2.5 ml/min) → 5.00 min 100% A; oven: 50°C;
flow rate: 2 ml/min; UV detection: 210 nm.
Method 4 (LC-MS):
MS instrument: Micromass ZQ; HPLC instrument: HP 1100 Series; UV DAD; column:
Phenomenex Gemini 3µ 30 mm x 3.00 mm; eluent A: 1 l water + 0.5 ml 50% strength formic acid,
eluent B: 1 l acetonitrile + 0.5 ml 50% strength formic acid; gradient: 0.0 min 90% A → 2.5 min
% A → 3.0 min 5% A → 4.5 min 5% A; flow rate: 0.0 min 1 ml/min → 2.5 min/3.0 min/4.5 min
2 ml/min; oven: 50°C; UV detection: 210 nm.
Method 5 (HPLC):
Instrument: HP 1090 Series II; column: Merck Chromolith SpeedROD RP-18e, 50 mm x 4.6 mm;
preliminary column: Merck Chromolith Guard Cartridge Kit RP-18e, 5 mm x 4.6 mm; injection
volume: 5 µl; eluent A: 70% HClO4 in water (4 ml/litre), eluent B: acetonitrile; gradient: 0.00 min
% B → 0.50 min 20% B → 3.00 min 90% B → 3.50 min 90% B → 3.51 min 20% B → 4.00
min 20% B; flow rate: 5 ml/min; column temperature: 40°C.
Method 6 (HPLC):
Instrument: Waters 2695 with DAD 996; column: Merck Chromolith SpeedROD RP-18e, 50 mm x
4.6 mm; Ord. No.: 1.51450.0001, inary column: Merck Chromolith Guard Cartridge Kit RP-
18e, 5 mm x 4.6 mm; Ord. No.: 0.0001, eluent A: 70% HClO4 in water (4 ml/litre), eluent
B: acetonitrile; gradient: 0.00 min 5% B → 0.50 min 5% B → 3.00 min 95% B → 4.00 min 95%
B; flow rate: 5 ml/min.
Method 7 (LC-MS):
MS instrument: Waters ZQ; HPLC instrument: Agilent 1100 ; UV DAD; column: Thermo
Hypersil GOLD 3µ 20 mm x 4 mm; eluent A: 1 l water + 0.5 ml 50% strength formic acid, eluent
B: 1 l acetonitrile + 0.5 ml 50% strength formic acid; gradient: 0.0 min 100% A → 3.0 min 10% A
→ 4.0 min 10% A → 4.1 min 100% A (flow rate 2.5 ml/min); oven: 55°C; flow rate: 2 ml/min;
UV detection: 210 nm.
Method 8 (LC-MS):
MS instrument: Waters ZQ; HPLC instrument: Agilent 1100 Series; UV DAD; column: Thermo
Hypersil GOLD 3µ 20 mm x 4 mm; eluent A: 1 l water + 0.5 ml 50% strength formic acid, eluent
B: 1 l acetonitrile + 0.5 ml 50% th formic acid; gradient: 0.0 min 100% A → 2.0 min 60% A
→ 2.3 min 40% A → 3.0 min 20% A → 4.0 min 10% A → 4.2 min 100% A (flow rate
2.5 ml/min); oven: 55°C; flow rate: 2 ml/min; UV detection: 210 nm.
Method 9 (LC-MS):
Instrument: Waters Acquity SQD UPLC System; column: Waters Acquity UPLC HSS T3 1.8µ
50 mm x 1 mm; eluent A: 1 l water + 0.25 ml 99% strength formic acid, eluent B: 1 l acetonitrile +
0.25 ml 99% strength formic acid; nt: 0.0 min 95% A → 6.0 min 5% A → 7.5 min 5% A;
oven: 50°C; flow rate: 0.35 ml/min; UV detection: 210-400 nm.
Method 10 :
Instrument: Agilent 1200 Series; column: Agilent Eclipse 8 5µ 4.6 mm x 150 mm;
preliminary column: Phenomenex KrudKatcher Disposable Pre-Column; injection volume: 5 µl;
eluent A: 1 l water + 0.01% trifluoroacetic acid; eluent B: 1 l acetonitrile + 0.01% trifluoroacetic
acid; nt: 0.00 min 10% B → 1.00 min 10% B → 1.50 min 90% B → 5.5 min 10% B; flow
rate: 2 ml/min; column temperature: 30°C.
For all reactants or reagents whose preparation is not explicitly described below, they were
ed commercially from generally available sources. For all other reactants or reacents whose
preparation is likewise not described below, and which were not available commercially or were
obtained from sources which are not generally available, a reference is given to the published
literature in which their preparation is described.
Method 11 (LC-MS):
Instrument: Waters ACQUITY SQD UPLC System; column: Waters Acquity UPLC HSS T3 1.8 µ
x 2 mm; eluent A: 1 l water + 0.25 ml 99% strength formic acid , eluent B: 1 l acetonitrile +
0.25 ml 99% strength formic acid; gradient: 0.0 min 90% A → 1.2 min 5% A → 2.0 min 5% A
oven: 50°C; flow rate: 0.60 ; UV ion: 208 – 400 nm.
Method 12 (HPLC):
ment: Agilent 1200 Series with column oven and DAD; column: Merck Chromolith
SpeedROD RP-18e, 50 mm x 4.6 mm; Ord. No.: 1.51450.0001; preliminary column: Merck
Chromolith Guard Cartridge Kit RP-18e, 5 mm x 4.6 mm; Ord. No.: 0.0001; eluent A: 70%
HClO 4 in water (4 ml/litre), eluent B: acetonitrile; gradient: 0.00 min 5% B → 0.50 min 5% B →
3.00 min 95% B → 4.00 min 95% B; flow rate: 5 ml/min; column temperature: 30°C.
Starting Compounds and Intermediates:
Starting nd 1
(2R,3R)[(2S)(tert-butoxycarbonyl)pyrrolidinyl]methoxymethylpropanoic acid (Bocdolaproine
H C CH
3 N
O O O
O CH
3
The title compound can be prepared in various ways according to literature methods; see, for
example, Pettit et al., Synthesis 1996, 719; Shioiri et al., Tetrahedron Lett. 1991, 32, 931; Shioiri
et al., Tetrahedron 1993, 49, 1913; Koga et al., Tetrahedron Lett. 1991, 32, 2395; Vidal et al.,
Tetrahedron 2004, 60, 9715; Poncet et al., edron 1994, 50, 5345. It was prepared either as
the free acid or as a 1:1 salt with dicyclohexylamine.
Starting nd 2a
tert-butyl (3R,4S,5S)methoxymethyl(methylamino)heptanoate hydrochloride
soleucine-OtBu x HCl)
H C H C 3
3 3 CH
H C O
3 N
H x HCl
O O
The title compound can be prepared in various ways according to literature methods; see, for
example, Pettit et al., J. Org. Chem. 1994, 59, 1796; Koga et al., Tetrahedron Lett. 1991, 32, 2395;
Shioiri et al., Tetrahedron Lett. 1991, 32, 931; Shioiri et al., Tetrahedron 1993, 49, 1913.
Starting Compound 2b
tert-butyl (3R,4S,5S)methoxymethyl(methylamino)heptanoate
(dolaisoleucine-OtBu)
H C H C 3
3 3 CH
H C O
3 N
O O
The compound was prepared in analogy to starting compound 2a, except that the hydrogenation
was performed without addition of 1N hydrochloric acid.
ng nd 3
Nα-(tert-butoxycarbonyl)-N-hydroxy-L-phenylalaninamide
H C H
3 O N
H3C O
CH O
The title compound was prepared by the literature method (A. Ritter et al., J. Org. Chem. 1994, 59,
4602).
Yield: 750 mg (75% of theory)
LC-MS (Method 3): Rt = 1.67 min; MS (ESIpos): m/z = 281 (M+H)+.
Starting Compound 4
1,2-oxazolidine hydrochloride
x HCl
The title compound can be prepared by literature methods (see, for example, H. King, J. Chem.
Soc. 1942, 432); it is also commercially available.
ng Compound 5
1,2-oxazinane hydrochloride
O x HCl
The title compound can be prepared by literature methods (see, for example, H. King, J. Chem.
Soc. 1942, 432).
Starting Compound 6
2-oxaazabicyclo[2.2.2]octene
The title compound can be prepared in otected form by the literature method (see, for
example, C. Johnson et al., edron Lett. 1998, 39, 2059); the deprotection was effected in a
customary manner by treatment with trifluoroacetic acid and subsequent neutralization.
Yield: 149 mg (89% of theory)
Starting Compound 7
tert-butyl (1S,2R)(hydroxycarbamoyl)phenylcyclopropyl carbamate
H C H
3 O N
H C O
CH O
The title compound was prepared by a literature method (A. Ritter et al., J. Org. Chem. 1994, 59,
4602) proceeding from commercially available (1S,2R)[(tert-butoxycarbonyl)amino]
phenylcyclopropanecarboxylic acid (C. ela et al., Chirality 1999, 11, 583).
Yield: 339 mg (59% of theory)
LC-MS (Method 1): Rt = 0.82 min; MS s): m/z = 293 (M+H)+.
Intermediate 1
tert-butyl ,5S)[{N-[(benzyloxy)carbonyl]-L-valyl}(methyl)amino]methoxy
methylheptanoate
H3C H C 3
O CH3
O N O
O CH O O
H C CH CH3
3 3
10.65 g (41.058 mmol) of utyl (3R,4S,5S)methoxymethyl(methylamino)heptanoate
(starting nd 2b) were taken up in 250 ml of dichloromethane and the solution was cooled
to -10°C. Then, while stirring, 10.317 g (41.058 mmol) of N-[(benzyloxy)carbonyl]-L-valine,
16.866 g (61.586 mmol) of 2-bromoethylpyridinium tetrafluoroborate (BEP) and 28.6 ml of
N,N-diisopropylethylamine were added, and the mixture was subsequently stirred at RT for 20 h.
The reaction mixture was then diluted with dichloromethane and shaken twice with saturated
sodium chloride on, dried over sodium sulphate, filtered and concentrated. The residue was
purified by flash chromatography on silica gel with 4:1 petroleum ether/ethyl acetate as the eluent.
The ponding ons were concentrated and the residue was dried under high vacuum
overnight. 10.22 g (51% of theory) of the title compound were obtained as a yellowish oil.
HPLC (Method 5): Rt = 2.3 min;
LC-MS (Method 2): Rt = 1.59 min; MS (ESIpos): m/z = 493 (M+H)+.
Intermediate 2
tert-butyl (3R,4S,5S)methoxymethyl[methyl(L-valyl)amino]heptanoate
H C 3
3 H C
O 3 CH
H N O
2 N
CH O O
H C CH 3 CH
3 3 3
500 mg (1 mmol) of tert-butyl (3R,4S,5S)[{N-[(benzyloxy)carbonyl]-L-valyl}(methyl)amino]
methoxymethylheptanoate (intermediate 1) were dissolved in 50 ml of methanol and, after
addition of 100 mg of 10% palladium on activated carbon, hydrogenated under standard hydrogen
re at RT for 1 h. The catalyst was then filtered off and the solvent was removed under
reduced pressure. This gave 370 mg (quant.) of the title compound as a lly colourless oil.
HPLC (Method 5): Rt = 1.59 min;
LC-MS (Method 1): Rt = 0.74 min; MS (ESIpos): m/z = 359 (M+H)+.
ediate 3
N-[(9H-fluorenylmethoxy)carbonyl]-N-methyl-L-valyl-N-[(3R,4S,5S)tert-butoxymethoxy-
-methyloxoheptanyl]-N-methyl-L-valinamide
H C CH H C H C 3
3 3 3
O 3
O CH
N O
O N N
CH O CH O O
3 3
H C CH CH
3 3 3
4.64 g (13.13 mmol) of N-[(9H-fluorenylmethoxy)carbonyl]-N-methyl-L-valine were dissolved
in 20 ml of DMF and admixed successively with 4.28 g (11.94 mmol) of tert-butyl (3R,4S,5S)
methoxymethyl[methyl(L-valyl)amino]heptanoate (Intermediate 2), 2.75 g (14.33 mmol) of
1-(3-dimethylaminopropyl)ethylcarbodiimide hydrochloride and 2.2 g (14.33 mmol) of 1-
hydroxy-1H-benzotriazole hydrate. The mixture was stirred at RT overnight. The reaction mixture
was then poured into a mixture of semisaturated aqueous um chloride solution and ethyl
acetate. The organic phase was removed, washed sively with saturated sodium
encarbonate solution and saturated sodium chloride solution, dried over magnesium
sulphate, filtered and concentrated. The residue was used directly in the next stage, without further
purification.
Yield: 9.1 g (quant., 60% purity)
HPLC d 5): Rt = 2.7 min;
LC-MS (Method 2): Rt = 1.99 min; MS (ESIpos): m/z = 694 (M+H)+.
Intermediate 4
N-[(9H-fluorenylmethoxy)carbonyl]-N-methyl-L-valyl-N-[(2R,3S,4S)carboxymethoxy
methylhexanyl]-N-methyl-L-valinamide
H C CH H C
3 3 3
O O
N OH
O N N
CH O CH O O
3 3
H C CH CH
3 3 3
9.1 g of the crude product N-[(9H-fluorenylmethoxy)carbonyl]-N-methyl-L-valyl-N-[(3R,4S,5S)-
1-tert-butoxymethoxymethyloxoheptanyl]-N-methyl-L-valinamide (Intermediate 3)
were taken up in 56.6 ml of dichloromethane, 56.6 ml of trifluoroacetic acid were added, and the
mixture was stirred at RT for 2 h. Subsequently, the reaction mixture was concentrated under
reduced re and the remaining residue was purified by flash chromatography, using
dichloromethane, 3:1 dichloromethane/ethyl acetate and 15:5:0.5 dichloromethane/ethyl
acetate/methanol as eluent. After purification of the corresponding fractions and concentration, 5.8
g (86% of ) of the title compound were ed as a colourless foam.
HPLC (Method 5): Rt = 2.2 min;
LC-MS (Method 1): Rt = 1.3 min; MS (ESIpos): m/z = 638 (M+H)+.
Intermediate 5
tert-butyl (2S)(1,2-oxazinanyl)oxophenylpropanyl carbamate
3 CH3 O
H C N
3 H
O N
500 mg (1.9 mmol) of N-(tert-butoxycarbonyl)-L-phenylalanine were ved in 10 ml of DMF
and admixed successively with 466 mg (3.8 mmol) of 1,2-oxazinane hydrochloride (Starting
Compound 5), 433 mg (2.3 mmol) of imethylaminopropyl)ethylcarbodiimide
hydrochloride, 382 mg (2.8 mmol) of 1-hydroxy-1H-benzotriazole hydrate and 731 mg (5.7 mmol)
of isopropylethylamine. The mixture was stirred at RT overnight. The reaction mixture was
then poured into a mixture of semisaturated aqueous ammonium chloride solution and ethyl
e. The organic phase was removed, washed sively with saturated sodium
hydrogencarbonate solution and saturated sodium chloride solution, dried over magnesium
sulphate, filtered and concentrated. 620 mg (98% of theory) of the title compound were obtained.
HPLC (Method 5): Rt = 1.8 min;
LC-MS (Method 2): Rt = 1.62 min; MS (ESIpos): m/z = 235 (M-C4H8-CO2+H)+.
Intermediate 6
-amino(1,2-oxazinanyl)phenylpropanone trifluoroacetate
CF3COOH x H N
2 O
620 mg (1.85 mmol) of tert-butyl (2S)(1,2-oxazinanyl)oxophenylpropanyl carbamate
(Intermediate 5) were taken up in 5 ml of romethane, 10 ml of trifluoroacetic acid were
added and the mixture was stirred at RT for 30 min. Subsequently, the reaction e was
concentrated under reduced pressure and the remaining residue was lyophilized from
water/acetonitrile. In this way, 779 mg (91% of theory) of the title compound were obtained as a
colourless foam.
HPLC (Method 5): Rt = 0.45 min;
LC-MS (Method 3): Rt = 1.09 min; MS (ESIpos): m/z = 235 (M+H)+.
Intermediate 7
(2R,3R)methoxymethyl-N-[(2S)(1,2-oxazinanyl)oxophenylpropanyl][(2S)-
pyrrolidinyl]propanamide trifluoroacetate
WO 87716
3 N
CF3COOH x N O
O O
360 mg (1.25 mmol) of (2R,3R)[(2S)(tert-butoxycarbonyl)pyrrolidinyl]methoxy
methylpropanoic acid ing Compound 1) were taken up in 10 ml of DMF and admixed
successively with 579.2 mg (1.25 mmol) of (2S)amino(1,2-oxazinanyl)phenylpropan
one trifluoroacetate (Intermediate 6), 714.5 mg (1.88 mmol) of O-(7-azabenzotriazolyl)-
N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU) and 655 µl of N,N-
diisopropylethylamine. The mixture was stirred at RT for 16 h. The reaction mixture was then
concentrated, and the residue was taken up in ethyl acetate and extracted by shaking first with 5%
aqueous citric acid solution, then with 5% aqueous sodium hydrogencarbonate solution and
subsequently with saturated sodium chloride solution. The c phase was concentrated and the
residue was ed by flash chromatography on silica gel with 16:4 dichloromethane/methanol as
the . The corresponding fractions were combined and the solvent was removed under
reduced pressure. After the residue had been dried under high vacuum, 503.5 mg (74% of theory)
of the Boc-protected intermediate utyl (2S)[(1R,2R)methoxymethyl{[(2S)(1,2-
oxazinanyl)oxophenylpropanyl]amino}oxopropyl]pyrrolidinecarboxylate were
obtained.
HPLC (Method 12): Rt = 2.0 min;
LC-MS (Method 1): Rt = 1.12 min; MS (ESIpos): m/z = 504 (M+H)+.
503 mg (1 mmol) of this intermediate were taken up in 20 ml of dichloromethane, 10 ml of
trifluoroacetic acid were added, and the mixture was stirred at RT for 30 min. Subsequently, the
reaction mixture was concentrated under reduced re and redistilled with dichloromethane.
The remaining residue was precipitated from ethyl acetate with n-pentane, and the solvent was
decanted off. The residue thus obtained was ved in water and extracted by shaking with ethyl
acetate, and the aqueous phase was subsequently lyophilized. In this way, 462 mg (89% of theory)
of the title compound were obtained as a colourless foam.
HPLC (Method 12): Rt = 1.53 min;
LC-MS d 11): Rt = 0.57 min; MS (ESIpos): m/z = 404 (M+H)+.
Intermediate 8
N-(tert-butoxycarbonyl)-N-methyl-L-valyl-N-[(2R,3S,4S)carboxymethoxymethylhexan
yl]-N-methyl-L-valinamide
H C CH3 H3C
CH3 O O
N OH
3 O N N
3 CH O CH O O
3 3
H C CH CH3
3 3
51 mg (0.08 mmol) of N-[(9H-fluorenylmethoxy)carbonyl]-N-methyl-L-valyl-N-[(2R,3S,4S)
carboxymethoxymethylhexanyl]-N-methyl-L-valinamide mediate 4) were dissolved
in 10 ml of DMF, and 0.5 ml of piperidine was added. After stirring at RT for 10 min, the reaction
mixture was concentrated under reduced pressure and the residue was stirred with diethyl ether.
The insoluble constituents were ed off and washed repeatedly with diethyl ether. Then the
filter residue was taken up in 5 ml of dioxane/water and the solution was adjusted to pH 11 with 1
N sodium hydroxide solution. Under ultrasound treatment, a total of 349 mg (1.6 mmol) of di-tertbutyl
dicarbonate were added in several ns, in the course of which the pH of the solution was
kept at 11. After the reaction had ended, the dioxane was evaporated off and the aqueous solution
was adjusted to a pH of 2-3 with citric acid. The mixture was extracted twice with 50 ml each time
of ethyl acetate. The organic phases were combined, dried over magnesium sulphate and
concentrated under reduced re. The residue was taken up in diethyl ether and the of the title
nd was precipitated with pentane. The solvent was removed by decantation. The residue
was digested several times more with pentane and finally dried under high vacuum. 40 mg (97% of
) of the title compound were thus obtained.
HPLC d 6): Rt = 2.2 min;
LC-MS (Method 2): Rt = 1.32 min; MS (ESIpos): m/z = 516 (M+H)+.
Intermediate 9
tert-butyl (2S)[(1R,2R)methoxymethyl{[(1S,2R)(1,2-oxazinanylcarbonyl)
phenylcyclopropyl]amino}oxopropyl]pyrrolidinecarboxylate
3 N
H C CH
3 N O
3 O O O
O CH
The title compound was prepared in analogy to the synthesis of Intermediates 5, 6 and 7 over three
stages, by coupling of commercially available (1S,2R)[(tert-butoxycarbonyl)amino]
phenylcyclopropanecarboxylic acid with 1,2-oxazinane hydrochloride (Starting Compound 5),
uent deprotection with trifluoroacetic acid and ng with Starting Compound 1. The end
product was purified by preparative HPLC.
HPLC (Method 5): Rt = 2.12 min;
LC-MS d 2): Rt = 1.25 min; MS (ESIpos): m/z = 516 (M+H)+.
Intermediate 10
N-[(9H-fluorenylmethoxy)carbonyl]-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R)
carboxymethoxypropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-
valinamide
H C CH H C CH
3 3 3 3
O O
H OH
N N
O N N
O O
CH O CH O O CH
3 3 3
H C CH CH
3 3 3
315 mg (0.494 mmol) of N-[(9H-fluorenylmethoxy)carbonyl]-N-methyl-L-valyl-N-[(2R,3S,4S)-
oxymethoxymethylhexanyl]-N-methyl-L-valinamide (Intermediate 4) were
dissolved in 12 ml of DMF, and admixed with 104 mg (0.543 mmol) of 1-(3-
dimethylaminopropyl)ethylcarbodiimide hydrochloride and 83 mg (0.543 mmol) of 1-hydroxy-
1H-benzotriazole hydrate, and the mixture was stirred at RT for 90 min. Subsequently, 112 µl of
N,N-diisopropylethylamine and 149 mg (0.494 mmol) of (2 R,3R)methoxymethyl[(2S)-
pyrrolidinyl]propanoic acid trifluoroacetate, which had been prepared beforehand from Starting
Compound 1 by elimination of the Boc protecting group by means of oroacetic acid, were
added. The mixture was stirred at RT for 2 h and then concentrated under high . The
remaining residue was purified twice by preparative HPLC. 140 mg (35% of theory) of the title
compound were obtained in the form of a colourless foam.
HPLC (Method 5): Rt = 2.40 min;
LC-MS (Method 1): Rt = 1.38 min; MS s): m/z = 807 (M+H)+.
Intermediate 11
N-[(benzyloxy)carbonyl]-N-methyl-L-threonyl-N-[(2R,3S,4S)carboxymethoxy
methylhexanyl]-N-methyl-L-valinamide
H C OH H C
3 3
O O
N OH
O N N
CH O CH O O
3 3
H C CH CH
3 3 3
First, N-[(benzyloxy)carbonyl]-N-methyl-L-threonine was released from 237 mg (0.887 mmol) of
its dicyclohexylamine salt thereof by taking it up in ethyl acetate and extractive shaking with 5%
aqueous sulphuric acid. The organic phase was dried over magnesium sulphate, filtered and
concentrated. The e was taken up in 16 ml of DMF and admixed successively with 365 mg
(1 mmol) of tert-butyl ,5S)methoxymethyl[methyl(L-valyl)amino]heptanoate
(Intermediate 2), 185 mg (0.967 mmol) of 1-(3-dimethylaminopropyl)ethylcarbodiimide
hydrochloride and 148 mg (0.967 mmol) of 1-hydroxy-1H-benzotriazole hydrate. The mixture was
stirred at RT for 2 h. The reaction mixture was then poured into a mixture of semisaturated
aqueous ammonium chloride solution and ethyl e. The organic phase was removed, washed
successively with saturated sodium hydrogencarbonate solution and saturated sodium chloride
solution, dried over magnesium sulphate, filtered and concentrated. The residue was purified by
preparative HPLC. 283 mg (53% of theory) of the utyl ester intermediate N-
[(benzyloxy)carbonyl]-N-methyl-L-threonyl-N-[(3R,4S,5S)tert-butoxymethoxymethyl
oxoheptanyl]-N-methyl-L-valinamide were thus obtained.
HPLC (Method 5): Rt = 2.17 min.
283 mg (0.466 mmol) of this intermediate were taken up in 5 ml of dichloromethane, 5 ml of
ous trifluoroacetic acid were added, and the mixture was d at RT for 2 h.
Subsequently, the reaction mixture was concentrated under high vacuum and the remaining residue
was purified by means of preparative HPLC. This gave 156 mg (61% of theory) of the title
nd as a colourless foam.
HPLC (Method 5): Rt = 1.50 min;
LC-MS (Method 2): Rt = 1.09 min; MS (ESIpos): m/z = 552 (M+H)+.
Intermediate 12
benzyl N-{(2R,3R)methoxymethyl[(2S)-pyrrolidinyl]propanoyl}-L-phenylalaninate
oroacetate
CH O
3 H
CF3COOH x N O
O O
In the first step, Starting Compound 1 was released from 600 mg (1.28 mmol) of the corresponding
dicyclohexylammonium salt by dissolving the salt in 100 ml of ethyl acetate and extractive
shaking, first with 50 ml of 0.5% sulphuric acid and then with saturated sodium de solution.
Then the organic phase was dried over magnesium sulphate, filtered, concentrated and d
immediately with benzyl L-phenylalaninate in analogy to the synthesis of Intermediate 7, and then
deprotected.
Yield: 650 mg (94% over 2 stages)
HPLC (Method 6): Rt = 1.76 min;
LC-MS (Method 2): Rt = 1.68 min; MS (ESIpos): m/z = 425 (M+H)+.
Intermediate 13
benzyl (βS)-N-{(2R,3R)methoxymethyl[(2S)-pyrrolidinyl]propanoyl}-β-methyl-L-
phenylalaninate trifluoroacetate
CH O
3 H
CF3COOH x N O
O O
3 H3C
First, (2R,3R)[(2S)(tert-butoxycarbonyl)pyrrolidinyl]methoxymethylpropanoic acid
was released from 351 mg (0.75 mmol) of the dicyclohexylamine salt (Starting Compound 1) by
taking it up in ethyl acetate and tive shaking with aqueous 5% potassium hydrogensulphate
solution. The organic phase was dried over ium sulphate, filtered and concentrated. The
residue was taken up in 10 ml of DMF and admixed successively with 373 mg (0.75 mmol) of
benzyl (βS)-β-methyl-L-phenylalaninate trifluoroacetate [prepared from commercially available
(βS)-N-(tert-butoxycarbonyl)-β-methyl-L-phenylalanine by EDC/DMAP-mediated esterification
with benzyl alcohol and uent detachment of the Boc protecting group with trifluoroacetic
acid], 428 mg (1.125 mmol) of O-(7-azabenzotriazolyl)-N,N,N',N'-tetramethyluronium
hexafluorophosphate (HATU) and 392 µl of N,N-diisopropylethylamine. The mixture was stirred
at RT for 20 h. The reaction mixture was then poured onto a mixture of turated aqueous
ammonium de solution and ethyl acetate. The organic phase was removed, washed
successively with saturated sodium hydrogencarbonate solution and saturated sodium de
solution, and subsequently concentrated. The residue was purified by means of preparative HPLC.
This gave 230 mg (57% of theory) of the Boc-protected ediate benzyl (βS)-N-{(2R,3R)
[(2S)(tert-butoxycarbonyl)pyrrolidinyl]methoxymethylpropanoyl}-β-methyl-L-
phenylalaninate.
HPLC (Method 6): Rt = 2.3 min;
LC-MS (Method 1): Rt = 1.36 min; MS (ESIpos): m/z = 539 (M+H)+.
230 mg (0.42 mmol) of this intermediate were taken up in 5 ml of dichloromethane, 5 ml of
trifluoroacetic acid were added, and the mixture was stirred at RT for 30 min. Subsequently, the
reaction mixture was concentrated under reduced pressure. The remaining residue was the on
mixture dried further under d pressure and then lyophilized from acetonitrile/water. In this
way, 230 mg (quant.) of the title compound were obtained.
HPLC (Method 6): Rt = 1.6 min.
Intermediate 14
N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxymethyl{[(2S)
(1,2-oxazinanyl)oxophenylpropanyl]amino}oxopropyl]pyrrolidinyl}methyl
oxoheptanyl]-N-methyl-L-valinamide trifluoroacetate
H C CH H C CH N
3 3 3
O 3 H
H N
N N O
HN N
O O
CH O CH O O
3 3 CH
H C CH CH 3
3 3 3
x CF3COOH
143 mg (0.223 mmol) of -fluorenylmethoxy)carbonyl]-N-methyl-L-valyl-N-[(2R,3S,4S)-
1-carboxymethoxymethylhexanyl]-N-methyl-L-valinamide (Intermediate 4) were taken up
in 15 ml of DMF and d successively with 141 mg (0.22 mmol) of (2R,3R)methoxy
methyl-N-[(2S)(1,2-oxazinanyl)oxophenylpropanyl][(2S)-pyrrolidin
yl]propanamide trifluoroacetate (Intermediate 7), 102 mg (0.27 mmol) of O-(7-azabenzotriazol
yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU) and 128 µl (0.74 mmol) of N,N-
diisopropylethylamine. The mixture was stirred at RT for 3 h. The reaction mixture was then
poured into a mixture of semisaturated aqueous ammonium chloride solution and ethyl acetate.
The organic phase was removed, washed successively with saturated sodium hydrogencarbonate
solution and saturated sodium chloride solution, dried over magnesium te, filtered and
concentrated. This gave 275 mg (quant.) of the Fmoc-protected intermediate N-[(9H-fluoren
ylmethoxy)carbonyl]-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxy-
2-methyl{[(2S)(1,2-oxazinanyl)oxophenylpropanyl]amino}
oxopropyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-valinamide.
HPLC d 5): Rt = 2.73 min;
LC-MS (Method 4): Rt = 3.19 min; MS (ESIpos): m/z = 1023 (M+H)+.
46 mg (0.045 mmol) of this intermediate were dissolved in 4 ml of DMF. After 1 ml of piperidine
had been added, the on mixture was stirred at RT for 1 h. Subsequently, the reaction e
was concentrated under d pressure and the residue was purified by means of preparative
HPLC (eluent: acetonitrile + 0.01% TFA / water + 0.01% TFA). 22 mg (54% of theory) of the title
compound were obtained as a colourless foam.
WO 87716
HPLC (Method 5): Rt = 1.68 min;
LC-MS (Method 2): Rt = 1.03 min; MS (ESIpos): m/z = 801 (M+H)+
1H NMR (600 MHz, DMSO-d
6): δ = 8.8 (m, 2H), 8.7 (m, 1H), 8.42 and 8.15 (2d, 1H), 7.3-7.1 (m,
5H), 5.12 and 4.95 (2m, 1H), 4.70 and 4.62 (2m, 1H), 4.62 and 4.50 (2t, 1H), 4.1-3.9 (m, 3H), 3.85
(m, 1H), 3.75-3.6 (m, 2H), 3.23, 3.18, 3.17, 3.14, 3.02 and 2.96 (6s, 9H), 3.1-2.9 and 2.75 (2m,
2H), 2.46 (m, 3H), 2.4-2.1 (m, 2H), 2.05 (br. m, 2H), 1.85-1.55 (br. m, 6H), 1.5-1.2 (br. m, 3H),
8 (m, 18H), 0.75 (t, 3H) [further s hidden under H2O peak].
Intermediate 15
N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxymethyl{[(2S,3S)-
1-(1,2-oxazinanyl)oxophenylbutanyl]amino}oxopropyl]pyrrolidinyl}methyl
oxoheptanyl]-N-methyl-L-valinamide trifluoroacetate
H C CH H C CH3 N
3 3 3
O H
H N
N N O
HN N
O O
CH O CH3 O O H C
3 3 H C
H C CH CH3 3
3 3
x CF3COOH
126 mg (0.198 mmol) of N-[(9H-fluorenylmethoxy)carbonyl]-N-methyl-L-valyl-N-[(2R,3S,4S)-
1-carboxymethoxymethylhexanyl]-N-methyl-L-valinamide (Intermediate 4) were taken up
in 10 ml of DMF and admixed successively with 105 mg (0.198 mmol) of (2R,3R)methoxy
methyl-N-[(2S,3S)(1,2-oxazinanyl)oxophenylbutanyl][(2S)-pyrrolidin
yl]propanamide trifluoroacetate (Intermediate 17), 41.6 mg (0.217 mmol) of 1-(3-
dimethylaminopropyl)ethylcarbodiimide hydrochloride, 33 mg (0.217 mmol) of 1-hydroxy-1H-
benzotriazole hydrate and 79 µl (0.454 mmol) of isopropylethylamine. The mixture was
stirred at RT overnight. The reaction mixture was then poured into a mixture of semisaturated
aqueous ammonium chloride solution and ethyl acetate. The organic phase was removed, washed
successively with ted sodium hydrogencarbonate solution and saturated sodium de
solution, dried over magnesium sulphate, filtered and concentrated. This gave 220 mg (quant.) of
the Fmoc-protected intermediate N-[(9H-fluorenylmethoxy)carbonyl]-N-methyl-L-valyl-N-
[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxymethyl{[(2S,3S)(1,2-oxazinanyl)-
2012/075277
1-oxophenylbutanyl]amino}oxopropyl]pyrrolidinyl}methyloxoheptanyl]-N-
methyl-L-valinamide.
HPLC d 5): Rt = 2.77 min;
LC-MS (Method 1): Rt = 1.5 min; MS (ESIpos): m/z = 1037 .
220 mg (0.212 mmol) of this intermediate were dissolved in 5 ml of DMF. After 1 ml of piperidine
had been added, the reaction mixture was stirred at RT for 1 h. Subsequently, the reaction mixture
was concentrated under reduced pressure and the residue was purified by means of preparative
HPLC (eluent: acetonitrile + 0.01% TFA / water + 0.01% TFA). 91 mg (46% of theory) of the title
compound were obtained as a colourless foam.
HPLC (Method 5): Rt = 1.71 min;
LC-MS d 1): Rt = 0.9 min; MS (ESIpos): m/z = 815 (M+H)+
1H NMR (600 MHz, DMSO-d
6): δ = 8.87 and 8.80 (2d, 2H), 8.75 (m, 1H), 8.40 and 7.98 (2d, 1H),
7.3-7.1 (m, 5H), 5.45 and 5.2 (2t, 1H), 4.78 and 4.62 (2m, 1H), 4.73 and 4.58 (2t, 1H), 4.2-4.0 (m,
3H), 3.7-3.6 (m, 1H), 3.35, 3.20, 3.18, 3.14, 3.12 and 3.00 (6s, 9H), 3.1 and 2.95 (2m, 2H), 2.46
(m, 3H), 2.4-2.0 (m, 4H), 1.9-1.6 (m, 4H), 1.6-1.2 (m, 5H), 1.1-0.75 (m, 21H), 0.80 (t, 3H) [further
signals hidden under H2O peak].
Intermediate 16
N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxymethyl{[(1S,2R)-
1-(1,2-oxazinanylcarbonyl)phenylcyclopropyl]amino}oxopropyl]pyrrolidinyl}
methyloxoheptanyl]-N-methyl-L-valinamide trifluoroacetate
H C CH H C
3 3 CH3
3 N
O H
H N
N N O
HN N
O O
CH O CH O O H C
3 3 3
H C CH CH3
3 3
617 mg (1.2 mmol) of tert-butyl (2S)[(1R,2R)methoxymethyl{[(1S,2R)(1,2-oxazinan-
2-ylcarbonyl)phenylcyclopropyl]amino}oxopropyl]pyrrolidinecarboxylate (Intermediate
24) were taken up in 44 ml of dichloromethane, 4.4 ml of trifluoroacetic acid were added and the
e was stirred at RT for 30 min. Subsequently, the reaction mixture was concentrated under
reduced pressure and the remaining residue was lyophilized from dioxane/water. 702 mg (quant.)
of the deprotected compound (2R,3 ethoxymethyl-N-[(1 S,2 1,2-oxazinan
ylcarbonyl)phenylcyclopropyl][(2 S)-pyrrolidinyl]propanamide trifluoroacetate were
obtained as a crude product, which was used in the following stage without further cation.
470 mg (0.74 mmol) of N-[(9 H-fluorenylmethoxy)carbonyl]-N-methyl-L-valyl-N-[(2 R,3 S,4 S)
carboxymethoxymethylhexanyl]-N-methyl-L-valinamide (Intermediate 4) were taken up in
57 ml of DMF and admixed successively with 390 mg (approx. 0.74 mmol) of the above-obtained
(2 R,3 R)methoxymethyl-N-[(1 S,2 R)(1,2-oxazinanylcarbonyl)phenylcyclopropyl]
[(2 S)-pyrrolidinyl]propanamide trifluoroacetate, 336 mg (0.88 mmol) of zabenzotriazol-
N,N,N',N' -tetramethyluronium hexafluorophosphate (HATU) and 423 µl (2.4 mmol) of N,N -
diisopropylethylamine. The mixture was d at RT for 2 h. The on mixture was then
poured into a mixture of semisaturated aqueous ammonium chloride solution and ethyl acetate.
The organic phase was removed, washed successively with saturated sodium hydrogencarbonate
solution and saturated sodium chloride solution, dried over sodium sulphate, filtered and
concentrated. The e was purified by preparative HPLC. This gave 453 mg (59% of theory) of
the Fmoc-protected intermediate N-[(9 H-fluorenylmethoxy)carbonyl]-N-methyl-L-valyl-N-
[(3 R,4 S,5 S)methoxy{(2 S)[(1 R,2 R)methoxymethyl{[(1 S,2 R)(1,2-oxazinan
ylcarbonyl)phenylcyclopropyl]amino}oxopropyl]pyrrolidinyl}methyloxoheptan
yl]-N-methyl-L-valinamide.
HPLC (Method 5): Rt = 2.58 min;
LC-MS (Method 1): Rt = 3.10 min; MS (ESIpos): m/z = 1035 (M+H)+.
453 mg (0.438 mmol) of this intermediate were dissolved in 24 ml of DMF. After 2.4 ml of
piperidine had been added, the reaction mixture was stirred at RT for 30 min. Subsequently, the
reaction mixture was concentrated under reduced pressure and the residue was purified by
preparative HPLC (eluent: acetonitrile / 0.1% TFA in water). 260 mg (64% of ) of the title
compound were obtained as a colourless foam.
HPLC (Method 5): Rt = 1.64 min;
LC-MS (Method 1): Rt = 0.86 min; MS (ESIpos): m/z = 813 (M+H)+
1H NMR (400 MHz, DMSO-d
6): δ = 8.8 (m, 2H), 8.65 (m, 2H), 1 (m, 5H), 4.8-4.05 (m, 2H),
4.0 and 3.82 (2m, 2H), 3.8-3.5 (m, 8H), 3.32, 3.29, 3.20, 3.19, 3.12 and 3.00 (6s, 9H), 2.65 (t, 1H),
45 (m, 3H), 3 (m, 15H), 1.15-0.85 (m, 18H), 0.8 and 0.75 (2d, 3H) [further signals
hidden under H2O peak].
Intermediate 17
N-benzyl-N-methyl-L-phenylalaninamide trifluoroacetate
3 N
CF3COOH x H N
2 O
1000 mg (3.77 mmol) of N-(tert-butoxycarbonyl)-L-phenylalanine were dissolved in 10 ml of
DMF and admixed with 457 mg (3.77 mmol) of N-methylbenzylamine, 2150 mg (5.65 mmol) of
O-(7-azabenzotriazolyl)-N,N,N',N'-tetramethyluronium hexafluorophosphate and 657 µl of N,N-
ropylethylamine. The reaction mixture was stirred at RT for 30 min and then concentrated
under reduced pressure. The residue was taken up in dichloromethane and extracted by shaking
three times with water. The organic phase was dried over magnesium sulphate and trated.
The residue was purified by flash chromatography on silica gel with 3:1 petroleum ether/ethyl
acetate as the eluent. The product fractions were concentrated and the e was dried under high
vacuum. This gave 1110 mg (75% of theory) of the Boc-protected intermediate N-benzyl-Nα-(tert-
butoxycarbonyl)-N-methyl-L-phenylalaninamide.
HPLC (Method 6): Rt = 2.1 min;
LC-MS (Method 1): Rt = 1.14 min; MS (ESIpos): m/z = 369 (M+H)+.
1108 mg (3,007 mmol) of this intermediate were taken up in 30 ml of dichloromethane, 10 ml of
trifluoroacetic acid were added, and the mixture was stirred at RT for 30 min. Subsequently, the
reaction e was concentrated under reduced pressure, the remaining residue was stirred with
dichloromethane and the solvent was distilled off. The e was stirred twice more with
pentane, the solvent was decanted off again each time and the of the title compound was finally
dried under high vacuum. 1075 mg (93% of theory) of the title compound were thus obtained as a
resin.
HPLC (Method 6): Rt = 1.6 min;
LC-MS (Method 1): Rt = 0.6 min; MS (ESIpos): m/z = 269 (M+H)+.
Intermediate 18
N-benzyl-Nα-{(2R,3R)methoxymethyl[(2S)-pyrrolidinyl]propanoyl}-N-methyl-L-
phenylalaninamide trifluoroacetate
CH 3 N
3 H
CF3COOH x N O
O O
First, (2R,3R)[(2S)(tert-butoxycarbonyl)pyrrolidinyl]methoxymethylpropanoic acid
(Starting Compound 1) was ed from 141 mg (0.491 mmol) of its dicyclohexylamine salt by
taking it up in ethyl acetate and tive shaking with 5% aqueous sulphuric acid. The organic
phase was dried over magnesium sulphate, filtered and concentrated. The residue was taken up in
ml of DMF and 187.6 mg (0.49 mmol) of N-benzyl-N-methyl-L-phenylalaninamide
trifluoroacetate (Intermediate 9), 190.3 mg (1.47 mmol) of O-(7-azabenzotriazolyl)-N,N,N',N'-
tetramethyluronium hexafluorophosphate (HATU) and 256 µl of N,N-diisopropylethylamine were
added. The mixture was stirred at RT for 1 h. The reaction mixture was then concentrated, the
residue was taken up in ethyl acetate and the solution was subsequently extracted by shaking
successively with saturated ammonium chloride solution, saturated sodium hydrogencarbonate
on and water. The organic phase was dried over ium sulphate and concentrated. The
residue was ed by flash chromatography on silica gel with 30:1 acetonitrile/water as the
. The product fractions were concentrated and the residue was dried under high vacuum.
This gave 168 mg (64% of theory) of the Boc-protected intermediate tert-butyl (2S)[(1R,2R)
({(2S)[benzyl(methyl)amino]oxophenylpropanyl}amino)methoxymethyl
oxopropyl]pyrrolidinecarboxylate.
HPLC (Method 6): Rt = 2.2 min;
LC-MS (Method 2): Rt = 1.22 min; MS (ESIpos): m/z = 538 (M+H)+.
168 mg (0.312 mmol) of this intermediate were taken up in 15 ml of dichloromethane, 3 ml of
trifluoroacetic acid were added, and the mixture was stirred at RT for 30 min. Subsequently, the
reaction mixture was trated under reduced pressure. The remaining e was stirred first
with dichloromethane, then with diethyl ether, and the solvent was distilled off again each time.
After drying under high vacuum, 170 mg (99% of theory) of the title compound were obtained as a
resin.
HPLC (Method 6): Rt = 1.7 min;
LC-MS (Method 1): Rt = 0.73 min; MS (ESIpos): m/z = 438 (M+H)+.
Intermediate 19
methyl N-{(2R,3R)methoxymethyl[(2S)-pyrrolidinyl]propanoyl}-L-phenylalaninate
trifluoroacetate
CH O 3
3 H
CF3COOH x N O
O O
The title nd was prepared in analogy to the synthesis of Intermediate 18, proceeding from
(2R,3R)[(2S)(tert-butoxycarbonyl)pyrrolidinyl]methoxymethylpropanoic acid
(Starting Compound 1), which was released from the dicyclohexylamine salt, and methyl L-
phenylalaninate hydrochloride.
HPLC (Method 5): Rt = 0.6 min;
LC-MS (Method 3): Rt = 1.17 min; MS (ESIpos): m/z = 349 .
Intermediate 20
benzyl N-{(2R,3R)methoxymethyl[(2S)-pyrrolidinyl]propanoyl}-L-tryptophanate
trifluoroacetate
CH O
3 H
CF3COOH x N O
O O
The title compound was prepared in analogy to the synthesis of Intermediate 18, proceeding from
)[(2S)(tert-butoxycarbonyl)pyrrolidinyl]methoxymethylpropanoic acid
(Starting Compound 1), which was released from the ohexylamine salt, and benzyl L-
tryptophanate.
WO 87716
HPLC (Method 6): Rt = 2.0 min;
LC-MS (Method 1): Rt = 0.8 min; MS (ESIpos): m/z = 464 (M+H)+.
Intermediate 21
benzyl (1S,2R)({(2R,3R)methoxymethyl[(2S)-pyrrolidinyl]propanoyl}amino)
phenylcyclopropanecarboxylate trifluoroacetate
3 O
CF3COOH x N O
O O
The title compound was prepared in analogy to the synthesis of Intermediate 18, proceeding from
(2R,3R)[(2S)(tert-butoxycarbonyl)pyrrolidinyl]methoxymethylpropanoic acid
(Starting Compound 1), which was released from the dicyclohexylamine salt, and benzyl (1S,2R)-
ophenylcyclopropanecarboxylate. Benzyl (1S,2R)amino
phenylcyclopropanecarboxylate had been prepared beforehand by standard methods, by esterifying
commercially available (1S,2R)[(tert-butoxycarbonyl)amino]phenylcyclopropanecarboxylic
acid with benzyl alcohol and subsequent Boc detachment with trifluoroacetic acid.
HPLC d 5): Rt = 1.5 min;
LC-MS d 2): Rt = 0.93 min; MS (ESIpos): m/z = 437 (M+H)+.
Intermediate 22
6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)-N'-methylhexanehydrazide trifluoroacetate
O CH
CF3COOH x 3
N NH
100 mg (473 µmol) of 6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexanoic acid were dissolved in 71
µl of DMF and then admixed with 139 mg (947 µmol) of tert-butyl ylhydrazinecarboxylate,
182 mg (947 µmol) of 1-(3-dimethylaminopropyl)ethylcarbodiimide hydrochloride and 145 mg
(947 µmol) of 1-hydroxy-1H-benzotriazole hydrate. The mixture was stirred at RT overnight and
then concentrated under reduced pressure. The remaining residue was purified by means of
preparative HPLC. After lization from dioxane/water, 129 mg (80% of theory) of the
protected intermediate were obtained as a colourless foam.
Subsequently, the 129 mg (380 µmol) were deblocked with 2 ml of trifluoroacetic acid in 8 ml of
dichloromethane. After stirring at RT for 1 h, the reaction mixture was concentrated under reduced
pressure. The residue was lyophilized from acetonitrile/water, which left 125 mg (83% of )
of the title compound as a colourless foam.
LC-MS (Method 1): Rt = 0.38 min; MS (ESIpos): m/z = 240 (M+H)+
Intermediate 23
N-(2-aminoethyl)(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)-N-methylbutanamide trifluoroacetate
CH O
H x H N N
First, 35 mg (164 µmol) of tert-butyl 2-(methylamino)ethyl carbamate hydrochloride
trifluoroacetate, 30 mg (164 µmol) of 4-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)butanoic acid, 75
mg (197 µmol) of O-(7-azabenzotriazolyl)-N,N,N',N'-tetramethyluronium hexafluorophosphate
and 57 µl of isopropylethylamine were ed in 5 ml of DMF and stirred at RT
ght. Subsequently, the solvent was removed under reduced pressure and the remaining
residue was purified by means of preparative HPLC. The corresponding fractions were
concentrated and, by lyophilization from dioxane/water, 35 mg (63% of ) of the protected
intermediate were obtained.
HPLC (Method 12): Rt = 1.6 min;
LC-MS (Method 1): Rt = 0.71 min; MS (ESIpos): m/z = 340 (M+H)+.
Subsequently, the entire amount of the protected ediate was deblocked with 1 ml of
trifluoroacetic acid in 5 ml of dichloromethane to obtain 28 mg (77% of theory) of the title
compound.
LC-MS (Method 3): Rt = 0.75 min; MS (ESIpos): m/z = 240 (M+H)+.
2012/075277
Intermediate 24
4-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)-N-[2-(methylamino)ethyl]butanamide trifluoroacetate
H C N
3 N N
CF3COOH x H
First, 35 mg (164 µmol) of tert-butyl noethyl)methyl carbamate hydrochloride
trifluoroacetate, 30 mg (164 µmol) of 4-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)butanoic acid, 75
mg (197 µmol) of O-(7-azabenzotriazolyl)-N,N,N',N'-tetramethyluronium hexafluorophosphate
and 57 µl of N,N-diisopropylethylamine were combined in 5 ml of DMF and stirred at RT for 30
min. Subsequently, the solvent was removed under reduced pressure and the remaining residue
was purified by means of preparative HPLC. The corresponding fractions were trated and,
by lyophilization from dioxane/water, 51 mg (91% of theory) of the protected intermediate were
obtained.
HPLC (Method 12): Rt = 1.6 min;
LC-MS (Method 1): Rt = 0.77 min; MS (ESIpos): m/z = 340 (M+H)+.
Subsequently, the entire amount was deprotected with 1 ml of trifluoroacetic acid in 5 ml of
dichloromethane to obtain 45 mg (69% of theory) of the title compound.
LC-MS d 1): Rt = 0.19 min; MS s): m/z = 240 (M+H)+.
Intermediate 25
benzyl (2R,3R)methoxymethyl[(2S)-pyrrolidinyl]propanoate trifluoroacetate
CF3COOH x O
O O
First, (2R,3R)[(2S)(tert-butoxycarbonyl)pyrrolidinyl]methoxymethylpropanoic acid
was released from 1.82 g (388 mmol) of its dicyclohexylamine salt by taking it up in ethyl acetate
and extractive shaking with 100 ml of 0.5% sulphuric acid. The organic phase was dried over
magnesium sulphate, filtered and concentrated. The residue was taken up in 10 ml of dioxane and
WO 87716
ml of water, 1517 mg (4.66 mmol) of caesium carbonate were added, and the mixture was
treated in an ultrasound bath for 5 min and concentrated under reduced pressure and redistilled
once with DMF. The residue was then taken up in 15 ml of dichloromethane, and 1990 mg (11.64
mmol) of benzyl bromide were added. The mixture was treated in an ultrasound bath for 15 min
and then concentrated under reduced pressure. The residue was partitioned between ethyl e
and water, and the c phase was removed and extracted by shaking with saturated sodium
chloride solution and then concentrated. The residue was then purified by preparative HPLC. This
gave 1170 mg (80% of theory) of the Boc-protected intermediate.
Subsequently, these 1170 mg were deprotected immediately with 5 ml of trifluoroacetic acid in 15
ml of dichloromethane. After stirring at RT for 15 min, the reaction e was concentrated
under reduced pressure. The residue was lyophilized from dioxane. After drying under high
vacuum, there remained 1333 mg (84% of theory) of the title compound as a yellow oil.
HPLC (Method 6): Rt = 1.5 min;
LC-MS (Method 1): Rt = 0.59 min; MS (ESIpos): m/z = 278 (M+H)+.
Intermediate 26
N-(tert-butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R)carboxy
methoxypropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide
H C CH H C CH
3 3 3 3
CH O O
3 H OH
H C N N
3 O N N
3 O O
CH O CH O O CH
3 3 CH 3
H C CH
3 3 3
1200 mg (2.33 mmol) of N-(tert-butoxycarbonyl)-N-methyl-L-valyl-N-[(2R,3S,4S)carboxy
methoxymethylhexanyl]-N-methyl-L-valinamide (Intermediate 5) were combined with 910.8
mg (2.33 mmol) of benzyl (2R,3R)methoxymethyl[(2S)-pyrrolidinyl]propanoate
trifluoroacetate (Intermediate 14), 1327 mg (3.49 mmol) of O-(7-azabenzotriazolyl)-N,N,N',N'-
tetramethyluronium hexafluorophosphate and 2027 µl of N,N-diisopropylethylamine in 50 ml of
DMF, and the mixture was d at RT for 5 min. Thereafter, the solvent was removed under
reduced pressure. The remaining residue was taken up in ethyl acetate and extracted by shaking
successively with 5% aqueous citric acid solution and saturated sodium hydrogencarbonate
on. The organic phase was removed and concentrated. The residue was ed by means of
preparative HPLC. The product ons were ed and concentrated, and the residue was
dried under high vacuum. This gave 1000 mg (55% of theory) of the benzyl ester intermediate N-
(tert-butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R)(benzyloxy)
methoxymethyloxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-
L-valinamide as a resin.
LC-MS (Method 1): Rt = 1.56 min; MS (ESIpos): m/z = 775 (M+H)+.
The entire amount of this intermediate obtained was taken up in 25 ml of a mixture of methanol
and dichloromethane (20:1), and the benzyl ester group was d by hydrogenation under
standard en re with 10% palladium on activated carbon as a catalyst. After stirring at
RT for 30 min, the catalyst was filtered off and the filtrate was concentrated under reduced
pressure. This gave 803 mg (91% of theory) of the title compound as a white solid.
HPLC (Method 6): Rt = 2.1 min;
LC-MS (Method 1): Rt = 1.24 min; MS (ESIpos): m/z = 685 (M+H)+.
Intermediate 27
)aminophenyl-N-propylcyclopropanecarboxamide trifluoroacetate
HN 3
2 O
CF3COOH x
The title compound was prepared by ng commercially available (1S,2R)[(tertbutoxycarbonyl
]phenylcyclopropanecarboxylic acid with n-propylamine in the presence
of O-(7-azabenzotriazolyl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU) and
subsequent Boc detachment with trifluoroacetic acid (yield: 85% of theory over both stages).
HPLC (Method 6): Rt = 1.2 min;
LC-MS (Method 1): Rt = 0.52 min; MS (ESIpos): m/z = 219 (M+H)+.
Intermediate 28
ethyl (1S,2R)aminophenylcyclopropanecarboxylate trifluoroacetate
O CH
CF3COOH x O
The title compound was prepared by standard methods, by esterifying commercially available
(1S,2R)[(tert-butoxycarbonyl)amino]phenylcyclopropanecarboxylic acid with l and
subsequent Boc detachment with trifluoroacetic acid.
LC-MS (Method 1): Rt = 0.50 min; MS s): m/z = 206 (M+H)+.
Intermediate 29
4-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)-2,2-dimethylbutanoic acid
H C CH
3 3 O
To a solution of 1.39 g (8.95 mmol) of N-methoxycarbonylmaleimide in 44 ml of ted sodium
hydrogencarbonate solution were added, at 0°C, 1.5 g (8.95 mmol) of 4-amino-2,2-dimethylbutyric
acid, and the mixture was stirred for 40 min. Subsequently, the g bath was removed and the
reaction mixture was stirred for a further 1 h. While cooling with ice, the reaction mixture was
then adjusted to pH 3 by adding sulphuric acid, and ted with ethyl acetate. The combined
organic phases were dried over magnesium sulphate and concentrated. 1.17 g (79% purity, 49% of
theory) of the title compound were obtained.
LC-MS (Method 1): Rt = 0.64 min; m/z = 212 (M+H)+.
Intermediate 30
tert-butyl 2-[4-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)-2,2-dimethylbutanoyl]hydrazinecarboxylate
H C CH O
3 3 O
H C H
3 O N N
HH C CH
O 3 3 O
To a solution of 50 mg (237 µmol) of 4-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)-2,2-
dimethylbutanoic acid in 2 ml of THF were added, at 0°C, first 26 µl (237 µmol) of 4-
methylmorpholine and then 31 µl (237 µmol) of isobutyl chloroformate. After removing the
cooling bath and stirring at RT for a further 15 min, 31.3 mg (237 µmol) of tert-butyloxycarbonyl
hydrazide were added. The on e was stirred overnight and then concentrated. The
residue was ed by preparative HPLC. 50.8 mg (66% of theory) of the title compound were
obtained.
LC-MS (Method 1): Rt = 0.71 min; m/z = 324 (M-H)-.
Intermediate 31
4-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)-2,2-dimethylbutanehydrazide trifluoroacetate
CF3COOH x H N N
2 N
HH C CH
3 3 O
50 mg (154 mmol) of utyl 2-[4-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)-2,2-
dimethylbutanoyl]hydrazinecarboxylate were dissolved in 2 ml of dichloromethane, and 0.4 ml of
trifluoroacetic acid was added. The reaction mixture was d at RT for 30 min and then
concentrated. 55.2 mg (93% purity, 99% of theory) of the title compound were obtained.
LC-MS (Method 1): Rt = 0.36 min; m/z = 226 (M+H)+.
Intermediate 32
adamantanylmethyl N-(tert-butoxycarbonyl)-L-phenylalaninate
CH HN
H C O
3 O O
To a on of 500 mg (1.89 mmol) of N-Boc-L-phenylalanine in 25 ml of dichloromethane were
added, at RT, 1192 mg (6.2 mmol) of EDC, 578 µl (4.1 mmol) of triethylamine, 345 mg (2.8
mmol) of DMAP and 345 mg (2.1 mmol) of 1-adamantylmethanol. The reaction mixture was
stirred overnight, then diluted with 50 ml of dichloromethane, and was successively washed with
% aqueous citric acid on, water and saturated sodium chloride solution. The c phase
was dried over magnesium sulphate, then concentrated, and the residue was purified by preparative
HPLC. 769 mg (90% of theory) of the title compound were obtained.
LC-MS (Method 2): Rt = 1.84 min; m/z = 414 (M+H)+.
Intermediate 33
adamantanylmethyl L-phenylalaninate hydrochloride
HCl x H N
769 mg (1.86 mmol) of adamantanylmethyl N-(tert-butoxycarbonyl)-L-phenylalaninate
(Intermediate 13) were dissolved in 25 ml of a 4 N solution of hydrogen chloride in dioxane and
stirred at RT for 1 h. Subsequently, the reaction mixture was concentrated and the e was
dried under reduced pressure. 619 mg (95% of theory) of the title compound were obtained.
LC-MS (Method 1): Rt = 0.82 min; m/z = 314 .
Intermediate 34
N-(tert-butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)
ntanylmethoxy)oxophenylpropanyl]amino}methoxymethyl
oxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide
WO 87716 2012/075277
H C CH H C CH
3 3 O
3 3
CH O O H
3 H N
H C N N O
3 O N N
3 O O
CH O CH3 O O CH
3 CH3 3
H C CH3
To a solution of 20 mg (29 µmol) of N-(tert-butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S)
{(2S)[(1R,2R)carboxymethoxypropyl]pyrrolidinyl}methoxymethyloxoheptan-
4-yl]-N-methyl-L-valinamide in 1 ml of DMF were added, at RT, 15.3 µl (88 µmol) of N,N-
diisopropylethylamine, 6.7 mg (44 µmol) of HOBt and 6.7 mg (35 µmol) of EDC, and the mixture
was stirred for 30 min. Subsequently, 10.1 mg (32 µmol) of adamantanyl L-phenylalaninate
hydrochloride were added. After stirring overnight, the reaction mixture was separated directly
into its components via preparative HPLC. 27.5 mg (93% of theory) of the title compound were
obtained.
LC-MS d 1): Rt = 1.70 min; m/z = 980 (M+H)+.
Intermediate 35
N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)(adamantanylmethoxy)oxo
phenylpropanyl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxy
methyloxoheptanyl]-N-methyl-L-valinamide trifluoroacetate
H C CH H C
3 CH
3 3 O
3 O H
H N
N N O
HN N
O O
CH O CH O O CH
3 3
H C CH CH 3
3 3 3
27.5 mg (28 µmol) of N-(tert-butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)
[(1R,2R){[(2S)(adamantanylmethoxy)oxophenylpropanyl]amino}methoxy
methyloxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-
valinamide were dissolved in 1.8 ml of dichloromethane, and 361 µl of TFA were added. The
reaction mixture was stirred for 30 min and then concentrated. The residue was taken up in water
and lyophilized. 22.7 mg (81% of theory) of the title compound were obtained.
2012/075277
LC-MS d 1): Rt = 1.14 min; m/z = 880 (M+H)+.
ediate 36
tert-butyl (2S)(benzyloxy)phenylpropanyl carbamate
CH HN
3 O O
Under an argon atmosphere, 500 mg (1.99 mmol) of N-Boc-L-phenylalaninol were dissolved in 5
ml of DMF and cooled to 0°C. Subsequently, 159 mg (3.98 mmol) of a 60% suspension of sodium
hydride in paraffin oil were added. The reaction mixture was stirred until the evolution of gas had
ended and then 260 µl (2.19 mmol) of benzyl bromide were added. The cooling bath was removed
and the reaction mixture was stirred at RT for 2 h. Thereafter, the reaction mixture was
concentrated, the e was taken up in ice-water and the mixture was extracted with
dichloromethane. The organic phase was washed with saturated sodium chloride solution, dried
over ium sulphate and concentrated. The residue was purified by means of preparative
HPLC. 226 mg (33% of theory) of the title compound were obtained.
LC-MS (Method 1): Rt = 1.28 min; m/z = 342 (M+H)+.
Intermediate 37
(2S)(benzyloxy)phenylpropanamine hydrochloride
x HCl
220 mg (644 µmol) of tert-butyl (2S)(benzyloxy)phenylpropanyl carbamate were
dissolved in 11 ml of a 4 N solution of hydrogen chloride in dioxane and d at RT for 1 h.
Then the reaction mixture was concentrated and the residue was dried under reduced pressure.
138 mg (77% of theory) of the title compound were obtained.
LC-MS (Method 1): Rt = 0.65 min; m/z = 242 .
Intermediate 38
N-(tert-butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)
(benzyloxy)phenylpropanyl]amino}methoxymethyloxopropyl]pyrrolidinyl}
methoxymethyloxoheptanyl]-N-methyl-L-valinamide
H C CH3 H C
3 CH
3 3
CH O O H
3 H N
H C N N O
3 O N N
3 O O
CH O CH3 O O CH
3 3
H C CH CH
3 3 3
To a solution of 20 mg (29 µmol) of N-(tert-butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S)
{(2S)[(1R,2R)carboxymethoxypropyl]pyrrolidinyl}methoxymethyloxoheptan-
4-yl]-N-methyl-L-valinamide in 1 ml of DMF were added, at RT, 15.3 µl (88 µmol) of N,N-
diisopropylethylamine, 6.7 mg (44 µmol) of HOBt and 6.7 mg (35 µmol) of EDC, and the mixture
was stirred for 30 min. Subsequently, 7.8 mg (32 µmol) of (2S)(benzyloxy)phenylpropan
amine hydrochloride were added. After stirring overnight, the reaction mixture was separated
directly into its components via preparative HPLC. 26 mg (98% of theory) of the title compound
were obtained.
LC-MS (Method 1): Rt = 1.51 min; m/z = 909 (M+H)+.
Intermediate 39
N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)(benzyloxy)phenylpropan
yl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxymethyloxoheptan
methyl-L-valinamide oroacetate
H C CH H C CH
3 3 3 3
O H
H N
N N O
HN N
O O
CH O CH O O CH
3 3
H3C CH 3
3 3
x CF3COOH
26 mg (29 µmol) of N-(tert-butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R)-
3-{[(2S)(benzyloxy)phenylpropanyl]amino}methoxymethyloxopropyl]pyrrolidin-
1-yl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide were ved in 1.8 ml of
dichloromethane, and 370 µl of TFA were added. The reaction mixture was stirred at RT for 30
min and then concentrated. The residue was taken up in water and lyophilized. 26.4 mg (quant.) of
the title compound were obtained.
LC-MS d 1): Rt = 0.97 min; m/z = 809 (M+H)+.
Intermediate 40
N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(1S,2R)hydroxyphenylpropan
yl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxymethyloxoheptan
methyl-L-valinamide
H3C CH H C
3 3 CH3 OH
O H
H N
N N
HN N
O O CH
CH3 O CH O O 3
3 CH
H C CH CH 3
3 3 3
50 mg (70 µmol) of Intermediate 26 and 11 mg (70 µmol) of (1S, 2R)aminophenylpropan
ol in 10 ml of DMF were admixed with 42 mg (0.11 µmol) of O-(7-azabenzotriazolyl)-
N,N,N',N'-tetramethyluronium hexafluorophosphate and 25 µl of N,N-diisopropylethylamine, and
the reaction e was stirred at RT for 5 min. This was ed by concentration and
purification of the residue by means of ative HPLC. After combining the corresponding
fractions, concentrating and drying under high vacuum, 49 mg (81%) of the protected intermediate
were obtained. Subsequently, the Boc group was detached by known conditions with
trifluoroacetic acid in dichloromethane. Concentration was followed by the purification of the title
compound by preparative HPLC, and 26 mg (52%) of the title compound were obtained.
HPLC (Method 12): Rt = 1.65 min;
LC-MS (Method 1): Rt = 0.77 min; MS (ESIpos): m/z = 718 (M+H)+.
Intermediate 41
3-{2-[2-(2-aminoethoxy)ethoxy]ethoxy}propanoic acid trifluoroacetate
O OH
O 2
x CF3COOH
150 mg (541 µmol) of tert-butyl 3-{2-[2-(2-aminoethoxy)ethoxy]ethoxy}propanoate were
dissolved in 3 ml of dichloromethane, 1.5 ml of trifluoroacetic acid were added, and the reaction
mixture was stirred at RT for 1 h, then concentrated.
181 mg (100% of theory) of the title nd were obtained.
MS (EI): m/z 222 (M+H)+
ediate 42
3-(2-{2-[2-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)ethoxy]ethoxy}ethoxy)propanoic acid
O OH
O O
186 mg (555 µmol) of 3-{2-[2-(2-aminoethoxy)ethoxy]ethoxy}propanoic acid trifluoroacetate
were dissolved in 2.6 ml of saturated sodium hydrogencarbonate solution and admixed at 0°C with
86 mg (555 µmol) of N-methoxycarbonylmaleimide. The reaction mixture was stirred at 0°C for
40 min and at RT for 1 h, then cooled again to 0°C, adjusted to pH 3 with sulphuric acid and
extracted 3x with 25 ml of ethyl acetate. The combined organic phases were dried over magnesium
sulphate and trated.
126 mg (75% of theory) of the title compound were ed.
LC-MS (Method 1): Rt = 0.53 min; m/z = 302 (M+H)+.
Intermediate 43
tert-butyl 5-dioxo-2,5-dihydro-1H-pyrrolyl)oxo-7,10,13-trioxa-2,3-diazapentadecan
oate
H C 3
O 3 CH3
N O
O N
O O O
125 mg (417 µmol) of 3-(2-{2-[2-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)ethoxy]ethoxy}ethoxy)
propanoic acid were dissolved at 0°C in 2.1 ml of THF and admixed with 46 µl (417 mmol) of 4-
methylmorpholine and 54.5 µl (417 µmol) of isobutyl chloroformate. The ice bath was removed
and the reaction mixture was stirred at RT for 30 min. Subsequently, at 0°C, 55 mg (417 µmol) of
tert-butyloxycarbonyl ide were added. The reaction e was warmed to RT overnight,
concentrated and purified by preparative HPLC.
60 mg (33% of theory) of the title compound were obtained.
LC-MS (Method 1): Rt = 0.66 min; m/z = 416 (M+H)+.
Intermediate 44
3-(2-{2-[2-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)ethoxy]ethoxy}ethoxy)propanehydrazide
trifluoroacetate
O N
O O
x CF3COOH
60 mg (145 µmol) of tert-butyl 15-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)oxo-7,10,13-trioxa-
2,3-diazapentadecanoate were dissolved in 1 ml of dichloromethane, and 0.2 ml of
trifluoroacetic acid was added. The reaction mixture was d at RT for 30 min and then
concentrated.
62 mg (100% of theory) of the title compound were obtained.
LC-MS (Method 1): Rt = 0.35 min; m/z = 316 (M+H)+.
Intermediate 45
benzyl (1S,2R)aminophenylcyclopropanecarboxylate trifluoroacetate
2 O
CF3COOH x
The title compound was ed by standard methods, by esterifying commercially available
(1S,2R)[(tert-butoxycarbonyl)amino]phenylcyclopropanecarboxylic acid with benzyl l
and subsequent Boc detachment with trifluoroacetic acid.
LC-MS (Method 1): Rt = 0.72 min; MS s): m/z = 268 (M+H)+.
Intermediate 46
N-(tert-butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(1S)carboxy-
2-phenylethyl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxymethyl
oxoheptanyl]-N-methyl-L-valinamide
H C CH H C CH
3 3 3 3 O
CH O O H
3 H N
H C N N OH
3 O N N
3 O O
CH O CH O O CH
3 3 3
H C CH CH
3 3 3
383 mg (0.743 mmol) of N-(tert-butoxycarbonyl)-N-methyl-L-valyl-N-[(2R,3S,4S)carboxy
methoxymethylhexanyl]-N-methyl-L-valinamide (Intermediate 8) were combined with 485
mg (0.743 mmol) of benzyl N-{(2R,3R)methoxymethyl[(2S)-pyrrolidinyl]propanoyl}-L-
phenylalaninate trifluoroacetate (Intermediate 12), 424 mg (1.114 mmol) of O-(7-azabenzotriazol-
1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate and 388 µl of N,N-diisopropylethylamine
in 15 ml of DMF, and the mixture was stirred at RT for 10 min. Subsequently, the solvent was
removed under reduced re. The remaining residue was taken up in ethyl acetate and
extracted by shaking successively with 5% s citric acid on and saturated sodium
hydrogencarbonate solution. The organic phase was removed and concentrated, and the residue
was ed by means of preparative HPLC. The product fractions were combined and
trated, and the residue was dried under high vacuum. 335 mg (48% of theory) of the benzyl
ester intermediate were obtained as a foam.
LC-MS (Method 1): Rt = 1.49 min; MS (ESIpos): m/z = 922 (M+H)+.
100 mg (0.11 mmol) of this intermediate were taken up in 15 ml of methanol and the benzyl ester
group was d by hydrogenation under standard hydrogen pressure with 10% palladium on
activated carbon as a catalyst. After stirring at RT for 1 h, the catalyst was filtered off and the
filtrate was concentrated under reduced pressure. After lyophilization from dioxane, 85 mg (94%
of theory) of the title compound were obtained as a solid.
HPLC (Method 12): Rt = 2.4 min;
LC-MS (Method 1): Rt = 1.24 min; MS (ESIpos): m/z = 832 (M+H)+.
Intermediate 47
N-benzyl-L-tryptophanamide oroacetate
2 O
H
202 mg (0.5 mmol) of 2,5-dioxopyrrolidinyl t-butoxycarbonyl)-L-tryptophanate and 45
mg (0.42 mmol) of benzylamine were ved in 10 ml of DMF, and 110 µl (630 µmol) of N,N-
diisopropylethylamine were added. The reaction mixture was stirred at RT for 3 h. Subsequently,
the reaction mixture was concentrated under reduced pressure and the residue was purified by
flash chromatography on silica gel (eluent: 20:0.5:0.05 dichloromethane/methanol/17% aq.
ammonia). The corresponding fractions were combined and concentrated. The resulting residue
was digested with diethyl ether and then dried under high vacuum. Subsequently, this residue was
taken up in 10 ml of dichloromethane, and 3 ml of anhydrous trifluoroacetic acid were added.
After stirring at RT for 45 minutes, the mixture was concentrated and the residue was purified by
preparative HPLC. After drying under high vacuum, 117 mg (57% of theory over both stages) of
the title compound were obtained.
HPLC (Method 12): Rt = 1.6 min;
LC-MS (Method 1): Rt = 0.66 min; MS (ESIpos): m/z = 294 (M+H)+.
Intermediate 48
(1S,2R)aminophenylcyclopropanecarboxamide oroacetate
50 mg (180 µmol) of commercially available (1S,2R)[(tert-butoxycarbonyl)amino]
phenylcyclopropanecarboxylic acid were dissolved in 5 ml of DMF, 94 µl (541 µmol) of N,N-
diisopropylethylamine, 31 mg (270 µmol) of N-hydroxysuccinimide and 41.5 mg (216 µmol) of
EDC were added, and then the mixture was stirred at RT overnight. The reaction mixture was then
concentrated, the residue was taken up in dioxane, 71 mg (901 µmol) of ammonium
hydrogencarbonate were added, and the reaction mixture was then left to stand at RT for 3 days.
The reaction mixture was then diluted with a 1:1 mixture of ethyl e and water. The organic
phase was removed, dried over magnesium sulphate and concentrated. The resulting residue was
subsequently taken up in 3 ml of dichloromethane, and 3 ml of ous trifluoroacetic acid were
added. Stirring at RT for 1 h was followed by concentration. The e was stirred with pentane,
ed off with suction and lyophilized from dioxane. In this way, 32 mg (62% of theory over
both stages) of the title compound were obtained.
HPLC (Method 6): Rt = 0.38 min;
LC-MS (Method 1): Rt = 0.20 min; MS (ESIpos): m/z = 177 (M+H)+.
Intermediate 49
Nα-{(2R,3R)methoxymethyl[(2S)-pyrrolidinyl]propanoyl}-L-tryptophanamide
trifluoroacetate
CH3 NH2
CF3COOH x N O
O O
The title compound was prepared in analogy to the synthesis of Intermediate 13 from Starting
Compound 1 and tophanamide hydrochloride.
HPLC (Method 5): Rt = 1.4 min;
LC-MS (Method 1): Rt = 0.92 min; MS (ESIpos): m/z = 473 (M+H)+.
Intermediate 50
4-nitrophenyl -dioxo-2,5-dihydro-1H-pyrrolyl)ethyl carbamate
O O
N N
813 mg (3.1 mmol) of triphenylphosphine were dissolved in 25 ml of THF and cooled to -70°C
under argon. After dropwise addition of 627 mg (3.1 mmol) of diisopropyl azodicarboxylate, the
e was stirred for 5 min. Subsequently, 500 mg (3.1 mmol) of tert-butyl 2-aminoethyl
carbamate dissolved in 5 ml of THF were added dropwise, and the reaction mixture was stirred at -
70°C for a further 5 min. Then 136.6 mg (1.55 mmol) of 2,2-dimethylpropanol dissolved in 1 ml
of THF and 301 mg (3.1 mmol) of maleimide were added, the reaction mixture was stirred at -
70°C for a further 10 min and then the e was warmed to RT. After ng at RT for a
further 16 h, the solvent was removed under reduced pressure and the residue was purified by
means of ative HPLC. This gave 463 mg (62%) of the protected intermediate.
After removing the Boc protecting group under standard conditions, 652 mg of 1-(2-aminoethyl)-
1H-pyrrole-2,5-dione were obtained as the trifluoroacetate.
112.9 mg (543 µmol) of nitrophenyl chloroformate were dissolved in 30 ml of THF and, after
addition of 100 mg (271.6 µmol) of 1-(2-aminoethyl)-1H-pyrrole-2,5-dione trifluoroacetate, the
mixture was d at RT for 30 min. The e was filtered and the filtrate was concentrated to
dryness and then slurried with diethyl ether. After filtration with suction and drying, 60 mg (95%
of theory) of the title compound were obtained.
HPLC d 5): Rt = 0.65 min;
LC-MS (Method 1): Rt = 0.74 min; MS (ESIpos): m/z = 306 (M+H)+.
Intermediate 51
-phenyl(5-phenyl-1,3,4-oxadiazolyl)ethanamine trifluoroacetate
CF3COOH x
200 mg (0.75 mmol) of N-(tert-butoxycarbonyl)-L-phenylalanine were initially charged at 0°C in
.5 ml of dichloromethane, and 128 mg (0.79 mmol) of 1,1'-carbonyldiimidazole were added. After
min, 103 mg (0.75 mmol) of l hydrazide were added. After a further 45 min at 0°C, 500
mg (1.5 mmol) of carbon romide and 395 mg (1.5 mmol) of triphenylphosphine were finally
added. The reaction mixture was stirred first at 0°C for 2 h and then at RT overnight. The mixture
was subsequently concentrated on a rotary ator, and the residue was dried under high
. The crude product thus obtained was purified by means of preparative HPLC. 217 mg
(78% of theory) of the Boc-protected intermediate tert-butyl (1S)phenyl(5-phenyl-1,3,4-
oxadiazolyl)ethyl carbamate were obtained.
LC-MS (Method 12): Rt = 1.15 min; MS (ESIpos): m/z = 366 (M+H) +
217 mg (0.59 mmol) of this intermediate were taken up in 3 ml of dichloromethane, 0.6 ml of
trifluoroacetic acid were added, and the e was stirred at RT for 30 min. Subsequently, the
reaction mixture was concentrated under reduced pressure. The remaining residue was the reaction
mixture dried further under reduced pressure and then lyophilized from dioxane. In this way, 214
mg (90% of theory) of the title compound were obtained.
LC-MS (Method 11): Rt = 0.62 min; MS (ESIpos): m/z = 266 (M+H) +
2012/075277
Intermediate 52
(1R)phenyl(5-phenyl-1,3,4-oxadiazolyl)ethanamine trifluoroacetate
CF3COOH x N N
200 mg (0.75 mmol) of t-butoxycarbonyl)-D-phenylalanine were lly charged at 0°C in
5.5 ml of dichloromethane, and 128.3 mg (0.79 mmol) of 1,1'-carbonyldiimidazole were added.
After 30 min, 103 mg (0.75 mmol) of benzoyl hydrazide were added. After a further 45 min at 0°C,
500 mg (1.5 mmol) of carbon tetrabromide and 395 mg (1.5 mmol) of triphenylphosphine were
finally added. The reaction mixture was stirred first at 0°C for 2 h and then at RT ght. The
mixture was subsequently concentrated on a rotary evaporator, and the residue was dried under
high vacuum. The crude product thus obtained was purified by means of preparative HPLC. 219
mg (80% of theory) of the Boc-protected intermediate tert-butyl (1R)phenyl(5-phenyl-1,3,4-
oxadiazolyl)ethyl carbamate were obtained.
LC-MS (Method 2): Rt = 1.36 min; MS (ESIpos): m/z = 366 (M+H) +
219 mg (0.6 mmol) of this intermediate were taken up in 3 ml of romethane, 0.6 ml of
trifluoroacetic acid were added, and the mixture was stirred at RT for 30 min. Subsequently, the
reaction mixture was concentrated under reduced pressure. The remaining residue was the reaction
mixture dried further under reduced pressure and then lyophilized from dioxane. In this way, 196
mg (86% of theory) of the title compound were obtained as a solid.
HPLC (Method 10): Rt = 2.41 min
Intermediate 53
-(benzylsulphonyl)phenylpropanamine
NH2 O
200 mg (1.13 mmol) of -benzyl-1,3-oxazolidinone were initially charged in 3 ml of tertbutanol
, and 280 mg (2.26 mmol) of benzyl mercaptan were added. The mixture was subsequently
2012/075277
heated under reflux for 2 days. Thereafter, the reaction mixture was concentrated on a rotary
evaporator and the resulting (2S)(benzylsulphanyl)phenylpropanamine ediate was
converted further directly, without .
HPLC (Method 10): Rt = 2.63 min
LC-MS (Method 1): Rt = 0.67 min; MS (ESIpos): m/z = 258 (M+H) +
The crude intermediate obtained above was dissolved in a solution of 2 ml of 30% hydrogen
peroxide and 5 ml of formic acid, and the mixture was stirred at RT for 12 h. Then the reaction
e was added to saturated sodium sulphate on and extracted three times with ethyl
acetate. The organic phase was dried over magnesium sulphate and concentrated under reduced
pressure. The crude product ed was purified by means of preparative HPLC. 343 mg (61%
of theory) of the title compound were thus obtained.
HPLC (Method 10): Rt = 2.40 min;
LC-MS (Method 12): Rt = 0.65 min; MS (ESIpos): m/z = 290 (M+H) +
Intermediate 54
(2S,3E)-1,4-diphenylbutenamine
552.7 mg (9.85 mmol) of potassium hydroxide were dissolved in methanol, adsorbed onto 1.1 g of
neutral aluminium oxide and then dried under high vacuum. To a solution of 240 mg (0.82 mmol)
of (2S)(benzylsulphonyl)phenylpropanamine and 1.56 g of the potassium hydroxide on
aluminium oxide thus prepared in 6.2 ml of n-butanol were added dropwise, at 5-10°C, 307 µl (3.3
mmol) of dibromodifluoromethane. The reaction mixture was stirred at RT for 2 h, then filtered
through , and the residue was washed thoroughly with dichloromethane. The filtrate was
concentrated and the resulting residue was dried under reduced re. The crude product thus
obtained was purified by means of ative HPLC. 98 mg (35% of theory) of the title
compound were obtained with an E/Z diastereomer ratio of 4:1.
HPLC (Method 10): Rt = 2.46 min;
LC-MS (Method 12): Rt = 0.75 min; MS (ESIpos): m/z = 224 (M+H) +
The E/Z diastereomer mixture obtained above was dissolved in 2 ml of ethanol and 0.2 ml of N,N-
diisopropylethylamine, and separated by means of HPLC on chiral phase [column: Daicel
Chiralpak AD-H, 5 µm 250 mm x 20 mm, eluent: hexane/(ethanol + 0.2% diethylamine) 50:50 v/v;
UV detection: 220 nm; temperature: 30°C]. The appropriate fractions were concentrated on a
rotary evaporator, and the residue was dried under reduced pressure. 45 mg of the title nd
were obtained.
1H NMR (400 MHz, DMSO-d
6) δ [ppm] = 2.62 - 2.83 (m, 2 H) 3.52 - 3.71 (m, 1 H) 6.18 - 6.30 (m,
1 H) 6.34 - 6.46 (m, 1 H) 6.98 - 7.57 (m, 10 H) [further signals hidden under solvent peaks].
Intermediate 55
yl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxymethyloxo
{[(1S)phenyl(5-phenyl-1,3,4-oxadiazolyl)ethyl]amino}propyl]pyrrolidinyl}methyl
oxoheptanyl]-N-methyl-L-valinamide trifluoroacetate
H3C CH H C
3 3 CH3 O
O H N
H N x CF3COOH
N N N
HN N
O O
CH O CH
3 O O CH3
3 H C CH3
3 CH
20 mg (29 µmol) of N-(tert-butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R)-
2-carboxymethoxypropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-
valinamide were dissolved in 1 ml of DMF, 13.3 mg (35 µmol) of HATU and 15.3 µl (88 µmol) of
N,N-diisopropylethylamine were added, and the mixture was stirred at RT for 30 min.
Subsequently, 12.2 mg (32 µmol) of (1S)phenyl(5-phenyl-1,3,4-oxadiazolyl)ethanamine
trifluoroacetate were added. The reaction e was stirred at RT overnight and then separated
by preparative HPLC. This gave 22 mg (81% of ) of N-(tert-butoxycarbonyl)-N-methyl-L-
valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxymethyloxo{[(1S)phenyl-
1-(5-phenyl-1,3,4-oxadiazolyl)ethyl]amino}propyl]pyrrolidinyl}methyloxoheptan
methyl-L-valinamide.
LC-MS (Method 12): Rt = 1.45 min; MS (ESIpos): m/z = 933 (M+H)+
By subsequently detaching the BOC protecting group with trifluoroacetic acid, 22.4 mg (98% of
) of the title compound were then obtained.
LC-MS (Method 11): Rt = 0.85 min; MS s): m/z = 833 (M+H)+
Intermediate 56
N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxymethyloxo
{[(1R)phenyl(5-phenyl-1,3,4-oxadiazolyl)ethyl]amino}propyl]pyrrolidinyl}methyl-
1-oxoheptanyl]-N-methyl-L-valinamide trifluoroacetate
H C CH3 H C
3 CH O
O 3 3 H N
H N
N N N x CF3COOH
HN N
O O
CH O CH O O CH
3 3
3 H C CH
3 3 CH
N-(tert-Butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)
ymethyloxo{[(1R)phenyl(5-phenyl-1,3,4-oxadiazol
yl)ethyl]amino}propyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-valinamide was
prepared in analogy to the synthesis of Intermediate 55, by reaction of 20 mg (29 µmol) of N-(tertbutoxycarbonyl
)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R)carboxy
methoxypropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide
with 12.2 mg (32 µmol) of (1R)phenyl(5-phenyl-1,3,4-oxadiazolyl)ethanamine
trifluoroacetate.
Yield: 17 mg (64% of theory)
HPLC (Method 10): Rt = 3.74 min;
LC-MS (Method 1): Rt = 1.45 min; MS (ESIpos): m/z = 933 (M+H) +
By subsequently detaching the BOC protecting group with trifluoroacetic acid, 17.1 mg (99% of
) of the title compound were then obtained.
HPLC (Method 10): Rt = 2.55 min;
LC-MS (Method 11): Rt = 0.85 min; MS (ESIpos): m/z = 833 (M+H) +
Intermediate 57
N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)(benzylsulphonyl)phenylpropan-
2-yl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxymethyloxoheptan-
4-yl]-N-methyl-L-valinamide trifluoroacetate
3 O S
H C CH H C
3 3 3 CH
O 3 O
H N
N N x CF3COOH
HN N
O O
CH O CH O CH
3 H C CH 3 O 3
3 3 CH
N-(tert-Butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)
(benzylsulphonyl)phenylpropanyl]amino}methoxymethyloxopropyl]pyrrolidin
yl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide was prepared in analogy to the
synthesis of Intermediate 55, by reaction of 20 mg (29 µmol) of N-(tert-butoxycarbonyl)-N-methyl-
L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R)carboxymethoxypropyl]pyrrolidinyl}
methoxymethyloxoheptanyl]-N-methyl-L-valinamide with 9.3 mg (20 µmol) of (2S)
lsulphonyl)phenylpropanamine.
Yield: 19.2 mg (68 % of theory)
HPLC d 10): Rt = 3.5 min;
LC-MS d 12): Rt = 1.41 min; MS (ESIpos): m/z = 957 (M+H) +
By subsequently detaching the BOC protecting group with trifluoroacetic acid, 19.3 mg (99% of
theory) of the title compound were then obtained.
HPLC (Method 10): Rt = 2.52 min;
LC-MS (Method 1): Rt = 0.86 min; MS (ESIpos): m/z = 857 (M+H) +
Intermediate 58
N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S,3E)-1,4-diphenylbuten
yl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxymethyloxoheptan
yl]-N-methyl-L-valinamide trifluoroacetate
H C CH H C
3 3 3 CH
O 3 H
H N
N N x H
HN N
O O
CH O CH O O CH
3 H C CH 3
3 3 CH
N-(tert-Butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S,3E)-1,4-
diphenylbutenyl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxy
oxoheptanyl]-N-methyl-L-valinamide was prepared in analogy to the synthesis of
Intermediate 55, by reaction of 20 mg (29 µmol) N-(tert-butoxycarbonyl)-N-methyl-L-valyl-N-
[(3R,4S,5S){(2S)[(1R,2R)carboxymethoxypropyl]pyrrolidinyl}methoxymethyl-
1-oxoheptanyl]-N-methyl-L-valinamide with 7.1 mg (32 µmol) of (2S,3E)-1,4-diphenylbuten-
2-amine.
Yield: 15.1 mg (58 % of theory)
HPLC (Method 10): Rt = 4.2 min;
LC-MS (Method 12): Rt = 1.51 min; MS (ESIpos): m/z = 891 (M+H) +
By subsequently ing the BOC protecting group with trifluoroacetic acid, 15.7 mg (99% of
theory) of the title compound were then obtained.
HPLC (Method 10): Rt = 2.62 min;
LC-MS (Method 12): Rt = 0.97 min; MS (ESIpos): m/z = 791 (M+H) +
Intermediate 61
N-(3-carboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxy
methyl{[(1S,2R)(1,2-oxazinanylcarbonyl)phenylcyclopropyl]amino}
oxopropyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-valinamide
H C CH H C CH
3 3 3 N
O 3 H
H N
HO N N O
N N
O O
O CH O CH O O H C
3 3 3
H C CH CH
3 3 3
50 mg (0.054 mmol) of N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)
methoxymethyl{[(1S,2R)(1,2-oxazinanylcarbonyl)phenylcyclopropyl]amino}
oxopropyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-valinamide trifluoroacetate
mediate 16) were dissolved in 8 ml of dioxane/water, and 70 ml (0.108 mmol) of a 15%
solution of 4-oxobutanoic acid in water were added. The reaction e was subsequently stirred
at 100°C for 1 h. After cooling to RT, 3.7 mg (0.059 mmol) of sodium cyanoborohydride were
added and the mixture was adjusted to a pH of 3 by adding about 300 µl of 0.1 N hydrochloric
acid. The reaction mixture was then stirred at 100°C for a further 2 h. After cooling, another 70 ml
(0.108 mmol) of the 15% utanoic acid solution were added and the reaction mixture was
again stirred at 100°C for 1 h. Then a further 3.7 mg (0.059 mmol) of sodium cyanoborohydride
were added and about 300 µl of 0.1 N hydrochloric acid were uently used to adjust the pH
back to 3. The reaction mixture was then d at 100°C for another 2 h. In the event of
conversion still being incomplete, this procedure was repeated for a third time. The on
mixture was finally concentrated and the residue was purified by means of preparative HPLC. In
this way, 32 mg (65% of theory) of the title compound were obtained in the form of a colourless
foam.
HPLC (Method 5): Rt = 1.64 min;
LC-MS (Method 9): Rt = 4.76 min; MS (ESIpos): m/z = 899 (M+H)+
1H NMR (500 MHz, DMSO-d6): δ = 8.95 and 8.8 (2m, 1H), 8.88 and 8.65 (2s, 1H), 7.4-7.1 (m,
5H), 5.0, 4.78, 4.65 and 4.55 (4m, 2H), 4.1-3.7 (m, 5H), 3.32, 3.29, 3.20, 3.12, 3.1 and 3.0 (6s,
9H), 2.75 (m, 2H), 2.63 (t, 1H), 2.4-2.2 (m, 4H), 2.1-1.2 (m, 12H), 1.2-0.8 (m, 16H), 0.75 (m, 3H)
er signals hidden under H2O and DMSO peaks].
Intermediate 62
arboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxy
methyl{[(2S)(1,2-oxazinanyl)oxophenylpropanyl]amino}oxopropyl]pyrrolidin-
1-yl}methyloxoheptanyl]-N-methyl-L-valinamide
H C CH H C CH
3 3 3
O 3 N
H N
HO N N O
N N
O O
O CH O CH O O H C
3 3 CH 3
H C CH
3 3 3
The title compound was prepared in analogy to the synthesis of Intermediate 61, by reaction of
50 mg of N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxymethyl
(1,2-oxazinanyl)oxophenylpropanyl]amino}oxopropyl]pyrrolidinyl}
methyloxoheptanyl]-N-methyl-L-valinamide trifluoroacetate (Intermediate 14) with 4-
oxobutanoic acid.
Yield: 34 mg (70% of theory)
HPLC (Method 5): Rt = 1.64 min;
LC-MS (Method 9): Rt = 4.77 min; MS (ESIpos): m/z = 887 (M+H)+.
Intermediate 63
N-(4-carboxybenzyl)-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxy
methyl{[(1S,2R)(1,2-oxazinanylcarbonyl)phenylcyclopropyl]amino}
oxopropyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-valinamide
H C CH H C CH
3 3 3
O 3 N
H N
N N O
N N
O O
HO CH O CH O O H C
3 3 CH 3
H C CH
3 3 3
The title compound was prepared in analogy to the synthesis of Intermediate 61, by reaction of
mg of N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxymethyl
{[(1S,2R)(1,2-oxazinanylcarbonyl)phenylcyclopropyl]amino}oxopropyl]pyrrolidin
yl}methyloxoheptanyl]-N-methyl-L-valinamide trifluoroacetate (Intermediate 16) with 4-
formylbenzoic acid.
Yield: 7.5 mg (48% of theory)
HPLC (Method 5): Rt = 1.75 min;
LC-MS d 1): Rt = 0.97 min; MS s): m/z = 947 (M+H)+.
Intermediate 64
N-(5-carboxypentyl)-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxy
methyl{[(1S,2R)(1,2-oxazinanylcarbonyl)phenylcyclopropyl]amino}
oxopropyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-valinamide
H C CH H C CH
3 3 3 3 N
O H
H N
HO N N O
N N
O O
O CH O CH O O H C
3 3
C CH CH 3
3 3 3
10 mg (0.011 mmol) of N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)
methoxymethyl{[(1S,2R)(1,2-oxazinanylcarbonyl)phenylcyclopropyl]amino}
oxopropyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-valinamide trifluoroacetate
(Intermediate 16) were ved in 2 ml of dioxane/water, and 2.8 mg (0.022 mmol) of 6-
2012/075277
oxohexanoic acid were added. The reaction mixture was subsequently stirred at 100°C for 1 h.
After cooling to RT, 0.75 mg (0.012 mmol) of sodium cyanoborohydride was added and the
mixture was adjusted to a pH of 3 by adding 0.1 N hydrochloric acid. The reaction mixture was
then stirred at 100°C for a further hour. After cooling, r 2.8 mg (0.022 mmol) of 6-
oxohexanoic acid were added and the reaction e was again stirred at 100°C for 1 h. A
further 0.75 mg (0.012 mmol) of sodium cyanoborohydride was added and 0.1 N hydrochloric acid
was subsequently used to adjust the pH back to 3. The reaction mixture was then stirred at 100°C
for another 1 h. This procedure was then repeated for a third time. The reaction mixture was finally
concentrated and the crude product was purified by means of preparative HPLC. This gave 6.4 mg
(64% of theory) of the title compound in the form of a less foam.
HPLC (Method 5): Rt = 1.68 min;
LC-MS (Method 9): Rt = 4.86 min; MS s): m/z = 927 (M+H)+.
Intermediate 65
N-(2-aminoethyl)-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxy
methyl{[(2S)(1,2-oxazinanyl)oxophenylpropanyl]amino}oxopropyl]pyrrolidin-
1-yl}methyloxoheptanyl]-N-methyl-L-valinamide fluoroacetate
H3C CH H C
3 CH
3 O 3 N
H N
H N N N
2 O
N N
O O
CH O CH O O H C
3 3 3
H C CH3 CH
3 3
x 2 CF3COOH
The title compound was prepared by reaction of 68 mg of N-methyl-L-valyl-N-[(3R,4S,5S)
methoxy{(2S)[(1R,2R)methoxymethyl{[(2S)(1,2-oxazinanyl)oxo
phenylpropanyl]amino}oxopropyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-
valinamide trifluoroacetate (Intermediate 14) with tert-butyl 2-oxoethyl ate and subsequent
detachment of the Boc protecting group with trifluoroacetic acid.
Yield: 49 mg (62% of theory over two stages)
HPLC (Method 5): Rt = 1.58 min;
LC-MS (Method 2): Rt = 1.05 min; MS (ESIpos): m/z = 844 (M+H)+
1H NMR (600 MHz, DMSO-d6): δ = 8.25 (m, 1H), 8.45 and 8.15 (2d, 1H), 7.65-7.55 (m, 3H),
7.23-7.1 (m, 5H), 5.12 and 4.95 (2m, 1H), 4.72 and 4.62 (2m, 1H), 4.6 and 4.52 (2t, 1H), 4.2-3.8
(m, 4H), 3.7 (d, 1H), 3.23, 3.20, 3.19, 3.18, 3.03 and 2.98 (6s, 9H), 7 (m, 6H), 2.4-1.2 (m,
15H), 1.05, 1.0, 0.88 and 0.82 (4d, 6H), 0.92 (m, 6H), 0.73 (m, 6H) er signals hidden under
H2O peak].
Intermediate 66
N-(3-aminopropyl)-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxy
methyl{[(1S,2R)(1,2-oxazinanylcarbonyl)phenylcyclopropyl]amino}
oxopropyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-valinamide
H C CH H C CH
3 3 3 N
O 3
H N
N N O
H N N N
2 O O
CH O CH O O H C
3 3
H C CH CH 3
3 3 3
The title compound was prepared in analogy to the synthesis of Intermediate 65, by reaction of
mg (0.027 mmol) of N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)
methoxymethyl{[(1S,2R)(1,2-oxazinanylcarbonyl)phenylcyclopropyl]amino}
oxopropyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-valinamide trifluoroacetate
(Intermediate 16) with benzyl 3-oxopropyl carbamate and subsequent hydrogenolytic detachment
of the Z protecting group (with 10% palladium on charcoal as a catalyst, in ethanol as a solvent).
Yield: 11 mg (41% of theory over two stages)
HPLC (Method 5): Rt = 1.53 min;
LC-MS d 1): Rt = 0.72 min; MS (ESIpos): m/z = 870 (M+H)+.
Intermediate 67
arboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)(adamantan-
1-ylmethoxy)oxophenylpropanyl]amino}methoxymethyloxopropyl]pyrrolidin
yl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide
H C CH H C
3 CH O
3 3 3
O H
H N
O N N O
N N
O O
OH CH O CH O O CH
3 3 3
H C CH CH
3 3 3
26 mg (26 µmol) of N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)(adamantan
ylmethoxy)oxophenylpropanyl]amino}methoxymethyloxopropyl]pyrrolidin
yl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide trifluoroacetate and 33.9 µl of
a 15% aqueous aldehydic acid solution (53 µmol) were dissolved in 957 µl of a 1:1-
dioxane/water mixture and heated to 100°C for 1 h. After brief cooling, 1.81 mg (29 µmol) of
sodium cyanoborohydride were added. The reaction mixture was adjusted to pH 3 by adding 0.1 N
hydrochloric acid and the mixture was heated to 100°C for a r 2 h. After again adding the
same amounts of succinaldehydic acid solution, sodium cyanoborohydride and hydrochloric acid,
the mixture was heated once again to 100°C for 2 h. The reaction mixture was then separated
ly into its components by means of preparative HPLC. 18.5 mg (73% of theory) of the title
compound were thus obtained.
LC-MS d 1): Rt = 1.17 min; m/z = 967 (M+H)+.
Intermediate 68
N-(3-carboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)(benzyloxy)-
ylpropanyl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxy
methyloxoheptanyl]-N-methyl-L-valinamide
H C CH H C CH
3 3 3 3
O H
H N
O N N O
N N
O O
OH CH O CH O O CH
3 3 3
H C CH CH
3 3 3
24 mg (26 µmol) of N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)(benzyloxy)
phenylpropanyl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxy
methyloxoheptanyl]-N-methyl-L-valinamide trifluoroacetate and 33.7 µl of a 15% aqueous
succinaldehydic acid solution (52 µmol) were dissolved in 953 µl of a 1:1-dioxane/water mixture
and heated to 100°C for 1 h. After brief cooling, 1.80 mg (29 µmol) of sodium cyanoborohydride
were added. The reaction mixture was adjusted to pH 3 by adding 0.1 N hydrochloric acid and the
e was heated to 100°C for a further 2 h. After again adding the same amounts of
succinaldehydic acid solution, sodium cyanoborohydride and hloric acid, the mixture was
heated once again to 100°C for 2 h. The reaction mixture was then separated directly into its
components by means of preparative HPLC. 15.2 mg (65% of ) of the title compound were
thus obtained.
LC-MS (Method 1): Rt = 1.01 min; m/z = 895 (M+H)+
Intermediate 69
N-(3-carboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)(benzyloxy)-
1-oxophenylpropanyl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxy-
5-methyloxoheptanyl]-N-methyl-L-valinamide
H C CH H C CH O
3 3 3 3
O H
H N
O N N O
N N
O O
OH CH O CH O O CH
3 3
H C CH CH 3
3 3 3
53 mg (84 µmol) of N-[(9H-fluorenylmethoxy)carbonyl]-N-methyl-L-valyl-N-[(2R,3S,4S)
carboxymethoxymethylhexanyl]-N-methyl-L-valinamide mediate 4) and 45 mg (84
µmol) of benzyl N-{(2R,3R)methoxymethyl[(2S)-pyrrolidinyl]propanoyl}-L-
alaninate trifluoroacetate (Intermediate 12) were taken up in 2 ml of DMF, 19 µl of N,N-
diisopropylethylamine, 14 mg (92 µmol) of HOBt and 17.6 mg (92 µmol) of EDC were added and
then the mixture was stirred at RT overnight. Subsequently, the reaction mixture was concentrated
and the residue was purified by means of preparative HPLC. This gave 59 mg (68% of ) of
the Fmoc-protected intermediate N-[(9H-fluorenylmethoxy)carbonyl]-N-methyl-L-valyl-N-
[(3R,4S,5S){(2S)[(1R,2R){[(2S)(benzyloxy)oxophenylpropanyl]amino}
methoxymethyloxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-
L-valinamide.
LC-MS (Method 1): Rt = 1.55 min; m/z = 1044 (M+H)+.
57 mg (0.055 mmol) of this intermediate were treated with 1.2 ml of piperidine in 5 ml of DMF to
detach the Fmoc protecting group. After concentration and purification by means of preparative
HPLC, 39 mg (76% of theory) of the free amine intermediate N-methyl-L-valyl-N-[(3R,4S,5S)
{(2S)[(1R,2R){[(2S)(benzyloxy)oxophenylpropanyl]amino}methoxymethyl-
ropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide were
obtained as the trifluoroacetate.
HPLC (Method 5): Rt = 1.9 min;
LC-MS (Method 1): Rt = 1.01 min; m/z = 822 .
37 mg (0.045 mmol) of this intermediate were dissolved in 5 ml of dioxane/water and, analogously
to the preparation of the nd in Intermediate 66, d with a 15% aqueous on of 4-
oxobutanoic acid in the presence of sodium cyanoborohydride. 16 mg (39% of theory) of the title
compound were obtained in the form of a colourless foam.
HPLC (Method 6): Rt = 2.1 min;
LC-MS (Method 1): Rt = 1.01 min; MS (ESIpos): m/z = 908 (M+H)+.
Intermediate 70
N-(3-carboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S,3S)
(benzyloxy)oxophenylbutanyl]amino}methoxymethyloxopropyl]pyrrolidinyl}-
3-methoxymethyloxoheptanyl]-N-methyl-L-valinamide
H C CH H C
3 3 3 CH
3 O
O H
H N
O N N O
N N
O O
OH CH O CH O O CH
3 3 3 H C
H C CH CH 3
3 3 3
First, in analogy to the synthesis described in Intermediate 14, proceeding from Intermediates 4
and 26, the amine nd N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S,3S)
(benzyloxy)oxophenylbutanyl]amino}methoxymethyloxopropyl]pyrrolidinyl}-
3-methoxymethyloxoheptanyl]-N-methyl-L-valinamide was prepared.
30 mg (0.032 mmol) of this compound were dissolved in 6 ml of dioxane/water, and 41 µl (0.063
mmol) of a 15% aqueous solution of 4-oxobutanoic acid were added. The reaction mixture was
subsequently stirred at 100°C for 1 h. After cooling to RT, 2.2 mg (0.035 mmol) of sodium
cyanoborohydride were added and the mixture was adjusted to a pH of 3 by adding about 300 µl of
0.1 N hydrochloric acid. The reaction mixture was then d at 100°C for a further 2 h. After
cooling, another 41 µl (0.063 mmol) of the 15% 4-oxobutanoic acid solution were added and the
reaction mixture was again stirred at 100°C for 1 h. Then a further 2.2 mg (0.035 mmol) of sodium
cyanoborohydride were added and about 300 µl of 0.1 N hloric acid were subsequently used
to adjust the pH back to 3. The reaction mixture was then stirred at 100°C for another 2 h. In the
event of conversion still being incomplete, this procedure was repeated for a third time. The
reaction mixture was finally concentrated and the crude product was purified by means of
preparative HPLC. This gave 24 mg (82% of theory) of the title compound in the form of a
colourless foam.
HPLC (Method 5): Rt = 1.9 min;
LC-MS d 9): Rt = 5.15 min; MS (ESIpos): m/z = 922 (M+H)+.
Intermediate 71
N-(3-carboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxy
{[(2S)methoxyoxophenylpropanyl]amino}methyloxopropyl]pyrrolidinyl}
methyloxoheptanyl]-N-methyl-L-valinamide
H C CH H C CH
3 3 3 3 O
O H
H N CH
N O 3
O N
N N
O O
OH CH O CH O O CH
3 3 3
H C CH CH
3 3 3
First, in analogy to the synthesis described in Intermediate 14, ding from Intermediates 4
and 39, the amine compound N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)
methoxy{[(2S)methoxyoxophenylpropanyl]amino}methyl
oxopropyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-valinamide was prepared. 7
mg (0.009 mmol) of this compound were then used, in analogy to the preparation of Intermediate
61, by reaction with 4-oxobutanoic acid in the presence of sodium cyanoborohydride, to obtain
2 mg (22% of theory) of the title compound in the form of a colourless foam.
HPLC (Method 6): Rt = 1.9 min;
LC-MS (Method 2): Rt = 1.06 min; MS (ESIpos): m/z = 832 (M+H)+.
Intermediate 72
arboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)(benzyloxy)-
3-(1H-indolyl)oxopropanyl]amino}methoxymethyloxopropyl]pyrrolidinyl}
methoxymethyloxoheptanyl]-N-methyl-L-valinamide
WO 87716
H C CH H C
3 3 3 CH
3 O
O H
H N
O N N O
N N
O O
OH CH O CH O O CH3
3 3
H C CH CH
3 3 3
212 mg (411 µmol) of N-(tert-butoxycarbonyl)-N-methyl-L-valyl-N-[(2R,3S,4S)carboxy
methoxymethylhexanyl]-N-methyl-L-valinamide (Intermediate 8) and 237 mg (411 µmol) of
benzyl-N-{(2R,3R)methoxymethyl[(2S)-pyrrolidinyl]propanoyl}-L-tryptophanate
oroacetate (Intermediate 20) were taken up in 30 ml of DMF, and 188 mg (493 µmol) of O-
(7-azabenzotriazolyl)-N,N,N',N'-tetramethyluronium hexafluorophosphate and 215 µl N,N-
diisopropylethylamine were added. The reaction mixture was stirred at RT for 20 h, then
trated under reduced pressure, and the residue was purified by means of preparative HPLC.
The product fractions were ed and concentrated, and the e was dried under high
vacuum. This gave 315 mg (80% of theory) of the Boc-protected intermediate N-(tert-
butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)(benzyloxy)
(1H-indolyl)oxopropanyl]amino}methoxymethyloxopropyl]pyrrolidinyl}
methoxymethyloxoheptanyl]-N-methyl-L-valinamide as a colourless foam.
LC-MS (Method 1): Rt = 1.45 min; m/z = 961 (M+H)+.
50 mg (52 µmol) of this intermediate were treated with 1 ml of trifluoroacetic acid in 9 ml of
dichloromethane to detach the Boc protecting group. After concentration and purification by
means of preparative HPLC, 29 mg (57% of theory) of the free amine intermediate N-methyl-L-
valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)(benzyloxy)(1H-indolyl)oxopropan
yl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxymethyloxoheptan
methyl-L-valinamide were obtained as the trifluoroacetate.
LC-MS (Method 1): Rt = 0.99 min; m/z = 861 (M+H)+.
29 mg (0.03 mmol) of this intermediate were dissolved in 6 ml of dioxane/water, and 39 µl (0.059
mmol) of a 15% aqueous solution of 4-oxobutanoic acid were added. The reaction e was
subsequently stirred at 100°C for 1 h. After cooling to RT, 2 mg (0.033 mmol) of sodium
cyanoborohydride were added and the mixture was adjusted to a pH of 3 by adding about 300 µl of
0.1 N hydrochloric acid. The reaction mixture was then d at 100°C for a further 2 h. After
cooling, another 39 µl (0.059 mmol) of the 15% 4-oxobutanoic acid solution were added and the
reaction mixture was again stirred at 100°C for 1 h. Then a further 2 mg (0.033 mmol) of sodium
2012/075277
cyanoborohydride were added and about 300 µl of 0.1 N hydrochloric acid were subsequently used
to adjust the pH back to 3. The mixture was then stirred at 100°C for another 2 h. Thereafter, the
reaction mixture was poured onto a 1:1 mixture of semisaturated aqueous ammonium chloride
solution and ethyl acetate. The organic phase was removed, washed with saturated sodium chloride
solution, dried over sodium te and concentrated. The e was freeze-dried from water/
acetonitrile. This gave 27 mg (94% of ) of the title compound in the form of a colourless
foam.
HPLC (Method 5): Rt = 2.2 min;
LC-MS (Method 9): Rt = 5.04 min; MS (ESIpos): m/z = 947 (M+H)+.
Intermediate 73
N-(3-carboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R)({(2S)
[benzyl(methyl)amino]oxophenylpropanyl}amino)methoxymethyl
oxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide
3 H C
H C CH H C CH 3 N
3 3 3 3
O H
H N
O N N O
N N
O O
OH CH O CH O O CH
3 3 CH 3
H C CH
3 3 3
First, in analogy to the synthesis described in ediate 14, proceeding from Intermediates 4
and 38, the amine compound N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R)({(2S)
[benzyl(methyl)amino]oxophenylpropanyl}amino)methoxymethyl
oxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide was
prepared. 25 mg (0.026 mmol) of this compound were then used, in analogy to the preparation of
Intermediate 61, by reaction with utanoic acid in the presence of sodium cyanoborohydride,
to obtain 13 mg (54% of theory) of the title compound in the form of a colourless foam.
HPLC (Method 12): Rt = 2.2 min;
LC-MS (Method 9): Rt = 5.01 min; MS (ESIpos): m/z = 921 (M+H)+.
Intermediate 74
N-(3-carboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R)({(1S,2R)
[(benzyloxy)carbonyl]phenylcyclopropyl}amino)methoxymethyloxopropyl]pyrrolidin-
1-yl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide
H C CH H C CH
3 3 3 3 O
O H
H N
O N N O
N N
O O
OH CH O CH O O
3 CH
3 H C CH CH 3
3 3 3
50 mg (73 µmol) of N-(tert-butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R)-
2-carboxymethoxypropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-
valinamide (Intermediate 26) and 28 mg (73 µmol) of benzyl (1S,2R)amino
phenylcyclopropanecarboxylate oroacetate (Intermediate 45) were taken up in 5 ml of DMF,
and 42 mg (110 µmol) of zabenzotriazolyl)-N,N,N',N'-tetramethyluronium
hexafluorophosphate and 38 µl of N,N-diisopropylethylamine were added. The reaction mixture
was stirred at RT for 5 h, then concentrated under reduced pressure, and the residue was purified
by means of preparative HPLC. The product fractions were combined and concentrated. After
lyophilization from dioxane/water, 35 mg (51% of theory) of the Boc-protected intermediate N-
(tert-butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R)({(1S,2R)
[(benzyloxy)carbonyl]phenylcyclopropyl}amino)methoxymethyloxopropyl]pyrrolidin-
1-yl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide were obtained as a
less foam.
LC-MS d 1): Rt = 1.52 min; m/z = 934 (M+H)+.
35 mg of this intermediate were treated with 1 ml of trifluoroacetic acid in 5 ml of
romethane to detach the Boc protecting group. After concentration and lyophilization from
dioxane/water, 34 mg (97% of theory) of the free amine intermediate N-methyl-L-valyl-N-
[(3R,4S,5S){(2S)[(1R,2R)({(1S,2R)[(benzyloxy)carbonyl]
phenylcyclopropyl}amino)methoxymethyloxopropyl]pyrrolidinyl}methoxy
methyloxoheptanyl]-N-methyl-L-valinamide were obtained as the trifluoroacetate.
LC-MS d 1): Rt = 0.91 min; m/z = 834 (M+H)+.
11 mg (0.011 mmol) of this intermediate were then used, in analogy to the preparation of
Intermediate 66, by reaction with utanoic acid in the presence of sodium cyanoborohydride,
to obtain 2.5 mg (24% of theory) of the title compound in the form of a colourless foam.
HPLC (Method 12): Rt = 2.2 min;
LC-MS d 9): Rt = 5.1 min; MS (ESIpos): m/z = 920 (M+H)+.
Intermediate 75
N-(3-carboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxy
methyloxo{[(1S,2R)phenyl(propylcarbamoyl)cyclopropyl]amino}propyl]pyrrolidin
yl}methyloxoheptanyl]-N-methyl-L-valinamide
H C CH H C CH 3
3 3 3 3 HN
O H
H N
O N N O
N N
O O
OH CH O CH O O
3 3 CH
H C CH CH 3
3 3 3
First, in analogy to the synthesis described in Intermediate 74, by coupling of N-(tert-
butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R)carboxy
methoxypropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide
(Intermediate 26) and )aminophenyl-N-propylcyclopropanecarboxamide
trifluoroacetate (Intermediate 27) in the presence of O-(7-azabenzotriazolyl)-N,N,N',N'-
tetramethyluronium hexafluorophosphate and subsequent detachment of the Boc protecting group
by means of trifluoroacetic acid, the amine nd N-methyl-L-valyl-N-[(3R,4S,5S)methoxy-
1-{(2S)[(1R,2R)methoxymethyloxo{[(1S,2R)phenyl
(propylcarbamoyl)cyclopropyl]amino}propyl]pyrrolidinyl}methyloxoheptanyl]-NL-valinamide was prepared as the trifluoroacetate. 14 mg (0.016 mmol) of this compound
were then used, in analogy to the preparation of ediate 61, by reaction with 4-oxobutanoic
acid in the presence of sodium cyanoborohydride, to obtain 11.3 mg (83% of theory) of the title
compound.
HPLC (Method 6): Rt = 1.9 min;
LC-MS (Method 2): Rt = 1.27 min; MS (ESIpos): m/z = 871 (M+H)+.
Intermediate 76
arboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(1S,2R)
(ethoxycarbonyl)phenylcyclopropyl]amino}methoxymethyloxopropyl]pyrrolidinyl}-
3-methoxymethyloxoheptanyl]-N-methyl-L-valinamide
H C CH H C CH
3 3 3 3 O CH
O H 3
H N
HO N N O
N N
O O
O CH O CH O O H C
3 3
H C CH CH 3
3 3 3
First, by coupling of Intermediate 46 (N-(tert-butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S)
{(2S)[(1R,2R)carboxymethoxypropyl]pyrrolidinyl}methoxymethyloxoheptan-
4-yl]-N-methyl-L-valinamide) with Intermediate 48 (ethyl (1 1-amino
phenylcyclopropanecarboxylate trifluoroacetate) in the presence of O-(7-azabenzotriazolyl)-
N,N,N',N'-tetramethyluronium hexafluorophosphate and subsequent Boc ment, the starting
compound N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(1S,2R)(ethoxycarbonyl)
phenylcyclopropyl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxy
methyloxoheptanyl]-N-methyl-L-valinamide trifluoroacetate was ed. 70 mg (0.079
mmol) of this starting material were then used, by reaction with 4-oxobutanoic acid, in analogy to
Intermediate 61, to obtain 46 mg (68% of theory) of the title compound.
HPLC (Method 6): Rt = 1.9 min;
LC-MS (Method 2): Rt = 1.28 min; MS (ESIpos): m/z = 858 (M+H)+
Intermediate 77
N-(3-carboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)aminooxo-
3-phenylpropanyl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxy
methyloxoheptanyl]-N-methyl-L-valinamide
H C CH H C CH O
3 3 3 3
O H
H N
O N N NH
N N 2
O O
OH CH3 O CH O O CH
H CH CH 3
3 3 3
First, in analogy to the synthesis described in Intermediate 75, by coupling of N-(tert-
butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R)carboxy
methoxypropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide
mediate 26) and L-phenylalaninamide hydrochloride in the presence of O-(7-azabenzotriazol-
N,N,N',N'-tetramethyluronium hexafluorophosphate and subsequent detachment of the Boc
protecting group by means of trifluoroacetic acid, the amine compound N-methyl-L-valyl-N-
[(3R,4S,5S){(2S)[(1R,2R){[(2S)aminooxophenylpropanyl]amino}methoxy-
2-methyloxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-
valinamide was prepared as the trifluoroacetate. 47 mg (0.049 mmol) of this compound were then
used, in analogy to the preparation of Intermediate 61, by reaction with 4-oxobutanoic acid in the
presence of sodium orohydride, to obtain 39 mg (96% of theory) of the title nd.
HPLC (Method 6): Rt = 1.7 min;
LC-MS (Method 9): Rt = 4.44 min; MS (ESIpos): m/z = 817 (M+H)+
1H NMR (500 MHz, DMSO-d
6): δ = 8.95 and 8.8 (2m, 1H), 8.25 and 8.0 (2d, 1H), 7.45, 7.35 and
7.0 (3s, broad, 2H), 7.3-7.1 (m, 5H), 4.8-4.4 (2m, 3H), 3.95 (m, 1H), 3.82 (m, 1H), 3.72 (d, 1H),
3.22, 3.18, 3.15, 3.05 and 3.00 (5s, 9H), 2.85-2.7 (m, 4H), 2.45-1.6 (m, 12H), 1.5-1.2 (m, 3H), 1.1-
0.7 (m, 21H) [further signals hidden under solvent .
Intermediate 78
N-(6-aminohexyl)-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxy
methyl{[(2S)(1,2-oxazinanyl)oxophenylpropanyl]amino}oxopropyl]pyrrolidin-
1-yl}methyloxoheptanyl]-N-methyl-L-valinamide
H C CH H C CH N
3 3 3
O 3
H N
H2N N N O
N N
O O
CH3 O CH O O H C
H C CH CH 3
3 3 3
This compound was prepared in analogy to Intermediate 66 over 2 stages, proceeding from 20 mg
(16 µmol) of the compound from Intermediate 14 and benzyl 6-oxohexyl carbamate, and the
hydrogenation was performed in methanol as the t.
Yield: 7.6 mg (55% of theory over 2 stages)
HPLC (Method 6): Rt = 1.8 min;
LC-MS (Method 1): Rt = 0.7 min; MS (ESIpos): m/z = 901 (M+H)+.
Intermediate 79
N-(3-carboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)
(benzylamino)oxophenylpropanyl]amino}methoxymethyloxopropyl]pyrrolidin
methoxymethyloxoheptanyl]-N-methyl-L-valinamide
H C CH H C CH
3 3 3 3 HN
O H
H N
O N N O
N N
O O
OH CH O CH O O CH
3 3 CH 3
H C CH
3 3 3
36 mg (43 µmol) of N-(tert-butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R)-
3-{[(1S)carboxyphenylethyl]amino}methoxymethyloxopropyl]pyrrolidinyl}
methoxymethyloxoheptanyl]-N-methyl-L-valinamide (Intermediate 46) and 4.6 mg (43
µmol) of benzylamine were taken up in 5 ml of DMF, 7.5 µl (88 µmol) of N,N-
ropylethylamine, 10 mg (65 µmol) of HOBt and 10 mg (52 µmol) of EDC were added, and
then the mixture was stirred at RT overnight. Subsequently, the reaction mixture was concentrated
and the residue was purified by means of ative HPLC. 29 mg (73% of theory) of the Boc-
protected intermediate N-(tert-butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)
[(1R,2R){[(2S)(benzylamino)oxophenylpropanyl]amino}methoxymethyl
oxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide were
obtained.
LC-MS (Method 1): Rt = 1.43 min; m/z = 921 (M+H)+.
29 mg of this intermediate were treated with 1 ml of trifluoroacetic acid in 6 ml of
dichloromethane to detach the Boc protecting group. After concentration and lyophilization from
dioxane/water, 30 mg (quant.) of the free amine ediate N-methyl-L-valyl-N-[(3R,4S,5S)
{(2S)[(1R,2R){[(2S)(benzylamino)oxophenylpropanyl]amino}methoxy
methyloxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-
valinamide were obtained as the trifluoroacetate.
LC-MS (Method 1): Rt = 0.95 min; m/z = 821 (M+H)+.
17 mg (0.018 mmol) of this intermediate were then used, in analogy to the preparation of
Intermediate 61, by reaction with 4-oxobutanoic acid in the presence of sodium orohydride,
to obtain 13 mg (80% of theory) of the title nd in the form of a colourless foam.
HPLC (Method 5): Rt = 1.7 min;
LC-MS (Method 9): Rt = 4.97 min; MS (ESIpos): m/z = 907 (M+H)+.
Intermediate 80
N-(3-carboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)
(benzylamino)(1H-indolyl)oxopropanyl]amino}methoxymethyl
oxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide
H C CH H C
3 CH HN
3 3 3
O H
H N
O N N O
N N
O O
OH CH O CH O O CH3
3 3
H C CH CH
3 3 3
H
First, in analogy to the synthesis described in Intermediate 74, by coupling of N-(tert-
butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R)carboxy
methoxypropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide
(Intermediate 26) and N-benzyl-L-tryptophanamide oroacetate (Intermediate 47) in the
presence of O-(7-azabenzotriazolyl)-N,N,N',N'-tetramethyluronium hexafluorophosphate and
2012/075277
uent detachment of the Boc protecting group by means of trifluoroacetic acid, the amine
compound N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)(benzylamino)(1H-
3-yl)oxopropanyl]amino}methoxymethyloxopropyl]pyrrolidinyl}
ymethyloxoheptanyl]-N-methyl-L-valinamide was prepared as the trifluoroacetate.
10 mg (0.01 mmol) of this compound were then used, in analogy to the preparation of Intermediate
61, by reaction with utanoic acid in the presence of sodium cyanoborohydride, to obtain
2.5 mg (26% of theory) of the title compound.
HPLC (Method 5): Rt = 1.7 min;
LC-MS (Method 2): Rt = 1.13 min; MS (ESIpos): m/z = 946 (M+H)+.
ediate 81
N-(3-carboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(1S,2R)
carbamoylphenylcyclopropyl]amino}methoxymethyloxopropyl]pyrrolidinyl}
methoxymethyloxoheptanyl]-N-methyl-L-valinamide
H C CH H C
3 CH3
3 3 NH
O H 2
H N
O N N O
N N
O O
OH CH O CH O O
3 3 CH
H C CH CH3 3
3 3
First, in analogy to the synthesis described in Intermediate 74, by coupling of N-(tert-
butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R)carboxy
methoxypropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide
(Intermediate 26) and (1S,2R)aminophenylcyclopropanecarboxamide trifluoroacetate
(Intermediate 48) in the presence of O-(7-azabenzotriazolyl)-N,N,N',N'-tetramethyluronium
hexafluorophosphate and subsequent detachment of the Boc protecting group by means of
trifluoroacetic acid, the amine compound N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R)
{[(1S,2R)carbamoylphenylcyclopropyl]amino}methoxymethyloxopropyl]pyrrolidin-
1-yl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide was prepared as the
trifluoroacetate. 14 mg (0.0163 mmol) of this compound were then used, in analogy to the
preparation of Intermediate 61, by reaction with 4-oxobutanoic acid in the presence of sodium
cyanoborohydride, to obtain 8 mg (57% of theory) of the title compound.
HPLC (Method 5): Rt = 1.6 min;
LC-MS (Method 9): Rt = 4.64 min; MS (ESIpos): m/z = 829 (M+H)+.
Intermediate 82
N-(3-carboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)amino(1H-
3-yl)oxopropanyl]amino}methoxymethyloxopropyl]pyrrolidinyl}
methoxymethyloxoheptanyl]-N-methyl-L-valinamide
H C CH H C CH
3 3 3 3 NH
O H 2
H N
O N N O
N N
O O
OH CH3 O CH3 O O CH
H C CH CH 3
3 3 3
First, in analogy to the synthesis described in Intermediate 69, by coupling of N-[(9H-fluoren
oxy)carbonyl]-N-methyl-L-valyl-N-[(2R,3S,4S)carboxymethoxymethylhexanyl]-
N-methyl-L-valinamide (Intermediate 4) and Nα-{(2R,3R)methoxymethyl[(2S)-pyrrolidin-
ropanoyl}-L-tryptophanamide trifluoroacetate (Intermediate 49) in the presence of O-(7-
azabenzotriazolyl)-N,N,N',N'-tetramethyluronium hexafluorophosphate and subsequent
ment of the Fmoc protecting group by means of piperidine, the amine compound N-methyl-
L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)amino(1H-indolyl)oxopropan
no}methoxymethyloxopropyl]pyrrolidinyl}methoxymethyloxoheptan
yl]-N-methyl-L-valinamide was prepared as the trifluoroacetate. 78 mg (0.088 mmol) of this
compound were then used, in analogy to the preparation of Intermediate 61, by reaction with 4-
oxobutanoic acid in the presence of sodium cyanoborohydride, to obtain 68 mg (90% of theory) of
the title compound.
HPLC (Method 5): Rt = 1.8 min;
LC-MS (Method 9): Rt = 4.49 min; MS (ESIpos): m/z = 856 (M+H)+.
Intermediate 83
N-(5-carboxypentyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)amino(1H-
indolyl)oxopropanyl]amino}methoxymethyloxopropyl]pyrrolidinyl}
methoxymethyloxoheptanyl]-N-methyl-L-valinamide
H C CH H C
3 3 3 CH
O 3 NH
H 2
H N
N N O
N N
O O
O CH O CH O O
3 3 CH
H C CH CH 3
3 3 3
OH H
This compound was prepared in analogy to the compound in ediate 82, proceeding from 20
mg (26 µmol) of N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)amino(1H-
indolyl)oxopropanyl]amino}methoxymethyloxopropyl]pyrrolidinyl}
methoxymethyloxoheptanyl]-N-methyl-L-valinamide trifluoroacetate, by reaction with 4-
oxobutanoic acid in the presence of sodium cyanoborohydride prepared.
Yield: 5 mg (25% of theory)
HPLC (Method 5): Rt = 1.6 min;
LC-MS (Method 11): Rt = 0.72 min; MS s): m/z = 884 (M+H)+.
Intermediate 84
arboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxy
methyl{[(2S)(morpholinyl)oxophenylpropanyl]amino}oxopropyl]pyrrolidin
yl}methyloxoheptanyl]-N-methyl-L-valinamide
H C CH H C CH N
3 3 3
O 3
H N
HO N N O
N N
O O
O CH O CH O O H C
3 3
C CH CH 3
3 3 3
First, in analogy to the synthesis described in Intermediate 79, by ng of N-(tert-
butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(1S)carboxy
phenylethyl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxymethyl
oxoheptanyl]-N-methyl-L-valinamide (Intermediate 46) and morpholine in the presence of EDC
and HOBT and subsequent detachment of the Boc protecting group by means of trifluoroacetic
acid, the amine compound N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)
methoxymethyl{[(2S)(morpholinyl)oxophenylpropanyl]amino}
oxopropyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-valinamide was prepared as
the trifluoroacetate. 30 mg (0.033 mmol) of this compound were then used, in analogy to the
preparation of Intermediate 61, by reaction with 4-oxobutanoic acid in the ce of sodium
cyanoborohydride, to obtain 22 mg (76% of theory) of the title compound.
HPLC (Method 5): Rt = 1.6 min;
LC-MS (Method 9): Rt = 4.58 min; MS (ESIpos): m/z = 887 (M+H)+.
Intermediate 85
N-(3-carboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S,3R)
(benzylamino)hydroxyoxobutanyl]amino}methoxymethyloxopropyl]pyrrolidin
yl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide
H C CH H C
3 CH
3 3 HN
3 H
H N
HO N N O
N N
O O
O CH O CH O O H C
3 3 H C
H C CH CH 3 3 OH
3 3 3
First, in analogy to the sis described in Intermediate 79, by coupling of N-(tert-
butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(1S)carboxy
phenylethyl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxymethyl
oxoheptanyl]-N-methyl-L-valinamide (Intermediate 46) and N-benzyl-L-threoninamide
trifluoroacetate in the presence of HATU and subsequent detachment of the Boc protecting group
by means of trifluoroacetic acid, the amine compound N-methyl-L-valyl-N-[(3R,4S,5S){(2S)
R){[(2S,3R)(benzylamino)hydroxyoxobutanyl]amino}methoxymethyl
oxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide was
prepared as the oroacetate. 21 mg (0.024 mmol) of this compound were then used, in analogy
to the preparation of Intermediate 61, by reaction with 4-oxobutanoic acid in the presence of
sodium orohydride, to obtain 20 mg (97% of theory) of the title compound.
HPLC (Method 5): Rt = 1.54 min;
LC-MS (Method 9): Rt = 4.49 min; MS (ESIpos): m/z = 861 (M+H)+.
Intermediate 86
4-{[(2S){[(2S){[(3R,4S,5S){(2S)[(1R,2R){[(2S)tert.-Butoxyoxo
propanyl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxy
methyloxoheptanyl](methyl)amino}methylbutanyl]amino}methyloxobutan
yl](methyl)amino}butanoic acid
CH 3
3 H C
H C CH H C CH O CH
3 3 3 3 3
H N
HO N N O
N N
O O
O CH O CH O O H C
3 3 CH 3
H C CH
3 3 3
First, in y to the synthesis described in Intermediate 74, by coupling of N-(tert-
butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R)carboxy
methoxypropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide
(Intermediate 26) and tert-butyl-L-phenylalaninate hydrochloride in the presence of O-(7-
azabenzotriazolyl)-N,N,N',N'-tetramethyluronium hexafluorophosphate and subsequent
detachment of the Boc protecting group by means of trifluoroacetic acid to obtain the tert-butyl
ester (stirring with trifluoroacetic acid in dichloromethane for 40 minutes), the amine compound
N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)tert-butoxyoxophenylpropan-
2-yl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxymethyloxoheptan-
N-methyl-L-valinamide was prepared as the oroacetate. 22 mg (0.02 mmol) of this
compound were then used, in analogy to the preparation of Intermediate 61, by reaction with 4-
oxobutanoic acid in the presence of sodium cyanoborohydride, to obtain 16 mg (94% of theory) of
the title compound.
HPLC (Method 5): Rt = 2.0 min;
LC-MS d 9): Rt = 5.05 min; MS (ESIpos): m/z = 874 (M+H)+.
Intermediate 87
4-{[(2S){[(2S){[(3R,4S,5S){(2S)[(1R,2R){[(2S)tert-Butoxy(1H-indolyl)
oxopropanyl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxymethyl
oxoheptanyl](methyl)amino}methylbutanyl]amino}methyloxobutan
yl](methyl)amino}butanoic acid
CH 3
3 H C
H C CH H C CH
3 3 3 3 O CH
H N
HO N N O
N N
O O
O CH O CH O O H C
3 3 3
H C CH CH
3 3 3
This compound was prepared in analogy to the synthesis described in Intermediate 86, proceeding
from 230 mg (336 µmol) of N-(tert-butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)
[(1R,2R)carboxymethoxypropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-
methyl-L-valinamide (Intermediate 26) and utyl-L-tryptophanate hydrochloride over 3 stages.
Yield: 95 mg (31% of theory over 3 )
HPLC (Method 5): Rt = 2.0 min;
LC-MS (Method 9): Rt = 5.05 min; MS (ESIpos): m/z = 913 (M+H)+.
Intermediate 88
N-(6-aminohexyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)amino(1H-
indolyl)oxopropanyl]amino}methoxymethyloxopropyl]pyrrolidinyl}
methoxymethyloxoheptanyl]-N-methyl-L-valinamide
H C CH H C
3 3 3 CH NH
O 3
H 2
H N
N N O
N N
O O
CH O CH O O
3 3 CH
H C CH CH 3
3 3 3
2 H
First, in analogy to the syntheses described in Intermediate 69, by ng of N-[(9H-fluoren
ylmethoxy)carbonyl]-N-methyl-L-valyl-N-[(2R,3S,4S)carboxymethoxymethylhexanyl]-
N-methyl-L-valinamide (Intermediate 4) and Nα-{(2R,3R)methoxymethyl[(2S)-pyrrolidin-
2-yl]propanoyl}-L-tryptophanamide trifluoroacetate (Intermediate 49) in the ce of O-(7-
azabenzotriazolyl)-N,N,N',N'-tetramethyluronium hexafluorophosphate and subsequent
detachment of the Fmoc protecting group by means of piperidine, the amine compound N-methyl-
L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)amino(1H-indolyl)oxopropan
yl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxymethyloxoheptan
yl]-N-methyl-L-valinamide was prepared as the trifluoroacetate. 30 mg (0.03 mmol) of this
compound were then used, in analogy to the preparation of the compound of Intermediate 61, by
reaction with benzyl 6-oxohexyl carbamate, which had been obtained hand by oxidation of
benzyl 6-hydroxyhexyl carbamate, in the presence of sodium cyanoborohydride, to obtain 17 mg
(45% of ) of the Z-protected compound. Subsequently, hydrogenolysis in methanol over
% palladium/activated carbon afforded the title compound.
Yield: 14 mg (95% of theory)
HPLC (Method 5): Rt = 1.5 min;
LC-MS (Method 1): Rt = 0.73 min; MS (ESIpos): m/z = 869 (M+H)+.
Intermediate 89
N-(6-aminohexyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)tert-butoxy
(1H-indolyl)oxopropanyl]amino}methoxymethyloxopropyl]pyrrolidinyl}
methoxymethyloxoheptanyl]-N-methyl-L-valinamide
CH 3
3 H C
H C CH H C
3 3 3 CH
3 O CH
O H 3
H N
N N O
N N
O O
CH O CH O O
3 3 CH
H C CH CH 3
3 3 3
2 H
First, in analogy to the synthesis described in Intermediate 86, by coupling of N-(tert-
butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R)carboxy
methoxypropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide
(Intermediate 26) and utyl-L-tryptophanate hydrochloride in the presence of O-(7-
azabenzotriazolyl)-N,N,N',N'-tetramethyluronium hexafluorophosphate and subsequent
ment of the Boc protecting group by means of trifluoroacetic acid to obtain the tert-butyl
ester (stirring with 1:10 trifluoroacetic acid/dichloromethane for 30 min), the amine compound N-
-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)tert-butoxy(1H-indolyl)
oxopropanyl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxymethyl
oxoheptanyl]-N-methyl-L-valinamide was prepared as the trifluoroacetate. 71 mg (0.075 mmol)
of this nd were then used, in analogy to the preparation of the compound of ediate
61, by reaction with benzyl 6-oxohexyl carbamate, which had been obtained beforehand by
ion of benzyl 6-hydroxyhexyl carbamate, in the presence of sodium cyanoborohydride, to
obtain 35 mg (44% of theory) of the Z-protected compound. Subsequently, hydrogenolysis in
methanol over 10% palladium/activated carbon afforded the title compound.
Yield: 30 mg (98% of theory)
HPLC (Method 5): Rt = 1.9 min;
LC-MS (Method 1): Rt = 0.77 min; MS (ESIpos): m/z = 926 (M+H)+.
Intermediate 90
N-(3-carboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[2-(1H-indol
yl)ethyl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxymethyl
oxoheptanyl]-N-methyl-L-valinamide
H C CH3 H3C CH
3 O 3 H
H N
O N N
N N
O O
OH CH O CH O O CH
3 3
H C CH CH 3 NH
3 3 3
First, in analogy to the synthesis described in Intermediate 74, by coupling of N-(tert-
carbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R)carboxy
methoxypropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide
(Intermediate 26) and 2-(1H-indolyl)ethanamine in the presence of O-(7-azabenzotriazolyl)-
N,N,N',N'-tetramethyluronium hexafluorophosphate and subsequent detachment of the Boc
protecting group by means of trifluoroacetic acid, the amine compound N-methyl-L-valyl-N-
[(3R,4S,5S){(2S)[(1R,2R){[2-(1H-indolyl)ethyl]amino}methoxymethyl
oxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide was
prepared as the trifluoroacetate. 100 mg (0.119 mmol) of this compound were then used, in
analogy to the preparation of Intermediate 61, by reaction with 4-oxobutanoic acid in the presence
of sodium cyanoborohydride, to obtain 50 mg (49% of theory) of the title compound. The title
compound was purified here by flash tography on silica gel with
dichloromethane/methanol/17% ammonia as the , in the course of which the mixing ratio
was switched from initially 2 to 15/4/0.5.
HPLC (Method 6): Rt = 1.8 min;
LC-MS (Method 1): Rt = 0.87 min; MS (ESIpos): m/z = 813 (M+H)+.
Intermediate 91
N-(3-carboxypropyl)-N-methyl-L-valyl-N-{(3R,4S,5S)methoxy[(2S){(1R,2R)methoxy-
2-methyloxo[(2-phenylethyl)amino]propyl}pyrrolidinyl]methyloxoheptanyl}-N-
methyl-L-valinamide
H C CH H C CH
3 3 3
O 3 H
H N
O N N
N N
O O
OH CH O CH O O
3 3 CH
H C CH CH 3
3 3 3
First, in analogy to the synthesis described in Intermediate 74, by ng of N-(tert-
butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R)carboxy
methoxypropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide
(Intermediate 26) and phenylethylamine in the ce of O-(7-azabenzotriazolyl)-N,N,N',N'-
tetramethyluronium hexafluorophosphate and subsequent detachment of the Boc protecting group
by means of trifluoroacetic acid, the amine compound yl-L-valyl-N-{(3R,4S,5S)
methoxy[(2S){(1R,2R)methoxymethyloxo[(2-
phenylethyl)amino]propyl}pyrrolidinyl]methyloxoheptanyl}-N-methyl-L-valinamide
was prepared as the trifluoroacetate. 57 mg (0.071 mmol) of this compound were then used, in
analogy to the preparation of Intermediate 61, by reaction with 4-oxobutanoic acid in the ce
of sodium cyanoborohydride, to obtain 44 mg (80% of theory) of the title compound. The title
compound can also be purified here by flash tography on silica gel with
dichloromethane/methanol/17% ammonia as the eluent (15/2/02 -> 15/4/0.5).
HPLC (Method 5): Rt = 1.7 min;
LC-MS (Method 9): Rt = 4.64 min; MS (ESIpos): m/z = 774 (M+H)+.
Intermediate 92
N-(3-carboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(1S,2R)hydroxy-
1-phenylpropanyl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxy
methyloxoheptanyl]-N-methyl-L-valinamide
2012/075277
H C CH H C
3 3 3 CH
3 OH
O H
H N
HO N N
N N
O O CH
O CH O CH O O CH 3
3 3
H C CH CH 3
3 3 3
100 mg (0.139 mmol) of N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(1S,2R)
hydroxyphenylpropanyl]amino}methoxymethyloxopropyl]pyrrolidinyl}
methoxymethyloxoheptanyl]-N-methyl-L-valinamide (Intermediate 40) were used, in
analogy to the preparation of Intermediate 61, by reaction with 4-oxobutanoic acid in the presence
of sodium cyanoborohydride, to obtain 94 mg (84% of theory) of the title compound. The title
compound was purified by preparative HPLC.
HPLC (Method 5): Rt = 1.5 min;
LC-MS (Method 9): Rt = 4.46 min; MS s): m/z = 804 (M+H)+.
Intermediate 93
N-(3-carboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxy
methyloxo{[(1S)phenyl(5-phenyl-1,3,4-oxadiazolyl)ethyl]amino}propyl]pyrrolidin-
1-yl}methyloxoheptanyl]-N-methyl-L-valinamide
H C CH H C O
3 3 O 3 CH
3 H N
H N
HO N N N
N N
O O
O CH O CH3 O O CH
3 H C CH3
3 CH3
22.4 mg (24 µmol) of N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxy-
yloxo{[(1S)phenyl(5-phenyl-1,3,4-oxadiazol
yl)ethyl]amino}propyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-valinamide
trifluoroacetate were dissolved in 1.4 ml of dioxane/water and, analogously to the ation of
Intermediate 61, reacted with 15% aqueous solution of 4-oxobutanoic acid in the presence of
sodium cyanoborohydride. After lyophilization from dioxane, 8.2 mg (38% of theory) of the title
compound were obtained in the form of a white solid.
HPLC (Method 10): Rt = 2.54 min
LC-MS (Method 12): Rt = 0.94 min; MS (ESIpos): m/z = 919 (M+H)+
Intermediate 94
N-(3-carboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxy
methyloxo{[(1R)phenyl(5-phenyl-1,3,4-oxadiazolyl)ethyl]amino}propyl]pyrrolidin-
1-yl}methyloxoheptanyl]-N-methyl-L-valinamide
H3C CH3 H3C CH O
O 3 H N
H N
HO N N N
N N
O O
O CH O CH3 O O CH3
3 H C CH3
3 CH3
17.1 mg (18 µmol) of N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxy-
2-methyloxo{[(1R)phenyl(5-phenyl-1,3,4-oxadiazol
yl)ethyl]amino}propyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-valinamide
trifluoroacetate were ved in 1.1 ml of dioxane/water and, analogously to the preparation of
Intermediate 61, reacted with 15% aqueous solution of utanoic acid in the ce of
sodium cyanoborohydride. After lyophilization from dioxane, 14.8 mg (89% of theory) of the title
compound were obtained in the form of a white solid.
HPLC (Method 10): Rt = 2.54 min;
LC-MS (Method 12): Rt = 0.92 min; MS (ESIpos): m/z = 919 (M+H) +
ediate 95
N-(3-carboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)
(benzylsulphonyl)phenylpropanyl]amino}methoxymethyloxopropyl]pyrrolidin
yl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide
3 O S
H3C CH H3C
3 CH3
O O
H N
HO N N
N N
O O
O CH O CH O CH
3 H C CH 3 O 3
3 3 CH
19.3 mg (20 µmol) N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)
(benzylsulphonyl)phenylpropanyl]amino}methoxymethyloxopropyl]pyrrolidin
yl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide trifluoroacetate were ved
in 1.2 ml of dioxane/water and, analogously to the preparation of Intermediate 61, reacted with
% aqueous on of 4-oxobutanoic acid in the presence of sodium cyanoborohydride. After
lyophilization from dioxane, 8.6 mg (45% of theory) of the title compound were obtained in the
form of a solid.
LC-MS (Method 11): Rt = 0.85 min; MS (ESIpos): m/z = 943 (M+H) +
Intermediate 96
N-(3-carboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S,3E)-1,4-
diphenylbutenyl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxy
methyloxoheptanyl]-N-methyl-L-valinamide
H C CH3 H C
3 3 CH
O 3 H
H N
HO N N
N N
O O
O CH O CH O CH
3 3 O 3
H C CH
3 3 CH
15.5 mg (10 µmol) of yl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S,3E)-1,4-
diphenylbutenyl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxy
methyloxoheptanyl]-N-methyl-L-valinamide trifluoroacetate were dissolved in 1.0 ml of
2012/075277
dioxane/water and, analogously to the preparation of Intermediate 61, reacted with 15% aqueous
solution of 4-oxobutanoic acid in the presence of sodium orohydride. After lization
from dioxane, 10.3 mg (68% of theory) of the title compound were obtained in the form of a white
solid.
HPLC (Method 10): Rt = 2.59 min;
LC-MS (Method 11): Rt = 0.94 min; MS s): m/z = 877 (M+H) +
Intermediate 97
minohexyl)-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxy
methyl{[(1S,2R)(1,2-oxazinanylcarbonyl)phenylcyclopropyl]amino}
oxopropyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-valinamide
H C CH H C CH
3 3 3 N
O 3 H
H N
H N N N
2 O
N N
O O
CH O CH O O H C
3 3
H C CH 3
3 3 3
The title compound was prepared in analogy to the synthesis of Intermediate 66, by reaction of
200 mg (0.108 mmol) of N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)
methoxymethyl{[(1S,2R)(1,2-oxazinanylcarbonyl)phenylcyclopropyl]amino}
oxopropyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-valinamide trifluoroacetate
(Intermediate 16) with benzyl 3-oxohexyl carbamate and subsequent hydrogenolytic detachment of
the Z protecting group (with 5% palladium on charcoal as a catalyst, in methanol as a solvent).
Yield: 69 mg (65% of theory over two stages)
HPLC (Method 5): Rt = 1.7 min;
LC-MS (Method 1): Rt = 0.76 min; MS (ESIpos): m/z = 912 (M+H)+.
Intermediate 98
N-(5-carboxypentyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)
(benzylamino)(1H-indolyl)oxopropanyl]amino}methoxymethyl
oxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide
H C CH H C
3 3 CH
3 3 HN
O H
H N
HO N N O
N N
O O
O CH O CH O O H C
3 3
H C CH CH 3 NH
3 3 3
This compound was prepared in analogy to the synthesis described in Intermediate 80. The
purification was ed by preparative HPLC.
Yield: 40 mg (29% of theory over 3 stages)
HPLC (Method 5): Rt = 1.9 min;
LC-MS (Method 1): Rt = 0.92 min; MS (ESIpos): m/z = 974 (M+H)+.
Intermediate 99
(2S)amino(1H-indolyl)(1,2-oxazinanyl)propanone trifluoroacetate
CF3COOH x H N
2 O
324 mg (0.81 mmol) of 2,5-dioxopyrrolidinyl N-(tert-butoxycarbonyl)-L-tryptophanate were
dissolved in 20 ml of DMF, and 200 mg (1.62 mmol) of 1,2-oxazinane hloride (Starting
Compound 5) and 850 µl of N,N-diisopropylethylamine were added. The reaction mixture was
d at 50°C overnight and then concentrated under d pressure. The residue was taken up
in dichloromethane and extracted with water. The organic phase was dried over magnesium
sulphate and concentrated. The residue was purified by flash tography on silica gel with 4:1
dichloromethane/ethyl acetate as the eluent. The product fractions were concentrated and the
residue was dried under high vacuum. This gave 147.5 mg (48% of theory) of the Boc-protected
intermediate.
HPLC (Method 12): Rt = 1.9 min;
LC-MS (Method 1): Rt = 1.03 min; MS (ESIpos): m/z = 374 (M+H)+.
Using 166 mg (444.5 µmol) of this intermediate, under standard conditions with 3 ml of
trifluoroacetic acid in 20 ml of dichloromethane, the Boc protecting group was detached and, after
HPLC purification, 155 mg (86% of theory) of the title compound were obtained.
HPLC (Method 12): Rt = 1.43 min;
LC-MS (Method 11): Rt = 0.56 min; MS (ESIpos): m/z = 274 (M+H)+.
Intermediate 100
[(benzyloxy)carbonyl]amino}hexyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R)
{[(2S)(1H-indolyl)(1,2-oxazinanyl)oxopropanyl]amino}methoxymethyl
oxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide
H C CH H C
3 3 CH
3 O 3 N
H H N
O N N N O
N N
O O
O CH O CH O O H C
3 3 3
H C CH CH
3 3 3
177 mg (260 µmol) of N-(tert-butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)
[(1R,2R)carboxymethoxypropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-NL-valinamide (Intermediate 26) and 100 mg (260 µmol) of (2S)amino(1H-indolyl)-
1-(1,2-oxazinanyl)propanone trifluoroacetate (Intermediate 99) were taken up in 15 ml of
DMF, and 118 mg (310 µmol) of O-(7-azabenzotriazolyl)-N,N,N',N'-tetramethyluronium
hexafluorophosphate and 140 µl of N,N-diisopropylethylamine were added. The reaction mixture
was stirred at RT for 30 min, then concentrated under d pressure, and the residue was
purified by means of preparative HPLC. The product fractions were combined and concentrated.
After lyophilization from dioxane, 170 mg (68% of theory) of the Boc-protected ediate were
obtained.
LC-MS (Method 1): Rt = 1.36 min; m/z = 940 (M+H)+.
170 mg of this intermediate were treated with 3 ml of oroacetic acid in 30 ml of
dichloromethane for 30 min to detach the Boc protecting group. Then the reaction mixture was
concentrated under reduced pressure and the residue was purified by means of preparative HPLC
to obtain 155 mg (86% of ) of the deprotected N-methyl-L-valyl-N-[(3R,4S,5S){(2S)
[(1R,2R){[(2S)(1H-indolyl)(1,2-oxazinanyl)oxopropanyl]amino}methoxy
oxopropyl] pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-
valinamide intermediate.
HPLC (Method 12): Rt = 1.85 min;
LC-MS (Method 1): Rt = 0.86 min; MS (ESIpos): m/z = 840 (M+H)+.
50 mg (0.052 mmol) of this intermediate were then used, in analogy to the preparation of
Intermediate 97, with benzyl 3-oxohexyl carbamate in the presence of sodium cyanoborohydride
and subsequent hydrogenolytic detachment of the Z ting group (with 5% palladium on
charcoal as a catalyst, in methanol as a solvent), prepared to prepare the title nd.
Yield: 21 mg (37% of theory)
HPLC d 12): Rt = 2.1 min;
LC-MS (Method 1): Rt = 1.02 min; MS (ESIpos): m/z = 1073 (M+H)+.
Intermediate 101
N-(6-aminohexyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)(1H-indolyl)oxazinanyl)oxopropanyl]amino}methoxymethyloxopropyl]pyrrolidin
yl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide
H C CH H C
3 3 3 CH
O 3 N
H N
H N N N
2 O
N N
O O
CH O CH O O H C
3 3
H C CH 3
3 3 3
26.7 mg (24.87 µmol) of Intermediate 100 were dissolved in 10 ml of methanol and hydrogenated
over palladium/activated carbon (5%) under standard hydrogen pressure for 30 min. The catalyst
was filtered off and the solvent was evaporated off under d pressure. After the residue had
been dried under high vacuum, 22.5 mg (96% of theory) of the title compound were obtained.
HPLC (Method 5): Rt = 1.7 min;
LC-MS (Method 1): Rt = 0.76 min; MS (ESIpos): m/z = 939 (M+H)+.
Intermediate 102
N-(4-{2-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexanoyl]hydrazino}oxobutyl)-N-methyl-L-
valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxymethyl{[(2S)(morpholin
yl)oxophenylpropanyl]amino}oxopropyl]pyrrolidinyl}methyloxoheptanyl]-
N-methyl-L-valinamide
H C CH H C
3 3 O 3
O 3 N
N H H N
N N N O
N N N
O H O O
O CH O CH O O
3 CH
H C CH 3 CH 3
3 3 3
This compound was prepared in y to the synthesis described in Intermediate 157 from N-(3-
carboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxy
{[(2S)(morpholinyl)oxophenylpropanyl]amino}oxopropyl]pyrrolidin
yl}methyloxoheptanyl]-N-methyl-L-valinamide and commercially available 6-(2,5-dioxo-
2,5-dihydro-1H-pyrrolyl)hexanehydrazide.
Yield: 8 mg (71% of theory)
HPLC d 12): Rt = 1.9 min;
LC-MS (Method 1): Rt = 0.87 min; MS (ESIpos): m/z = 1094 (M+H)+.
Intermediate 103
N-(4-{2-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexanoyl]hydrazino}oxobutyl)-N-methyl-L-
valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S,3R)(benzylamino)hydroxyoxobutan
yl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxymethyloxoheptan
yl]-N-methyl-L-valinamide
H C CH H C
3 3 3 CH HN
O O 3 H
N H H N
N N N O
N N N
O H O O
O CH O CH O O
3 3 CH OH
3 H C
CH 3
H C CH
3 3 3
This compound was prepared in analogy to the synthesis bed in Intermediate 157 from N-(3-
carboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S,3R)(benzylamino)-
3-hydroxyoxobutanyl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxy-
-methyloxoheptanyl]-N-methyl-L-valinamide and commercially available 6-(2,5-dioxo-2,5-
dihydro-1H-pyrrolyl)hexanehydrazide.
Yield: 3 mg (22% of theory)
HPLC (Method 5): Rt = 1.6 min;
LC-MS d 1): Rt = 0.78 min; MS (ESIpos): m/z = 1069 (M+H)+.
Intermediate 104
N-{4-[(trans{[(2,5-dioxopyrrolidinyl)oxy]carbonyl}cyclohexyl)amino]oxobutyl}-N-
methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)amino(1H-indolyl)
oxopropanyl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxymethyl
oxoheptanyl]-N-methyl-L-valinamide
H C CH H C
3 3 3 CH3 NH
O H 2
H H N
N N N O
O N N
O O
O O CH O CH O O
N 3 3 CH
H3C CH CH 3
3 3
O H
First, benzyl transaminocyclohexanecarboxylate trifluoroacetate was prepared from trans
aminocyclohexanecarboxylic acid by introducing the Boc protecting group, then introducing the
benzyl ester protecting group and subsequently detaching the Boc protecting group by
conventional peptide chemistry methods.
mg (18 µmol) of N-(3-carboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R)
{[(2S)amino(1H-indolyl)oxopropanyl]amino}methoxymethyloxopropyl]
pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide were then
ved in 5 ml of dimethylformamide and subsequently admixed with 13 mg (35 µmol) of O-(7-
azabenzotriazolyl)-N,N,N',N'-tetramethyluronium uorophosphate, 9 µl of N,N-
diisopropylethylamine and with 15 mg (44 µmol) of benzyl transaminocyclohexanecarboxylate
trifluoroacetate. The e was d at RT for 1 h and then concentrated under reduced
pressure. The remaining residue was purified by means of preparative HPLC. The corresponding
fractions were combined and the solvent was evaporated off under reduced pressure. After the
e had been dried under high vacuum, 14.7 mg (78% of theory) of the protected intermediate
were obtained as a colourless foam.
HPLC (Method 6): Rt = 2.0 min;
LC-MS (Method 1): Rt = 0.95 min; MS (ESIpos): m/z = 1072 (M+H)+.
From this protected intermediate, the benzyl ester was first removed by hydrogenolytic means and
the free carboxyl component was obtained in quantitative yield. 14 mg (14 µmol; 1 equiv.) of the
deprotected compound were taken up in 5 ml of DMF and admixed with 3.3 mg (29 µmol; 2.1
equiv.) of N-hydroxysuccinimide in the presence of 4.1 mg (21 µmol; 1.5 equiv.) of 1-(3-
dimethylaminopropyl)ethylcarbodiimide hydrochloride, 7.5 µl (44 µmol; 3.1 equiv.) of N,N-
diisopropylethylamine and 0.9 mg (7 µmol; 0.5 equiv.) of thylaminopyridine, and the
mixture was stirred at RT overnight. Then another 10 equiv. of N-hydroxysuccinimide, 5 equiv. of
1-(3-dimethylaminopropyl)ethylcarbodiimide hydrochloride, 5 equiv. of N,N-
diisopropylethylamine and 0.5 equiv. of thylaminopyridine were added and the reaction
mixture was treated in an ultrasound bath for 5 h. Subsequently, the solvent was evaporated off,
the residue was purified by means of ative HPLC and the corresponding fractions were
combined and concentrated. After lyophilization of the e from dioxane, 9.7 mg (62% of
theory) of the title compound were obtained as a colourless foam.
HPLC (Method 6): Rt = 1.8 min;
LC-MS (Method 11): Rt = 0.77 min; MS s): m/z = 1078 .
Intermediate 105
N-(4-{2-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexanoyl]hydrazino}oxobutyl)-N-methyl-L-
valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(1S)carboxyphenylethyl]amino}methoxy
methyloxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-
valinamide
H C CH H C
3 3 3 CH
3 OH
O O H
N H H N
N N N O
N N N
O H O O
O CH O CH O O
3 3 CH
H C CH CH 3
3 3 3
This compound was prepared in analogy to the synthesis bed in Intermediate 157, proceeding
from 4-{[(2S){[(2S){[(3R,4S,5S){(2S)[(1R,2R){[(2S)tert-butoxyoxo
phenylpropanyl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxy
methyloxoheptanyl](methyl)amino}methylbutanyl]amino}methyloxobutan
yl](methyl)amino}butanoic acid and commercially available -dioxo-2,5-dihydro-1H-pyrrol-
1-yl)hexanehydrazide. The ester intermediate was obtained in 42% yield. In a second step, 6 mg (6
µmol) of this intermediate were cleaved with trifluoroacetic acid the tert-butyl ester. After HPLC
cation, 3.4 mg (48% of theory) of the title compound were obtained.
HPLC d 5): Rt = 1.66 min;
LC-MS (Method 2): Rt = 1.04 min; MS (ESIpos): m/z = 1025 (M+H)+.
Intermediate 106
N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexyl]-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)
[(1R,2R){[(2S)amino(1H-indolyl)oxopropanyl]amino}methoxymethyl
oxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide
O H C CH H C
3 3 3 CH3 NH
O H 2
H N
N N N O
N N
O O
O CH3 O CH3 O O CH
H3C CH3 CH 3
14 mg (16 µmol) of N-(6-aminohexyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R)
{[(2S)amino(1H-indolyl)oxopropanyl]amino}methoxymethyloxopropyl]
idinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide (Intermediate 87)
were taken up in 750 µl of dioxane and admixed with 1.5 ml of saturated sodium
hydrogencarbonate solution and then with 3.2 mg (21 µmol) of methyl 2,5-dioxo-2,5-dihydro-1H-
pyrrolecarboxylate. The reaction mixture was stirred at RT for 1 h and then concentrated under
reduced pressure. The remaining e was purified by means of preparative HPLC. After
lization, 5.5 mg (36% of theory) of the title compound were obtained.
HPLC (Method 5): Rt = 1.7 min;
LC-MS (Method 1): Rt = 0.84 min; MS (ESIpos): m/z = 949 (M+H)+.
Intermediate 107
N-(4-{2-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexanoyl]hydrazino}oxobutyl)-N-methyl-L-
valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[2-(1H-indolyl)ethyl]amino}methoxymethyl
oxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide
O H C CH H C
3 3 3 CH
O O 3
H H O
N N N N
N N N
H O HN
O O CH O CH O O
3 H C
H C CH CH 3
3 3 3
38 mg (47 µmol) of N-(3-carboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R)
{[2-(1H-indolyl)ethyl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxy
methyloxoheptanyl]-N-methyl-L-valinamide were ved in 37 ml of DMF and then
admixed with 71 mg (187 µmol) of O-(7-azabenzotriazolyl)-N,N,N',N'-tetramethyluronium
hexafluorophosphate, 33 µl of N,N-diisopropylethylamine and with 37 mg (140 µmol) of
commercially available 6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexanehydrazide. The mixture
was d at RT for 1 h. This was followed by tration under high vacuum and purification
of the remaining residue by means of preparative HPLC. Thus, 12.2 mg (26% of theory) of the title
compound were obtained as a colourless foam.
HPLC (Method 5): Rt = 1.6 min;
LC-MS (Method 1): Rt = 0.85 min; MS (ESIpos): m/z = 1020 (M+H)+.
Intermediate 108
N-(4-{2-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexanoyl]hydrazino}oxobutyl)-N-methyl-L-
valyl-N-{(3R,4S,5S)methoxy[(2S){(1R,2R)methoxymethyloxo[(2-phenylethyl)
amino]propyl}pyrrolidinyl]methyloxoheptanyl}-N-methyl-L-valinamide
O H C CH H C
3 3 3 CH
O O 3
H H O
N N N N
N N N
H O HN
O O CH O CH O O H C
3 3
H C CH CH 3
3 3 3
The compound was prepared in analogy to Intermediate 107.
Yield: 2.5 mg (30% of theory)
HPLC (Method 12): Rt = 1.9 min;
LC-MS (Method 1): Rt = 0.9 min; MS (ESIpos): m/z = 981 .
Intermediate 109
N-(4-{2-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexanoyl]hydrazino}oxobutyl)-N-methyl-L-
valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(1S,2R)hydroxyphenylpropanyl]amino}
ymethyloxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-
L-valinamide
O H C CH H C
3 3 3 CH OH
O O 3
H H N
N N N N
N N N
H O O CH
O O CH O CH O O CH 3
3 3
H C CH CH 3
3 3 3
The compound was prepared in analogy to Intermediate 107 from the compound in Intermediate
92.
Yield: 35 mg (65% of theory)
HPLC (Method 5): Rt = 1.9 min;
LC-MS (Method 11): Rt = 0.76 min; MS (ESIpos): m/z = 1011 .
Intermediate 110
N-{6-[(2,5-dioxopyrrolidinyl)oxy]oxohexyl}-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)
[(1R,2R){[(2S)amino(1H-indolyl)oxopropanyl]amino}methoxymethyl
oxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide
O O H C CH H C
N 3 3 3 CH NH
O 3 H 2
H N
O N N O
N N
O O
O CH O CH O O
3 3 CH
H C CH CH 3
3 3 3
This compound was prepared in analogy to Intermediate 147 from the compound in Intermediate
83.
Yield: 2.4 mg (24% of theory)
HPLC (Method 6): Rt = 1.8 min;
LC-MS (Method 1): Rt = 0.87 min; MS (ESIpos): m/z = 981 (M+H)+.
Intermediate 111
N-(4-{2-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexanoyl]methylhydrazino}oxobutyl)-N-
methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)amino(1H-indolyl)
oxopropanyl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxymethyl
oxoheptanyl]-N-methyl-L-valinamide
O H C CH H C
3 3 CH
O CH 3 O 3
3 H O
N N N N O
N N N
H O HN
O O CH O CH O O
3 H NH
3 C
CH CH 3 2
3 3 3
This nd was prepared in analogy to Intermediate 140 from Intermediate 82 and
Intermediate 22.
Yield: 6.5 mg (51% of theory)
HPLC (Method 6): Rt = 1.8 min;
LC-MS (Method 1): Rt = 4.71 min; MS (ESIpos): m/z = 1077 .
Intermediate 112
N-(4-{2-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexanoyl]hydrazino}oxobutyl)-N-methyl-L-
valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(1S,2R)carbamoylphenylcyclopropyl]amino}
methoxymethyloxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-
L-valinamide
2012/075277
O H C CH H C
3 3 3 CH NH
O O 3 H 2
H H N
N N N N O
N N N
H O O
O O CH O CH O O
3 3 CH
H C CH CH 3
3 3 3
This compound was ed in analogy to Intermediate 157 from the nd in Intermediate
Yield: 5.7 mg (57 % of theory)
HPLC (Method 5): Rt = 1.6 min;
LC-MS (Method 1): Rt = 0.87 min; MS (ESIpos): m/z = 1036 (M+H)+.
Intermediate 113
N-(4-{2-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexanoyl]hydrazino}oxobutyl)-N-methyl-L-
valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(1S)carboxy(1H-indolyl)ethyl]amino}
methoxymethyloxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-
L-valinamide
O H C CH H C
3 3 3 CH
3 OH
O O H
H H N
N N N N O
N N N
H O O
O O CH O CH O O
3 3 CH
H C CH CH 3
3 3 3
95 mg (104 µmol) of 4-{[(2S){[(2S){[(3R,4S,5S){(2S)[(1R,2R){[(2S)tert-butoxy-
3-(1H-indolyl)oxopropanyl]amino}methoxymethyloxopropyl]pyrrolidinyl}
methoxymethyloxoheptanyl](methyl)amino}methylbutanyl]amino}methyl
oxobutanyl](methyl)amino}butanoic acid were ved in DMF and then admixed with 79.5
mg (209 µmol) of O-(7-azabenzotriazolyl)-N,N,N',N'-tetramethyluronium hexafluorophosphate,
73 µl of N,N-diisopropylethylamine and with 68 mg (261 µmol) of commercially available 6-(2,5-
dioxo-2,5-dihydro-1H-pyrrolyl)hexanehydrazide. The mixture was stirred at RT for 2 h. This
was followed by concentration under high vacuum and purification of the remaining residue by
means of preparative HPLC. Thus, 104 mg (89% of theory) of the tert-butyl ester of the title
compound were obtained as a colourless foam.
HPLC (Method 5): Rt = 2.0 min;
LC-MS (Method 1): Rt = 0.93 min; MS (ESIpos): m/z = 1121 (M+H)+.
The intermediate was taken up in 33.4 ml of dichloromethane, 17 ml of trifluoroacetic acid were
added, and the mixture was stirred at RT for 1 h. Subsequently, the reaction mixture was
concentrated under reduced re and the residue was purified by preparative HPLC.
Thus, 61 mg (62 % of theory) of the title compound were obtained as a colourless foam.
HPLC (Method 5): Rt = 1.7 min;
LC-MS (Method 1): Rt = 0.86 min; MS (ESIpos): m/z = 1064 (M+H)+.
Intermediate 114
N-[6-({[2-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)ethyl]carbamoyl}amino)hexyl]-N-methyl-L-valyl-
N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)amino(1H-indolyl)oxopropanyl]amino}
methoxymethyloxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-
L-valinamide
H3C CH H3C
O 3 CH3 NH
O H 2
H H H N
N N N N O
N N N
O O
O CH O CH3 O O
3 H3C
O H C CH CH3
3 3
mg (5 µmol) of minohexyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)-
1-amino(1H-indolyl)oxopropanyl]amino}methoxymethyloxopropyl]pyrrolidin-
1-yl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide were taken up in 885 µl of
DMF and admixed with 5.3 mg (8 µmol) of 4-nitrophenyl 2-(2,5-dioxo-2,5-dihydro-1H-pyrrol
yl)ethyl carbamate and 2.8 µl of N,N-diisopropylethylamine. The reaction mixture was d at
RT for 2 h and then trated to dryness. The residue was purified by means of preparative
HPLC.
Yield: 0.58 mg (11% of theory) of a colourless foam
HPLC (Method 5): Rt = 1.6 min;
LC-MS (Method 1): Rt = 0.83 min; MS (ESIpos): m/z = 1035 (M+H)+.
Intermediate 115
N-{4-[(2,5-dioxopyrrolidinyl)oxy]oxobutyl}-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy
{(2S)[(1R,2R)methoxymethyl{[(1S,2R)(1,2-oxazinanylcarbonyl)
phenylcyclopropyl]amino}oxopropyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-
valinamide
H C CH H C
3 3 3 CH N
O O 3 H
H N
O N N O
N N N
O O
O CH O CH O O
3 3 CH
H C CH CH 3
O 3 3 3
This compound was prepared in analogy to the compound in Intermediate 147, proceeding from 8
mg (9 µmol) of N-(3-carboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)
[(1R,2R)methoxymethyl{[(1S,2R)(1,2-oxazinanylcarbonyl)
phenylcyclopropyl]amino}oxopropyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-
mide. After concentration, the activated ester was purified by means of preparative HPLC
and, after removal of the solvent under reduced pressure, reacted immediately with the antibody.
Yield: 3 mg (27% of theory) (hydrolysis-sensitive)
HPLC (Method 5): Rt = 1.7 min;
LC-MS (Method 1): Rt = 0.87 min; MS (ESIpos): m/z = 996 (M+H)+.
Intermediate 116
(2,5-dioxopyrrolidinyl)oxy]oxobutyl}-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy
{(2S)[(1R,2R)methoxymethyl{[(2S)(1,2-oxazinanyl)oxophenylpropan
yl]amino}oxopropyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-valinamide
WO 87716
H C CH H C
3 3 3 CH
O 3 N
O H
H N
O N N O
N N N
O O
O CH O CH O O
3 3 CH3
O H3C CH CH
3 3
This compound was prepared in analogy to the compound in Intermediate 147, ding from 5
mg (6 µmol) of N-(3-carboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)
[(1R,2R)methoxymethyl{[(2S)(1,2-oxazinanyl)oxophenylpropanyl]amino}-
3-oxopropyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-valinamide. After
concentration, the activated ester was purified by means of preparative HPLC and, after removal of
the solvent under reduced pressure, reacted immediately with the antibody.
Yield: 3.2 mg (43% of theory) (hydrolysis-sensitive)
HPLC (Method 5): Rt = 1.7 min;
LC-MS (Method 1): Rt = 0.92 min; MS (ESIpos): m/z = 984 .
Intermediate 117
N-(4-{2-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexanoyl]hydrazino}oxobutyl)-N-methyl-L-
valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)tert-butoxyoxophenylpropanyl]amino}-
oxymethyloxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-
methyl-L-valinamide
CH3 3 CH
O H C CH3 H C
3 3 CH3 O
O O H
H H N
N N N N O
N N N
H O O
O O CH3 O CH O O
3 H C
H3C CH CH 3
3 3
This compound was prepared in analogy to Intermediate 157 from the compound in Intermediate
86.
Yield: 7 mg (42% of theory)
WO 87716
HPLC (Method 5): Rt = 1.6 min;
LC-MS (Method 1): Rt = 0.94 min; MS (ESIpos): m/z = 1081 (M+H)+.
Intermediate 118
N-(4-{2-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexanoyl]hydrazino}oxobutyl)-N-methyl-L-
valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2R)(benzyloxy)phenylpropanyl]amino}
ymethyloxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-
L-valinamide
O H C CH H3C
3 CH
O 3 O 3 H
H H N
N N N N
N N N
H O O
O O
O CH O CH O O CH
3 H C CH3 3
3 CH3
The target compound was prepared analogously to ediate 157 from 7 mg (7.8 µmol) of the
compound in Intermediate 68. Yield: 6.3 mg (53% of theory)
LC-MS (Method 1): Rt = 1.00 min; MS (ESIpos): m/z = 1102 (M+H)+.
Intermediate 119
N-(4-{2-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexanoyl]hydrazino}oxobutyl)-N-methyl-L-
valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxymethyloxo{[(1S)phenyl-
1-(5-phenyl-1,3,4-oxadiazolyl)ethyl]amino}propyl]pyrrolidinyl}methyloxoheptan
yl]-N-methyl-L-valinamide
O H3C CH3 H3C CH3 O
O O H N
H H N
N N N N N
N N N
H O O
O O CH3 O CH3 O O CH3
H C CH3
3 CH
7.4 mg (8.1 mmol) of N-(3-carboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)
[(1R,2R)methoxymethyloxo{[(1S)phenyl(5-phenyl-1,3,4-oxadiazol
yl)ethyl]amino}propyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-valinamide and
6.3 mg (24.2 mmol) of 6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexanehydrazide hydrochloride
were coupled and worked up in analogy to Intermediate 157. 1.6 mg (13% of theory) of the title
compound were obtained as a solid.
LC-MS (Method 11): Rt = 0.89 min; MS (ESIpos): m/z = 1126 (M+H) +
Intermediate 120
N-(4-{2-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexanoyl]hydrazino}oxobutyl)-N-methyl-L-
valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxymethyloxo{[(1R)phenyl-
1-(5-phenyl-1,3,4-oxadiazolyl)ethyl]amino}propyl]pyrrolidinyl}methyloxoheptan
yl]-N-methyl-L-valinamide
O H3C CH H3C CH3 O
O 3 O H N
H H N
N N N N N
N N N
H O
CH3 O CH3O O O CH O O
3 H3C CH
3 CH3
12.8 mg (13.9 mmol) of N-(3-carboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)-
2-[(1R,2R)methoxymethyloxo{[(1R)phenyl(5-phenyl-1,3,4-oxadiazol
yl)ethyl]amino}propyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-valinamide and
.9 mg (41.8 mmol) of 6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexanehydrazide hydrochloride
were d and worked up in analogy to Intermediate 157. 10.8 mg (59% of ) of the title
compound were obtained as a solid.
LC-MS d 11): Rt = 0.90 min; MS (ESIpos): m/z = 1126 (M+H) +
Intermediate 121
N-(4-{2-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexanoyl]hydrazino}oxobutyl)-N-methyl-L-
valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)(benzylsulphonyl)phenylpropan
yl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxymethyloxoheptan
yl]-N-methyl-L-valinamide
3 O
O H C CH H C CH
O 3 3 O 3 3 S
H H N
N N N N
N N N
H O O
O O CH O CH O CH
3 O
3 3
H C CH
3 3 CH
7.4 mg (7.9 mmol) of N-(3-carboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R)
(benzylsulphonyl)phenylpropanyl]amino}methoxymethyl
oxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide and
6.2 mg (23.5 mmol) of 6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexanehydrazide hydrochloride
were coupled and worked up in analogy to Intermediate 157. 6.9 mg (74% of theory) of the title
compound were obtained as a solid.
LC-MS (Method 11): Rt = 0.87 min; MS s): m/z = 1150 (M+H) +
Intermediate 122
N-(4-{2-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexanoyl]hydrazino}oxobutyl)-N-methyl-L-
valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S,3E)-1,4-diphenylbutenyl]amino}methoxy-
2-methyloxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-
valinamide
O H3C CH3 H3C CH3
O O H
H H N
N N N N
N N N
H O O
O O CH O CH3 O O CH3
3 H C CH3
3 CH3
8 mg (9.1 mmol) of N-(3-carboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R)
{[(2S,3E)-1,4-diphenylbutenyl]amino}methoxymethyloxopropyl]pyrrolidinyl}
methoxymethyloxoheptanyl]-N-methyl-L-valinamide and 7.2 mg (27.4 mmol) of 6-(2,5-
dioxo-2,5-dihydro-1H-pyrrolyl)hexanehydrazide hloride were coupled and worked up in
analogy to Intermediate 157. 8.2 mg (82% of theory) of the title compound were obtained as a
white solid.
LC-MS (Method 11): Rt = 0.95 min; MS (ESIpos): m/z = 1083 (M+H) +
Intermediate 123
N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexyl]-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)
[(1R,2R){[(2S)tert-butoxy(1H-indolyl)oxopropanyl]amino}methoxymethyl-
3-oxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide
CH 3
3 H C
O H C CH H C
3 3 3 CH
O 3 O CH
H 3
H N
N N N O
N N
O O
O CH O CH O O
3 3 CH
H C CH CH 3
3 3 3
H
mg (30 µmol) of Intermediate 89 were taken up in 2 ml of 1,4-dioxane and admixed with 4 ml
of saturated sodium hydrogencarbonate solution and then with 7.5 mg (50 µmol) of methyl 2,5-
dioxo-2,5-dihydro-1H-pyrrolecarboxylate. The reaction mixture was stirred at RT for 1 h and
then concentrated under reduced pressure. The remaining residue was ed by means of
preparative HPLC. After lyophilization, 24 mg (74% of theory) of the title compound were
obtained.
HPLC (Method 5): Rt = 2.2 min;
LC-MS (Method 1): Rt = 1.01 min; MS (ESIpos): m/z = 1006 (M+H)+.
Intermediate 124
N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexyl]-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)
R){[(1S)carboxy(1H-indolyl)ethyl]amino}methoxymethyl
oxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide
O H C CH H C
3 3 3 CH
3 OH
O H
H N
N N N O
N N
O O
O CH O CH O O
3 3 CH
H C CH CH 3
3 3 3
22 mg (20 µmol) of Intermediate 123 were d with 4 ml of trifluoroacetic acid in 8 ml of
dichloromethane at RT for 1 h. Thereafter, the reaction e was concentrated under reduced
re. The remaining residue was purified by means of preparative HPLC. After lyophilization,
11 mg (54% of theory) of the title compound were obtained.
WO 87716
HPLC (Method 5): Rt = 1.8 min;
LC-MS (Method 11): Rt = 0.85 min; MS (ESIpos): m/z = 950 (M+H)+.
Intermediate 125
2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexyl]-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)
[(1R,2R){[(2S)(1H-indolyl)(1,2-oxazinanyl)oxopropanyl]amino}methoxy
methyloxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-
valinamide
O H C CH H C
3 3 3 CH
O 3 N
H N
N N N O
N N
O O
O CH O CH O O
3 3 CH
H C CH CH 3
3 3 3
22.5 mg (20 µmol) of Intermediate 101 were taken up in 2 ml of 1:1 e/water and then
admixed with 5.6 mg (40 µmol) of methyl 2,5-dioxo-2,5-dihydro-1H-pyrrolecarboxylate and
with 0.25 ml of saturated sodium hydrogencarbonate solution. The reaction mixture was stirred at
RT for 30 min. Then another 0.25 ml of the saturated sodium hydrogencarbonate solution was
added and the reaction mixture was stirred at RT for a further 15 min and then trated under
reduced re. The remaining residue was purified by means of preparative HPLC. After
lyophilization, 12.8 mg (50% of theory) of the title compound were obtained as a colourless foam.
HPLC (Method 5): Rt = 1.9 min;
LC-MS (Method 1): Rt = 0.95 min; MS (ESIpos): m/z = 1019 (M+H)+.
Intermediate 126
N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexyl]-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy
{(2S)[(1R,2R)methoxymethyl{[(1S,2R)(1,2-oxazinanylcarbonyl)
phenylcyclopropyl]amino}oxopropyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-
valinamide
O H3C CH H C
3 3 CH3 N
O H
H N
N N N O
N N
O O
O CH O CH3 O O
3 CH3
H C CH CH
3 3 3
64 mg (70 µmol) of N-(6-aminohexyl)-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)
[(1R,2R)methoxymethyl{[(1S,2R)(1,2-oxazinanylcarbonyl)phenylcyclopropyl]
amino}oxopropyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-valinamide
(Intermediate 97) were taken up in 3 ml of 1:1 dioxane/water, then adjusted to pH 9 with 4 ml of
saturated sodium encarbonate solution and uently admixed with 16.3 mg (110 µmol)
of methyl 2,5-dioxo-2,5-dihydro-1H-pyrrolecarboxylate. The reaction mixture was stirred at RT
for 1 h and then concentrated under reduced pressure. Then another 8 mg (55 µmol) of methyl 2,5-
dioxo-2,5-dihydro-1H-pyrrolecarboxylate were added, and the reaction mixture was adjusted
again to pH 9 and stirred at RT for a further hour. This was followed by concentration and
purification of the remaining residue by means of preparative HPLC. At first, 31 mg of an as yet
uncyclized intermediate were obtained. 27 mg of this intermediate were taken up again in 2 ml of
1:1 dioxane/water and then admixed with 250 µl of saturated sodium encarbonate solution.
After stirring at RT for 2 hours, the on mixture was concentrated and the residue was purified
by means of ative HPLC. After lyophilization, 20 mg (29% of theory) of the title compound
were obtained.
HPLC d 5): Rt = 1.96 min;
LC-MS (Method 1): Rt = 0.97 min; MS (ESIpos): m/z = 992 (M+H)+.
Intermediate 127
N-{6-[(2,5-dioxopyrrolidinyl)oxy]oxohexyl}-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)
[(1R,2R){[(2S)(benzylamino)(1H-indolyl)oxopropanyl]amino}methoxy
methyloxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-
valinamide
H C CH H C
O O 3 3 3 CH3 HN
N O H
H N
O N N O
N N
O O
O CH O CH O O
3 3 CH3
H C CH CH
3 3 3
17 mg (18 µmol) of N-(5-carboxypentyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R)
{[(2S)(benzylamino)(1H-indolyl)oxopropanyl]amino}methoxymethyl
oxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide
(Intermediate 98) were ved in 2.8 ml of dichloromethane and admixed with 20 mg (174
mmol) of 1-hydroxypyrrolidine-2,5-dione and then with 10 mg (52 µmol) of 1-(3-
dimethylaminopropyl)ethylcarbodiimide hydrochloride and 0.21 mg (0.17 µmol) of DMAP.
After stirring at RT for 4 h, the reaction mixture was concentrated under reduced pressure. The
remaining residue was purified by means of preparative HPLC. After lyophilization, 8.2 mg (43%
of theory) of the title compound were obtained.
HPLC (Method 5): Rt = 2.0 min;
LC-MS (Method 1): Rt = 0.98 min; MS s): m/z = 1071 (M+H)+.
Intermediate 128
N-(4-{2-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexanoyl]hydrazino}oxobutyl)-N-methyl-L-
valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxymethyl{[(2S)(1,2-oxazinan-
1-oxophenylpropanyl]amino}oxopropyl]pyrrolidinyl}methyloxoheptan
yl]-N-methyl-L-valinamide
O H C CH H C
3 3 CH
3 N
O 3 O H
H H N
N N N N O
N N N
H O O
O O CH O CH O O
3 3 CH
H C CH CH 3
3 3 3
5 mg (5.6 µmol) of N-(3-carboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)
[(1R,2R)methoxymethyl{[(2S)(1,2-oxazinanyl)oxophenylpropanyl]amino}-
3-oxopropyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-valinamide were dissolved
in 845 µl of DMF and then d with 3.2 mg (17 µmol) of 1-(3-dimethylaminopropyl)
ethylcarbodiimide hydrochloride, 2.6 mg (17 µmol) of 1-hydroxy-1H-benzotriazole hydrate, 1.96
µl of N,N-diisopropylethylamine and with 5.9 mg (22.5 µmol) of commercially available 6-(2,5-
dioxo-2,5-dihydro-1H-pyrrolyl)hexanehydrazide. The mixture was stirred at RT overnight and
then concentrated under high vacuum. The remaining residue was purified by means of preparative
HPLC. Thus, 2.2 mg (36% of theory) of the title compound were obtained as a colourless foam.
HPLC (Method 5): Rt = 1.7 min;
LC-MS (Method 1): Rt = 0.88 min; MS (ESIpos): m/z = 1094 (M+H)+.
Intermediate 129
N-(6-{2-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexanoyl]hydrazino}oxohexyl)-N-methyl-L-
N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxymethyl{[(1S,2R)(1,2-
oxazinanylcarbonyl)phenylcyclopropyl]amino}oxopropyl]pyrrolidinyl}methyl
oxoheptanyl]-N-methyl-L-valinamide
O H C CH H C
3 3 3 CH N
O O 3 H
H H N
N N N N O
N N N
H O O
O O CH O CH O O
3 3 CH
H C CH CH 3
3 3 3
4 mg (4.3 µmol) of N-(5-carboxypentyl)-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)
[(1R,2R)methoxymethyl{[(1S,2R)(1,2-oxazinanylcarbonyl)phenylcyclopropyl]
oxopropyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-valinamide were
dissolved in 646 µl of DMF and then d with 2.5 mg (13 µmol) of 1-(3-
dimethylaminopropyl)ethylcarbodiimide hydrochloride, 2.0 mg (13 µmol) of 1-hydroxy-1H-
riazole hydrate, 2.25 µl of N,N-diisopropylethylamine and with 4.5 mg (17 µmol) of
commercially available 6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexanehydrazide. The mixture
was stirred at RT for 3 h and then concentrated under high vacuum. The remaining residue was
purified by means of preparative HPLC. Thus, 1.9 mg (39% of theory) of the title nd were
obtained as a colourless foam.
HPLC (Method 5): Rt = 1.7 min;
LC-MS (Method 9): Rt = 4.9 min; MS (ESIpos): m/z = 1134 (M+H)+.
Intermediate 130
N-(4-{[(2R)({5-[(2,5-dioxopyrrolidinyl)oxy]oxopentanoyl}amino)propanyl]oxy}
oxobutyl)-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxymethyl
2R)(1,2-oxazinanylcarbonyl)phenylcyclopropyl]amino}oxopropyl]pyrrolidin
yl}methyloxoheptanyl]-N-methyl-L-valinamide
O H C CH H C N
O O 3 3 3 CH
O 3
H N
N O N N O
O N N N
H O O
O CH O CH O CH O O CH
3 3 3
H C CH CH 3
3 3 3
.5 mg (11.7 µmol) of N-(3-carboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)-
2-[(1R,2R)methoxymethyl{[(1S,2R)(1,2-oxazinanylcarbonyl)phenylcyclopropyl]
amino}oxopropyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-valinamide were
dissolved in 3.7 ml of dichloromethane and then d with 6.7 mg (35 µmol) of 1-(3-
dimethylaminopropyl)ethylcarbodiimide hydrochloride, 0.7 mg (5.8 µmol) of 4-
dimethylaminopyridine and with 8.2 mg (47 µmol) of commercially available tert-butyl (2R)
hydroxypropyl ate. The mixture was stirred at RT overnight and then concentrated under
high vacuum. The remaining residue was purified by means of preparative HPLC. Thus, 7.5 mg
(61% of theory) of the otected intermediate were obtained as a colourless foam.
HPLC (Method 5): Rt = 2.0 min;
LC-MS d 1): Rt = 1.03 min; MS (ESIpos): m/z = 1056 (M+H)+.
Subsequently, the Boc protecting group was ed with trifluoroacetic acid. 4.9 mg (0.005
mmol) of the deprotected crude product were then, without further purification, taken up in 1.8 ml
of dichloromethane and admixed with 3.7 mg (0.011 mmol) of 1,1'-[(1,5-dioxopentane-1,5-
diyl)bis(oxy)]dipyrrolidine-2,5-dione, 2.4 µl (0.014 mmol) of N,N-diisopropylethylamine and 0.6
mg (5 µmol) of 4-dimethylaminopyridine. The mixture was d at RT for 2 h and then
concentrated under high vacuum. The remaining residue was purified by means of preparative
HPLC. Thus, 0.77 mg (15% of theory) of the title compound were obtained as a colourless foam.
HPLC (Method 5): Rt = 1.8 min;
LC-MS (Method 1): Rt = 0.93 min; MS (ESIpos): m/z = 1167 (M+H)+.
Intermediate 131
N-{4-[(1-{5-[(2,5-dioxopyrrolidinyl)oxy]oxopentanoyl}piperidinyl)oxy]oxobutyl}-N-
methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxymethyl{[(1S,2R)
(1,2-oxazinanylcarbonyl)phenylcyclopropyl]amino}oxopropyl]pyrrolidinyl}methyl-
1-oxoheptanyl]-N-methyl-L-valinamide
H C CH H C
3 3 3 CH3 N
O H
H N
O N N O
O N N
O O
O N O CH O CH3 O O CH
N 3
H C CH3 CH 3
3 3
O O
mg (11 µmol) of N-(3-carboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)
[(1R,2R)methoxymethyl{[(1S,2R)(1,2-oxazinanylcarbonyl)phenylcyclopropyl]
amino}oxopropyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-valinamide were
dissolved in 2 ml of dichloromethane and then admixed with 4.3 mg (22 µmol) of 1-(3-
dimethylaminopropyl)ethylcarbodiimide hydrochloride, 0.88 mg (6 µmol) of 4-
dimethylaminopyridine and with 5.2 mg (22 µmol) of commercially ble benzyl 4-
hydroxypiperidinecarboxylate. The e was stirred at RT overnight and then concentrated
under high vacuum. The remaining residue was purified by means of preparative HPLC. Thus, 5
mg (40% of theory) of the Z-protected intermediate were obtained as a colourless foam.
HPLC (Method 5): Rt = 2.1 min;
LC-MS d 1): Rt = 1.04 min; MS (ESIpos): m/z = 1116 (M+H)+.
Subsequently, the Z protecting group was detached by hydrogenolytic means in ethanol over
palladium/activated carbon. 4.6 mg (0.005 mmol) of the deprotected crude product were then,
without r purification, taken up in 1.8 ml of dichloromethane and admixed with 3.8 mg
(0.012 mmol) of 1,1'-[(1,5-dioxopentane-1,5-diyl)bis(oxy)]dipyrrolidine-2,5-dione, 0.8 µl (0.005
mmol) of N,N-diisopropylethylamine and 0.6 mg (5 µmol) of 4-dimethylaminopyridine. The
mixture was stirred at RT overnight and then trated under high vacuum. The remaining
e was purified by means of preparative HPLC. Thus, 0.96 mg (16% of theory) of the title
compound were obtained as a colourless foam.
HPLC (Method 5): Rt = 1.8 min;
LC-MS (Method 1): Rt = 0.94 min; MS (ESIpos): m/z = 1193 (M+H)+.
Intermediate 132
N-(4-{2-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexanoyl]hydrazinyl}oxobutyl)-N-methyl-L-
valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxymethyl{[(1S,2R)(1,2-
anylcarbonyl)phenylcyclopropyl]amino}oxopropyl]pyrrolidinyl}methyl
oxoheptanyl]-N-methyl-L-valinamide
O H C CH H C
3 3 3 CH N
O O 3 H
H H N
N N N N O
N N N
H O O
O O CH O CH O O
3 3 CH
H C CH CH 3
3 3 3
mg (16.7 µmol) of N-(3-carboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)
[(1R,2R)methoxymethyl{[(1S,2R)(1,2-oxazinanylcarbonyl)phenylcyclopropyl]
oxopropyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-valinamide were
dissolved in 2500 µl of DMF and then admixed with 9.6 mg (50 µmol) of 1-(3-
ylaminopropyl)ethylcarbodiimide hydrochloride, 7.6 mg (50 µmol) of 1-hydroxy-1H-
benzotriazole hydrate, 5.8 µl of N,N-diisopropylethylamine and with 17.4 mg (67 µmol) of
commercially available 6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexanehydrazide. The mixture
was stirred at RT overnight and then concentrated under high vacuum. The remaining residue was
purified by means of preparative HPLC. Thus, 11.2 mg (52% of theory) of the title compound
were obtained as a less foam.
HPLC (Method 5): Rt = 1.7 min;
LC-MS (Method 2): Rt = 1.09 min; MS (ESIpos): m/z = 1106 (M+H)+.
Intermediate 133
N-(4-{2-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexanoyl]hydrazinyl}oxobutyl)-N-methyl-L-
valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S,3S)(benzyloxy)oxophenylbutan
yl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxymethyloxoheptan
yl]-N-methyl-L-valinamide
O H C CH H C
O 3 3 3 CH O
O 3 H
H H N
N N N N O
N N N
H O O
O O CH O CH O O
3 H C
3 H C CH CH 3 H C
3 3
3 3
.8 mg (6.3 µmol) of N-(3-carboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R)
{[(2S,3S)(benzyloxy)oxophenylbutanyl]amino}methoxymethyl
oxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide were
dissolved in 943 µl of DMF and then admixed with 3.6 mg (19 µmol) of 1-(3-
ylaminopropyl)ethylcarbodiimide hydrochloride, 2.9 mg (19 µmol) of 1-hydroxy-1H-
benzotriazole hydrate, 2.2 µl of N,N-diisopropylethylamine and with 6.6 mg (25 µmol) of
commercially available 6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexanehydrazide. The e
was stirred at RT overnight and then concentrated under high vacuum. The remaining residue was
purified by means of preparative HPLC. Thus, 4.5 mg (64% of theory) of the title compound were
obtained as a less foam.
HPLC (Method 5): Rt = 2.0 min;
LC-MS (Method 1): Rt = 1.03 min; MS (ESIpos): m/z = 1129 (M+H)+.
Intermediate 134
N-[3-({[2-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)ethyl]carbamoyl}amino)propyl]-N-methyl-L-
valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxymethyl{[(1S,2R)(1,2-
oxazinanylcarbonyl)phenylcyclopropyl]amino}oxopropyl]pyrrolidinyl}methyl
oxoheptanyl]-N-methyl-L-valinamide
O H C CH H C
3 3 3 CH3 N
O O H
H N
N N N O
N N N N
H H O O
O CH3 O CH3 O O H C
H C CH CH3 3
3 3
First, 4-nitrophenyl -dioxo-2,5-dihydro-1H-pyrrolyl)ethyl carbamate was prepared under
standard conditions, proceeding from commercially ble 1-(2-aminoethyl)-1H-pyrrole-2,5-
dione trifluoroacetate and ophenyl carbonate.
mg (6 µmol) of N-(3-aminopropyl)-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)
[(1R,2R)methoxymethyl{[(1S,2R)(1,2-oxazinanylcarbonyl)phenylcyclopropyl]
amino}oxopropyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-valinamide were
dissolved in 1000 µl of DMF and then d with 2 µl of N,N-diisopropylethylamine and with
2.2 mg (9 µmol) of 4-nitrophenyl 2-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)ethyl carbamate. The
mixture was stirred at RT for 1 h and then concentrated under high vacuum. The remaining residue
was purified by means of preparative HPLC. Thus, 1.6 mg (23% of theory) of the title compound
were obtained as a colourless foam.
HPLC (Method 5): Rt = 1.7 min;
LC-MS (Method 2): Rt = 1.09 min; MS (ESIpos): m/z = 1036 (M+H)+.
Intermediate 135
N-(4-{2-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexanoyl]hydrazino}oxobutyl)-N-methyl-L-
valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)(benzyloxy)oxophenylpropan
yl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxymethyloxoheptan
yl]-N-methyl-L-valinamide
O H C CH H3C
3 3 CH3 O
O O H
H H N
N N N N O
N N N
H O O
O O CH O CH O O
3 3 CH3
H C CH3 CH3
10 mg (11 µmol) of N-(3-carboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R)
(benzyloxy)oxophenylpropanyl]amino}methoxymethyl
oxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide were
dissolved in 4000 µl of DMF and then admixed with 6.3 mg (33 µmol) of 1-(3-
dimethylaminopropyl)ethylcarbodiimide hydrochloride, 4.5 mg (33 µmol) of 1-hydroxy-1H-
benzotriazole hydrate, 5.7 µl of N,N-diisopropylethylamine and with 11.5 mg (44 µmol) of
commercially available 6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexanehydrazide. The mixture
was stirred at RT overnight and then concentrated under high vacuum. The remaining residue was
purified by means of preparative HPLC. Thus, 2.6 mg (14% of theory) of the title compound were
obtained as a colourless foam.
HPLC (Method 6): Rt = 2.1 min;
LC-MS (Method 1): Rt = 1.01 min; MS (ESIpos): m/z = 1115 (M+H)+.
Intermediate 136
N-(4-{4-[4-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)butanoyl]piperazinyl}oxobutyl)-N-methyl-
L-valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxymethyl{[(1S,2R)(1,2-
oxazinanylcarbonyl)phenylcyclopropyl]amino}oxopropyl]pyrrolidinyl}methyl
oxoheptanyl]-N-methyl-L-valinamide
O CH
N H C CH H C
3 CH N
N 3 3
O 3
H N
O N N N O
N N
O O
O CH O CH O O
3 3 CH
H C CH CH 3
3 3 3
First, 1-[4-oxo(piperazinyl)butyl]-1H-pyrrole-2,5-dione trifluoroacetate was ed under
standard conditions, proceeding from tert-butyl piperazinecarboxylate and 4-(2,5-dioxo-2,5-
dihydro-1H-pyrrolyl)butanoic acid over 2 stages.
mg (5.6 µmol) of N-(3-carboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)
[(1R,2R)methoxymethyl{[(1S,2R)(1,2-oxazinanylcarbonyl)phenylcyclopropyl]
amino}oxopropyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-valinamide were
dissolved in 1000 µl of DMF and then admixed with 2.1 mg (11 µmol) of 1-(3-
ylaminopropyl)ethylcarbodiimide hydrochloride, 1.7 mg (11 µmol) of 1-hydroxy-1H-
benzotriazole hydrate, 2 µl of N,N-diisopropylethylamine and with 3.5 mg (5.6 µmol) of 1-[4-oxo-
4-(piperazinyl)butyl]-1H-pyrrole-2,5-dione trifluoroacetate. The mixture was stirred at RT
ght. Then 2.1 mg (5.6 µmol) of O-(7-azabenzotriazolyl)-N,N,N',N'-tetramethyluronium
hexafluorophosphate were added and the reaction mixture was d at RT for a further 3 h.
Subsequently, the solvent was removed under d pressure and the remaining residue was
purified by means of preparative HPLC. The corresponding fractions were concentrated and, by
lyophilization from water, 0.6 mg (10% of theory) of the title compound was obtained as a
colourless foam.
HPLC (Method 6): Rt = 1.9 min;
LC-MS (Method 1): Rt = 0.9 min; MS (ESIpos): m/z = 1132 (M+H)+.
Intermediate 137
N-(4-{2-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexanoyl]methylhydrazino}oxobutyl)-N-
methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxymethyl{[(2S)(1,2-
anyl)oxophenylpropanyl]amino}oxopropyl]pyrrolidinyl}methyl
oxoheptanyl]-N-methyl-L-valinamide
O H C CH H C
3 3 3 CH
O 3 N
CH O
3 H
H N
N N N N O
N N N
H O O
O O CH O CH O O
3 3 CH
H C CH CH 3
3 3 3
First, 6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)-N'-methylhexanehydrazide trifluoroacetate was
prepared under rd conditions, proceeding from commercially available 6-(2,5-dioxo-2,5-
dihydro-1H-pyrrolyl)hexanoic acid and tert-butyl ylhydrazinecarboxylate over 2 stages.
6.9 mg (8 µmol) of N-(3-carboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)
[(1R,2R)methoxymethyl{[(2S)(1,2-oxazinanyl)oxophenylpropanyl]amino}-
3-oxopropyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-valinamide were dissolved
in 2540 µl of DMF and then admixed with 3.6 mg (9 µmol) of O-(7-azabenzotriazolyl)-
N,N,N',N'-tetramethyluronium hexafluorophosphate, 3 µl of N,N-diisopropylethylamine and with
4.1 mg (12 µmol) of 6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)-N'-methylhexanehydrazide
trifluoroacetate. The e was stirred at RT overnight. Subsequently, the solvent was removed
under reduced pressure and the remaining residue was purified by means of preparative HPLC.
Thus, 3.9 mg (45% of theory) of the title compound were obtained as a colourless foam.
HPLC (Method 5): Rt = 1.8 min;
LC-MS (Method 1): Rt = 0.93 min; MS (ESIpos): m/z = 1108 (M+H)+.
ediate 138
N-{4-[(2-{[4-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)butanoyl](methyl)amino}ethyl)(methyl)
amino]oxobutyl}-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxy
methyl{[(1S,2R)(1,2-oxazinanylcarbonyl)phenylcyclopropyl]amino}
oxopropyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-valinamide
O H C CH H C
3 3 CH N
O CH3 3 O 3
H N
N N N N O
N N N
O O
O CH3 O CH O CH O O
3 3 CH
H C CH CH 3
3 3 3
Proceeding from tert-butylmethyl 2-(methylamino)ethyl carbamate and 4-(2,5-dioxo-2,5-dihydro-
1H-pyrrolyl)butanoic acid, over 2 stages, 4-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)-N-methyl-N-
[2-(methylamino)ethyl]butanamide trifluoroacetate was first prepared by.
6.6 mg (7.3 µmol) of N-(3-carboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)
[(1R,2R)methoxymethyl{[(1S,2R)(1,2-oxazinanylcarbonyl)
phenylcyclopropyl]amino}oxopropyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-
valinamide were dissolved in 2000 µl of DMF and then admixed with 5.6 mg (14.7 µmol) of O-(7-
azabenzotriazolyl)-N,N,N',N'-tetramethyluronium hexafluorophosphate, 2.6 µl of N,N-
diisopropylethylamine and with 4.1 mg (9 µmol) of 4-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)-N-
methyl-N-[2-(methylamino)ethyl]butanamide trifluoroacetate. After stirring at RT for 3 h, the same
amounts of HATU and N,N-diisopropylethylamine were added once again, and the reaction
mixture was then d at RT overnight. Subsequently, the solvent was removed under reduced
re and the remaining residue was purified by means of preparative HPLC. Thus, 4 mg (44%
of ) of the title compound were obtained as a colourless foam.
HPLC (Method 6): Rt = 2.0 min;
LC-MS d 1): Rt = 0.91 min; MS (ESIpos): m/z = 1134 .
Intermediate 139
(2R,3S)amino{2-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexanoyl]hydrazino}oxobutan-
2-yl (3R,4S,7S,10S)[(2S)-butanyl]-7,10-diisopropyl(2-{(2S)[(1R,2R)methoxy
methyl{[(2S)(1,2-oxazinanyl)oxophenylpropanyl]amino}oxopropyl]pyrrolidin-
1-yl}oxoethyl)-5,11-dimethyl-6,9-dioxooxa-5,8,11-triazapentadecanoate
O H C CH H C
3 CH N
O NH 3 O 3 3 H
H 2 H N
N N O N N O
N N N
H O O
O O CH O CH O CH O O
3 3 CH
H C CH3 3 CH3 3
13 mg (14.7 µmol) of N-(3-carboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)
[(1R,2R)methoxymethyl{[(2S)(1,2-oxazinanyl)oxophenylpropanyl]amino}-
3-oxopropyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-valinamide were dissolved
in 10 ml of dichloromethane and then d with 8.4 mg (44 µmol) of 1-(3-
dimethylaminopropyl)ethylcarbodiimide hydrochloride, 5.4 mg (44 µmol) of 4-
dimethylaminopyridine and with 9 mg (29.3 µmol) of commercially available benzyl N-(tert-
butoxycarbonyl)-L-threoninate. The mixture was stirred at RT for 5 h. uently, the reaction
mixture was twice ted by shaking with water and the c phase was dried over sodium
sulphate and concentrated under reduced pressure. The ing residue was purified by means
of preparative HPLC. After lyophilization from dioxane/water, 14 mg (81% of theory) of the
protected intermediate were obtained as a colourless foam.
HPLC (Method 12): Rt = 2.3 min;
LC-MS (Method 1): Rt = 1.13 min; MS (ESIpos): m/z = 1178 (M+H)+.
Subsequently, the Z protecting group was ed by hydrogenolytic means in methanol over
% palladium/activated carbon. 9.5 mg (0.0087 mmol) of the deprotected crude product were
then, without further purification, taken up in 5 ml of DMF, and admixed 5 mg (26.2 µmol) of 1-
(3-dimethylaminopropyl)ethylcarbodiimide hydrochloride, 4 mg (26.2 µmol) of 1-hydroxy-1H-
benzotriazole hydrate, 54.6 µl of N,N-diisopropylethylamine and with 9.1 mg (34.9 µmol) of
commercially available 6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexanehydrazide. The mixture
was stirred at RT for 1 h and then concentrated under high vacuum. The remaining residue was
purified by means of preparative HPLC. After lyophilization from dioxane, 9.5 mg (84% of theory)
of the Boc-protected intermediate were obtained.
HPLC d 12): Rt = 2.1 min;
LC-MS (Method 1): Rt = 0.97 min; MS (ESIpos): m/z = 1295 .
Subsequently, 9.5 mg (7.3 µmol) were deprotected with 0.5 ml of trifluoroacetic acid in 2 ml of
dichloromethane of the Boc-protected intermediate and, after lyophilization from dioxane, 9 mg
(82% of theory) of the title compound were obtained as a colourless foam.
HPLC (Method 12): Rt = 2.1 min;
LC-MS (Method 1): Rt = 0.84 min; MS (ESIpos): m/z = 1195 (M+H)+.
Intermediate 140
N-(4-{2-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexanoyl]methylhydrazino}oxobutyl)-N-
methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxymethyl{[(1S,2R)
(1,2-oxazinanylcarbonyl)phenylcyclopropyl]amino}oxopropyl]pyrrolidinyl}methyl-
eptanyl]-N-methyl-L-valinamide
O H C CH H C
3 3 3 CH N
O CH O 3
3 H
H N
N N N N O
N N N
H O O
O O CH O CH O O
3 3 CH
H C CH CH 3
3 3 3
4.1 mg (12 µmol) of 6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)-N'-methylhexanehydrazide
trifluoroacetate (Intermediate 22) were dissolved together with 6.9 mg (8 µmol) of the compound
from Intermediate 61 in 2.5 ml of DMF and then admixed with 3.5 mg (9 µmol) of O-(7-
azabenzotriazolyl)-N,N,N',N'-tetramethyluronium uorophosphate and 3 µl of N,N-
diisopropylethylamine. The mixture was d at RT overnight and then concentrated under high
vacuum. The remaining residue was purified by means of preparative HPLC. After lyophilization
from dioxane, 2.6 mg (30% of theory) of the title compound were obtained.
HPLC (Method 5): Rt = 1.8 min;
LC-MS (Method 1): Rt = 0.90 and 0.91 min; MS (ESIpos): m/z = 1120 (M+H)+.
Intermediate 141
N-[4-({1-[4-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)butanoyl]piperidinyl}oxy)oxobutyl]-N-
methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxymethyl{[(1S,2R)
(1,2-oxazinanylcarbonyl)phenylcyclopropyl]amino}oxopropyl]pyrrolidinyl}methyl-
1-oxoheptanyl]-N-methyl-L-valinamide
2012/075277
H C CH H C
3 3 3 CH
O 3 N
H N
O N N O
O N N
O O
N O CH O CH O O
3 3 CH
N H C CH CH 3
3 3 3
44 mg (49 µmol) of N-(3-carboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)
[(1R,2R)methoxymethyl{[(1S,2R)(1,2-oxazinanylcarbonyl)phenylcyclopropyl]
oxopropyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-valinamide were
dissolved in 2 ml of dichloromethane and then admixed with 18.8 mg (98 µmol) of 1-(3-
dimethylaminopropyl)ethylcarbodiimide hydrochloride, 3.8 mg (24 µmol) of 4-
dimethylaminopyridine and with 23 mg (98 µmol) of commercially available benzyl 4-
hydroxypiperidinecarboxylate. The mixture was stirred at RT overnight and then concentrated
under high vacuum. The remaining residue was purified by means of preparative HPLC. Thus, 22
mg (40% of theory) of the Z-protected intermediate were obtained as a colourless foam.
HPLC (Method 5): Rt = 2.1 min;
LC-MS d 1): Rt = 1.04 min; MS (ESIpos): m/z = 1116 (M+H)+.
Subsequently, the Z protecting group was detached by hydrogenolytic means in l over
palladium/activated carbon.
19 mg (19 µmol) of the ected crude product were then, t further purification, taken up
in 4 ml of DMF and admixed with 7 mg (39 µmol) of 4-(2,5-dioxo-2,5-dihydro-1H-pyrrol
yl)butanoic acid, 11 mg (29 µmol) of O-(7-azabenzotriazolyl)-N,N,N',N'-tetramethyluronium
hexafluorophosphate and 5 µl of N,N-diisopropylethylamine. The e was stirred at RT for 1 h
and then concentrated under high vacuum. The remaining residue was purified by means of
preparative HPLC. After lyophilization from dioxane, 7.5 mg (34% of theory) of the title
compound were obtained.
HPLC (Method 5): Rt = 1.8 min;
LC-MS (Method 1): Rt = 0.94 min; MS (ESIpos): m/z = 1147 (M+H)+.
Intermediate 142
N-(4-{2-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexanoyl]hydrazino}oxobutyl)-N-methyl-L-
valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)(benzyloxy)(1H-indolyl)oxopropan
yl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxymethyloxoheptan
yl]-N-methyl-L-valinamide
O H C CH H C
O 3 3 3 CH O
O 3 H
H H N
N N N N O
N N N
H O O
O O CH O CH O O
3 3 H C
H C CH CH 3
3 3 3
9 mg (9.5 µmol) of arboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R)
{[(2S)(benzyloxy)(1H-indolyl)oxopropanyl]amino}methoxymethyl
oxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide
(Intermediate 72) were dissolved in 1000 µl of DMF and then admixed with 10 mg (38 µmol) of
commercially available 6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexanehydrazide, 7.2 mg (19
µmol) of O-(7-azabenzotriazolyl)-N,N,N',N'-tetramethyluronium hexafluorophosphate and 8 µl
of N,N-diisopropylethylamine, and the reaction mixture was stirred at RT for 1 h. Subsequently,
the solvent was removed under reduced pressure and the remaining e was purified by means
of preparative HPLC. The corresponding ons were concentrated and, by lyophilization, 6.4
mg (58% of theory) of the title compound were obtained as a colourless foam.
HPLC (Method 5): Rt = 1.9 min;
LC-MS (Method 1): Rt = 0.99 min; MS s): m/z = 1154 (M+H)+.
Intermediate 143
N-(4-{2-[4-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)-2,2-dimethylbutanoyl]hydrazino}oxobutyl)-
N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxymethyl{[(1S,2R)-
1-(1,2-oxazinanylcarbonyl)phenylcyclopropyl]amino}oxopropyl]pyrrolidinyl}
methyloxoheptanyl]-N-methyl-L-valinamide
O H C CH H C
3 3 CH N
O O 3 3 H
H C H H N
N 3 N N N O
N N N
H O O
O CH O CH O CH O O
3 3 H C CH 3 CH
CH 3
3 3 3
6 mg (6.7 µmol) of N-(3-carboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)
[(1R,2R)methoxymethyl{[(1S,2R)(1,2-oxazinanylcarbonyl)phenylcyclopropyl]
amino}oxopropyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-valinamide
(Intermediate 61) were reacted with 3 mg (8.7 µmol) of 4-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)-
2,2-dimethylbutanehydrazide trifluoroacetate in analogy to Intermediate 142 to give 2 mg (27% of
theory) of the title nd.
HPLC (Method 12): Rt = 2.1 min;
LC-MS (Method 3): Rt = 1.92 min; MS (ESIpos): m/z = 1106 (M+H)+.
Intermediate 144
N-(4-{2-[4-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)-2,2-dimethylbutanoyl]hydrazino}oxobutyl)-
N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxymethyl{[(2S)
(1,2-oxazinanyl)oxophenylpropanyl]amino}oxopropyl]pyrrolidinyl}methyl
oxoheptanyl]-N-methyl-L-valinamide
O H C CH H C
3 3 3 CH N
O O 3
H C H H N
N 3 N N N O
N N N
H O O
O CH O CH O CH O O CH
3 3 3
H C CH CH 3
3 3 3
To a solution of 5 mg (5.6 µmol) of arboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S)
methoxy{(2S)[(1R,2R)methoxymethyl{[(2S)(1,2-oxazinanyl)oxo
phenylpropanyl]amino}oxopropyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-
valinamide in 1 ml of DMF were added 7.65 mg (22.5 µmol) of 4-(2,5-dioxo-2,5-dihydro-1H-
pyrrolyl)-2,2-dimethylbutanehydrazide trifluoroacetate, 3.2 mg (16.9 µmol) of EDC, 1.96 µl
(11.3 µmol) of diisopropylethylamine and 2.6 mg (16.9 µmol) of HOBT. The reaction e was
stirred at RT for 3 h. Subsequently, a further 0.95 mg (2.8 µmol) of 4-(2,5-dioxo-2,5-dihydro-1H-
pyrrolyl)-2,2-dimethylbutanehydrazide trifluoroacetate was added. After ng overnight, the
reaction mixture was concentrated and ed by preparative HPLC. 3.5 mg (85% purity, 48% of
theory) of the title compound were obtained.
LC-MS (Method 3): Rt = 1.86 min; m/z = 1094 (M+H)+.
Intermediate 145
N-[3-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)propyl]-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy
2-[(1R,2R)methoxymethyl{[(1S,2R)(1,2-oxazinanylcarbonyl)phenyl
cyclopropyl]amino}oxopropyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-
valinamide
H C CH H C
3 3 3 CH N
O O 3
H N
N N O
N N N
O O
CH O CH O O
3 3 CH
O H C CH CH
3 3 3
12 mg (14 µmol) of N-(3-aminopropyl)-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)
[(1R,2R)methoxymethyl{[(1S,2R)(1,2-oxazinanylcarbonyl)phenylcyclopropyl]
amino}oxopropyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-valinamide
mediate 66) were taken up in 750 µl of dioxane and admixed with 1.5 ml of saturated sodium
hydrogencarbonate solution and then with 3.2 mg (21 µmol) of methyl 2,5-dioxo-2,5-dihydro-1H-
pyrrolecarboxylate. The reaction mixture was stirred at RT for 1 h and then concentrated under
reduced pressure. The remaining residue was purified by means of ative HPLC. After
lization, 4.2 mg (32% of theory) of the title compound were obtained.
HPLC (Method 5): Rt = 1.7 min;
LC-MS (Method 1): Rt = 0.94 min; MS (ESIpos): m/z = 950 (M+H)+.
Intermediate 146
N-(4-{2-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexanoyl]hydrazino}oxobutyl)-N-methyl-L-
valyl-N-[(3R,4S,5S){(2S)[(1R,2R)({(2S)[benzyl(methyl)amino]oxophenylpropan-
2-yl}amino)methoxymethyloxopropyl]pyrrolidinyl}methoxymethyloxoheptan-
4-yl]-N-methyl-L-valinamide
O H C CH H3C CH 3
O 3 3 3 N
O H
H H N
N N N N O
N N N
H O O
O O CH O CH O O
3 CH
H C CH 3 CH 3
3 3 3
9 mg (9.8 µmol) of N-(3-carboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R)
({(2S)[benzyl(methyl)amino]oxophenylpropanyl}amino)methoxymethyl
oxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide
(Intermediate 73) were reacted in analogy to Intermediate 133 with 10 mg (39 µmol) of 6-(2,5-
dioxo-2,5-dihydro-1H-pyrrolyl)hexanehydrazide to give 1.8 mg (15% of theory) of the title
compound.
HPLC (Method 12): Rt = 2.2 min;
LC-MS (Method 9): Rt = 5.11 min; MS s): m/z = 1128 (M+H)+.
Intermediate 147
N-{4-[(2,5-dioxopyrrolidinyl)oxy]oxobutyl}-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)
[(1R,2R){[(2S,3S)(benzyloxy)oxophenylbutanyl]amino}methoxymethyl
oxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide
H C CH H C
O O 3 3 3 CH O
N O 3
H N
O N N O
N N
O O
O CH O CH O O
3 3 CH H C
H C CH CH 3 3
3 3 3
16 mg (17 µmol) of N-(3-carboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R)
{[(2S,3S)(benzyloxy)oxophenylbutanyl]amino}methoxymethyl
oxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide
(Intermediate 70) were dissolved in 2 ml of dichloromethane and admixed with 2.6 mg (23 mmol)
of 1-hydroxypyrrolidine-2,5-dione and then with 4 mg (21 µmol) of imethylaminopropyl)
ethylcarbodiimide hydrochloride. After stirring at RT for 2 h, the same amounts of 1-
hydroxypyrrolidine-2,5-dione and 1-(3-dimethylaminopropyl)ethylcarbodiimide hydrochloride
were added once again. Then stirring at RT ght, the reaction mixture was concentrated under
reduced pressure. The remaining residue was purified by means of preparative HPLC. After
lyophilization, 10 mg (56% of theory) of the title compound were ed.
HPLC (Method 5): Rt = 2.0 min;
Intermediate 148
(2-{[4-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)butanoyl](methyl)amino}ethyl)amino]
oxobutyl}-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxymethyl
{[(1S,2R)(1,2-oxazinanylcarbonyl)phenylcyclopropyl]amino}oxopropyl]pyrrolidin
yl}methyloxoheptanyl]-N-methyl-L-valinamide
O H C CH H C
3 3 3 CH
3 N
O O H
H H N
N N N N O
N N N
O O
O CH O CH O CH O O
3 3 3 CH
H C CH3 CH 3
3 3
6 mg (7 µmol) of N-(3-carboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)
[(1R,2R)methoxymethyl{[(1S,2R)(1,2-oxazinanylcarbonyl)phenylcyclopropyl]
amino}oxopropyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-valinamide
(Intermediate 61) were combined with 2.8 mg (8 µmol) of N-(2-aminoethyl)(2,5-dioxo-2,5-
dihydro-1H-pyrrolyl)-N-methylbutanamide trifluoroacetate, 10.1 mg (27 µmol) of O-(7-
zotriazolyl)-N,N,N',N'-tetramethyluronium hexafluorophosphate and 5 µl of N,N-
diisopropylethylamine in 2 ml of DMF and stirred at RT ght. Then another 5 mg (23.5 µmol)
of O-(7-azabenzotriazolyl)-N,N,N',N'-tetramethyluronium uorophosphate and 3 µl of N,N-
diisopropylethylamine were added. After stirring at RT for a further 5 h, the solvent was removed
under reduced pressure and the remaining residue was purified by means of preparative HPLC.
The corresponding fractions were concentrated and, by lyophilization from dioxane, 1.3 mg (15%
of theory) of the title compound were obtained.
HPLC (Method 12): Rt = 2.1 min;
LC-MS d 2): Rt = 1.21 min; MS (ESIpos): m/z = 1120 (M+H)+.
Intermediate 149
N-{4-[(2-{[4-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)butanoyl]amino}ethyl)(methyl)amino]
oxobutyl}-N-methyl-L-valyl-N-[(3 R,4 S,5 S)methoxy{(2 (1 R,2R)methoxymethyl
{[(1 S,2 R)(1,2-oxazinanylcarbonyl)phenylcyclopropyl]amino}oxopropyl]pyrrolidin
yl}methyloxoheptanyl]-N-methyl-L-valinamide
6 mg (7 µmol) of N-(3-carboxypropyl)-N-methyl-L-valyl-N-[(3 R,4 S,5 S)methoxy{(2 S)
[(1 R,2 R)methoxymethyl{[(1 S,2 R)(1,2-oxazinanylcarbonyl)phenylcyclopropyl]
amino}oxopropyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-valinamide
(Intermediate 61) were combined with 3.1 mg (9 µmol) of 4-(2,5-dioxo-2,5-dihydro-1 H-pyrrol
[2-(methylamino)ethyl]butanamide trifluoroacetate, 10.1 mg (27 µmol) of O-(7-
azabenzotriazolyl)-N,N,N',N' -tetramethyluronium hexafluorophosphate and 5 µl of N,N -
diisopropylethylamine in 2 ml of DMF, and the mixture was stirred at RT for 4 h. Then the solvent
was removed under reduced pressure and the remaining residue was purified by means of
preparative HPLC. The corresponding fractions were concentrated and, by lyophilization from
dioxane, 1 mg (13.4% of theory) of the title compound were obtained.
HPLC (Method 12): Rt = 2.1 min;
LC-MS d 1): Rt = 0.89 min; MS (ESIpos): m/z = 1121 (M+H)+.
Intermediate 150
2-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexanoyl]hydrazino}oxobutyl)-N-methyl-L-
valyl-N-[(3 R,4 S,5 S)methoxy{(2 S)[(1 R,2 R)methoxymethyloxo{[(1 S,2 R)
phenyl(propylcarbamoyl)cyclopropyl]amino}propyl]pyrrolidinyl}methyloxoheptan
yl]-N-methyl-L-valinamide
O H3C CH H3C
3 CH
3 HN
O O H
H H N
N N N N O
N N N
H O O
O O CH3 O CH O O
3 CH
H3C CH CH 3
3 3
7.9 mg (9 µmol) of N-(3-carboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)
[(1R,2R)methoxymethyloxo{[(1S,2R)phenyl(propylcarbamoyl)cyclopropyl]
amino}propyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-valinamide were dissolved
in 3 ml of DMF and then admixed with 10.4 mg (54 µmol) of 1-(3-dimethylaminopropyl)
arbodiimide hydrochloride, 8.3 mg (54 µmol) of 1-hydroxy-1H-benzotriazole hydrate, 9 µl
of N,N-diisopropylethylamine and with 9.5 mg (36 µmol) of commercially available 6-(2,5-dioxo-
2,5-dihydro-1H-pyrrolyl)hexanehydrazide. The mixture was d at RT overnight and then
concentrated under high vacuum. The remaining residue was purified by means of preparative
HPLC. Thus, 4.3 mg (22% of theory) of the title compound were obtained as a colourless foam.
HPLC (Method 6): Rt = 1.9 min;
LC-MS (Method 9): Rt = 4.93 min; MS (ESIpos): m/z = 1078 (M+H)+.
ediate 151
N-(4-{2-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexanoyl]hydrazino}oxobutyl)-N-methyl-L-
valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(1S,2R)carbamoylphenylcyclopropyl]amino}
methoxymethyloxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-
namide
O H C CH H C
3 3 3 CH
O O 3 NH
H 2
H H N
N N N N O
N N N
H O O
O O CH O CH O O
3 3 CH
H C CH CH 3
3 3 3
The compound was prepared analogously to Intermediate 150, proceeding from the compound in
Intermediate 81.
HPLC (Method 5): Rt = 1.7 min;
LC-MS (Method 1): Rt = 0.87 min; MS (ESIpos): m/z = 1036 (M+H)+.
Intermediate 152
N-(4-{2-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexanoyl]hydrazino}oxobutyl)-N-methyl-L-
valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(1S,2R)(ethoxycarbonyl)phenylcyclopropyl]
amino}methoxymethyloxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-
N-methyl-L-valinamide
CH 3
O H C CH H C
3 3 3 CH O
O O 3 H
H H N
N N N N O
N N N
H O O
O O CH O CH O O
3 3 CH
H C CH CH 3
3 3 3
mg (12 µmol) of arboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R)
2R)(ethoxycarbonyl)phenylcyclopropyl]amino}methoxymethyloxopropyl]
pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide were dissolved in
3 ml of DMF and then admixed with 8.9 mg (23 µmol) of O-(7-azabenzotriazolyl)-N,N,N',N'-
tetramethyluronium hexafluorophosphate, 10 µl of N,N-diisopropylethylamine and with 12 mg (47
µmol) of commercially available 6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexanehydrazide. The
mixture was stirred at RT for 1 h. This was followed by concentration under high vacuum and
purification of the ing residue by means of preparative HPLC. Thus, 5.8 mg (37 % of
theory) of the title compound were obtained as a colourless foam.
HPLC (Method 6): Rt = 2.0 min;
LC-MS (Method 9): Rt = 4.99 min; MS (ESIpos): m/z = 1066 (M+H)+.
Intermediate 153
N-[1-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)-12,15-dioxo-3,6,9-trioxa-13,14-diazaoctadecan
methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxymethyl{[(2S)-
1-(1,2-oxazinanyl)oxophenylpropanyl]amino}oxopropyl]pyrrolidinyl}methyl-
1-oxoheptanyl]-N-methyl-L-valinamide
2012/075277
H C CH H C O
3 3 3 CH N
O O H
H H N
N N N O
O N N N
O H
O CH O
O 3 O CH
3 O O CH
H C CH H C
3 3 3
To a solution of 5 mg (5.6 µmol) of N-(3-carboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S)
methoxy{(2S)[(1R,2R)methoxymethyl{[(2S)(1,2-oxazinanyl)oxo
phenylpropanyl]amino}oxopropyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-
valinamide in 1 ml of DMF were added 9.7 mg (22.5 µmol) of 3-(2-{2-[2-(2,5-dioxo-2,5-dihydro-
1H-pyrrolyl)ethoxy]ethoxy}ethoxy)propanehydrazide trifluoroacetate, 3.2 mg (16.9 µmol) of
EDC, 1.96 µl (11.3 µmol) of isopropylethylamine and 2.6 mg (16.9 µmol) of HOBT. The
reaction mixture was stirred at RT for 3 h. uently, a further 1.2 mg (2.8 µmol) of 3-(2-{2-[2-
ioxo-2,5-dihydro-1H-pyrrolyl)ethoxy]ethoxy}ethoxy)propanehydrazide trifluoroacetate
were added. The reaction mixture was stirred at RT overnight and then purified by preparative
HPLC.
3.6 mg (51% of theory) of the title compound were obtained.
LC-MS (Method 1): Rt = 0.90 min; m/z = 1185 (M+H)+.
Intermediate 154
(2R,3S)amino{2-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexanoyl]hydrazino}oxobutan-
2-yl (3R,4S,7S,10S)[(2S)-butanyl]-7,10-diisopropyl(2-{(2S)[(1R,2R)methoxy
methyl{[(1S,2R)(1,2-oxazinanylcarbonyl)phenylcyclopropyl]amino}
oxopropyl]pyrrolidinyl}oxoethyl)-5,11-dimethyl-6,9-dioxooxa-5,8,11-triazapentadecan-
-oate
O H C CH H C
3 3 3 CH N
O NH O 3 H
H 2 H N
N N O N N O
N N N
H O O
O O CH O CH O CH O O
3 CH
3 H C CH 3 CH 3
3 3 3
mg (17 µmol) of N-(3-carboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)
[(1R,2R)methoxymethyl{[(1S)(1,2-oxazinanyl)phenylcyclopropyl]amino}
oxopropyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-valinamide were dissolved in
ml of dichloromethane and then admixed with 12.8 mg (67 µmol) of 1-(3-
dimethylaminopropyl)ethylcarbodiimide hydrochloride, 10 mg (83 µmol) of 4-
dimethylaminopyridine and with 10.3 mg (33 µmol) of commercially ble benzyl N-(tert-
butoxycarbonyl)-L-threoninate. The mixture was heated to reflux for 4 h. Then the same amounts
of coupling reagent and 4-dimethylaminopyridine were added again and the reaction mixture was
heated under reflux overnight. Subsequently, the reaction mixture was diluted with
dichloromethane and ted by shaking once with water, and the organic phase was removed
and concentrated under high . The ing residue was purified by means of preparative
HPLC. Thus, 7.7 mg (37% of theory) of the protected intermediate were obtained as a colourless
foam.
HPLC (Method 12): Rt = 2.5 min;
LC-MS (Method 1): Rt = 1.13 min; MS (ESIpos): m/z = 1190 (M+H)+.
Subsequently, the benzyl ester protecting group was removed by hydrogenation under rd
hydrogen pressure in methanol over 10% palladium/activated carbon, and the acid thus obtained,
as described in Intermediate 151, was joined to 6-(2,5-dioxo-2,5-dihydro-1H-pyrrol
yl)hexanehydrazide. In a last step, the Boc protecting group was detached with trifluoroacetic acid.
The remaining residue was ed by means of preparative HPLC. Thus, 0.22 mg (2.5% of theory
over 3 stages) of the title compound was obtained as a colourless foam.
HPLC (Method 12): Rt = 2.0 min;
LC-MS (Method 1): Rt = 0.81 min; MS (ESIpos): m/z = 1207 (M+H)+.
Intermediate 155
N-(4-{2-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexanoyl]hydrazino}oxobutyl)-N-methyl-L-
N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)aminooxophenylpropanyl]amino}
methoxymethyloxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-
L-valinamide
O H C CH H C
3 CH
O 3 O 3 3 NH
H 2
H H N
N N N N O
N N N
H O O
O O CH O CH O O
3 3 CH
H C CH CH 3
3 3 3
This compound was prepared in analogy to the synthesis described in Intermediate 152, from N-(3-
carboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)aminooxo
phenylpropanyl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxy
methyloxoheptanyl]-N-methyl-L-valinamide and commercially available -dioxo-2,5-
dihydro-1H-pyrrolyl)hexanehydrazide.
HPLC (Method 5): Rt = 1.6 min;
LC-MS (Method 1): Rt = 0.82 min; MS s): m/z = 1024 (M+H)+.
Intermediate 156
N-(3-{[(1-{[(2,5-dioxopyrrolidinyl)oxy]carbonyl}cyclopropyl)carbonyl]amino}propyl)-N-
methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxymethyl{[(1S,2R)
(1,2-oxazinanylcarbonyl)phenylcyclopropyl]amino}oxopropyl]pyrrolidinyl}methyl-
eptanyl]-N-methyl-L-valinamide
O H3C CH3 H C CH N
O O O 3 3 H
H N
N N N O
O N N N
H O O
O CH3 O CH O O CH3
H3C CH3 3 CH
This compound was prepared in analogy to the synthesis described in the last stage of Intermediate
131, from N-(3-aminopropyl)-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)
methoxymethyl{[(1S,2R)(1,2-oxazinanylcarbonyl)phenylcyclopropyl]amino}
oxopropyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-valinamide and 1,1'-
[cyclopropane-1,1-diylbis(carbonyloxy)]dipyrrolidine-2,5-dione, which had been obtained from
the corresponding oxylic acid beforehand.
HPLC (Method 12): Rt = 2.0 min;
LC-MS (Method 1): Rt = 0.92 min; MS (ESIpos): m/z = 1080 (M+H)+.
Intermediate 157
N-(4-{2-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexanoyl]hydrazino}oxobutyl)-N-methyl-L-
valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)amino(1H-indolyl)oxopropan
yl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxymethyloxoheptan
yl]-N-methyl-L-valinamide
O H C CH H C
3 3 3 CH NH
O O 3 H 2
H H N
N N N N O
N N N
H O O
O O CH O CH O O
3 3 CH
H C CH CH 3
3 3 3
mg (18 µmol) of (N-(3-carboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R)
{[(2S)amino(1H-indolyl)oxopropanyl]amino}methoxymethyl
pyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide were
dissolved in 3.8 ml of DMF and then admixed with 27 mg (70 µmol) of O-(7-azabenzotriazol
yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate, 12 µl of N,N-diisopropylethylamine and
with 14 mg (53 µmol) of commercially available 6-(2,5-dioxo-2,5-dihydro-1H-pyrrol
yl)hexanehydrazide. The reaction mixture was stirred at RT for 1 h. This was followed by
concentration under high vacuum and cation of the remaining residue by means of
preparative HPLC. Thus, 6.2 mg (33% of theory) of the title compound were obtained as a
colourless foam.
HPLC (Method 5): Rt = 1.6 min;
LC-MS (Method 1): Rt = 0.85 min; MS (ESIpos): m/z = 1063 (M+H)+.
1H-NMR (500 MHz, DMSO-d6, characteristic s): δ = 10.8 (d, 1H), 9.8-9.7 (m, 2H), 9.6 and
9.4 (2m, 1H), 8.9, 8.88, 8.78 and 8.75 (4d, 1H), 8.08 and 7.85 (2d, 1H), 7.6-6.9 (m, 9H), 4.7-4.4
(m, 3H), 3.4 (t, 2H), 3.23, 3.2, 3.18, 3.0, and 2.99 (5s, 9H), 2.8 (m, 3H), 2.1 (t, 2H), 1.06 and 1.01
(2d, 3H), 0.95-0.8 (m, 15H), 0.8-0.75 (dd, 3H).
Intermediate 158
N-[4-({(2R)[(2,5-dioxopyrrolidinyl)oxy]methyloxopentanyl}amino)oxobutyl]-N-
methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)(benzylamino)oxo
propanyl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxy
methyloxoheptanyl]-N-methyl-L-valinamide
O H3C CH H C
3 3 CH
3 HN
O O H
H H N
N N N N O
O N N
O O
O H C
3 O CH O CH3 O O
3 CH
H C CH3 CH 3
3 3
3
WO 87716
13 mg (14.7 µmol) of N-(3-carboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R)
{[(2S)(benzylamino)oxophenylpropanyl]amino}methoxymethyl
oxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide were
dissolved in 4 ml of dimethylformamide and then admixed with 9.4 mg (25 µmol) of O-(7-
zotriazolyl)-N,N,N',N'-tetramethyluronium hexafluorophosphate, 6 µl of N,N-
diisopropylethylamine and with 7 mg (31 µmol) of commercially available tert-butyl D-leucinate
hloride trifluoroacetate. The mixture was stirred at RT for 5 h and then concentrated under
reduced re. The remaining residue was purified by means of preparative HPLC. After
lyophilization from dioxane/water, 6.5 mg (49% of theory) of the protected intermediate were
obtained as a colourless foam.
HPLC (Method 5): Rt = 2.2 min;
LC-MS (Method 1): Rt = 1.21 min; MS (ESIpos): m/z = 1076 (M+H)+.
Trifluoroacetic acid in dichloromethane was first used to detach the Boc protecting group from this
protected intermediate, giving 6.2 mg (99% of theory) of the ected compound. 5.2 mg (5
µmol) of this intermediate were taken up in 1.5 ml of dichloromethane and reacted with 0.8 mg (7
µmol) of N-hydroxysuccinimide in the presence of 1.2 mg (6 µmol) of 1-(3-dimethylaminopropyl)-
3-ethylcarbodiimide hydrochloride and 0.16 mg (1 µmol) of thylaminopyridine. After
stirring at RT for 2 h, the reaction mixture was concentrated and purified by means of preparative
HPLC. 1.3 mg of the title compound were obtained, some of which was hydrolysed to the reactant.
Intermediate 159
N-(4-{2-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexanoyl]hydrazino}oxobutyl)-N-methyl-L-
valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)(benzylamino)oxophenylpropan
yl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxymethyloxoheptan
yl]-N-methyl-L-valinamide
H C CH H3C
3 3 CH H
O O 3 N
N H H N
N N N O
N N N
O H O O
O CH3 O CH3 O O CH
H3C CH CH3 3
This nd was prepared in analogy to the synthesis described in Intermediate 157, from N-(3-
ypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)(benzylamino)
oxophenylpropanyl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxy
methyloxoheptanyl]-N-methyl-L-valinamide and commercially available 6-(2,5-dioxo-2,5-
dihydro-1H-pyrrolyl)hexanehydrazide.
2012/075277
Yield: 6 mg (53% of theory)
HPLC (Method 5): Rt = 1.9 min;
LC-MS (Method 1): Rt = 0.94 min; MS (ESIpos): m/z = 1114 .
Intermediate 160
N-(4-{2-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexanoyl]hydrazino}oxobutyl)-N-methyl-L-
valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)(benzylamino)(1H-indolyl)oxopropan-
2-yl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxymethyloxoheptan-
4-yl]-N-methyl-L-valinamide
H C CH H C
3 3 3 CH NH
O O 3
N H H N
N N N O
N N N
O H O O
O CH O CH O O
3 3 H C
H C CH CH 3
3 3 3 HN
This compound was prepared in analogy to the synthesis described in Intermediate 157, from 20
mg (21 µmol) of N-(3-carboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R)
{[(2S)(benzylamino)(1H-indolyl)oxopropanyl]amino}methoxymethyl
oxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide and
commercially available 6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexanehydrazide.
Yield: 13 mg (52% of theory)
HPLC (Method 5): Rt = 1.9 min;
LC-MS d 1): Rt = 0.92 min; MS (ESIpos): m/z = 1153 (M+H)+.
Intermediate 161
N-(6-{2-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexanoyl]hydrazino}oxohexyl)-N-methyl-L-
valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)amino(1H-indolyl)oxopropan
yl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxymethyloxoheptan
yl]-N-methyl-L-valinamide
H C CH H C
3 3 3 CH
O 3 NH2
O H
N H H N
N N N O
N N N
O H O O
O CH O CH O O
3 3 H C
H C CH3 CH 3
3 3
This compound was prepared in analogy to the sis described in Intermediate 157, from N-(5-
carboxypentyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)amino(1H-indol-
3-yl)oxopropanyl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxy
methyloxoheptanyl]-N-methyl-L-valinamide and commercially available 6-(2,5-dioxo-2,5-
dihydro-1H-pyrrolyl)hexanehydrazide.
Yield: 0.8 mg (16% of theory)
HPLC (Method 5): Rt = 1.6 min;
LC-MS (Method 1): Rt = 0.78 min; MS s): m/z = 1092 .
Intermediate 162
N-{6-[(2,5-dioxopyrrolidinyl)oxy]oxohexyl}-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy
{(2S)[(1R,2R)methoxymethyl{[(1S,2R)(1,2-oxazinanylcarbonyl)
phenylcyclopropyl]amino}oxopropyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-
valinamide
H C CH H C
3 3 3 CH
3 N
O O H
H N
O N N O
N N N
O O
O CH O CH O O
3 3 CH
H C CH CH 3
O 3 3 3
18 mg (20 µmol) of N-(5-carboxypentyl)-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)
[(1R,2R)methoxymethyl{[(1S,2R)(1,2-oxazinanylcarbonyl)phenylcyclopropyl]
amino}oxopropyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-valinamide
(Intermediate 64) were dissolved in 3.2 ml of dichloromethane and admixed with 22 mg (190
mmol) of 1-hydroxypyrrolidine-2,5-dione and then with 11 mg (60 µmol) of 1-(3-
dimethylaminopropyl)ethylcarbodiimide hydrochloride and 0.24 mg (0.17 µmol) of DMAP.
After stirring at RT for 2 h, another 22 mg (190 mmol) of 1-hydroxypyrrolidine-2,5-dione, 11 mg
WO 87716 2012/075277
(60 µmol) of 1-(3-dimethylaminopropyl)ethylcarbodiimide hydrochloride and 0.24 mg (0.17
µmol) of DMAP were added and the reaction mixture was stirred at RT for a further hour. This
was followed by concentration under reduced pressure. The remaining residue was purified by
means of preparative HPLC. After lyophilization, 8.2 mg (41% of ) of the title compound
were obtained.
HPLC (Method 5): Rt = 2.0 min;
LC-MS d 11): Rt = 0.9 min; MS (ESIpos): m/z = 1024 (M+H)+.
Intermediate 163
[(1S,2R)aminophenylcyclopropyl](1,4-dihydro-3H-2,3-benzoxazinyl)methanone
trifluoroacetate
CF3COOH x H N
2 O
First, proceeding from 265 mg (0.82 mmol) of tert-butyl (1S,2R)(hydroxycarbamoyl)
phenylcyclopropyl carbamate (Starting Compound 7), by reaction with 1,2-
bis(bromomethyl)benzene, analogously to a literature method (see H. King, J. Chem. Soc. 1942,
432), the Boc-protected tert-butyl (1S,2R)(1,4-dihydro-3H-2,3-benzoxazinylcarbonyl)
phenylcyclopropyl carbamate intermediate was prepared.
Yield: 108 mg (34% of )
LC-MS (Method 2): Rt = 1.3 min; MS (ESIpos): m/z = 395 (M+H)+.
108 mg (0.27 mmol) of this intermediate were taken up in 3.7 ml of dichloromethane, 1.8 ml of
trifluoroacetic acid were added, and the mixture was stirred at RT for 15 min. This was followed
by concentration under reduced pressure and lyophilization of the remaining residue from dioxane.
112 mg of the title compound were obtained in tative yield as a colourless foam.
WO 87716
LC-MS (Method 1): Rt = 0.7 min; MS (ESIpos): m/z = 295 (M+H)+.
Intermediate 164
N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(1S,2R)(1,4-dihydro-3H-2,3-
benzoxazinylcarbonyl)phenylcyclopropyl]amino}methoxymethyl
oxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide
trifluoroacetate
H C CH H C CH
3 3 3 3 N
O H
H N
N N O
HN N
O O
CH O CH O O H C
3 3 3
H C CH CH
3 3 3
x CF3COOH
166 mg (0.196 mmol) of N-[(9H-fluorenylmethoxy)carbonyl]-N-methyl-L-valyl-N-[(3R,4S,5S)-
1-{(2S)[(1R,2R)carboxymethoxypropyl]pyrrolidinyl}methoxymethyl
oxoheptanyl]-N-methyl-L-valinamide (Intermediate 10) were taken up in 40 ml of DMF and
admixed successively with 80 mg (0.196 mmol) of R)aminophenylcyclopropyl](1,4-
o-3H-2,3-benzoxazinyl)methanone trifluoroacetate (Intermediate 163), 112 mg (0.294
mmol) of O-(7-azabenzotriazolyl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU)
and 682 µl (3.9 mmol) of N,N-diisopropylethylamine. The mixture was uently d at RT
overnight. The reaction mixture was then concentrated under reduced pressure, the residue was
taken up in ethyl acetate and the solution was washed with saturated aqueous sodium chloride
solution. The organic phase was dried over magnesium sulphate, filtered and concentrated. The
residue was finally ed by preparative HPLC. In this way, 19 mg (9% of theory) of the Fmocprotected
intermediate N-[(9H-fluorenylmethoxy)carbonyl]-N-methyl-L-valyl-N-[(3R,4S,5S)
{(2S)[(1R,2R){[(1S,2R)(1,4-dihydro-3H-2,3-benzoxazinylcarbonyl)
phenylcyclopropyl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxy
methyloxoheptanyl]-N-methyl-L-valinamide were obtained.
HPLC (Method 5): Rt = 1.68 min;
LC-MS (Method 1): Rt = 1.51 min; MS (ESIpos): m/z = 1083 (M+H)+.
19 mg (0.015 mmol) of this ediate were dissolved in 4 ml of DMF. After 817 µl of
piperidine had been added, the reaction mixture was stirred at RT for 5 min. This was followed by
concentration under reduced pressure, and the residue was first digested with diethyl ether and
then purified by means of preparative HPLC (eluent: itrile + 0.1% TFA / 0.1% aq. TFA).
The corresponding fractions were combined, the solvent was removed under reduced re and
then the residue was lyophilized from dioxane/water. 12 mg (92% of theory) of the title compound
were obtained as a colourless foam.
HPLC (Method 6): Rt = 2.0 min;
LC-MS (Method 1): Rt = 0.94 min; MS (ESIpos): m/z = 861 (M+H)+.
Intermediate 165
N-(6-aminohexyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(1S,2R)(1,4-
dihydro-3H-2,3-benzoxazinylcarbonyl)phenylcyclopropyl]amino}methoxymethyl
oxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide
H3C CH H C CH
3 3 N
O 3
H N
H N N N
2 O
N N
O O
CH O CH O O H C
3 3 3
H3C CH CH
3 3
20 mg (0.021 mmol) of ediate 164 were used, in y to the preparation of Intermediate
97, with benzyl 3-oxohexyl carbamate in the presence of sodium cyanoborohydride and subsequent
hydrogenolytic detachment of the Z protecting group (with 5% palladium on charcoal as a catalyst,
in methanol as a solvent), to prepare the title compound.
Yield: 4.5 mg (23% of theory over 2 stages)
HPLC (Method 12): Rt = 1.9 min;
LC-MS d 1): Rt = 0.9 min; MS (ESIpos): m/z = 960 (M+H)+.
Intermediate 166
N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexyl]-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)
[(1R,2R){[(1S,2R)(1,4-dihydro-3H-2,3-benzoxazinylcarbonyl)
phenylcyclopropyl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxy
oxoheptanyl]-N-methyl-L-valinamide
O O
H C CH H C
3 3 3 CH
3 N
O H
H N
N N N O
N N
O O
O CH O CH O O H C
3 3 3
H C CH CH
3 3 3
4.4 mg (4.5 µmol) of Intermediate 165 were taken up in 1 ml of 1:1 dioxane/water and then
admixed with 1 mg (6.8 µmol) of methyl 2,5-dioxo-2,5-dihydro-1H-pyrrolecarboxylate and with
50 µl of saturated aqueous sodium hydrogencarbonate solution. The reaction mixture was stirred at
RT for 30 min. Then another 50 µl of the saturated aqueous sodium hydrogencarbonate on
were added and the on mixture was stirred at RT for a further 15 min and then concentrated
under reduced pressure. The remaining residue was purified by means of preparative HPLC. After
lyophilization, 1 mg (21% of theory) of the title compound were obtained as a colourless foam.
HPLC d 12): Rt = 2.1 min;
LC-MS (Method 1): Rt = 1.08 min; MS (ESIpos): m/z = 1040 (M+H)+.
Intermediate 167
benzyl 3-{2-[2-(2-oxoethoxy)ethoxy]ethoxy}propanoate
O H
O O
The title compound was prepared from 6 g (21.55 mmol) of commercially available 3-{2-[2-(2-
hydroxyethoxy)ethoxy]ethoxy}propanoic acid under standard ions, first by esterification
with benzyl chloride and caesium carbonate and subsequent oxidation with sulphur trioxidepyridine
complex.
Yield: 611 mg (10% of theory over 2 stages)
LC-MS (Method 2): Rt = 1.69 min; MS (ESIpos): m/z = 311 (M+H)+.
Intermediate 168
N-(2-{2-[2-(2-carboxyethoxy)ethoxy]ethoxy}ethyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)
[(1R,2R){[(2S)amino(1H-indolyl)oxopropanyl]amino}methoxymethyl
pyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide
H C CH H C
3 3 3 CH NH
O 3
H 2
H N
HO O O N N O
O N N
O O
O CH O CH O O
3 3 CH
H C CH CH 3
3 3 3
First, in analogy to the synthesis bed in Intermediate 69, by coupling of N-[(9H-fluoren
ylmethoxy)carbonyl]-N-methyl-L-valyl-N-[(2R,3S,4S)carboxymethoxymethylhexanyl]-
N-methyl-L-valinamide (Intermediate 4) and Nα-{(2R,3R)methoxymethyl[(2S)-pyrrolidin-
ropanoyl}-L-tryptophanamide trifluoroacetate (Intermediate 49) in the presence of O-(7-
azabenzotriazolyl)-N,N,N',N'-tetramethyluronium hexafluorophosphate and uent
detachment of the Fmoc protecting group by means of piperidine, the amine compound N-methyl-
L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)amino(1H-indolyl)oxopropan
yl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxymethyloxoheptan
yl]-N-methyl-L-valinamide was prepared as the trifluoroacetate.
25 mg (0.028 mmol) of this compound and 17.5 mg (0.06 mmol) of Intermediate 167 were
combined in 2 ml of methanol and admixed with 12.6 mg (0.14 mmol) of borane-pyridine complex
and 2.5 ml of acetic acid. The reaction mixture was stirred at RT ght. Then the same
amounts of borane-pyridine complex and acetic acid were added once again and the reaction
mixture was stirred at RT for a further 24 h. This was ed by concentration under d
pressure, and the e was purified by means of preparative HPLC. After concentration of the
corresponding fractions and lyophilization from 1:1 dioxane/water, 26.5 mg (88% of theory) of the
Z-protected title compound were obtained.
HPLC (Method 12): Rt = 2.04 min;
LC-MS (Method 1): Rt = 0.97 min; MS s): m/z = 1064 (M+H)+.
mg (0.024 mmol) of this intermediate were taken up in 10 ml of methanol and hydrogenated
over 10% palladium on ted carbon under standard hydrogen pressure at RT for 45 min. The
st was then filtered off and the t was removed under reduced pressure. After
lyophilization from e, 19.7 mg (85% of theory) of the title compound were obtained.
HPLC d 12): Rt = 1.8 min;
LC-MS (Method 1): Rt = 0.83 min; MS (ESIpos): m/z = 974 (M+H)+.
Intermediate 169
N-{2-[2-(2-{3-[(2,5-dioxopyrrolidinyl)oxy]oxopropoxy}ethoxy)ethoxy]ethyl}-N-methyl-L-
valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)amino(1H-indolyl)oxopropan
yl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxymethyloxoheptan
yl]-N-methyl-L-valinamide
H C CH H C
3 3 3 CH NH
O O 3
H N
O O O N N O
N O N N
O O
O CH O CH O O
3 3 CH
O H C CH CH 3 NH
3 3 3
mg (10 µmol) of Intermediate 168 were dissolved in 3 ml of DMF and admixed with 3.5 mg (30
mmol) of 1-hydroxypyrrolidine-2,5-dione and then with 2.4 mg (10 µmol) of 1-(3-
dimethylaminopropyl)ethylcarbodiimide hydrochloride and 5 µl of N,N-diisopropylethylamine.
After stirring at RT for 20 h, 8 mg (0.02 mmol) of HATU were added and the reaction mixture was
stirred once again at RT overnight and then concentrated under reduced pressure. The remaining
residue was purified by means of preparative HPLC. After lyophilization from dioxane, 8.6 mg
(64% of theory) of the title compound were obtained.
HPLC (Method 12): Rt = 1.9 min;
LC-MS (Method 11): Rt = 0.81 min; MS (ESIpos): m/z = 1071 (M+H)+.
Intermediate 170
N-(6-aminohexyl)-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxy
methyl{[(2S,3S)(1,2-oxazinanyl)oxophenylbutanyl]amino}
oxopropyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-valinamide
H C CH H3C
3 3 CH
O 3 N
H N
H N N N O
2 N N
O O
CH O CH O O
3 H C
3 CH 3 H C
H C CH 3
3 3 3
This compound was prepared in analogy to Intermediate 101 over 2 stages, proceeding from 26 mg
(0.028 mmol) of Intermediate 15.
Yield: 16.7 mg (63% of theory over 2 stages)
HPLC (Method 12): Rt = 1.9 min;
LC-MS d 1): Rt = 0.81 min; MS (ESIpos): m/z = 914 (M+H)+.
Intermediate 171
N-(6-{[4-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)butanoyl]amino}hexyl)-N-methyl-L-valyl-N-
[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxymethyl{[(2S,3S)(1,2-oxazinan
yl)oxophenylbutanyl]amino}oxopropyl]pyrrolidinyl}methyloxoheptanyl]-N-
methyl-L-valinamide
H C CH H C
3 3 3 CH N
O 3
O H
H H N
N N N O
N N N
O O
O CH O CH O O H C
3 3 3 H C
O H C CH CH 3
3 3 3
6.7 mg (7.3 µmol) of the compound formed from Intermediate 170 and 3 mg (14.7 µmol) of
commercially available 4-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)butanoic acid were taken up in 2
ml of DMF and admixed with 5.6 mg (14.7 µmol) of O-(7-azabenzotriazolyl)-N,N,N',N'-
tetramethyluronium uorophosphate (HATU) and 2 µl of N,N-diisopropylethylamine. The
mixture was stirred at RT for 30 min. The reaction mixture was concentrated and the residue was
purified by means of preparative HPLC. The corresponding fractions were combined, the solvent
was removed under reduced re and then the residue was lyophilized from dioxane. Thus, 4.5
mg (56% of theory) of the title compound were ed.
HPLC (Method 12): Rt = 2.0 min;
LC-MS (Method 1): Rt = 1.12 min; MS (ESIpos): m/z = 1079 (M+H)+.
Intermediate 172
benzyl 2-{2-[2-(2-oxoethoxy)ethoxy]ethoxy}ethyl carbamate
O N O H
O O
O O
The title compound was prepared from commercially ble 2-(2-
aminoethoxy)ethoxy]ethoxy}ethanol under standard ions, by first introducing the Z
protecting group and then oxidizing with sulphur trioxide-pyridine complex.
HPLC (Method 12): Rt = 1.4 min;
LC-MS (Method 11): Rt = 0.65 min; MS (ESIpos): m/z = 326 (M+H)+.
Intermediate 173
benzyl {2-[2-(2-oxoethoxy)ethoxy]ethyl carbamate
O N O
O H
The title compound was prepared analogously to Intermediate 172 from commercially available 2-
[2-(2-aminoethoxy)ethoxy]ethanol under standard conditions, by first introducing the Z ting
group and then oxidizing with sulphur trioxide-pyridine complex.
HPLC d 12): Rt = 1.3 min;
LC-MS (Method 11): Rt = 0.68 min; MS (ESIpos): m/z = 282 (M+H)+.
Intermediate 174
N-(2-{2-[2-(2-aminoethoxy)ethoxy]ethoxy}ethyl)-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy
{(2S)[(1R,2R)methoxymethyl{[(1S,2R)(1,2-oxazinanylcarbonyl)phenyl
2012/075277
cyclopropyl]amino}oxopropyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-
valinamide
H C CH H C CH
3 3 3 3 N
O H
H N
O O N N O
H N O N N
2 O O
CH O CH O O H C
3 3 CH 3
H C CH
3 3 3
47 mg (0.05 mmol) of Intermediate 16 were reductively aminated in analogy to the preparation of
Intermediate 167 with benzyl 2-{2-[2-(2-oxoethoxy)ethoxy]ethoxy}ethyl carbamate in the
presence of borane-pyridine complex. Subsequently, the Z protecting group was removed by
hydrogenolytic means with 5% palladium on charcoal as a catalyst and in ol as a solvent,
and 38 mg (66% of theory over 2 stages) of the title nd were prepared.
HPLC (Method 5): Rt = 1.7 min;
LC-MS (Method 1): Rt = 0.8 min; MS (ESIpos): m/z = 988 (M+H)+.
Intermediate 175
N-[2-(2-{2-[2-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)ethoxy]ethoxy}ethoxy)ethyl]-N-methyl-L-
valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxymethyl{[(1S,2R)(1,2-
oxazinanylcarbonyl)phenylcyclopropyl]amino}oxopropyl]pyrrolidinyl}methyl
oxoheptanyl]-N-methyl-L-valinamide
H C CH H C
3 3 3 CH
3 N
O O H
H N
O O N N O
N O N N
O O
CH O CH O O H C
3 3 3
O H C CH CH
3 3 3
The preparation was effected in y zu Intermediate 166, proceeding from 34 mg (0.03 mmol)
of Intermediate 174.
Yield: 8.3 mg (23% of theory)
HPLC (Method 5): Rt = 1.9 min;
LC-MS (Method 1): Rt = 0.97 min; MS (ESIpos): m/z = 1068 (M+H)+.
Intermediate 176
N-(2-{2-[2-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)ethoxy]ethoxy}ethyl)-N-methyl-L-valyl-N-
[(3R,4S,5S){(2S)[(1R,2R){[(2S)amino(1H-indolyl)oxopropanyl]amino}
methoxymethyloxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-
namide
O H C CH H C CH
3 3 3 3 NH
O H 2
H N
N O N N O
O N N
O O
O CH O CH O O H C
3 3 CH 3
H C CH
3 3 3
The preparation was effected in analogy to Intermediates 174 and 175, commencing with the
reductive amination of Intermediate 16 with ediate 173, subsequent deprotection and
formation of the maleimide.
HPLC (Method 12): Rt = 1.8 min;
LC-MS (Method 11): Rt = 0.8 min; MS (ESIpos): m/z = 981 (M+H)+.
Intermediate 177
N-[2-(2-{2-[2-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)ethoxy]ethoxy}ethoxy)ethyl]-N-methyl-L-
N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)amino(1H-indolyl)oxopropan
yl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxymethyloxoheptan
methyl-L-valinamide
H C CH H C CH
3 3 3 3 NH
O O H
H N
O O N N O
N O N N
O O
CH O CH O O H C
3 3
O H C CH CH 3 NH
3 3 3
The preparation was effected in analogy to Intermediates 174 and 175, commencing with the
reductive amination of Intermediate 16 with Intermediate 172, subsequent deprotection and
formation of the maleimide.
HPLC (Method 12): Rt = 1.9 min;
LC-MS (Method 1): Rt = 0.86 min; MS (ESIpos): m/z = 1025 (M+H)+.
ediate 178
N-{4-[(2,5-dioxopyrrolidinyl)oxy]oxobutyl}-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)
[(1R,2R){[(2S)amino(1H-indolyl)oxopropanyl]amino}methoxymethyl
pyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide
H C CH H C
3 CH
3 NH
3 3 H 2
O O
H N
O N N O
N N N
O O
O CH O CH O O CH
3 3 CH 3
O H C CH
3 3 3
The preparation was effected in y to Intermediates 162, proceeding from 6 mg of
ediate 82.
LC-MS (Method 1): Rt = 0.82 min; MS (ESIpos): m/z = 953 (M+H)+.
Intermediate 179
4-[(1E,3S)aminophenylbutenyl]benzenesulphonic acid trifluoroacetate
x CF3COOH
A mixture of 13.6 mg (0.06 mmol) of palladium(II) acetate, 469 mg (1.46 mmol) of potassium 4-
iodobenzenesulphonate, 300 mg (1.21 mmol) of (S)-tert-butyl 1-phenylbutenyl carbamate,
16.5 mg (0.12 mmol) of phenylurea and 167.6 mg (1.21 mmol) of potassium carbonate in 7.5 ml of
DMF was heated to 160°C in a microwave for 15 min. The crude product was subsequently
purified directly by preparative HPLC. This gave 312 mg of a e of 31% of the BOC-
protected compound and 69% of the free amine.
This mixture was subsequently taken up in 30 ml of dichloromethane, admixed with 1 ml of
trifluoroacetic acid and stirred at RT for 20 h. After concentrating under reduced pressure, the
residue was stirred with diethyl ether, and the itate formed was filtered off with suction and
washed with diethyl ether. This gave 200 mg (62% of theory) of the title nd.
LC-MS (Method 11): Rt = 0.44 min; MS (ESIpos): m/z = 304 (M+H)+.
Intermediate 180
)aminophenylbutyl]benzenesulphonic acid
x CF3COOH
100 mg (0.25 mmol) of 4-[(1E,3S)aminophenylbutenyl]benzenesulphonic acid
trifluoroacetate were suspended in 10 ml of acetic acid and a few drops of DMF and water,
admixed with 70 mg (0.07 mmol) of palladium on charcoal (10%) and hydrogenated at hydrogen
pressure 2.2 bar for 24 h. The solution was filtered and the filtrate purified by prep. HPLC.
29 mg (76% purity, 21% of theory) of t were obtained.
LC-MS (Method 1): Rt = 0.46 min; MS (ESIpos): m/z = 306 (M+H)+.
Intermediate 181
N-(tert-butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)
methoxymethyloxo{[(2S,3E)phenyl(4-sulphophenyl)buten
yl]amino}propyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-valinamide
H C CH H C CH
CH3 O 3 3 O 3 3 H
H C H
3 N
N N
H C O N N
3 O O
CH3 O CH O O CH
3 3
H C CH
3 3 CH
O O
To a solution of 90 mg (0.13 mmol) of N-(tert-butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S)-
1-{(2S)[(1R,2R)carboxymethoxypropyl]pyrrolidinyl}methoxymethyl
oxoheptanyl]-N-methyl-L-valinamide in 4 ml of DMF were added 60 mg (0.16 mmol) of HATU
and 69 µl of (0.39 mmol) Hünig's base. The reaction mixture was stirred at RT for 30 min and then
admixed with 60 mg (0.15 mmol) 60.3 mg (0.13 mmol) of 4-[(1E,3S)aminophenylbuten
zenesulphonic acid trifluoroacetate. After ng overnight, the reaction mixture was
purified by prep. HPLC. This gave 127 mg of a 44:56 mixture of the title compound and of the
already deprotected amine.
LC-MS (Method 1): Rt = 1.21 min; MS (ESIpos): m/z = 971 (M+H)+; R t = 0.84 min; MS
(ESIpos): m/z = 871 (M+H)+ for the deprotected compound.
Intermediate 182
N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxymethyloxo
{[(2S,3E)phenyl(4-sulphophenyl)butenyl]amino}propyl]pyrrolidinyl}methyl
oxoheptanyl]-N-methyl-L-valinamide trifluoroacetate
H3C CH H C
3 O 3 CH
3 H
H N
N N
HN N
O O
CH O CH3 O O CH
3 H C CH
3 3 CH
CF3COOH x
O O
OH
90 mg of Intermediate 180 were dissolved in 4.6 ml of dichloromethane, and 0.92 ml of
oroacetic acid was added. The reaction mixture was stirred at RT for 30 min and then
concentrated. The crude t obtained was purified by prep. HPLC.
91 mg (98% of theory) of the target nd were obtained.
LC-MS (Method 1): Rt = 0.85 min; MS (ESIpos): m/z = 871 (M+H)+
Intermediate 183
N-(3-carboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxy-
2-methyloxo{[(2S,3E)phenyl(4-sulphophenyl)butenyl]amino}propyl]pyrrolidin
yl}methyloxoheptanyl]-N-methyl-L-valinamide
H C CH3 H3C
3 CH
O 3 H
H N
HO N N
N N
O O
O CH O CH O O CH
3 C CH3 3 3
H3 CH
O O
OH
16.7 µl (0.03 mmol) of a 15% aqueous succinaldehyde solution were initially charged in 943 µl of
methanol and admixed with 17 mg (0.02 mmol) of N-methyl-L-valyl-N-[(3R,4S,5S)methoxy
{(2S)[(1R,2R)methoxymethyloxo{[(2S,3E)phenyl(4-sulphophenyl)buten
yl]amino}propyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-valinamide
trifluoroacetate (Intermediate 181) and 1.1 µl (0.02 mmol) of acetic acid. The reaction mixture was
stirred for 5 min at RT and then 2.9 µl (0.02 mmol) of borane-pyridine complex were added. After
1 h, a further 2 lents each of succinaldehyde, acetic acid and borane-pyridine x were
added and the mixture was stirred at RT for 20 h. The reaction mixture was then purified by prep.
HPLC.
This gave 20 mg (83% , 80% of ) of the title compound.
LC-MS (Method 1): Rt = 0.87 min; MS (ESIpos): m/z = 957 (M+H)+
Intermediate 184
N-(4-{2-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexanoyl]hydrazino}oxobutyl)-N-methyl-L-
valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxymethyloxo{[(2S,3E)
phenyl(4-sulphophenyl)butenyl]amino}propyl]pyrrolidinyl}methyloxoheptan
yl]-N-methyl-L-valinamide
O H C CH H C CH
O 3 3 O 3 3 H
H H N
N N N N
N N N
H O O
O O CH O CH O O CH
3 3
H C CH 3
3 3 CH
O O
8 mg (7.5 µmol) of N-(3-carboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)
[(1R,2R)methoxymethyloxo{[(2S,3E)phenyl(4-sulphophenyl)buten
yl]amino}propyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-valinamide, 2.8 mg (8.2
µmol) of 6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexanehydrazide trifluoroacetate, 3.4 mg (9
µmol) of HATU and 3.9 µl of s base were stirred in 0.77 ml of DMF at RT for 20 h.
Subsequently, the reaction mixture was purified by prep. HPLC.
3 mg (31% of theory) of the title compound were obtained.
LC-MS (Method 1): Rt = 0.90 min; MS (ESIpos): m/z = 1164 (M+H)+
ediate 185
N-{4-[(2,5-dioxopyrrolidinyl)oxy]oxobutyl}-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy
{(2S)[(1R,2R)methoxymethyloxo{[(2S,3E)phenyl(4-sulphophenyl)buten
yl]amino}propyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-valinamide
O H C CH H C
3 3 CH
O 3 3 H
H N
N O N
N N
O O
O CH O CH O O CH
O 3 H C CH 3 3
3 3 CH
O O
To a solution of 8 mg (7.5 µmol) of N-(3-carboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S)
methoxy{(2S)[(1R,2R)methoxymethyloxo{[(2S,3E)phenyl(4-
phenyl)butenyl]amino}propyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-
L-valinamide in 2 ml of DMF were added 8.6 mg (74.8 µmol) of N-hydroxysuccinimide, 8.5 mg
(22.4 µmol) of EDCI and 0.1 mg (0.75 µmol) of DMAP. The reaction mixture was stirred at RT
for 20 h. Subsequently, 1.3 µl (7.5 µmol) of Hünig's base were added and the mixture was stirred
for 1 h. The reaction e was then purified by prep. HPLC. 2.6 mg (72% purity, 21% of
theory) of the title compound were obtained.
LC-MS (Method 1): Rt = 0.89 min; MS (ESIpos): m/z = 1054 (M+H)+
Intermediate 186
N-(tert-butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)
methoxymethyloxo{[(2R)phenyl(4-sulphophenyl)butan
yl]amino}propyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-valinamide
H C CH H C
O 3 3 CH
CH O 3 3
H C 3 H
3 N
N N
H C O N N
3 O O
CH O CH O CH
3 O 3
3 H C CH
3 3 CH
O O
To a solution of 43 mg (0.06 mmol) of N-(tert-butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S)-
1-{(2S)[(1R,2R)carboxymethoxypropyl]pyrrolidinyl}methoxymethyl
oxoheptanyl]-N-methyl-L-valinamide in 1.9 ml of DMF were added 29 mg (0.07 mmol) of
HATU and 33 µl (0.19 mmol) of Hünig's base. The reaction mixture was stirred at RT for 30 min
and then admixed with 29 mg (0.07 mmol) of 4-[(3R)aminophenylbutyl]benzenesulphonic
acid oroacetate. After stirring overnight, the reaction e was purified by prep. HPLC.
This gave 58 mg of a 45:55 mixture of the title compound and of the already ected amine.
LC-MS (Method 1): Rt = 1.09 min; MS (ESIpos): m/z = 973 (M+H)+; R t = 0.87 min; MS
s): m/z = 873 (M+H)+ for the deprotected compound.
Intermediate 187
N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxymethyloxo
{[(2R)phenyl(4-sulphophenyl)butanyl]amino}propyl]pyrrolidinyl}methyl
oxoheptanyl]-N-methyl-L-valinamide trifluoroacetate
H C CH H C
3 3 3 CH
O 3 H
H N
N N
CF3COOH x HN N
O O
CH O CH
3 O O CH
3 H C CH
3 3 CH
O O
58 mg of Intermediate 186 were dissolved in 4.1 ml of dichloromethane, 0.41 ml of trifluoroacetic
acid was added and the mixture was stirred at RT for 30 min. After concentration under reduced
pressure, the crude product was purified by prep. HPLC.
50 mg (90% purity, 85% of theory) of the title compound were ed.
LC-MS (Method 1): Rt = 0.87 min; MS (ESIpos): m/z = 873 (M+H)+
Intermediate 188
N-(3-carboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxy-
2-methyloxo{[(2R)phenyl(4-sulphophenyl)butanyl]amino}propyl]pyrrolidinyl}
methyloxoheptanyl]-N-methyl-L-valinamide
H C CH H C
3 3 3 CH
O 3 H
H N
HO N N
N N
O O
O CH O CH O O CH
3 3
3 H C CH
3 3 CH
O O
171 µl (0.26 mmol) of a 15% aqueous succinaldehyde solution were initially charged in 2.5 ml of
methanol and admixed with 50 mg (0.05 mmol) of N-methyl-L-valyl-N-[(3R,4S,5S)methoxy
{(2S)[(1R,2R)methoxymethyloxo{[(2R)phenyl(4-sulphophenyl)butan
yl]amino}propyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-valinamide
oroacetate and 11.6 µl (0.2 mmol) of acetic acid. The on mixture was stirred for 5 min at
RT and then 30 µl (0.24 mmol) of borane-pyridine complex were added. After stirring for 24
hours, a further equivalent of borane-pyridine complex was added and the mixture was stirred for a
further 2 h. The on mixture was then purified by prep. HPLC.
40 mg (90% purity, 66% of theory) of the title compound were obtained.
LC-MS (Method 1): Rt = 0.91 min; MS (ESIpos): m/z = 959 (M+H)+
Intermediate 189
2-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexanoyl]hydrazino}oxobutyl)-N-methyl-L-
valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxymethyloxo{[(2R)
phenyl(4-sulphophenyl)butanyl]amino}propyl]pyrrolidinyl}methyloxoheptanyl]-
N-methyl-L-valinamide
O H C CH3 H C
O 3 3 CH3
O H
H H N
N N N N
N N N
H O O
O O CH O CH O O CH
3 H3C CH 3
3 CH
O O
mg (9.3 µmol) of N-(3-carboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)
[(1R,2R)methoxymethyloxo{[(2R)phenyl(4-sulphophenyl)butan
no}propyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-valinamide, 3.5 mg
(10.3 µmol) of 6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexanehydrazide trifluoroacetate, 4.3 mg
(11.2 µmol) of HATU and 4.9 µl (28 µmol) of Hünig's base were stirred in 1 ml of DMF at RT for
h. Subsequently, the on mixture was purified by prep. HPLC.
4.2 mg (92% purity, 33% of theory) of the title compound were obtained.
LC-MS (Method 1): Rt = 0.91 min; MS (ESIpos): m/z = 1166 (M+H)+
Intermediate 190
N-{4-[(2,5-dioxopyrrolidinyl)oxy]oxobutyl}-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy
{(2S)[(1R,2R)methoxymethyloxo{[(2R)phenyl(4-sulphophenyl)butan
yl]amino}propyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-valinamide
H C CH H C
3 3 CH
O 3 H
H N
O N N
N N N
O O
O CH O CH O O CH
O H C CH 3
3 3 CH
O O
To a solution of 10 mg (9.3 µmol) of N-(3-carboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S)
methoxy{(2S)[(1R,2R)methoxymethyloxo{[(2R)phenyl(4-
sulphophenyl)butanyl]amino}propyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-
valinamide in 2.5 ml of DMF were added 10.7 mg (93 µmol) of N-hydroxysuccinimide, 10.6 mg
(28 µmol) of EDCI and 0.12 mg (0.9 µmol) of DMAP. The reaction mixture was stirred at RT for
h and then purified by prep. HPLC.
3.8 mg (72% purity, 25% of theory) of the title compound were obtained.
LC-MS (Method 1): Rt = 0.90 min; MS (ESIpos): m/z = 1055 (M+H)+
Intermediate 191
(2R,3R)-N-[(2S)(1H-indolyl)(1,2-oxazinanyl)oxopropanyl]methoxymethyl-
3-[(2S)-pyrrolidinyl]propanamide oroacetate
CH N
3 H
CF3COOH x N O
O O
The title compound was prepared in analogy to the synthesis of Intermediate 7 over two stages
from Starting nd 1 and -amino(1H-indolyl)(1,2-oxazinanyl)propanone
trifluoroacetate (Intermediate 99).
Yield over 2 stages: 62 mg (67% of theory)
WO 87716
HPLC d 6): Rt = 1.65 min;
LC-MS (Method 1): Rt = 0.7 min; MS (ESIpos): m/z = 443 (M+H)+.
Intermediate 192
N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)(1H-indolyl)(1,2-oxazinan-
2-yl)oxopropanyl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxy
methyloxoheptanyl]-N-methyl-L-valinamide
H C CH H C CH
3 3
O 3 N
3 H
H N
N N O
HN N
O O
CH O CH O O H C
3 3
H C CH CH 3
3 3 3
1015 mg (1.59 mmol) of N-[(9H-fluorenylmethoxy)carbonyl]-N-methyl-L-valyl-N-[(2R,3S,4S)-
oxymethoxymethylhexanyl]-N-methyl-L-valinamide mediate 4) were taken up
in 50 ml of DMF, admixed with 654 mg (2.39 mmol) of 2-bromoethylpyridinium
tetrafluoroborate (BEP) and 2.8 ml of N,N-diisopropylethylamine, and stirred at RT for 10 min.
Then 1083 mg (1.75 mmol) of (2R,3R)-N-[(2S)(1H-indolyl)(1,2-oxazinanyl)
oxopropanyl]methoxymethyl[(2S)-pyrrolidinyl]propanamide trifluoroacetate
(Intermediate 191) were added and then the mixture was treated in an ultrasound bath at RT for 30
min. The reaction mixture was then concentrated under reduced pressure and the e was taken
up in 300 ml of ethyl acetate. The organic phase was washed successively with 5% s citric
acid solution and 5% aqueous sodium hydrogencarbonate solution, dried over magnesium
sulphate, filtered and concentrated. The crude product thus obtained (1684 mg), without further
purification, was taken up in 20 ml of acetonitrile, 2 ml of piperidine were added and the reaction
mixture was then stirred at RT for 10 min. Then the mixture was concentrated under reduced
pressure and the residue was admixed with diethyl ether. The solvent was concentrated by
evaporation again and the residue was purified by flash chromatography on silica gel (eluent:
:1:0.1 -> 15:2:0.2 dichloromethane/methanol/17% a queous ammonia solution). The
corresponding ons were combined, the solvent was d under reduced pressure and the
residue was lyophilized from acetonitrile/water. Thus, 895 mg (67% over 2 stages) of the title
compound were obtained.
HPLC (Method 12): Rt = 1.8 min;
LC-MS (Method 1): Rt = 0.84 min; MS (ESIpos): m/z = 840 .
1H NMR (500 MHz, DMSO-d
6): δ = 10.8 (d, 1H), 8.3 and 8.05 (2d, 1H), 8.0 (d, 1H), 7.5 (m, 1H),
7.3 (m, 1H), 7.15 and 7.08 (2s, 1H) 7.05-6.9 (m, 2H), 5.12 and 4.95 (2m, 1H), 4.65 (m, 1H), 4.55
(m, 1H), 4.1-3.8 (m, 4H), 3.75 (d, 1H), 3.23, 3.18, 3.17, 3.12, 2.95 and 2.88 (6s, 9H), 3.1-3.0 and
2.85 (2m, 2H), 2.65 (d, 1H), 2.4-2.2 (m, 3H), 2.15 (m, 3H), 1.95 (br. m, 2H), 1.85-0.8 (br. m, 11H),
1.08 and 1.04 (2d, 3H), 0.9-0.75 (m, 15H), 0.75-0.65 (dd, 3H) [further signals hidden under H2O
peak].
Intermediate 193
N-(3-carboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)(1H-indol
yl)(1,2-oxazinanyl)oxopropanyl]amino}methoxymethyloxopropyl]pyrrolidin-
1-yl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide
H C CH H C CH
3 3 O 3 3 N
H N
HO N N O
N N
O O
O CH O CH O O H C
3 3 3
H C CH CH
3 3 3
50 mg (0.052 mmol) of N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)(1H-
indolyl)(1,2-oxazinanyl)oxopropanyl]amino}methoxymethyl
oxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide
(Intermediate 192) and 204 µl einer of a 15% aqueous on of 4-oxobutanoic acid were
combined in 2 ml of methanol and admixed with 23.4 mg (0.252 mmol) of borane-pyridine
complex and 6 µl of acetic acid. The on mixture was stirred at RT overnight. This was
followed by concentration under reduced re, and the residue was purified by means of
preparative HPLC. After concentration of the corresponding fractions, 38 mg (78% of theory) of
the title compound were obtained.
HPLC (Method 5): Rt = 1.7 min;
LC-MS (Method 9): Rt = 4.7 min; MS (ESIpos): m/z = 926 (M+H)+.
Intermediate 194
N-(4-{2-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexanoyl]hydrazino}oxobutyl)-N-methyl-L-
valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)(1H-indolyl)(1,2-oxazinanyl)
oxopropanyl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxymethyl
oxoheptanyl]-N-methyl-L-valinamide
O O
H C CH H C
3 3 3 CH3 N
O O H
N H H N
N N N O
N N N
O H O O
O CH O CH3 O O
3 H C
H3C CH CH 3
3 3 HN
This compound was prepared in analogy to the synthesis described in Intermediate 157 from 10 mg
(11 µmol) of N-(3-carboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)-
3-(1H-indolyl)(1,2-oxazinanyl)oxopropanyl]amino}methoxymethyl
oxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide and
commercially available 6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexanehydrazide.
Yield: 4.4 mg (35% of theory)
HPLC (Method 5): Rt = 1.8 min;
LC-MS (Method 1): Rt = 0.90 min; MS (ESIpos): m/z = 1133 .
ediate 195
2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexyl]-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy
{(2S)[(1R,2R)methoxymethyl{[(2S,3S)(1,2-oxazinanyl)oxophenylbutan
yl]amino}oxopropyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-valinamide
O H C CH H C
3 3 3 CH N
O 3 H
H N
N N N O
N N
O O
O CH O CH O O
3 H C
3 H C
H C CH CH3 3
3 3
This compound was prepared in analogy to Intermediate 166, proceeding from 9 mg (0.010 mmol)
of Intermediate 170.
Yield: 1.1 mg (10% of theory)
HPLC (Method 12): Rt = 2.0 min;
2012/075277
LC-MS (Method 1): Rt = 0.99 min; MS (ESIpos): m/z = 994 (M+H)+.
Intermediate 196
-amino(2-oxaazabicyclo[2.2.2]octenyl)phenylpropanone trifluoroacetate
CF3COOH x H N
2 O
41 mg (0.37 mmol) of 2,5-dioxopyrrolidinyl N-(tert-butoxycarbonyl)-L-phenylalaninate were
taken up in 10 ml of DMF and admixed with 149 mg (0.41 mmol) of 2-oxaazabicyclo[2.2.2]oct-
-ene (Starting Compound 6) and 72 µl (0.41 mmol) of N,N-diisopropylethylamine. The mixture
was stirred at RT for 1 h. The solvent was removed under reduced pressure, and the residue was
taken up in ethyl acetate and extracted by shaking with 5% aqueous citric acid solution and then
with 5% aqueous sodium hydrogencarbonate solution. The organic phase was concentrated and the
residue was ed by flash chromatography on silica gel with 10:1 toluene/ethanol as the eluent.
The corresponding fractions were ed and the solvent was removed under reduced pressure.
After the residue had been dried under high vacuum, 69 mg (47% of theory) of the Boc-protected
intermediate tert-butyl (2S)(2-oxaazabicyclo[2.2.2]octenyl)oxophenylpropanyl
carbamate were thus obtained as a reomer mixture.
LC-MS (Method 1): Rt = 1.1 min; MS s): m/z = 359 (M+H)+.
64 mg (0.18 mmol) of this intermediate were taken up in 10 ml of dichloromethane, 1 ml of
trifluoroacetic acid was added, and the mixture was stirred at RT for 30 min. This was followed by
concentration under reduced pressure and lyophilization of the remaining residue from
water/dioxane. In this way, 66 mg (quant.) of the title compound were obtained as a foam.
HPLC (Method 6): Rt = 1.45 min;
LC-MS (Method 3): Rt = 1.12 min; MS (ESIpos): m/z = 259 (M+H)+.
ediate 197
(2R,3R)methoxymethyl-N-[(2S)(2-oxaazabicyclo[2.2.2]octenyl)oxo
phenylpropanyl][(2S)-pyrrolidinyl]propanamide trifluoroacetate
CH N
CF3COOH x N
N O
O O
First, (2R,3R)[(2S)(tert-butoxycarbonyl)pyrrolidinyl]methoxymethylpropanoic acid
(Starting Compound 1) was released from 83 mg (0.18 mmol) of its dicyclohexylamine salt by
taking it up in ethyl acetate and extractive shaking with 5% aqueous potassium hydrogensulphate
solution. The organic phase was dried over magnesium sulphate, filtered and trated. The
e was taken up in 10 ml of DMF and d successively with 66 mg (0.18 mmol) of (2S)-
2-amino(2-oxaazabicyclo[2.2.2]octenyl)phenylpropanone trifluoroacetate
(Intermediate 196), 101 mg (0.266 mmol) of O-(7-azabenzotriazolyl)-N,N,N',N'-
tetramethyluronium hexafluorophosphate (HATU) and 93 µl (0.53 mmol) of N,N-
diisopropylethylamine. The mixture was stirred at RT for 30 min. The reaction mixture was then
trated and the residue was purified by preparative HPLC. This gave 52 mg (56% of theory)
of the Boc-protected intermediate tert-butyl (2S)[(1R,2R)methoxymethyl{[(2S)(2-
oxaazabicyclo[2.2.2]octenyl)oxophenylpropanyl]amino}
oxopropyl]pyrrolidinecarboxylate.
HPLC (Method 6): Rt = 2.13 min;
LC-MS d 1): Rt = 1.13 min; MS (ESIpos): m/z = 528 (M+H)+.
52 mg (0.1 mmol) of this intermediate were taken up in 10 ml of dichloromethane, 1 ml of
trifluoroacetic acid was added, and the mixture was stirred at RT for 20 min. This was followed by
concentration under reduced pressure and stirring of the ing residue with 20 ml of diethyl
ether. After 10 min, the mixture was filtered and the filter residue was dried under high vacuum. In
this way, 39 mg (72% of theory) of the title compound were obtained.
HPLC (Method 6): Rt = 1.62 min;
LC-MS (Method 1): Rt = 0.68 min; MS (ESIpos): m/z = 428 (M+H)+.
Intermediate 198
N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxymethyl{[(2S)(2-
oxaazabicyclo[2.2.2]octenyl)oxophenylpropanyl]amino}oxopropyl]pyrrolidin-
1-yl}methyloxoheptanyl]-N-methyl-L-valinamide trifluoroacetate
3 O
3 CH H C
3 3 CH N
O 3
H N
N N O
HN N
O O
3 O CH O
H3C 3 O CH
CH CH 3
3 3
x CF3COOH
44.5 mg (0.071 mmol) of N-[(9H-fluorenylmethoxy)carbonyl]-N-methyl-L-valyl-N-[(2R,3S,4S)-
1-carboxymethoxymethylhexanyl]-N-methyl-L-valinamide mediate 4) were taken up
in 10 ml of DMF and admixed successively with 38.6 mg (0.071 mmol) of (2R,3R)methoxy
methyl-N-[(2S)(2-oxaazabicyclo[2.2.2]octenyl)oxophenylpropanyl][(2S)-
pyrrolidinyl]propanamide trifluoroacetate (Intermediate 197), 32.5 mg (0.086 mmol) of O-(7-
azabenzotriazolyl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU) and 41 µl
(0.235 mmol) of isopropylethylamine. The mixture was stirred at RT for 1 h. The reaction
mixture was then concentrated under reduced pressure and the residue was taken up in ethyl
acetate. The organic phase was washed successively with 5% s citric acid solution and 5%
aqueous sodium hydrogencarbonate solution, dried over magnesium sulphate, filtered and
concentrated. This gave 73 mg (98% of theory) of the Fmoc-protected intermediate N-[(9H-
nylmethoxy)carbonyl]-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)
methoxymethyl{[(2S)(2-oxaazabicyclo[2.2.2]octenyl)oxophenylpropan
yl]amino}oxopropyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-valinamide.
HPLC (Method 6): Rt = 2.78 min;
LC-MS (Method 3): Rt = 2.96 min; MS (ESIpos): m/z = 1047 (M+H)+.
73 mg (0.071 mmol) of this intermediate were dissolved in 5 ml of DMF. After 0.5 ml of
piperidine had been added, the reaction mixture was d at RT for 10 min. This was followed
by concentration under reduced pressure, and the residue was digested edly with diethyl
ether. After the diethyl ether had been decanted off, the residue was purified by preparative HPLC
(eluent: acetonitrile / 0.1% aq. TFA). 16 mg (26% of theory) of the title compound were obtained
as a foam.
HPLC (Method 6): Rt = 1.94 min;
LC-MS (Method 3): Rt = 1.71 min; MS (ESIpos): m/z = 825 (M+H)+
1H NMR (400 MHz, DMSO-d6): δ = 8.9-8.6 (m, 3H), 8.4, 8.3, 8.1 and 8.0 (4d, 1H), 7.3-7.1 (m,
5H), 6.7-6.5 (m, 2H), 5.2-4.8 (m, 3H), 4.75-4.55 (m, 3H), 4.05-3.95 (m, 1H), 3.7-3.4 (m, 4H), 3.22,
3.17, 3.15, 3.05, 3.02 and 2.95 (6s, 9H), 3.0 and 2.7 (2 br. m, 2H), 2.46 (m, 3H), 2.4-1.2 (br. m,
13H), 1.1-0.85 (m, 18H), 0.75 (m, 3H) [further s hidden under H2O peak].
Intermediate 199
N-(4-{2-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexanoyl]hydrazino}oxobutyl)-N-methyl-L-
valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxymethyl{[(2S)(2-oxa
azabicyclo[2.2.2]octenyl)oxophenylpropanyl]amino}oxopropyl]pyrrolidinyl}-
-methyloxoheptanyl]-N-methyl-L-valinamide
3 O
O H C
3 CH H C
3 3 CH N
O O 3
H H
N N N
N N
N O
N N
O O O
O CH
3 O CH
3 O O CH
H C CH CH 3
3 3 3
The title compound was prepared in analogy to Intermediates 193 and 194, proceeding from 23 mg
(24 µmol) of N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxy
methyl{[(2S)(2-oxaazabicyclo[2.2.2]octenyl)oxophenylpropanyl]amino}
pyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-valinamide oroacetate
(Intermediate 198).
HPLC (Method 12): Rt = 1.9 min;
LC-MS (Method 2): Rt = 2.1 min; MS (ESIpos): m/z = 1118 (M+H)+.
Intermediate 200
N-[2-(2-{2-[2-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)ethoxy]ethoxy}ethoxy)ethyl]-N-methyl-L-
valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)(1H-indolyl)(1,2-oxazinanyl)
oxopropanyl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxymethyl
oxoheptanyl]-N-methyl-L-valinamide
H C CH H C CH
3 3 3 3 N
O O H
H N
O O N N O
N O N N
O O
CH O CH O O H C
3 3 CH 3
O H C CH
3 3 3
The preparation was effected in analogy to Intermediates 174 and 175, commencing with the
ive alkylation of Intermediate 192 with Intermediate 172, subsequent deprotection and
formation of the maleimide.
HPLC (Method 12): Rt = 1.9 min;
LC-MS (Method 1): Rt = 0.86 min; MS (ESIpos): m/z = 1025 (M+H)+.
ediate 201
N-{6-[(bromoacetyl)amino]hexyl}-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)-
3-(1H-indolyl)(1,2-oxazinanyl)oxopropanyl]amino}methoxymethyl
pyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide
H C CH H C CH
3 3 3 3 N
O H
H H N
N N N O
Br N N
O O
O CH O CH O O H C
3 3
C CH 3
H CH
3 3 3
22 mg (0.023 mmol) of N-(6-aminohexyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R)
{[(2S)(1H-indolyl)(1,2-oxazinanyl)oxopropanyl]amino}methoxymethyl
oxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide
(Intermediate 101) were dissolved in 9.5 ml of THF and admixed at 0°C with 4.2 µl of
triethylamine. A solution of bromoacetyl chloride in THF was added dropwise and the on
mixture was stirred at 0°C for 30 min. The reaction mixture was concentrated and the residue was
purified by preparative HPLC. Thus, 6.9 mg (26% of theory) of the title compound were obtained
as a foam.
HPLC (Method 5): Rt = 1.8 min;
LC-MS (Method 11): Rt = 0.9 min; MS (ESIpos): m/z = 1059 and 1061 (M+H)+.
Intermediate 202
2-(2-{3-[(2,5-dioxopyrrolidinyl)oxy]oxopropoxy}ethoxy)ethoxy]ethyl}-N-methyl-L-
valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)(1H-indolyl)(1,2-oxazinanyl)
oxopropanyl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxymethyl
oxoheptanyl]-N-methyl-L-valinamide
H C CH H C
3 3 3 CH
3 N
O O H
H N
O O O N N O
N O N N
O O
O CH O CH O O
3 3 CH
O H C CH CH 3
3 3 3
The preparation was at first effected in analogy to Intermediate 168, commencing with the
reductive tion of Intermediate 192 with ediate 167 and subsequent hydrogenolytic
cleavage of the benzyl ester of N-(2-{2-[2-(2-carboxyethoxy)ethoxy]ethoxy}ethyl)-N-methyl-L-
valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)(1H-indolyl)(1,2-oxazinanyl)
oxopropanyl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxymethyl
tanyl]-N-methyl-L-valinamide.
13 mg (10 µmol) of this intermediate were ved in 5 ml of DMF and admixed with 2.1 mg (20
mmol) of 1-hydroxypyrrolidine-2,5-dione, 6.5 µl of N,N-diisopropylethylamine and 7.1 mg (0.02
mmol) of HATU. The reaction mixture was stirred at RT overnight and then concentrated under
reduced pressure. The remaining residue was purified by means of preparative HPLC. After
lyophilization from acetonitrile/water, 9.2 mg (62% of theory) of the title compound were
obtained.
HPLC (Method 12): Rt = 2.0 min;
LC-MS (Method 2): Rt = 2.1 min; MS (ESIpos): m/z = 1141 (M+H)+.
Intermediate 203
tert-butyl 6-hydrazinooxohexyl carbamate
3 H
O N NH
H C N 2
3 H
CH O
This compound was prepared by rd peptide chemistry methods, by coupling of 6-[(tertbutoxycarbonyl
)amino]hexanoic acid with benzyl hydrazinecarboxylate in the presence of EDCI
and HOBT, and subsequent hydrogenolytic cleavage of the oxycarbonyl protecting group.
LC-MS (Method 11): Rt = 0.59 min; MS (ESIpos): m/z = 246 (M+H)+.
Intermediate 204
N-{4-[2-(6-aminohexanoyl)hydrazino]oxobutyl}-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)
[(1R,2R){[(2S)amino(1H-indolyl)oxopropanyl]amino}methoxymethyl
oxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide
trifluoroacetate
H3C CH H C
3 3 CH
3 NH
O O H 2
H H N
H N N N N
2 O
N N N
H O O
x CF3COOH O CH3 O CH3 O O CH
H3C CH CH 3
3 3
146 mg (50 µmol) of (N-(3-carboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R)-
3-{[(2S)amino(1H-indolyl)oxopropanyl]amino}methoxymethyl
pyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide were
ved in 5 ml of DMF and then admixed with 30.6 mg (80 µmol) of O-(7-azabenzotriazol
yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate, 19 µl of N,N-diisopropylethylamine and
with 22.4 mg (60 µmol) of tert-butyl 6-hydrazinooxohexyl carbamate. The reaction mixture was
d at RT for 1.5 h. This was followed by concentration under high vacuum and purification of
the remaining residue by means of ative HPLC. Thus, 43 mg (68% of theory) of the
protected intermediate were obtained, which were then taken up in 10 ml of dichloromethane and
ected with 1 ml of trifluoroacetic acid. The reaction mixture was concentrated and the
residue was stirred with dichloromethane, and the solvent was removed again under reduced
pressure. Thus, 45 mg (68% of theory over 2 stages) of the title compound were obtained.
HPLC (Method 12): Rt = 1.6 min;
LC-MS (Method 11): Rt = 0.66 min; MS (ESIpos): m/z = 983 (M+H)+.
Intermediate 205
N-(4-{2-[6-({[2-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)ethyl]carbamoyl}amino)hexanoyl]
hydrazino}oxobutyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)amino
(1H-indolyl)oxopropanyl]amino}methoxymethyloxopropyl]pyrrolidinyl}
methoxymethyloxoheptanyl]-N-methyl-L-valinamide
H C CH H C
3 3 3 CH
3 NH
O O O H 2
H H H H N
N N N N N O
N N N N
H O O
O O CH O CH O O
3 3 CH
H C CH CH 3
O 3 3 3
This compound was ed in analogy to Intermediate 114, proceeding from Intermediates 50
and 204.
Yield: 4 mg (78% of )
HPLC (Method 12): Rt = 1.7 min;
LC-MS d 11): Rt = 0.73 min; MS (ESIpos): m/z = 1149 (M+H)+.
Intermediate 206
N-(6-{[3-({3-[(2,5-dioxopyrrolidinyl)oxy]oxopropyl}disulphanyl)propanoyl]amino}hexyl)-
N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)(1H-indolyl)(1,2-oxazinan-
2-yl)oxopropanyl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxy
methyloxoheptanyl]-N-methyl-L-valinamide
O H C CH H C
3 CH3 N
O 3 3 O H
H H N
N S N N N O
O S N N
O O
O O CH3 O CH O O H C
C CH CH 3
3 3 3
8 mg (10 µmol) of Intermediate 101 were dissolved in 2 ml of DMF and admixed with 8.6 mg (20
µmol) of 1,1'-{disulphanediylbis[(1-oxopropane-3,1-diyl)oxy]}dipyrrolidine-2,5-dione and 3.7 µl
of N,N-diisopropylethylamine. The on mixture was stirred at RT for 2 h and then the solvent
was evaporated off under reduced pressure and the residue was purified by preparative HPLC. 7.2
mg (68% of theory) of the title compound were obtained.
HPLC (Method 5): Rt = 1.9 min;
LC-MS (Method 11): Rt = 0.94 min; MS (ESIpos): m/z = 615 [½ (M+2H+]
Intermediate 207
(1S,2R)aminophenylcyclopropanecarboxylic acid trifluoroacetate
CF3COOH x O
The title compound was obtained in quantitative yield by ecting 210 mg (0.76 mmol) of
commercially available (1S,2R)[(tert-butoxycarbonyl)amino]phenylcyclopropanecarboxylic
acid with trifluoroacetic acid.
LC-MS (Method 1): Rt = 0.23 min; MS (ESIpos): m/z = 178 .
Intermediate 208
9H-fluorenylmethyl 6-oxohexyl carbamate
O NH
The title compound was prepared from 1 g (2.95 mmol) of commercially available oren
ylmethyl 6-hydroxyhexyl carbamate under standard conditions, by oxidation with sulphur trioxide-
pyridine complex. 840 mg (85% of theory) of the title compound were obtained.
HPLC (Method 12): Rt = 2.0 min;
LC-MS (Method 1): Rt = 1.1 min; MS s): m/z = 338 (M+H)+.
2012/075277
Intermediate 209
N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexyl]-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)
[(1R,2R){[(1S,2R)carboxyphenylcyclopropyl]amino}methoxymethyl
oxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide
O H C CH H C
3 CH
3 3 OH
O 3 H
H N
N N N O
N N
O O
O CH O CH O O H C
3 3
H C CH CH 3
3 3 3
First, in analogy to the synthesis described in Intermediate 75, by coupling of tbutoxycarbonyl
)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R)carboxy
methoxypropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide
(Intermediate 26) and (1S,2R)aminophenylcyclopropanecarboxylic acid trifluoroacetate
(Intermediate 207) in the presence of O-(7-azabenzotriazolyl)-N,N,N',N'-tetramethyluronium
hexafluorophosphate and subsequent detachment of the Boc protecting group by means of
trifluoroacetic acid, the amine compound N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R)
{[(1S,2R)carboxyphenylcyclopropyl]amino}methoxymethyloxopropyl]pyrrolidin
yl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide was prepared as the
trifluoroacetate.
To 22 mg (0.026 mmol) of this compound in 10 ml of methanol were then added 17 mg (0.05
mmol) of 9H-fluorenylmethyl 6-oxohexyl carbamate (Intermediate 208) and 2.3 mg of acetic
acid, and also 11.4 mg (0.12 mmol) of borane-pyridine complex. The reaction mixture was stirred
at RT overnight. Then the same amounts of borane-pyridine complex and acetic acid, and also 8
mg of fluorenylmethyl 6-oxohexyl carbamate, were added once again and the reaction mixture
was stirred at RT for a r 24 h. This was followed by tration under reduced pressure,
and the residue was purified by means of preparative HPLC. After concentration of the
corresponding fractions, the product was used immediately in the next stage.
33 mg of the still contaminated intermediate were taken up in 5 ml of DMF, and 1 ml of piperidine
was added. After stirring at RT for 15 min, the reaction mixture was concentrated and the resulting
e was purified by preparative HPLC. Thus, 11 mg (55% of theory over 2 stages) of the
aminocarboxylic acid intermediate were ed.
HPLC (Method 12): Rt = 1.7 min;
LC-MS (Method 11): Rt = 0.7 min; MS (ESIpos): m/z = 843 .
6 mg (7.12 µmol) of this intermediate were taken up in 1 ml of dioxane and then admixed with 6.6
mg (42.7 µmol) of methyl 2,5-dioxo-2,5-dihydro-1H-pyrrolecarboxylate and with 5 µl of
saturated aqueous sodium hydrogencarbonate solution. The reaction mixture was stirred at RT for
1 h. Then another 3 portions each of 50 µl of the saturated aqueous sodium hydrogencarbonate
solution were added and the reaction mixture was stirred at RT for a further 30 min. Then the
reaction e was acidified to pH 2 with trifluoroacetic acid and subsequently trated
under reduced pressure. The ing residue was purified by means of preparative HPLC. After
lyophilization from acetonitrile/water, 4 mg (60% of theory) of the title compound were obtained
as a foam.
HPLC (Method 12): Rt = 1.9 min;
LC-MS (Method 11): Rt = 0.88 min; MS (ESIpos): m/z = 923 .
Intermediate 210
(2,5-dioxopyrrolidinyl)oxy]oxohexyl}-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)
[(1R,2R){[(2S)(1H-indolyl)(1,2-oxazinanyl)oxopropanyl]amino}methoxy
methyloxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-
valinamide
H C CH H C
3 3 3 CH
3 N
O O H
H N
O N N O
N N N
O O
O CH O CH O O CH
3 3
O H C CH CH 3
3 3 3
First, 6-oxohexanoic acid was prepared by a literature method (J. Org. Chem. 58, 1993, 2196-
2200).
80 mg (0.08 mmol) of N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)(1H-indol-
3-yl)(1,2-oxazinanyl)oxopropanyl]amino}methoxymethyl
oxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide
(Intermediate 192) and 65.4 mg (0.5 mmol) of 6-oxohexanoic acid were combined in 9 ml of
methanol and admixed with 10 µl of acetic acid and 37.4 mg (0.4 mmol) of borane-pyridine
complex. The reaction mixture was stirred at RT overnight. This was followed by concentration
under reduced pressure, and the residue was taken up in 1:1 acetonitrile/water and adjusted to pH 2
with trifluoroacetic acid. The reaction mixture was trated again and the residue was purified
by means of preparative HPLC. After concentration of the corresponding fractions, 70 mg (86% of
theory) of N-(5-carboxypentyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)
(1H-indolyl)(1,2-oxazinanyl)oxopropanyl]amino}methoxymethyl
pyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide were
obtained as the trifluoroacetate.
HPLC (Method 12): Rt = 1.9 min;
LC-MS (Method 1): Rt = 0.87 min; MS (ESIpos): m/z = 955 (M+H)+.
1H NMR (500 MHz, DMSO-d
6, characteristic signals): δ = 12.0 (br. M, 1H), 10.8 (s, 1H), 9.4 (m,
1H), 8.9 and 8.8 (2d, 1H), 8.3 and 8.02 (2d, 1H), 7.5 (m, 1H), 7.3 (m, 1H), 7.15 and 7.1 (2s, 1H)
7.05-6.9 (m, 2H), 5.12 and 4.95 (2m, 1H), 4.7-4.5 (m, 2H), 4.1-3.8 (m, 4H), 3.75 (d, 1H), 3.25, 3.2,
3.18, 3.13, 2.98 and 2.88 (6s, 9H), 2.8 (m, 3H), 1.08 and 1.04 (2d, 3H), 0.95-0.8 (m, 15H), 0.8-0.65
(dd, 3H).
22 mg (23 µmol) of this intermediate were dissolved in 1.8 ml of dichloromethane and admixed
with 13.2 mg (70 µmol) of 1-(3-dimethylaminopropyl)ethylcarbodiimide hydrochloride, 26.5
mg (230 µmol) of 1-hydroxypyrrolidine-2,5-dione and 0.28 mg (2 µmol) of
dimethylaminopyridine, and the on mixture was stirred at RT for 2 h. Subsequently, the
reaction mixture was concentrated under reduced pressure and the remaining residue was purified
by means of ative HPLC. After lization from itrile/water, 21.3 mg (88% of
theory) of the title compound were obtained.
HPLC (Method 12): Rt = 1.9 min;
LC-MS (Method 1): Rt = 0.94 min; MS (ESIpos): m/z = 1052 (M+H)+.
Intermediate 211
N-{6-[(2,5-dioxopyrrolidinyl)oxy]oxohexyl}-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy
{(2S)[(1R,2R)methoxymethyl{[(2S,3S)(1,2-oxazinanyl)oxophenylbutan
yl]amino}oxopropyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-valinamide
H C CH H C
3 3 3 CH N
O O 3 H
H N
O N N O
N N N
O O
O CH O CH O O
3 3 CH H C
O H C CH CH 3 3
3 3 3
mg (20 µmol) of N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxy
methyl{[(2S,3S)(1,2-oxazinanyl)oxophenylbutanyl]amino}oxopropyl]
pyrrolidin-yl}methyloxoheptanyl]-N-methyl-L-valinamide trifluoroacetate (Intermediate
15) were reductively alkylated with exanoic acid, in analogy to Intermediate 210.
Yield: 9.2 mg (61% of theory)
HPLC (Method 12): Rt = 1.9 min;
LC-MS (Method 1): Rt = 0.87 min; MS (ESIpos): m/z = 929 (M+H)+.
9 mg (10 µmol) of this intermediate were dissolved in 3 ml of DMF and admixed with 5.6 mg (48
µmol) of 1-hydroxypyrrolidine-2,5-dione, 5 µl of N,N-diisopropylethylamine and 5.5 mg (0.015
mmol) of HATU, and the reaction mixture was treated in an ultrasound bath for 6 h. In the course
of this, 5.5 mg of HATU were added every hour. Subsequently, the reaction mixture was
concentrated under reduced pressure, and the residue was taken up in itrile/water and
adjusted to pH 2 with trifluoroacetic acid. After concentrating again under reduced pressure, the
remaining e was ed by means of preparative HPLC. After lyophilization from
acetonitrile/water, 5.8 mg (57% of theory) of the title compound were obtained.
HPLC (Method 12): Rt = 2.0 min;
LC-MS (Method 1): Rt = 0.95 min; MS (ESIpos): m/z = 1027 (M+H)+.
Intermediate 212
2-(2-{3-[(2,5-dioxopyrrolidinyl)oxy]oxopropoxy}ethoxy)ethoxy]ethyl}-N-methyl-L-
valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxymethyl{[(2S,3S)(1,2-
oxazinanyl)oxophenylbutanyl]amino}oxopropyl]pyrrolidinyl}methyl
oxoheptanyl]-N-methyl-L-valinamide
H3C CH H C
3 3 CH
3 N
O O H
H N
O O O N N O
N O N N
O O
O CH O CH O O
3 3 CH H C
H C CH 3 3
O CH
3 3 3
The preparation was at first effected in analogy to Intermediate 168, commencing with the
reductive alkylation of Intermediate 15 with Intermediate 167 and subsequent hydrogenolytic
cleavage of the benzyl ester of 2-[2-(2-carboxyethoxy)ethoxy]ethoxy}ethyl)-N-methyl-L-
valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxymethyl{[(2S,3S)(1,2-
anyl)oxophenylbutanyl]amino}oxopropyl]pyrrolidinyl}methyl
oxoheptanyl]-N-methyl-L-valinamide.
8.4 mg (8 µmol) of this intermediate were dissolved in 3 ml of DMF and admixed with 9.5 mg (80
µmol) of 1-hydroxypyrrolidine-2,5-dione, 10 µl of N,N-diisopropylethylamine and 9.4 mg (25
µmol) of HATU, and the reaction mixture was stirred at RT overnight and then concentrated under
reduced pressure. Subsequently, the reaction e was trated under d re,
and the residue was taken up in acetonitrile/water and adjusted to pH 2 with trifluoroacetic acid.
After concentrating again under reduced pressure, the remaining residue was purified by means of
preparative HPLC. After lyophilization from acetonitrile/water, 4 mg (32% of theory) of the title
compound were obtained.
HPLC (Method 12): Rt = 2.0 min;
LC-MS (Method 1): Rt = 0.96 min; MS (ESIpos): m/z = 1117 (M+H)+.
Intermediate 213
N-{6-[(trans{[(2,5-dioxopyrrolidinyl)oxy]carbonyl}cyclohexyl)amino]oxohexyl}-N-
methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)(1H-indolyl)(1,2-oxazinan
yl)oxopropanyl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxy
methyloxoheptanyl]-N-methyl-L-valinamide
H C CH H C
3 3 3 CH3 N
O H
H H N
N N N O
O N N
O O
O O CH O CH O O
N 3 3 CH
H C CH3 CH 3
3 3
O H
This compound was prepared in analogy to Intermediate 104, proceeding from N-(5-
ypentyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)(1H-indolyl)
(1,2-oxazinanyl)oxopropanyl]amino}methoxymethyloxopropyl]pyrrolidinyl}-
3-methoxymethyloxoheptanyl]-N-methyl-L-valinamide, the sis of which was
described under Intermediate 210. 9.3 mg of the title compound (37% of theory over 3 stages)
were obtained.
HPLC (Method 12): Rt = 1.9 min;
LC-MS (Method 1): Rt = 0.9 min; MS (ESIpos): m/z = 1177 (M+H)+.
Intermediate 214
N-{4-[(2,5-dioxopyrrolidinyl)oxy]oxobutyl}-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)
[(1R,2R){[(1S,2R)hydroxyphenylpropanyl]amino}methoxymethyl
pyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide
H C CH H C
3 3 3 CH
O O H
H N CH
O N N 3
N N N
O O
O CH O CH O O
3 3 H C OH
O H C CH CH 3
3 3 3
This compound was prepared in analogy to Intermediate 210, by conversion of Intermediate 92 to
the active ester.
HPLC (Method 5): Rt = 1.6 min;
LC-MS (Method 11): Rt = 0.82 min; MS (ESIpos): m/z = 901 (M+H)+.
WO 87716
Intermediate 215
N-{6-[(2,5-dioxopyrrolidinyl)oxy]oxohexyl}-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)
R){[(1S,2R)hydroxyphenylpropanyl]amino}methoxymethyl
oxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide
H C CH H C
3 3 3 CH
O O 3 H
H N CH
O N N 3
N N N
O O
O CH O CH O O
3 3 H C OH
H C CH CH 3
O 3 3 3
First, Intermediate 40, in analogy to Intermediate 183, was used with borane-pyridine complex to
prepare N-(5-carboxypentyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(1S,2R)
hydroxyphenylpropanyl]amino}methoxymethyloxopropyl]pyrrolidinyl}
methoxymethyloxoheptanyl]-N-methyl-L-valinamide. From this compound, in analogy to
Intermediate 210, the active ester was then generated. 34 mg (36% of theory over 2 stages) of the
title compound were obtained.
HPLC (Method 5): Rt = 1.6 min;
LC-MS (Method 1): Rt = 0.85 min; MS (ESIpos): m/z = 930 (M+H)+.
Intermediate 216
N-(4-{[(2,5-dioxopyrrolidinyl)oxy]carbonyl}benzyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)-
2-[(1R,2R){[(2S)(1H-indolyl)(1,2-oxazinanyl)oxopropanyl]amino}methoxy-
2-methyloxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-
valinamide
H3C CH H C
3 3 CH N
O 3
H N
N N O
O N N
O O
O CH3 O CH3 O O CH
N H C CH3 CH3 3
O N
O
First, in analogy to the ation of Intermediate 183, Intermediate 192 was reacted with 4-
formylbenzoic acid with borane-pyridine complex to give N-(4-carboxybenzyl)-N-methyl-L-valyl-
N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)(1H-indolyl)(1,2-oxazinanyl)oxopropan-
2-yl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxymethyloxoheptan-
N-methyl-L-valinamide. This compound was then used, in analogy to Intermediate 210, to
generate 11 mg (68% of theory) of the title compound.
HPLC (Method 5): Rt = 1.8 min;
LC-MS (Method 1): Rt = 1.13 min; MS (ESIpos): m/z = 1072 (M+H)+.
Intermediate 217
N-(5-carboxypentyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)(benzyloxy)-
1-oxophenylpropanyl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxy-
-methyloxoheptanyl]-N-methyl-L-valinamide
H3C CH H C
3 CH3 O
3 O H
H N
O N N O
N N
O O
OH CH3 O CH O O CH
H CH 3
C CH3
3 3
53 mg (84 µmol) of N-[(9H-fluorenylmethoxy)carbonyl]-N-methyl-L-valyl-N-[(2R,3S,4S)
carboxymethoxymethylhexanyl]-N-methyl-L-valinamide (Intermediate 4) and 45 mg (84
µmol) of benzyl N-{(2R,3R)methoxymethyl[(2S)-pyrrolidinyl]propanoyl}-L-
phenylalaninate trifluoroacetate (Intermediate 12) were taken up in 2 ml of DMF, 19 µl of N,N-
ropylethylamine, 14 mg (92 µmol) of HOBt and 17.6 mg (92 µmol) of EDC were added and
then the mixture was stirred at RT ght. Subsequently, the reaction mixture was concentrated
and the residue was purified by means of preparative HPLC. This gave 59 mg (68% of theory) of
the Fmoc-protected intermediate N-[(9H-fluorenylmethoxy)carbonyl]-N-methyl-L-valyl-N-
S,5S){(2S)[(1R,2R){[(2S)(benzyloxy)oxophenylpropanyl]amino}
methoxymethyloxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-
L-valinamide.
LC-MS (Method 1): Rt = 1.55 min; m/z = 1044 (M+H)+.
57 mg (0.055 mmol) of this intermediate were treated with 1.2 ml of dine in 5 ml of DMF to
detach the Fmoc protecting group. After concentration and purification by means of preparative
HPLC, 39 mg (76% of theory) of the free amine intermediate N-methyl-L-valyl-N-[(3R,4S,5S)
WO 87716
{(2S)[(1R,2R){[(2S)(benzyloxy)oxophenylpropanyl]amino}methoxymethyl-
3-oxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide were
ed as the trifluoroacetate.
HPLC (Method 5): Rt = 1.9 min;
LC-MS (Method 1): Rt = 1.01 min; m/z = 822 (M+H)+.
60 mg (0.06 mmol) of this intermediate were reacted, in analogy to Intermediate 210, with 6-
oxohexanoic acid in the presence of borane-pyridine complex. 45 mg (75% of theory) of the title
compound were obtained as a foam.
HPLC (Method 5): Rt = 1.9 min;
LC-MS (Method 1): Rt = 0.97 min; MS (ESIpos): m/z = 9936 (M+H)+.
Intermediate 218
(2,5-dioxopyrrolidinyl)oxy]oxohexyl}-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)
[(1R,2R){[(2S)(benzyloxy)oxophenylpropanyl]amino}methoxymethyl
oxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide
H C CH H C
3 CH
3 O
3 3 O H
H N
O N N O
O N N
O O
O CH O CH O O CH
3 3
H C CH 3
N CH
3 3 3
O
This compound was prepared by conversion of 42 mg (0.05 mmol) of Intermediate 217 to the
active ester.
Yield: 26 mg (54%)
HPLC d 5): Rt = 2.1 min;
LC-MS (Method 1): Rt = 1.01 min; MS (ESIpos): m/z = 1034 (M+H)+.
Intermediate 219
N-{6-[(2,5-dioxopyrrolidinyl)oxy]oxohexyl}-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)
[(1R,2R){[(1S)carboxyphenylethyl]amino}methoxymethyloxopropyl]pyrrolidin-
1-yl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide
H C CH H C
3 CH
3 O
3 3 O H
H N
O N N OH
O N N
O O
O CH O CH O O CH
3 3
N C CH CH 3
3 3 3
mg (0.02 mol) of the nd from Intermediate 218 were taken up in 2.4 ml of methanol and
hydrogenated over 5% ium on ted carbon under standard en pressure at RT for
min. The st was then filtered off and the solvent was removed under reduced pressure.
The residue was lyophilized from 1:1 acetonitrile/water. This gave 14 mg (92% of theory) of the
title compound as a colourless foam.
HPLC (Method 5): Rt = 1.7 min;
LC-MS d 1): Rt = 0.86 min; MS (ESIpos): m/z = 944 (M+H)+.
Intermediate 220
N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)(1H-indolyl)(1,2-oxazinanyl)oxopropan-
2-yl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxymethyloxoheptan-
4-yl]-N-methyl-L-valinamide
3 CH
O 3 N
H N N
2 O
O O
CH O O
3 CH
H C CH CH 3
3 3 3
500 mg of this intermediate were dissolved in 20 ml of DMF and admixed with 466 mg (3.8 mmol)
of Intermediate 191, 382 mg (1.01 mmol) of zabenzotriazolyl)-N,N,N',N'-
tetramethyluronium hexafluorophosphate (HATU) and 440 µl (2.5 mmol) of N,N-
diisopropylethylamine. The mixture was stirred at RT for 1 h and then concentrated. The residue
was taken up in dichloromethane and extracted by shaking first twice with 5% aqueous citric acid
solution and then with saturated aqueous sodium hydrogencarbonate solution. The organic phase
was concentrated and the residue was purified by flash chromatography on silica gel with 95:5
dichloromethane/methanol as the eluent. The corresponding fractions were combined and the
solvent was removed under reduced pressure. After the residue had been dried under high vacuum,
562 mg (65% of theory over both stages) of the Z-protected intermediate were obtained.
562 mg (0.57 mmol) of this intermediate were taken up in 50 ml of methanol and enated
with 155 mg of 10% palladium on activated carbon under standard hydrogen pressure at RT for 20
min. The catalyst was then filtered off and the solvent was removed under d pressure. The
residue was purified by preparative HPLC. The corresponding fractions were combined, the
solvent was evaporated off under d pressure and the residue was lyophilized from dioxane.
This gave 361 mg (87% of theory) of the title nd as a foam.
HPLC (Method 5): double peak with Rt = 1.75 and 1.86 min;
LC-MS (Method 1): double peak at Rt = 0.84 min and 0.91 min with the same mass; MS (ESIpos):
m/z = 944 .
Intermediate 221
N-{(2S)[(tert-butoxycarbonyl)amino]phenylpropyl}-N-methyl-L-valine
H C CH
3 3
3 H
O N OH
3 N
CH O CH O
3 3
100 mg (0.76 mmol) of commercially available N-methyl-L-valine and 285 mg (1.14 mmol) of
commercially available tert-butyl (2S)oxophenylpropanyl carbamate were combined in 22
ml of methanol and admixed with 340 mg (3.66 mmol) of borane-pyridine complex and 70 µl of
acetic acid. The reaction mixture was d at RT overnight. This was followed by concentration
under reduced pressure, and the residue was ed by flash chromatography on silica gel with
dichloromethane/methanol/17% aqueous ammonia solution as the eluent. After concentration of
the corresponding ons and lyophilization from 1:1 dioxane/water, 259 mg (93% of theory) of
the title compound were obtained.
HPLC (Method 12): Rt = 1.6 min;
LC-MS (Method 11): Rt = 0.76 min; MS (ESIpos): m/z = 365 (M+H)+.
Intermediate 222
N-[(2S)aminophenylpropyl]-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)-
3-(1H-indolyl)(1,2-oxazinanyl)oxopropanyl]amino}methoxymethyl
oxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide
trifluoroacetate
H C CH H C
3 3 3 CH N
O 3
H N
H N N N O
2 N N
O O
CH O CH O O
3 3 CH
H C CH CH 3
3 3 3
x CF3COOH
40 mg (0.11 mmol) of N-{(2S)[(tert-butoxycarbonyl)amino]phenylpropyl}-N-methyl-L-
valine (Intermediate 221) were dissolved in 5 ml of DMF and admixed with 80 mg (0.11 mmol) of
N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)(1H-indolyl)(1,2-oxazinanyl)oxopropan-
2-yl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxymethyloxoheptan-
4-yl]-N-methyl-L-valinamide (Intermediate 220), 50 mg (0.13 mmol) of O-(7-azabenzotriazol
yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU) and 57 µl (2.5 mmol) of N,N-
diisopropylethylamine. The mixture was stirred at RT for 1 h and then concentrated. The residue
was taken up in ethyl acetate and washed first with 5% s citric acid solution and then with
water. The organic phase was concentrated and the residue was purified by means of preparative
HPLC. The corresponding ons were combined and the solvent was removed under reduced
pressure. After lyophilization from dioxane, 60 mg (50% of theory) of the protected intermediate
were obtained.
HPLC (Method 12): Rt = 2.2 min;
LC-MS (Method 1): Rt = 1.17 min; MS (ESIpos): m/z = 1073 (M+H)+.
60 mg (0.05 mmol) of this intermediate were taken up in 10 ml of dichloromethane, 2 ml of
trifluoroacetic acid were added, and the reaction mixture was stirred at RT for 1.5 h. Subsequently,
the reaction mixture was concentrated under reduced pressure and the remaining residue was
ed by means of preparative HPLC. The corresponding fractions were combined, the t
was d under reduced pressure and the residue was lyophilized from dioxane/water. In this
way, 25 mg (42% of ) of the title compound were obtained as a foam.
HPLC (Method 12): Rt = 1.9 min;
LC-MS (Method 1): Rt = 0.95 min; MS (ESIpos): m/z = 974 (M+H)+.
Intermediate 223
N-[(2S)({[2-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)ethyl]carbamoyl}amino)phenylpropyl]-
N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)(1H-indolyl)(1,2-oxazinan-
2-yl)oxopropanyl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxy
methyloxoheptanyl]-N-methyl-L-valinamide
H C CH H C
3 3 3 CH
O 3 N
O H
H H H N
N N N N O
N N N
O O
O CH O CH O O
3 3 CH
O H C CH CH 3
3 3 3
The preparation was effected in analogy to Intermediate 134, proceeding from 5 mg (4.6 µmol) of
Intermediate 222. 3.4 mg (65% of theory) of the title compound were obtained.
HPLC (Method 12): Rt = 2.0 min;
LC-MS (Method 1): Rt = 0.99 min; MS s): m/z = 1140 (M+H)+.
Intermediate 224
N-[(2S)({[2-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)ethyl]carbamoyl}amino)propyl]-N-methyl-
L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)(1H-indolyl)(1,2-oxazinanyl)
oxopropanyl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxymethyl
oxoheptanyl]-N-methyl-L-valinamide
H C CH H C
3 3 3 CH
3 N
O O H
H H H N
N N N N O
N N N
O O
O CH CH O CH O O
3 CH
3 3
O H C CH CH 3
3 3 3
The preparation was effected in y to the sis of Intermediate 223.
HPLC (Method 12): Rt = 1.9 min;
LC-MS (Method 1): Rt = 0.92 min; MS (ESIpos): m/z = 1064 (M+H)+.
Intermediate 225
N-(2-aminoethyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)(1H-indol
yl)(1,2-oxazinanyl)oxopropanyl]amino}methoxymethyloxopropyl]pyrrolidin-
1-yl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide trifluoroacetate
H C CH H C
3 3 3 CH
3 N
O H
H N
H N N N
2 O
N N
O O
x CF3COOH CH O CH O O
3 3 CH
H C CH CH 3
3 3 3
H
100 mg (0.76 mmol) of commercially ble yl-L-valine and 182 mg (1.14 mmol) of
commercially available tert-butyl 2-oxoethyl carbamate were combined in 20 ml of methanol and
admixed with 340 mg (3.66 mmol) of borane-pyridine x and 65 µl of acetic acid. The
reaction mixture was stirred at RT overnight. This was followed by concentration under reduced
pressure, and the residue was purified by flash tography on silica gel with
dichloromethane/methanol/17% aqueous ammonia solution (15/4/0.5) as the eluent. After
concentration of the corresponding fractions and lyophilization from 1:1 dioxane/water, 190 mg in
39% purity (35% of theory) of the intermediate were obtained, which were converted further
without further purification.
50 mg (0.07 mmol) of this intermediate were dissolved in 10 ml of DMF and admixed with 52 mg
(0.07 mmol) of N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)(1H-indolyl)(1,2-oxazinan
yl)oxopropanyl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxy
methyloxoheptanyl]-N-methyl-L-valinamide (Intermediate 220), 32 mg (0.09 mmol) of O-(7-
azabenzotriazolyl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU) and 37 µl (0.2
mmol) of N,N-diisopropylethylamine. The mixture was stirred at RT overnight and then
trated. The residue was taken up in ethyl acetate and ted by shaking first with 5%
aqueous citric acid solution and then with water. The organic phase was concentrated and the
residue was purified by means of preparative HPLC. The corresponding fractions were combined
and the solvent was removed under reduced pressure. After lyophilization from dioxane, 53 mg
(76% of theory) of the ted intermediate were obtained.
HPLC (Method 12): Rt = 2.0 min;
LC-MS d 1): Rt = 1.02 min; MS (ESIpos): m/z = 984 .
53 mg (0.05 mmol) of this intermediate were taken up in 10 ml of dichloromethane, 2 ml of
trifluoroacetic acid were added, and the reaction mixture was stirred at RT for 30 min.
WO 87716
Subsequently, the reaction mixture was concentrated under reduced pressure and the remaining
residue was purified by means of preparative HPLC. The corresponding fractions were combined,
the solvent was removed under reduced pressure and the residue was lyophilized from
dioxane/water. In this way, 21 mg (40% of theory) of the title nd were obtained in 65%
purity.
HPLC (Method 12): Rt = 1.7 min;
LC-MS (Method 1): Rt = 0.87 min; MS (ESIpos): m/z = 884 (M+H)+.
Intermediate 226
N-[2-({[2-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)ethyl]carbamoyl}amino)ethyl]-N-methyl-L-valyl-
N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)(1H-indolyl)(1,2-oxazinanyl)oxopropan-
2-yl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxymethyloxoheptan-
4-yl]-N-methyl-L-valinamide
H C CH H C
3 3 3 CH
3 N
O O H
H H H N
N N N N O
N N N
O O
O CH O CH O O
3 3 CH
O H C CH CH 3
3 3 3
The preparation was effected proceeding from Intermediate 225, in analogy to the synthesis of
Intermediate 134. 11.6 mg (59% of theory) of the title compound were obtained.
HPLC (Method 12): Rt = 1.9 min;
LC-MS (Method 1): Rt = 0.90 min; MS s): m/z = 1050 (M+H)+.
ediate 227
N-{6-[(2,5-dioxopyrrolidinyl)oxy]oxohexyl}-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)
[(1R,2R){[(2S)(benzyloxy)(1H-indolyl)oxopropanyl]amino}methoxy
methyloxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-
valinamide
H C CH H C CH O
3 3 3 3
O H
H N
O N N O
O N N
O O
O CH O CH O O CH
3 3 3
N H C CH CH
3 3 3
O H
This compound was prepared analogously to Intermediate 218, by conversion to the active ester.
Yield: 18 mg (51% of )
HPLC (Method 5): Rt = 2.1 min;
LC-MS (Method 1): Rt = 0.98 min; MS (ESIpos): m/z = 1073 .
Intermediate 228
(2R,3S)[(tert-butoxycarbonyl)amino]{2-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol
yl)hexanoyl]hydrazino}oxobutanyl(3R,4S,7S,10S)[(2S)-butanyl]-7,10-diisopropyl(2-
{(2S)[(1R,2R)methoxymethyl{[(1S,2R)(1,2-oxazinanylcarbonyl)
phenylcyclopropyl]amino}oxopropyl]pyrrolidinyl}oxoethyl)-5,11-dimethyl-6,9-dioxo
oxa-5,8,11-triazapentadecanoate
O CH CH
3 3
O H C CH H C
3 3 3 CH
HN O 3 N
O O H
H H N
N N O N N O
N N N
H O O
O O CH O CH O CH O O
3 3 3 CH
H C CH3 CH3 3
The title compound was obtained as intermediate in the synthesis of Intermediate 154.
HPLC (Method 12): Rt = 2.1 min;
LC-MS (Method 1): Rt = 0.97 min; MS (ESIpos): m/z = 1308 (M+H)+.
Intermediate 229
(2R,3S)acetamido{2-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexanoyl]hydrazino}
oxobutanyl (3R,4S,7S,10S)[(2S)-butanyl]-7,10-diisopropyl(2-{(2S)[(1R,2R)
methoxymethyl{[(1S,2R)(1,2-oxazinanylcarbonyl)phenylcyclopropyl]amino}
oxopropyl]pyrrolidinyl}oxoethyl)-5,11-dimethyl-6,9-dioxooxa-5,8,11-triazapentadecan-
CH CH
3 3
O H3C CH H C
3 3 CH N
O HN O O 3
H H N
N N O N N O
N N N
H O O
O O CH O CH O CH3 O O
3 3 CH
H C CH CH
3 3 3
The title compound was prepared from 7.5 mg (2.5 µmol) of Intermediate 154 by acetylation with
2.3 µl of acetic anhydride in 1 ml of DMF in the presence of 0.4 µl of isopropylethylamine.
Yield: 1.4 mg (40% of theory)
HPLC (Method 12): Rt = 1.9 min;
LC-MS (Method 1): Rt = 0.86 min; MS (ESIpos): m/z = 1250 (M+H)+.
Intermediate 230
(2R,3S)[(tert-butoxycarbonyl)amino]{2-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexanoyl]
hydrazino}oxobutanyl (3R,4S,7S,10S)[(2S)-butanyl](2-{(2S)[(1R,2R){[(2S)
(1H-indolyl)(1,2-oxazinanyl)oxopropanyl]amino}methoxymethyloxopropyl]
pyrrolidinyl}oxoethyl)-7,10-diisopropyl-5,11-dimethyl-6,9-dioxooxa-5,8,11-
triazapentadecanoate
O CH CH
3 3
O H C CH H C
3 3 CH N
O HN O 3 O 3
H H N
N N O N N O
N N N
H O O
O O CH O CH O CH O O
3 3 CH
3 H C CH CH 3
3 3 3
H
This nd was prepared in analogy to Intermediate 229, proceeding from Intermediate 193.
16 mg (30% of theory over 3 stages) of the title compound were obtained.
HPLC (Method 12): Rt = 2.0 min;
LC-MS (Method 1): Rt = 1.02 min; MS (ESIpos): m/z = 1335 (M+H)+.
WO 87716
Intermediate 231
(2R,3S)acetamido{2-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexanoyl]hydrazino}
oxobutanyl (3R,4S,7S,10S)[(2S)-butanyl](2-{(2S)[(1R,2R){[(2S)(1H-indol
yl)(1,2-oxazinanyl)oxopropanyl]amino}methoxymethyloxopropyl]pyrrolidin-
1-yl}oxoethyl)-7,10-diisopropyl-5,11-dimethyl-6,9-dioxooxa-5,8,11-triazapentadecan
oate
CH CH
3 3
O H C CH H C
3 3 3 CH
O HN O O 3 N
H H N
N N O N N O
N N N
H O O
O O CH O CH O CH O O
3 3 3 CH
H C CH CH 3
3 3 3
This compound was prepared from 8 mg (6 µmol) of Intermediate 230, first by deprotection with
trifluoroacetic acid and subsequent acetylation with acetic anhydride in DMF in the presence of
N,N-diisopropylethylamine. 2 mg (37% of theory over 2 stages) of the title compound were
obtained.
HPLC (Method 12): Rt = 1.9 min;
LC-MS (Method 1): Rt = 0.88 min; MS (ESIpos): m/z = 1277 (M+H)+.
ediate 232
benzyl N-[(4-nitrophenoxy)carbonyl]-beta-alaninate
O N O
O O
200 mg (0.57 mmol) of commercially available 4-methylbenzenesulphonic enzyl betaalaninate
and 229 mg (1.14 mmol) of 4-nitrophenyl chlorocarbonate were taken up in 15 ml of
tetrahydrofuran and the reaction mixture was then heated to reflux for 30 min. Subsequently, the
reaction mixture was concentrated under reduced pressure and the residue was purified by means
of preparative HPLC. After concentration of the corresponding fractions and drying of the residue
under high vacuum, 86 mg (44% of theory) of the title compound were obtained.
HPLC d 12): Rt = 1.8 min;
LC-MS (Method 1): Rt = 1.07 min; MS (ESIpos): m/z = 345 (M+H)+.
Intermediate 233
N-{2-[({3-[(2,5-dioxopyrrolidinyl)oxy]oxopropyl}carbamoyl)amino]ethyl}-N-methyl-L-
valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)(1H-indolyl)(1,2-oxazinanyl)
oxopropanyl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxymethyl
oxoheptanyl]-N-methyl-L-valinamide
H C CH H C
O O 3 3 3 CH
3 N
N O H
H H H N
O N N N N O
N N
O O
O O CH O CH O O
3 3 CH
H C CH CH 3
3 3 3
13 mg (10 µmol) of ediate 225 and 6.7 mg (20 µmol) of Intermediate 232 were dissolved in
3 ml of DMF, and then 7 µl of N,N-diisopropylethylamine were added. The mixture was stirred at
RT overnight and then concentrated under high vacuum. The remaining e was purified by
means of preparative HPLC. After concentration of the corresponding fractions and drying of the
residue under high vacuum, 5.4 mg (38% of theory) of the protected intermediate were obtained.
HPLC (Method 5): Rt = 2.1 min;
LC-MS (Method 1): Rt = 0. 6in; MS (ESIpos): m/z = 1089 (M+H)+.
.4 mg (5 µmol) of this intermediate were dissolved in 5 ml of methanol and, after addition of 2
mg of 10% palladium on activated carbon, hydrogenated under standard hydrogen pressure at RT
for 20 min. The catalyst was then filtered off and the solvent was removed under reduced pressure.
After the e had been dried under high vacuum, 5 mg (quant.) of the acid intermediate were
obtained.
HPLC (Method 12): Rt = 1.8 min;
LC-MS (Method 1): Rt = 0.84 min; MS (ESIpos): m/z = 999 (M+H)+.
mg (10 µmol) of this intermediate were ved in 1 ml of DMF and d with 5.8 mg (50
mmol) of 1-hydroxypyrrolidine-2,5-dione and then with 2.6 µl of N,N-diisopropylethylamine and
3.8 mg (10 µmol) of HATU. After ng at RT for 20 h, the reaction mixture was concentrated
under reduced pressure. The remaining residue was purified by means of preparative HPLC. After
lyophilization from 1:1 dioxane/water, 1.1 mg (20% of ) of the title compound were
obtained.
HPLC (Method 12): Rt = 1.9 min;
WO 87716
LC-MS (Method 1): Rt = 0.87 min; MS (ESIpos): m/z = 1096 (M+H)+.
Intermediate 234
N-(6-{[(benzyloxy)carbonyl]amino}hexyl)-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)
[(1R,2R)methoxymethyloxo{[(1S)phenyl(5-phenyl-1,3,4-oxadiazol
yl)ethyl]amino}propyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-valinamide
H C CH H C
3 O
3 3 CH
O 3 H N
H H N
O N N N N
N N
O O
O CH O CH O O CH
3 H C CH 3
3 3 CH
mg (30 µmol) of N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxy
methyloxo{[(1S)phenyl(5-phenyl-1,3,4-oxadiazolyl)ethyl]amino}propyl]pyrrolidin-
1-yl}methyloxoheptanyl]-N-methyl-L-valinamide (Intermediate 55) and 45 mg (180 µmol)
of benzyl 6-oxohexyl ate were taken up in 3 ml of methanol and acidified with acetic acid.
At room temperature, 15 µl (144 µmol; 9.4M) of borane-pyridine complex were subsequently
added. The mixture was subsequently stirred at RT for 24 h, and acetic acid and 15 µl (144 µmol;
9.4M) of borane-pyridine complex were added again after 8 h. The reaction mixture was
uently adjusted to pH 2 with TFA and purified by means of preparative HPLC. The product
fractions were combined and trated, and the residue was dried under high vacuum. This
gave 15 mg (46% of theory) of the title compound as a foam.
LC-MS (Method 1): Rt = 1.03 min; m/z = 1066 (M+H)+.
Intermediate 235
N-(6-aminohexyl)-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxy
methyloxo{[(1S)phenyl(5-phenyl-1,3,4-oxadiazolyl)ethyl]amino}propyl]pyrrolidin-
1-yl}methyloxoheptanyl]-N-methyl-L-valinamide
H C CH H C
3 3 CH O
O 3 H N
H N
H N N N N
2 N N
O O
CH O CH O O CH
3 3
3 H C CH
3 3 CH
mg (14 µmol) of [(benzyloxy)carbonyl]amino}hexyl)-N-methyl-L-valyl-N-[(3R,4S,5S)-
3-methoxy{(2S)[(1R,2R)methoxymethyloxo{[(1S)phenyl(5-phenyl-1,3,4-
oxadiazolyl)ethyl]amino}propyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-
valinamide (Intermediate 234) were taken up in 3 ml of methanol, and 1.8 mg of palladium on
al (5%) were added. The reaction mixture was subsequently hydrogenated under standard
hydrogen pressure at RT for 2 h. The catalyst was then filtered off and the solvent was removed
under d pressure. The residue was lyophilized from 1:1 acetonitrile/water. 11 mg (86% of
) of the title compound were obtained as a foam.
LC-MS (Method 1): Rt = 0.81 min; m/z = 932 (M+H)+.
Intermediate 236
N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexyl]-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy
{(2S)[(1R,2R)methoxymethyloxo{[(1S)phenyl(5-phenyl-1,3,4-oxadiazol
yl)ethyl]amino}propyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-valinamide
O H C CH H C
3 O
3 3 CH
O 3 H N
H N
N N N N
N N
O O
O CH O CH
3 O O CH
3 H C CH
3 3 CH
11 mg (12 µmol) of N-(6-aminohexyl)-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)
[(1R,2R)methoxymethyloxo{[(1S)phenyl(5-phenyl-1,3,4-oxadiazol
yl)ethyl]amino}propyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-valinamide
(Intermediate 235) were taken up in 500 µl of 1:1 dioxane/water and admixed with 253 µl of 1M
aqueous sodium hydrogencarbonate solution and then with 2.8 mg (18 µmol) of methyl 2,5-dioxo-
2,5-dihydro-1H-pyrrolecarboxylate. The reaction mixture was stirred at RT for 30 min and then
acidified with trifluoroacetic acid. The reaction mixture was purified by means of preparative
HPLC. After lyophilization, 0.8 mg (7% of theory) of the title compound was obtained.
LC-MS d 1): Rt = 1.01 min; m/z = 1012 (M+H)+.
Intermediate 237
N-(5-carboxypentyl)-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxy-
2-methyloxo{[(1S)phenyl(5-phenyl-1,3,4-oxadiazol
yl)ethyl]amino}propyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-valinamide
H C CH H C
3 O
3 3 CH
O 3 H N
H N
HO N N N
N N
O O
O CH O CH O CH
3 H C CH 3 O 3
3 3 CH
mg (30 µmol) of N-methyl-L-valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxy
methyloxo{[(1S)phenyl(5-phenyl-1,3,4-oxadiazolyl)ethyl]amino}propyl]pyrrolidin-
1-yl}methyloxoheptanyl]-N-methyl-L-valinamide (Intermediate 55) and 23 mg (180 µmol)
of exanoic acid were taken up in 3 ml of methanol and acidified with acetic acid. At room
temperature, 15 µl (144 µmol; 9.4M) of borane-pyridine complex were subsequently added. The
reaction mixture was subsequently stirred at RT for 20 h, and acetic acid and 15 µl (144 µmol;
9.4M) of borane-pyridine complex were added again after 8 h. The reaction mixture was
subsequently adjusted to pH 2 with trifluoroacetic acid and ed by means of preparative
HPLC. The product fractions were ed and trated, and the residue was lyophilized. 21
mg (74% of theory) of the title compound were thus obtained as a foam.
LC-MS (Method 1): Rt = 0.91 min; m/z = 947 (M+H)+.
Intermediate 238
N-{6-[(2,5-dioxopyrrolidinyl)oxy]oxohexyl}-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy
{(2S)[(1R,2R)methoxymethyloxo{[(1S)phenyl(5-phenyl-1,3,4-oxadiazol
yl)ethyl]amino}propyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-
valinamide
O O H C CH 3 O
3 3 CH
N O 3 H N
H N
O N N N
N N
O O
O CH O CH O CH
3 H 3 O 3
C CH
3 3 CH
21 mg (22 µmol) of Intermediate 237 were dissolved in 1 ml of DMF and admixed with 38 mg
(333 µmol) of 1-hydroxypyrrolidine-2,5-dione and then with 2.4 mg (10 µmol) of O-(7-
zotriazolyl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU) and 19 µl of
N,N-diisopropylethylamine. After stirring at RT for 2 h, the reaction mixture was purified by
means of preparative HPLC. After lyophilization from dioxane, 22 mg (96% of theory) of the title
compound were obtained.
LC-MS (Method 1): Rt = 0.95 min; m/z = 1044 (M+H)+.
Intermediate 239
N-methyl-L-threonyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)(1H-indolyl)(1,2-
oxazinanyl)oxopropanyl]amino}methoxymethyloxopropyl] pyrrolidinyl}
methoxymethyloxoheptanyl]-N-methyl-L-valinamide trifluoroacetate
H3C OH H C
3 CH
3 N
O H
H N
N N O
HN N
O O
CH O CH O O
3 3 CH3
H C CH CH3
3 3
First, N-[(benzyloxy)carbonyl]-N-methyl-L-threonine was released from 237 mg (0.887 mmol) of
its dicyclohexylamine salt by taking it up in ethyl acetate and extractive g with 5% aqueous
sulphuric acid. The organic phase was dried over magnesium sulphate, filtered and concentrated.
14.7 mg (0.055 mmol) of N-[(benzyloxy)carbonyl]-N-methyl-L-threonine were taken up in 3 ml of
DMF and d successively with 40 mg (0.055 mmol) of Intermediate 220, 12.7 mg (0.066
mmol) of imethylaminopropyl)ethylcarbodiimide hydrochloride and 10 mg (0.066 mmol)
of 1-hydroxy-1H-benzotriazole e. The mixture was subsequently stirred at RT for 2 h. The
solvent was then removed under reduced pressure and the residue purified by preparative HPLC.
29 mg (54% of theory) of the Z-protected intermediate were thus obtained.
LC-MS (Method 1): Rt = 1.15 min; MS (ESIpos): m/z = 976 (M+H)+.
29 mg (0.003 mmol) of this intermediate were ved in 5 ml of methanol and hydrogenated
over 5 mg of 5% palladium/charcoal at RT and standard re for 1 h. The catalyst was
subsequently filtered off and the solvent was evaporated off. The remaining residue was purified
by preparative HPLC. 17 mg (54% of theory) of the title compound were obtained.
LC-MS (Method 1): Rt = 0.77 min; MS (ESIpos): m/z = 842 (M+H)+.
Intermediate 240
N-{6-[(2,5-dioxopyrrolidinyl)oxy]oxohexyl}-N-methyl-L-threonyl-N-[(3R,4S,5S){(2S)
[(1R,2R){[(2S)(1H-indolyl)(1,2-oxazinanyl)oxopropanyl]amino}methoxy
methyloxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide
H C OH H C
3 3 CH
3 N
O O H
H N
O N N O
N N N
O O
O CH O CH O O
3 3 CH
O H C CH CH 3
3 3 3
This compound was prepared in analogy to Intermediate 210 from 15.6 mg (0.016 mmol) of
Intermediate 239. 10.8 mg (67% of theory over 2 stages) of the title compound were ed.
HPLC (Method 5): Rt = 1.7 min;
LC-MS (Method 1): Rt = 0.85 min; MS (ESIpos): m/z = 1053 .
Intermediate 241
N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)(4-hydroxyphenyl)(1,2-oxazinan-
1-oxopropanyl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxy
methyloxoheptanyl]-N-methyl-L-valinamide trifluoroacetate
H C CH H C CH N
3 3 3
O 3 H
H N
N N O
HN N
O O
CH O CH O O
3 3 CH
H C CH CH 3
3 3 3
First, in analogy to Intermediate 5, trifluoroacetic acid-(2S)amino(4-hydroxyphenyl)(1,2-
oxazinanyl)propanone (1:1) was prepared. This reagent was then used, in analogy to the
synthesis described in Intermediate 75, by ng with N-(tert-butoxycarbonyl)-N-methyl-L-
valyl-N-[(3R,4S,5S){(2S)[(1R,2R)carboxymethoxypropyl]pyrrolidinyl}methoxy-
-methyloxoheptanyl]-N-methyl-L-valinamide (Intermediate 26) in the presence of O-(7-
azabenzotriazolyl)-N,N,N',N'-tetramethyluronium uorophosphate and subsequent
detachment of the Boc protecting group by means of trifluoroacetic acid, to e the title
compound.
HPLC (Method 12): Rt = 1.7 min;
LC-MS (Method 1): Rt = 0.85 min; MS (ESIpos): m/z = 817 (M+H)+.
Intermediate 242
N-{6-[(2,5-dioxopyrrolidinyl)oxy]oxohexyl}-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)
[(1R,2R){[(2S)(4-hydroxyphenyl)(1,2-oxazinanyl)oxopropanyl]amino}
methoxymethyloxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-
namide
H C CH H C
3 3 3 CH
O 3 N
O H
H N
O N N O
N N N
O O
O CH O CH O O
3 3 CH
O H C CH CH
3 3
50 mg (0.05 mmol) of Intermediate 241 were reacted, in analogy to Intermediate 210, with 6-
oxohexanoic acid in the presence of borane-pyridine complex. Subsequently, 22.5 mg (0.02 mmol)
of the resulting acid were converted to the activated ester. 13.5 mg (36% of theory over 2 stages)
of the title compound were obtained.
HPLC (Method 12): Rt = 1.8 min;
LC-MS (Method 1): Rt = 0.86 min; MS (ESIpos): m/z = 1028 (M+H)+.
Alternatively, the title compound can also be obtained by one-hour catalytic hydrogenation of
Intermediate 250 at room temperature in ol over 10% palladium on active carbon under
hydrogen standard pressure.
Intermediate 243
N-(6-aminohexyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)(4-
hydroxyphenyl)(1,2-oxazinanyl)oxopropanyl]amino}methoxymethyl
oxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide
H C CH H C
3 3 3 CH N
O 3
H N
H N N N
2 O
N N
O O
CH O CH O O H C
3 3
H C CH 3
3 3 3
OH
The preparation was effected in analogy to ediate 78, by reductive alkylation of Intermediate
241 with benzyl exyl carbamate and borane-pyridine complex and subsequent
hydrogenation in methanol as the solvent.
Yield: 17.5 mg (34% of theory over 2 stages)
HPLC (Method 12): Rt = 1.7 min;
LC-MS (Method 1): Rt = 0.63 min; MS (ESIpos): m/z = 916 .
Intermediate 244
N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexyl]-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)
[(1R,2R){[(2S)(4-hydroxyphenyl)(1,2-oxazinanyl)oxopropanyl]amino}
methoxymethyloxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-
L-valinamide
O H3C CH H C CH3
3 3 N
O H
H N
N N N O
N N
O O
O CH O CH O O H C
3 3 3
H3C CH CH
3 3
The preparation was effected in analogy to Intermediate 166, proceeding from Intermediate 243.
Yield: 1.3 mg (12% of theory)
HPLC (Method 12): Rt = 1.9 min;
LC-MS (Method 1): Rt = 0.89 min; MS (ESIpos): m/z = 996 (M+H)+.
ediate 245
2,5-dioxopyrrolidinyl ,4S,7S,10S)[(2S)-butanyl](2-{(2S)[(1R,2R){[(2S)
(1H-indolyl)(1,2-oxazinanyl)oxopropanyl]amino}methoxymethyl
oxopropyl]pyrrolidinyl}oxoethyl)-7,10-diisopropyl-5,11-dimethyl-6,9,15-trioxooxa-
5,8,11-triazapentadecanyl]-N-(tert-butoxycarbonyl)-L-threonyl-beta-alaninate
O CH CH
3 3
H C CH H C
3 3 3 CH
HN O 3 N
O O H
H H N
O N O N N O
N N N
O O
O O CH O CH O CH O O
3 3 3 CH
H C CH CH 3
O 3 3 3
First, Intermediate 193, as described under Intermediate 154, was reacted with benzyl N-(tertbutoxycarbonyl
)-L-threoninate and then the benzyl ester was removed by hydrogenolysis. 30 mg
(0.027 mmol) of the N-[4-({(1S,2R)[(tert-butoxycarbonyl)amino]carboxypropanyl}oxy)
yl]-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)(1H-indolyl)(1,2-
oxazinanyl)oxopropanyl]amino}methoxymethyloxopropyl]pyrrolidinyl}
methoxymethyloxoheptanyl]-N-methyl-L-valinamide thus obtained were then coupled with
4-methylbenzenesulphonic acid-benzyl beta-alaninate (1:1) in the ce of HATU and the benzyl
ester was removed again by hydrogenolysis (yield: 24 mg (71% of theory over 2 stages)). Finally, 10
mg (0.008 mmol) of the resulting acid were converted to the activated ester. After HPLC
purification, 2.7 mg (23% of theory) of the title compound were obtained.
HPLC (Method 5): Rt = 1.9 min;
LC-MS (Method 1): Rt = 1.01 min; MS (ESIpos): m/z = 1295 (M+H)+
Intermediate 246a
(2S)amino(4-hydroxy-1,2-oxazolidinyl)(1H-indolyl)propanone trifluoroacetic acid
(1:1) Diastereomer 1
CF3COOH x H N
2 O
Diastereomer 1
CF3COOH x H N
2 O
Diastereomer 2
1.6 g (3.982 mmol) of 2,5-dioxopyrrolidinyl N-(tert-butoxycarbonyl)-L-tryptophanate were
dissolved in 15 ml of DMF and admixed with 500 mg (3.982 mmol) of 1,2-oxazolidinol and
100 µl of N,N-diisopropylethylamine. The reaction mixture was stirred at RT ght. Then
another 100 µl of N,N-diisopropylethylamine were added, and the mixture was first d in an
ultrasound bath for 5 h, then stirred at RT overnight, and subsequently concentrated under reduced
pressure. The remaining residue was taken up in ethyl acetate and shaken first twice with 5% citric
acid solution, then with ted sodium hydrogencarbonate solution and finally with water. The
organic phase was trated and the e was separated into the reomers by flash
chromatography on silica gel with 95:5 dichloromethane/methanol as the eluent. The
corresponding fractions of both diastereomers were combined and the solvent was removed under
reduced pressure. After the residues had been dried under high vacuum, 272 mg (18% of theory) of
Diastereomer 1 (Rf = 0.18 (95:5 dichloromethane/methanol) and 236 mg (16% of theory) of
Diastereomer 2 (Rf = 0.13 (95:5 dichloromethane/methanol), and also 333 mg (22% of theory) of
a mixed fraction of the Boc-protected intermediates were obtained.
Under standard conditions, 5 ml of trifluoroacetic acid in 20 ml of dichloromethane were used to
detach the Boc ting group from 272 mg (725 µmol) of Diastereomer 1 of this intermediate
and, after lyophilization from dioxane/water, 290 mg (quant) of the title compound were ed
in 75% purity and used in the next stage without further purification.
HPLC (Method 12): Rt = 1.1 min;
LC-MS d 13): Rt = 1.80 min; MS (ESIpos): m/z = 276 (M+H)+
Intermediate 246b
(2S)amino(4-hydroxy-1,2-oxazolidinyl)(1H-indolyl)propanone trifluoroacetic acid
(1:1) Diastereomer 2
CF3COOH x H N
2 O
Diastereomer 2
Under standard conditions, 5 ml of trifluoroacetic acid in 20 ml of dichloromethane were used to
detach the Boc protecting group from 236 mg (630 µmol) of Diastereomer 2 of the intermediate
described in 246a and, after tration, stirring with diethyl ether and drying of the residue
under high vacuum, 214 mg (76%) of the title nd were obtained.
LC-MS (Method 13): Rt = 1.84 min; MS (ESIpos): m/z = 276 (M+H)+
Intermediate 247a
N-{6-[(2,5-dioxopyrrolidinyl)oxy]oxohexyl}-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)
[(1R,2R){[(2S)(4-hydroxy-1,2-oxazolidinyl)(1H-indolyl)oxopropanyl]amino}
methoxymethyloxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-
valinamide
3 O
H C CH H C
3 3 3 CH N
O O 3 H
H N
O N N O
N N N
O O
O CH O CH O O
3 3 CH
O H C CH CH 3
3 3 3
Diastereomer 1
To synthesize this compound, the coupling of Intermediates 26 and 246a with subsequent
detachment of the Boc protecting group was first med as described for Intermediate 74.
Subsequently, the alkylation with 6-oxohexanoic acid in the presence of borane-pyridine x
and subsequent conversion of the acid to the active ester were performed as described in
Intermediate 210. The title nd was purified by preparative HPLC.
HPLC (Method 12): Rt = 1.8 min;
LC-MS (Method 1): Rt = 0.86 min; MS (ESIpos): m/z = 1053 (M+H)+
Intermediate 247b
(2,5-dioxopyrrolidinyl)oxy]oxohexyl}-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)
[(1R,2R){[(2S)(4-hydroxy-1,2-oxazolidinyl)(1H-indolyl)oxopropanyl]amino}
methoxymethyloxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-
valinamide
3 O
H C CH H C
3 3 3 CH
3 N
O O H
H N
O N N O
N N N
O O
O CH O CH O O
3 3 CH
C CH CH 3
O H
3 3 3
Diastereomer 2
To synthesize this compound, the coupling of Intermediates 26 and 246b with subsequent
detachment of the Boc protecting group was first performed as described for Intermediate 74.
Subsequently, the tion with exanoic acid in the presence of borane-pyridine complex
and subsequent conversion of the acid to the active ester were performed as described in
Intermediate 210. The title compound was purified by preparative HPLC.
HPLC d 12): Rt = 1.8 min;
LC-MS (Method 1): Rt = 0.86 min; MS (ESIpos): m/z = 1053 (M+H)+
Intermediate 248
N-(5-carboxypentyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)tert-butoxy-
ydroxyphenyl)oxopropanyl]amino}methoxymethyloxopropyl]pyrrolidinyl}-
3-methoxymethyloxoheptanyl]-N-methyl-L-valinamide
CH3 3
H C CH H3C CH CH
3 O
3 O 3 3
H N
HO N N O
N N
O O
O CH O CH O O H C
3 3 CH 3
H C CH
3 3 3
First, in analogy to the synthesis described in Intermediate 86, by coupling N-(tert-
butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R)carboxy
methoxypropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide
(Intermediate 26) and utyl L-tyrosinate in the presence of zabenzotriazolyl)-
N,N,N',N'-tetramethyluronium hexafluorophosphate and subsequent detachment of the Boc
protecting group by means of oroacetic acid to obtain the tert-butyl ester (stirring with
oroacetic acid in dichloromethane for 40 min), the amine compound tert-butyl N-[(2R,3R)
methoxy{(2S)[(3R,4S,5S)methoxymethyl(methyl{(2S)methyl[(N-methyl-L-
valyl)amino]butyl}amino)heptanoyl] pyrrolidinyl}methylpropanoyl]-L-tyrosinate was prepared
as the trifluoroacetate. 38 mg (0.04 mmol) of this compound were then used, in analogy to the
preparation of Intermediate 210, by reaction with 4-oxohexanoic acid in the presence of borane-
pyridine complex, to obtain 31 mg (99% of theory) of the title compound.
HPLC (Method 12): Rt = 1.8 min;
LC-MS (Method 1): Rt = 0.88 min; MS (ESIpos): m/z = 918 (M+H)+.
Intermediate 249
Trifluoroacetic acid-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)[4-(benzyl-
oxy)phenyl](1,2-oxazinanyl)oxopropanyl]amino}methoxymethyl
oxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide(1:1)
OH CH3
F H C CH H C CH N
3 3 3
O 3
H N
N N O
HN N
O O
CH O CH O O
3 3 CH
H C CH CH 3
3 3 3
First, in analogy to ediates 5 and 6, starting from O-benzyl-N-(tert-butoxycarbonyl)-L-
tyrosine, trifluoroacetic acid-(2S)amino[4-(benzyloxy)phenyl](1,2-oxazinanyl)propan-
1-one(1:1) was prepared. Then, from this building block, in analogy to the synthesis described in
Intermediate 75, coupling with N-(tert-butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)-
2-[(1R,2R)carboxymethoxypropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-
N-methyl-L-valinamide (Intermediate 26) in the presence of O-(7-azabenzotriazolyl)-N,N,N',N'-
tetramethyluronium hexafluorophosphate and subsequent elimination of the Boc protecting group
by means of trifluoroacetic acid gave the title compound.
HPLC (Method 12): Rt = 2.15 min;
LC-MS (Method 1): Rt = 0. 99 min; MS (ESIpos): m/z = 908 (M+H)+.
Intermediate 250
N-{6-[(2,5-Dioxopyrrolidinyl)oxy]oxohexyl}-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)
[(1R,2R){[(2S)[4-(benzyloxy)phenyl](1,2-oxazinanyl)oxopropanyl]amino}
methoxymethyloxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-
L-valinamide
H3C CH H3C
3 CH
3 N
O O H
H N
O N N O
N N N
O O
O CH O CH3 O O
3 CH3
H3C CH3 CH3
100 mg (0.088 mmol) of ediate 249 were d in analogy to Intermediate 210 with 6-
oxanoic acid in the presence of borane-pyridine complex. Then 30 mg (0.029 mmol) of the
2012/075277
resulting acid were converted into the activated ester. This gave 15 mg (40% of theory over 2
stages) of the title compound.
HPLC (Method 12): Rt = 2.26 min;
LC-MS (Method 1): Rt = 1.05 min; MS (ESIpos): m/z = 1119 (M+H)+.
Intermediate 251
N-[4-(2-{5-[(2,5-Dioxopyrrolidinyl)oxy]oxopentanoyl}methylhydrazino)oxobutyl]-N-
methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)(1H-indolyl)(1,2-oxazinan
yl)oxopropanyl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxy
methyloxoheptanyl]-N-methyl-L-valinamide
O H C CH H C
3 CH N
O 3 3
O O 3
H H N
N N N N O
O N N N
O O
O CH O CH O CH O O
3 3 3 CH
H C CH CH 3
3 3 3
H
First of all, 30 mg (0.032 mmol) of Intermediate 193 were converted into the activated N-
hydroxysuccinimide ester. 10.3 mg (0.009 mmol) of this active ester were dissolved in 2 ml of
DMF, admixed with 2.7 mg (0.018 mmol) of utyl 1-methylhydrazinecarboxylate and 8 µL
N,N-diisopropylethylamine, and stirred at RT for 16 h. This operation was repeated, and then the
batch was concentrated and the residue which remained was purified by preparative HPLC.
Concentration of the corresponding fractions and drying under a high vacuum gave 5.4 mg (43%)
of the intermediate.
LC-MS (Method 1): Rt = 0. 99 min; MS (ESIpos): m/z = 1054 (M+H)+.
The Boc protecting group was removed from 3.5 mg (0.002 mmol) of this intermediate, using
trifluoroacetic acid in dichloromethane. Following concentration and drying under a high vacuum,
the residue was taken up in 4 ml of romethane and admixed with 1,1'-[(1,5-dioxopentane-
1,5-diyl)bis(oxy)]dipyrrolidine-2,5-dione and 2 µl of N,N-diisopropylethylamine. After ng at
RT for 1 h, the batch was trated and the residue which remained was ed by preparative
HPLC. Concentration of the corresponding fractions and drying under a high vacuum gave 1.4 mg
(44%) of the title compound.
HPLC (Method 5): Rt = 1.6 min;
LC-MS d 1): Rt = 0.88 min; MS (ESIpos): m/z = 1166 (M+H)+.
Intermediate 252
N-(2-{2-[2-(2-Carboxyethoxy)ethoxy]ethoxy}ethyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)
R){[(2S)(4-hydroxyphenyl)(1,2-oxazinanyl)oxopropanyl]amino}methoxy-
2-methyloxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-
valinamide
H C CH H C CH
3 3 3 3 N
O H
H N
HO O O N N O
O N N
O O
O CH O CH O O
3 3 CH
H C CH CH
3 3 3
100 mg (0.088 mmol) of Intermediate 249 and 109 mg (0.350 mmol) of Intermediate 167 were
combined in 10 ml of ol and admixed with 39 mg (0.42 mmol) of borane-pyridine complex
and 15 µl of acetic acid. The batch was stirred at RT overnight. Then the same amounts of boranepyridine
complex and of acetic acid were added once again, and the batch was stirred for a further
24 h at RT. It was then concentrated under reduced pressure, and the residue was purified by
means of preparative HPLC. Concentration of the ponding fractions and lyophilization from
dioxane/water 1:1 gave 98 mg (93% of theory) of the bis-benzyl ediate. This intermediate
was taken up in 18.5 ml of methanol and subjected to catalytic hydrogenation over 5% palladium
on activated carbon under standard hydrogen pressure at room temperature for 1 h. Filtration,
concentration, and lyophilization of the residue from dioxane gave 73 mg (87% of theory) of the
title compound.
HPLC (Method 12): Rt = 1.85 min;
LC-MS (Method 1): Rt = 0.84 min; MS (ESIpos): m/z = 1021 .
Intermediate 253
N-{2-[2-(2-{3-[(2,5-Dioxopyrrolidinyl)oxy]oxopropoxy}ethoxy)ethoxy]ethyl}-N-methyl-L-
valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)(4-hydroxyphenyl)(1,2-oxazinanyl)
oxopropanyl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxymethyl
oxoheptanyl]-N-methyl-L-valinamide
2012/075277
O O H C CH CH3 N
N 3 3 3
O H
H N
O O O N N O
O N N
O O
O CH3 O CH O O
3 CH3
H C CH CH3
3 3
22 mg (22 µmol) of Intermediate 252 were dissolved in 8.5 ml of DMF and admixed with 25 mg
(215 µmol) of 1-hydroxypyrrolidine-2,5-dione and subsequently with 12.3 mg (32 µmol) of O-(7-
azabenzotriazolyl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU) and 37 µl of
N,N-diisopropylethylamine. After ng at RT for 2 h, the reaction e was purified by
means of preparative HPLC. Lyophilization from dioxane gave 16 mg (62% of theory) of the title
compound.
HPLC (Method 5): Rt = 1.57 min;
LC-MS d 1): Rt = 0.8 min; MS (ESIpos): m/z = 1118 (M+H)+.
Intermediate 254
N-(2-{2-[2-(2-Carboxyethoxy)ethoxy]ethoxy}ethyl)-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy
{(2S)[(1R,2R)methoxymethyloxo{[(1S)phenyl(5-phenyl-1,3,4-oxadiazol
yl)ethyl]amino}propyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-valinamide
O N
HO O O N N N
O N N
O O
O O O O
10 mg (0.012 mmol) of Intermediate 55 and 11 mg (0.036 mmol) of Intermediate 167 were
combined in 1 ml of methanol and admixed with 5.4 mg (0.058 mmol) of borane-pyridine complex
and 1 µl of acetic acid. The batch was stirred at RT overnight. Then the same amounts of boranepyridine
complex and of acetic acid were added once again, and the batch was stirred at RT for a
further 20 h. It was then concentrated under d pressure and the residue was purified by
means of preparative HPLC. Concentration of the corresponding fractions and lyophilization from
dioxane/water 1:1 gave 8 mg (58% of theory) of bis-benzyl intermediate. This intermediate was
taken up in 2 ml of methanol and subjected to catalytic hydrogenation over 5% palladium on
activated carbon under standard en pressure at room temperature for 1 h. Filtration,
concentration, and lyophilization of the residue from dioxane gave 7 mg (95% of theory) of the
title compound.
LC-MS d 1): Rt = 0.99 min; MS (ESIpos): m/z = 1036 (M+H)+.
Intermediate 255
N-{2-[2-(2-{3-[(2,5-Dioxopyrrolidinyl)oxy]oxopropoxy}ethoxy)ethoxy]ethyl}-N-methyl-L-
valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxymethyloxo{[(1S)phenyl
(5-phenyl-1,3,4-oxadiazolyl)ethyl]amino}propyl]pyrrolidinyl}methyloxoheptanyl]-N-
methyl-L-valinamide
O N O O
O N
O O O N N N
O N N
O O
O O O O
7.3 mg (7 µmol) of Intermediate 254 were dissolved in 0.3 ml of DMF and admixed with 12 mg
(106 µmol) of 1-hydroxypyrrolidine-2,5-dione and subsequently with 13.5 mg (35 µmol) of O-(7-
azabenzotriazolyl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU) and 6 µl of
N,N-diisopropylethylamine. After ng at RT for 2 h, the reaction mixture was purified by
means of preparative HPLC. lization from dioxane gave 7.7 mg (79% of theory) of the title
compound.
LC-MS (Method 1): Rt = 0.97 min; MS (ESIpos): m/z = 1134 (M+H)+.
ediate 256
N-(2-{2-[2-(2-Aminoethoxy)ethoxy]ethoxy}ethyl)-N-methyl-L-valyl-N-[(3R,4S,5S)methoxy
{(2S)[(1R,2R)methoxymethyloxo{[(1S)phenyl(5-phenyl-1,3,4-oxadiazol
yl)ethyl]amino}propyl]pyrrolidinyl}methyloxoheptanyl]-N-methyl-L-valinamide
O N
O O N N N
H N N N
2 O
O O
O O O
mg (0.02 mmol) of ediate 55 were subjected to reductive amination in analogy to the
preparation of Intermediate 254, with benzyl (2-{2-[2-(2-oxoethoxy)ethoxy]ethoxy}ethyl)-
carbamate (Intermediate 172) in the presence of borane-pyridine complex. The Z protecting group
was subsequently removed by hydrogenolysis, using 5% palladium on carbon as catalyst and in
methanol as solvent, and 21 mg (85% of theory over 2 stages) of the title compound were
prepared.
LC-MS (Method 1): Rt = 0.85 min; MS (ESIpos): m/z = 1008 (M+H)+.
Intermediate 257
2-{2-[2-(2,5-Dioxo-2,5-dihydro-1H-pyrrolyl)ethoxy]ethoxy}ethoxy)ethyl]-N-methyl-L-
valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxymethyloxo{[(1S)phenyl
(5-phenyl-1,3,4-oxadiazolyl)ethyl]amino}propyl]pyrrolidinyl}methyloxoheptanyl]-N-
methyl-L-valinamide
O O N
O O N N N
N O N N
O O
O O O
21 mg (20.8 µmol) of ediate 256 were taken up in 1 ml of dioxane/water 1:1 and then
admixed with 4.9 mg (31.2 µmol) of methyl 2,5-dioxo-2,5-dihydro-1H-pyrrolecarboxylate and
also wtih 42 µl of 1M s sodium hydrogen carbonate solution. The on mixture was
stirred at RT for 30 min. Then a further 374 µl of the 1M aqueous sodium hydrogen carbonate
solution were added, and the reaction mixture was d at RT for a r 30 min and then
concentrated under reduced pressure. The residue which remained was purified by means of
preparative HPLC. Lyophilization gave 4.5 mg (20% of theory) of the title compound, as a
colourless foam.
LC-MS (Method 1): Rt = 1.04 min; MS (ESIpos): m/z = 1088 (M+H)+.
Intermediate 258
N-{2-[2-(2-{3-[(2,5-Dioxopyrrolidinyl)oxy]oxopropoxy}ethoxy)ethoxy]ethyl}-N-methyl-L-
valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)[4-(benzyloxy)phenyl](1,2-oxazinanyl)-
1-oxopropanyl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxymethyl-
1-oxoheptanyl]-N-methyl-L-valinamide
O O H C CH H C
3 3 CH
3 O 3 N
N H
H N
O O O N N O
O N N
O O
O CH O CH O O
3 3 CH
H C CH CH 3
3 3 3
This compound was prepared starting from Intermediate 249 by reductive alkylation using tertbutyl
3-{2-[2-(2-oxoethoxy)ethoxy]ethoxy}propanoate, followed by t-butyl ester ge and
conversion into the N-hydroxysuccinimide ester.
HPLC (Method 5): Rt = 1.96 min;
LC-MS (Method 1): Rt = 1.11 min; MS (ESIpos): m/z = 1208 (M+H)+.
Intermediate 259
N-(5-Carboxypentyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S,3E)-1,4-
diphenylbutenyl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxy
methyloxoheptanyl]-N-methyl-L-valinamide
H C CH H C
3 3 3 CH
O 3 H
H N
HO N N
N N
O O
O CH O CH3 O O CH
3 H C CH3
3 CH
9.6 mg (8.4 µmol) of N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S,3E)-1,4-
diphenylbutenyl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxy
oxoheptanyl]-N-methyl-L-valinamide trifluoroacetate (Intermediate 58) and 6.5 mg
(51 µmol) of 6-oxohexanoic acid were taken up in 769 µl of methanol and acidified with acetic
acid. Then, at room temperature, 4 µl (40 µmol) of borane-pyridine x were added. The
reaction mixture was subsequently stirred at RT for 20 h. The reaction mixture was then adjusted
to a pH of 2 with trifluoroacetic acid, and purified by means of preparative HPLC. The production
fractions were combined and trated and the residue was lized. This gave 8 mg (93%
of theory) of the title compound, as a foam.
LC-MS (Method 1): Rt = 1.06 min; m/z = 1019 (M+H)+.
WO 87716
Intermediate 260
N-{6-[(2,5-Dioxopyrrolidinyl)oxy]oxohexyl}-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)
R){[(2S,3E)-1,4-diphenylbutenyl]amino}methoxymethyl
oxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide
O O H C CH H C
N 3 3 3 CH
O 3 H
H N
O N N
N N
O O
O CH O CH O O CH
3 H C CH 3
3 3 CH
7.5 mg (7.4 µmol) of Intermediate 259 were dissolved in 332 µl of DMF and admixed with
12.7 mg (110 µmol) of 1-hydroxypyrrolidine-2,5-dione and subsequently with 14 mg (37 µmol) of
O-(7-azabenzotriazolyl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU) and 6 µl
of N,N-diisopropylethylamine. After stirring at RT for 2 h, the reaction mixture was purified by
means of preparative HPLC. lization from dioxane gave 4 mg (55% of theory) of the title
compound.
LC-MS (Method 1): Rt = 1.19 min; m/z = 1002 (M+H)+.
Intermediate 261
N-{2-[2-(2-{3-[(2,5-Dioxopyrrolidinyl)oxy]oxopropoxy}ethoxy)ethoxy]ethyl}-N-methyl-L-
valyl-N-[(3R,4S,5S)methoxy{(2S)[(1R,2R)methoxymethyl{[(1S,2R)(1,2-
oxazinanylcarbonyl)phenylcyclopropyl]amino}oxopropyl]pyrrolidinyl}methyl
oxoheptanyl]-N-methyl-L-valinamide
H C CH H C
3 3 3 CH
3 N
O O H
H N
O O O N N O
N O N N
O O
O CH O CH O O
3 3 CH
CH CH 3
O H C
3 3 3
This compound was prepared starting from Intermediate 16 by reductive tion with benzyl 3-
{2-[2-(2-oxoethoxy)ethoxy]ethoxy}propanoate, subsequent benzyl ester cleavage by
hydrogenolysis, and conversion into the N-hydroxysuccinimide ester.
HPLC (Method 5): Rt = 1.83 min;
LC-MS (Method 1): Rt = 0.93 min; MS s): m/z = 1114 (M+H)+.
B: Preparation of antibody-drug conjugates (ADCs)
B-1. Generation of anti-FGFR2 antibodies
The human anti-FGFR2 antibodies M048-D01-hIgG1 and M048-D01-hIgG1-b of the present
invention were isolated by phage display logy, using the naïve Fab antibody library
n-CoDeR from Bioinvent International AB (Lund, Sweden; described in Söderling et al., Nat.
Biotech. 2000, 18:853-856). One ing hit was the parental Fab fragment M048-D01. The
variable region of the heavy chain Vh of this Fab fragment is given by SEQ ID NO: 21; the
variable region of the light chain Vl is given by SEQ ID NO: 22. Following identification of the
01 Fab fragment, it was expressed under the name M048-D01-hIgG1-b (SEQ ID NO: 10
for the heavy chain, and SEQ ID NO: 9 for the light chain) in the form of human IgG. For efficient
g, the first three amino acids of the N-terminus of the heavy chain of M048-D01-hIgG1-b
[EVQ] were also expressed, alternatively, as QVE. This variation gave the antibody M048-D01-
hIgG1 (SEQ ID NO: 8 for the heavy chain and SEQ ID NO: 7 for the light chain). The variable
regions Vh and Vl of M048-D01-hIgG1 are given by SEQ ID NO: 11 and SEQ ID NO: 12; the
variable regions Vh and Vl of M048-D01-hIgG1-b are given by SEQ ID NO: 13 and SEQ ID
NO: 14. Both antibodies have the same CDR sequences, which are given by SEQ ID NOs: 15
(H-CDR1), 16 (H-CDR2), 17 (H-CDR3), 18 (L-CDR1), 19 2) and 20 (L-CDR3).
The antibodies 21-mIgG1 and GAL-FR22-mIgG2a are described in WO2010/054265 as
mIgG1 (GAL-FR21) and mIgG2b (GAL-FR22). GAL-FR21 is defined therein via Vh (SEQ ID
NO: 4 in WO2010/054265) and via Vl (SEQ ID NO: 1 in WO2010/054265), and GAL-22 is
defined via Vh (SEQ ID NO: 8 in WO2010/054265) and via Vl (SEQ ID NO: 7 in
WO2010/054265). For the studies bed in the present application, Vl and Vh of GAL-FR21
were reformatted into the murine IgG1 format, resulting in the antibody GAL-FR21-mIgG1 (SEQ
ID NO: 3 and SEQ ID NO: 4 of the present ation). Vl and Vh of GAL-FR22 were
reformatted into the murine IgG2a format, resulting in the antibody GAL-FR22-mIgG2a (SEQ ID
NO: 5 and SEQ ID NO: 6 of the present application).
B-2. Expression of anti-FGFR2 antibodies
The dies M048-D01-hIgG1, M048-D01-hIgG1-b, GAL-FR21-mIgG1 and GAL-FR22-
mIgG2a were produced transiently in mammalian cell culture.
The expression constructs were produced as described below:
In order to transfer the Vh and Vl regions of the M048-D01 Fab originating from the phage display
into the IgG , and in order to change the sion system from E. coli to mammalian cells,
the Vh and Vl sequences from the phage display E. coli clone were amplified using PCR primers.
The ng restriction enzyme cleavage sites were uced at the 5’ and 3’ ends both of Vh
and of Vl. These restriction enzyme cleavage sites were used for the cloning of Vh and Vl into an
expression vector which contained the IgG backbone.
The E. coli cells were incubated in a test tube with 100 µl of water at 95°C for 10 minutes and then
placed on ice for 5 minutes. Following brief vortexing, the solution was clarified by centrifugation.
The supernatant separated off was used for DNA amplification. The PCR reactions were carried
out tely for Vh and Vl. This was done using specific primer pairs with BamHI and NotI
cleavage sites for Vl and MfeI, and MfeI and BlpI cleavage sites for Vh. The PCR reactions were
carried out using the ime Pfx rase (Invitrogen, # 12344-024) according to
manufacturer instructions. The PCR products were analysed on 1% agarose gels. To obtain
compatible ends, the expression vectors and PCR products were digested according to
cturer instructions with the corresponding restriction endonucleases at 37°C for 2 hours
(see Table 1). Digestion was halted by incubation at 70°C for 15 minutes. The resulting nts
were ligated into the expression vector, and E. coli or mammalian cells were transformed with the
constructs by standard methods.
The DNA sequences of the Vh and Vl domains or of complete light chains of certain antibodies
(GAL-FR21-mIgG1, GAL-FR22-mIgG2a and M048-D01-hIgG1-b) were synthesized by Geneart
gene synthesis and gene optimizer technology for mammalian gene sion (life technologies,
Grand Island, NY, USA). During the gene synthesis, the V domains on sequences coding for a
mammalian signal peptide were fused with upstream Kozaki sequence. Flanking restriction
cleavage sites were inserted on 5’ and 3’ ends of the synthesized DNA constructs. These
restriction cleavage sites were used for the cloning of the Vh and Vl or the light chains into an
expression vector which ned the coding constant regions of the IgG.
The expression vectors and the t constructs were digested according to cturer
instructions with the respective restriction endonucleases at 37°C for 2 hours, to give compatible
ends (see Table 1). Digestion was halted by incubation at 70°C for 15 minutes. The resulting
fragments were ligated, and E. coli cells were transformed with the ligates. Plasmids obtained from
these transformants were used to transform mammalian cells according to standard s.
Table1: Restriction cleavage sites for the cloning of Vh and Vl or of the light chain into IgG
expression vectors
Antibody Restriction ge site for the cloning of:
VH VL or light chain*
GAL-FR21-mIgG1 HindIII – BlpI XbaI – BsiWI
GAL-FR22-mIgG2a HindIII – BlpI XbaI – BsiWI
M048-D01-hIgG1# MfeI-BlpI BamHI – NotI*
M048-D01-hIgG1-b I-BlpI XbaI – NotI*
* Cloning of the complete light chain
# Cloning of the PCR product into EcoRI-BlpI and NotI-digested expression vectors.
The antibodies were expressed transiently in mammalian cell culture, as described in Tom et al.
(Tom et al., Chapter 12 in Methods Express: Expression Systems, edited by Michael R. Dyson and
Yves Durocher, Scion Publishing Ltd, 2007): for the expression of the anti-FGFR2 dies, for
example M048-D01-hIgG1, GAL-FR21-mIgG1 and GAL-FR22-mIgG2a, HEK293 6E cells were
transfected ently with a suitable CMV promoter-based expression plasmid. The cell culture
scale was either up to 1.5 l in a shake flask or 10 l in a bag”. Expression took place at 37°C
for 5-6 days in F17 medium (Invitrogen) supplemented with ne TN1 (Organotechnie) with
1% “FCS ultra low IgG” rogen) and 0.5 mM valproic acid.
Alternatively, the anti-FGFR2 antibodies, for example M048-D01-hIgG1-b, were expressed in a
stably transfected Chinese hamster ovary (CHO) cell line. This was done using a one-vector
system. Fermentation took place in bioreactors on a different scale in a fed-batch process.
The parental Fab fragment M048-D01 (Vh: SEQ ID NO: 21, Vl: SEQ ID NO: 22) belonging to the
M048-D01-based antibodies from the phase display was sed as s: 20-50 ml of LB
medium (admixed with 0.1 mg/ml ampicillin and 0.1% glucose) were inoculated with a
preliminary culture of a corresponding E. coli clone, which contained the initial pBif vector, which
was lacking the geneIII sequence, but which had had the M048-D01 Fab sequence cloned into it.
Production of the sFab was started by addition of 0.5 mM IPTG (final concentration). Incubation
took place at 30°C overnight at 250 rpm.
B-3. Purification of the FGFR-2 antibodies
The antibodies, for example 01-hIgG1, M048-D01-hIgG1-b, GAL-FR21-mIgG1 and
GAL-FR22-mIgG2a, were obtained from the cell culture supernatants. The cell supernatants were
clarified by centrifugation from cells. The cell supernatant was subsequently purified by affinity
chromatography on a MabSelect Sure (GE Healthcare) chromatography . For this purpose,
the column was equilibrated in DPBS pH 7.4 (Sigma/Aldrich), the cell supernatant was applied
and the column was washed with around 10 column s of DPBS pH 7.4 + 500 mM NaCl.
The antibodies were eluted in 50 mM Na acetate pH 3.5 + 500 mM NaCl, and subsequently
ed further by gel filtration chromatography on a Superdex 200 column (GE Heathlcare) in
DPBS pH 7.4.
The al 01 Fab fragment expressed in E. coli was purified as follows: the E. coli cells
were harvested by centrifugation and lysed by incubation at 4°C for 1 hour in lysis buffer (20%
sucrose (w/v), 30 mM TRIS, 1 mM EDTA, pH 8.0, 1 mg/ml lysozyme (Sigma L-6876) and
2.5 U/ml Benzonase (Sigma E1014)). fter the same volume of PBS was added. After that,
the ied supernatant was applied to Dynabeads for his-tag isolation (Invitrogen, 101-03D) and
the mixture was swirled at 4°C for 2 hours. Thereafter the matrix was washed three times with
buffer 1 (50 mM Na ate buffer, pH 7.4, 300 mM NaCl, 5 mM imidazole, 0.01% Tween 20).
Subsequently a single g step in buffer 2 was carried out (PBS admixed with 0.005% of
Tween 20). Lastly, the Fabs were eluted with buffer E (10 mM Na phosphate buffer, pH 7.4,
300 mM NaCl, 300 mM imidazole) and concentrated using PBS buffer in Vivaspin 500
concentrators (cut-off 10 000, from GE, 2825).
B-4. Construction of the cross-reactivity profile of the M048-D01-based antibodies
The cross-reactivity of the human antibodies M048-D01-hIgG1 and M048-D01-hIgG1-b of the
present application was determined using the parental Fab fragment M048-D01 (comprising Vh:
SEQ ID NO: 21 and Vl: SEQ ID NO: 22).
The M048-D01 Fab fragment was tested in an ELISA for binding to the various FGF receptor
variants listed in Table 2.
WO 87716
Table 2: List of inant proteins used for establishing the cross-reactivity profile of the
FGFR2 binders
Protein Origin Cat. No. (RnD Systems)
hFGFR2β-Fc (IIIb) Human 665-FR
mFGFR2β-Fc (IIIb) Mouse 708-MF
hFGFR2α-Fc (IIIb) Human 663-FR
hFGFR2β-Fc (IIIc) Human 684-FR
hFGFR1β-Fc (IIIc) Human 661-FR
hFGFR1β-Fc (IIIb) Human 765-FR
hFGFR3-Fc (IIIc) Human 766-FR
hFGFR3-Fc (IIIb) Human 1264-FR
hFGFR4-Fc Human 685-MF
mFGFR2β-Fc (IIIc) Mouse 716-MF
-Fc (IIIc) Mouse 710-MF
hTRAIL-Fc Human 630-TR
All of the variants took the form of Fc fusion proteins in r-free preparations. The proteins
were biotinylated according to manufacturer instructions, using a 2-fold molar excess of biotin-
LC-NHS (Pierce; Cat. No. 21347) and desalted using Zeba desalting columns (Pierce; Cat.
No. 89889).
For the ELISA, 96-well plates pretreated with streptavidin (Pierce, 15500) were loaded overnight
at 4°C with 1 µg/ml biotinylated protein. Wells which had been loaded with biotinylated TRAIL-
Fc served as a reference. The next day the plates were washed 3× with PBST (1 × PBS admixed
with 0.05% Tween 20 (Sigma, P7949)), treated with ng buffer (PBST admixed with 3%
BSA (Sigma A4503)), and again washed three times with PBST. 100 µl of the purified Fab
(1 µg/ml) were added, and incubation was carried out at room temperature for 1 hour. After
threefold washing with PBST, an HRP-coupled anti-hIgG (Fab-specific) (diluted 1:2500, Sigma,
A0293) was added, and tion took place at room temperature for 1 hour. The colour reaction
was activated by addition of 50 µl of TMB (Invitrogen, 2023) and halted after 5-15 s by
addition of 50 µl of H2SO4 (Merck, 1120801000). The colour reaction was monitored at 450 nm in
a plate reader (Tecan). The signal strengths of the wells containing TRAIL-Fc were used as
ound values, and the signal-to-background ratios were calculated as summarized in Table 3.
Table 3: y of the ELISA data on the cross-reactivity of M048-D01
hFGFR2β -Fc -Fc -Fc -Fc -Fc -Fc -Fc (IIIb ) hFGFR2β (IIIc ) hFGFR2α (IIIb ) mFGFR2β (IIIb ) mFGFR2β (IIIc) β (IIIb ) β (IIIc) hFGFR3-Fc (IIIb) hFGFR3-Fc (IIIc) mFGFR3-Fc (IIIc) hFGFR4-Fc
M048- +++ +++ +++ +++ +++ 0 0 0 0 0 0
Signal-to-background ratios: 0: <2; +: 2-3; ++: 3-5; +++: >5
As is evident from Table 2, the 01-based antibodies M048-D01-hIgG1 and M048-D01-
hIgG1-b bind to human and murine FGFR2, and do so independently of whether the forms in
question are alpha or beta isoforms, or are IIIb and IIIc splice forms. As is likewise apparent from
the table, the M048-D01-based antibodies of the invention do not bind to FGFR1, FGFR3 and
FGFR4.
B-5. Epitope mapping by means of CLIPS technology
In order to test the binding characteristics of the M048-D01-based antibodies, an intensive epitope
mapping operation was carried out on the basis of Pepscan’s proprietary “Chemically Linked
peptides on Scaffolds” (CLIPS) Technologie (Timmerman et al., J. Mol. Recognit. 2007, -
99). In all, 8653 different CLIPS peptides were designed, from 15 amino acids to 30 amino acids in
length, which cover linear, mational and discontinuous epitopes on the human FGFR2. The
peptides were synthesized on peptide arrays. The human antibody M048-D01-hIgG1 was tested on
the e arrays in an ELISA-based procedure. The peptides which gave the highest ELISA
values were analysed to isolate common, similar amino acid ces.
In order to truct discontinuous epitopes of the target molecule, a y of structured
peptides was synthesized. The CLIPS technology allows peptides to be structured in individual
loops, double loops, triple loops, sheet-like loops, helix-like loops, and combinations of these
structural elements: for this purpose, CLIPS templates are coupled to cysteine residues of the
e arrays. For example, a 0.5 mM solution of the T2 CLIPS template 1,3-
bis(bromomethyl)benzene was dissolved in ammonium bicarbonate (20 mM, pH 7.9)/acetonitrile
(1:1 (v/v)). This solution was added to the peptide arrays. The CLIPS template bound to the side
chains of 2 cysteines of the peptides present in the peptide arrays (455 well plate with 3 µl wells).
The peptide arrays were cautiously swirled in the solution for 30 to 60 minutes, with complete
coverage by the solution. At the conclusion, the arrays were washed thoroughly with water in
excess and were d in disrupt buffer (1% SDS, 0.1% beta-mercaptoethanol in PBS (pH 7.2)) at
70°C for 30 minutes in an ultrasound bath. The treatment in the ultrasound bath was uently
repeated in water for a r 45 minutes. T3 CLIPS-bearing peptides were prepared in a r
way.
The binding of the antibodies to each peptide was tested in a PEPSCAN-based ELISA (Sloostra et
al., Molecular Diversity 1996, 1: 87-96). The peptide arrays were preincubated (1 h, 20°C) with
% to 100% of binding buffer. The binding buffer consisted of 1% Tween 80, 4% horse serum and
% ovalbumin (w/v) in solution in PBS. After a washing step, the peptide arrays were ted at
4°C overnight with primary antibody solution (1 to 5 µg/ml) in 1% Tween 80 in PBS. After a
further washing step, the peptide arrays were incubated at 25°C for an hour in a 1/1000 dilution of
an antibody peroxidase conjugate (anti-human-IgG) in 100% binder buffer. After a further g
step, the peroxidase substrate 2,2’-azino-diethylbenzothiazolinesulphonate (ABTS) and 2 µl/ml
3% strength H2O2 were added. After an hour, the pment of colour was measured and was
quantified using a CCD camera and an image processing .
The crude data obtained in this method are optical values which range from 0-3000 mAU (milli-
absorption-units).
The result is that all the M048-D01-based antibodies bind on an epitope which consists of the 15
N-terminal residues of FGFR2 (1RPSFSLVEDTTLEPE 15 ). Analysis of 1257 CLIPS and linear
peptides gave consistently high ELISA values for N-terminal peptides.
The N-terminal residues (1RPSFSLVEDTTLEPE 15 ) are present in all splice variants of human
FGFR2, independently of alternative splicing in domain D3, which results in the IIIb and IIIc
isoforms. The epitope is also present if the domain D1 is removed from the full-length FGFR2
(FGFR2 alpha, SEQ ID NO: 1) by splicing, resulting in the r beta-form of FGFR2 (SEQ ID
NO: 2). In this case the epitope is situated ly before the domain D2.
A matter of particular interest is the fact that the N-terminal sequence is conserved in human,
mouse, rat and rhesus monkey. This allows the broad inter-species cross-reactivity of the M048-
D01 dies. The binding epitope of M048-D01-hIgG1 and M048-D01-hIgG1-b, two example
dies of the present ion, is marked as the striped box in Figure 1.
B-6. General process for coupling to cysteine side chains
The antibodies used in the coupling reactions were as follows:
M048-D01-hIgG1
M048-D01-hIgG1-b
Added to a solution of the corresponding antibody in PBS buffer in the concentration range
between 1 mg/ml and 10 mg/ml were 3 equivalents of tris(2-carboxyethyl)phosphine hydrochloride
(TCEP), in solution in PBS buffer, and the e was stirred at RT for 1 hour.
Subsequently, depending on the desired loading, between 2 and 10 equivalents of the maleimide
precursor compound or halide precursor nd for coupling from the Intermediates 102, 103,
105-109, 111-114, 117-126, 128, 129, 132-146, 148-155, 157, 159-161, 166, 171, 175-177, 184,
189, 194-195, 199-201, 205, 209, 223-224, 226, 228-231, 236, 244 and 257 were added as a
solution in DMSO. The amount of DMSO here ought not to exceed 10% of the overall volume.
The batch was stirred at RT for 60-120 s and then applied to PD 10 columns (Sephadex G-
, GE Healthcare) equilibrated with PBS, and eluted with PBS buffer. Optionally a tration
ure was carried out additionally by means of ultracentrifugation.
Normally, unless otherwise indicated, 5 mg of the corresponding antibody in PBS buffer were used
for the ion and the subsequent coupling. ing purification via the PD10 column, this
gave, in each case, solutions of the corresponding ADC in 3.5 ml of PBS buffer. The ular
protein concentration indicated was then determined for these solutions. Furthermore, the loading
of the antibody (drug/mAb ratio) was determined in ance with the methods described below.
This process was used to prepare the immunoconjugates represented in Examples 1, 3, 5-6, 8, 10-
12, 14, 15, 27 and 32.
In the structural formulae illustrated, the definition of AK1A and AK1B is as follows
AK 1
1A = anti-FGFR2 antibody M048-D01-hIgG1 (partially reduced)- S§
AK 1B = anti-FGFR2 antibody M048-D01-hIgG1-b (partially reduced)- S§1
where
§1 denotes the link with the succinimide group,
and
S stands for the sulphur atom of a cysteine residue of the partially d antibody.
B-7. General process for coupling to lysine side chains:
The following antibodies were used in the ng reactions:
M048-D01-hIgG1
01-hIgG1-b
GAL-FR21-mIgG1
GAL-FR22-mIgG2a
Added to a solution of the corresponding antibody in PBS buffer in the concentration range
between 1 mg/ml and 10 mg/ml were, depending on the desired loading, between 2 and 5
equivalents of the precursor compound for coupling from the Intermediates 104, 110, 115, 116,
127, 130, 131, 147, 156, 158, 162, 169, 178, 185, 190, 202, 206, 210-216, 218, 219, 227, 233, 238,
240, 242, 245, 247a, 247b, 250, 251, 253, 255, 258 and 260-261 as a solution in DMSO. After
minutes of stirring at RT, the same amount of precursor compound in DMSO was added again.
The amount of DMSO here ought not to exceed 10% of the overall volume. After a further
minutes of stirring at RT, the batch was applied to PD 10 columns (Sephadex G-25, and eluted
with PBS buffer. Optionally a concentration procedure was carried out additionally by means of
ultrafiltration. If necessary, for more effective l of low molecular mass constituents, the
concentration by ultrafiltration was repeated after ution with PBS buffer.
Normally, unless otherwise indicated, 5 mg of the corresponding antibody in PBS buffer were used
for the coupling. Following purification via the PD10 column, this gave, in each case, solutions of
the corresponding ADC in 3.5 ml of PBS buffer. The particular protein concentration ted
was then ined for these solutions and the loading of the antibody (drug/mAb ratio) was
determined in ance with the methods described below.
This process was used to prepare the immunoconjugates represented in Examples 2, 4, 7, 9, 13, 16-
17, 25, 26, 28-31 and 33-35.
In the structural formulae illustrated, the definition of AK2A, AK2B , AK2D and AK2E is as follows
AK 2
2A = anti-FGFR2 antibody M048-D01-hIgG1 - NH§
AK 2
2B = anti-FGFR2 antibody M048-D01-hIgG1-b - NH§
AK 2D = anti-FGFR2 antibody GAL-FR21-mIgG1 - NH§2
AK 2E = anti-FGFR2 antibody GAL-FR22-mIgG2a - NH§2
where
§2 denotes the link with the carbonyl group
NH stands for the side chain amino group of a lysine residue of the antibody.
B-8. General process for ing ne s:
µmol of the above-described maleimide precursor nds were taken up in 3 ml of DMF
and admixed with 2.1 mg (20 µmol) of L-cysteine. The reaction mixture was d at RT for
2 hours, then concentrated under reduced pressure and subsequently purified by preparative HPLC.
In the structural formulae illustrated, the definition of Cys is as follows
H N S §3
2 ,
where
§3 denotes the link with the -toxophore unit.
B-9. General process for preparing lysine s:
10 µmol of the above-described active ester precursor compounds were taken up in 5 ml of DMF
and d, in the presence of 30 µmol of N,N-diisopropylethylamine, with α-amino-protected
L-lysine. The reaction mixture was stirred at RT for 2 hours, then concentrated under reduced
pressure and subsequently purified by ative HPLC. The tive group was then removed
by known methods.
Further purification and characterization of the conjugates of the invention
After on had taken place, in certain cases the reaction mixture was concentrated, by
ultrafiltration, for example, and then desalted and purified by means of chromatography, for
example using a ex® G-25. Elution took place with, for example, phosphate-buffered saline
(PBS). The solution was subsequently subjected to sterile filtration and freezing. An alternative
option is to lyophilize the conjugate.
B-10. ination of the toxophore loading
The toxophore loading of the resultant ons of the conjugates described in the working
examples, in PBS buffer, was determined as follows:
The toxophore loading of lysine-linked ADCs was determined by mass-spectrometric
determination of the molecular weights of the individual ate species. In this case, to start
with, the antibody conjugates were deglycosylated by means of PNGaseF, and the sample was
acidified and, following HPLC separation, was analysed by mass spectrometry using an
ESI-MicroTofQ (Bruker Daltonik). All of the spectra were added via the signal in the TIC (Total
Ion Chromatogram), and the molecular weight of the various conjugate s was calculated on
the basis of MaxEnt Deconvolution. Following signal integration of the different species, the DAR
(Drug/Antibody Ratio) was then calculated.
For protein identification, in addition to the molecular weight determination, a tryptic digestion
was carried out after osylation and/or denaturing, and this digestion, after denaturing,
reduction and derivatization, med the ty of the protein on the basis of the tryptic
peptides ed.
The toxophore loading of cysteine-linked conjugates was determined via reversed-phase
chromatography of the reduced and denatured ADC. The ADC solution (1 mg/mL, 50 µL) was
admixed with guanidinium hydrochloride (GuHCl) (28.6 mg) and with a solution of
DL-dithiothreitol (DTT) (500 mM, 3 µL). The mixture was ted at 55°C for an hour and
analysed by HPLC.
The HPLC analysis was carried out on an Agilent 1260 HPLC System with detection at 220 nm.
The column used was a r Laboratories PLRP-S Polymeric Reversed Phase column
(catalogue number PL1912-3802) (2.1 × 150 mm, 8 µm particle size, 1000 Å) with a flow rate of
1 mL/min, using the following gradient: 0 min, 25% B; 3 min, 25 % B; 28 min, 50% B. Eluent A
consisted of 0.05% trifluoroacetic acid (TFA) in water, eluent B of 0.05% trifluoroacetic acid in
acetonitrile.
The peaks detected were assigned by retention time comparison with the light chain (L0) and the
heavy chain (H0) of the unconjugated antibody. Peaks which were detected ively in the
conjugated sample were assigned to the light chain, with a toxophore (L1), and to the heavy
chains, with one, two and three toxophores (H1, H2, H3).
The average loading of the dy with toxophores was determined from the peak
areas determined by integration as follows: the light-chain loading was calculated as the sum of the
ore number weighted integration results of the peaks belonging to the light chains d
by the sum of the singularly weighted ation results of the peaks belonging to the light .
The heavy-chain loading was calculated as the sum of the toxophore number weighted integration
s of the peaks belonging to the heavy chains divided by the sum of the singularly weighted
integration results of the peaks belonging to the heavy chains. The average drug load s
therefrom as the twofold sum of light-chain loading and heavy-chain loading. In certain individual
cases it may be impossible exactly to determine the toxophore loading, owing to co-elutions of
certain peaks.
B-11. Testing of the antigen binding of the ADC
The binding capacity of the binder to the target molecule was tested after coupling had taken place.
The skilled worker knows of diverse methods for achieving this – for example, the affinity of the
conjugate can be tested by means of ELISA technology or surface plasmon resonance analysis
(BIAcore™ measurements). The conjugate concentration can be measured by the skilled person
using common methods – for example, for antibody conjugates, by means of protein determination
2012/075277
(see also Doronina et al.; Nature Biotechnol. 2003; 21:778-784 and Polson et al., Blood 2007;
1102:616-623).
Working es - immunoconjugates
Example 1
AK O
1A H C CH H C
3 3 3 CH N
O 3 H
H N
N N N O
N N
O O
O CH O CH O O
3 3 CH
H C CH CH 3
3 3 3
Coupling here was carried out using 30 mg of M048-D01-hIgG1 in PBS and following the
Sephadex purification the batch was concentrated by ultracentrifugation, re-diluted with PBS and
concentrated again.
Protein concentration: 15.5 mg/ml
Drug/mAb Ratio: 3.7
Example 2
H C CH3 H C
3 3 CH
3 N
O H
H N
AK2A N N O
N N
O O
O CH3 O CH O O
3 CH3
H C CH3 CH
3 3
Coupling here was carried out using 32 mg of 01-hIgG1 in PBS and following the
Sephadex purification the batch was concentrated by ultracentifugation, re-diluted with PBS and
concentrated again.
Protein tration: 11.7 mg/ml
Drug/mAb Ratio: 3.9
WO 87716
Example 3
H C CH H C
3 3 3 CH
3 N
O O H
H N
AK O O N N O
1A N O N N
O O
CH O CH O O H C
3 3 3
O H C CH CH
3 3 3
ng here was carried out using 30 mg of M048-D01-hIgG1 in PBS and following the
Sephadex purification the batch was concentrated by ultracentrifugation, re-diluted with PBS and
concentrated again.
Protein concentration: 12.5 mg/ml
Drug/mAb Ratio: 3.7
Example 4
H C CH H3C
3 3 CH3 N
O H
AK2A H N
O O N N O
O N N
O O
O CH O CH O O
3 3 CH3
H C CH CH3
3 3
H n
Coupling here was carried out using 2 mg of M048-D01-hIgG1 in PBS and following the
ex purification the batch was concentrated by ultracentifugation and re-diluted with PBS.
Protein concentration: 1.92 mg/ml
Drug/mAb Ratio: 3.7
Example 5
3 O
AK1A O H C CH H C
3 3 3 CH N
O O 3 H
H H N
N N N N O
N N N
H O O
O O CH O CH O O
3 3 H C
H C CH CH3 3
3 3
Coupling here was carried out using 3 mg of M048-D01-hIgG1 in PBS and following the
Sephadex purification the batch was concentrated by ultracentrifugation and re-diluted.
Protein concentration: 2.54 mg/ml
Drug/mAb Ratio: 3.1
Example 6
1A O H C CH H C
3 3 3 CH
3 NH
O O H 2
H H N
N N N N O
N N N
H O O
O O CH O CH O O
3 3 CH
H C CH CH 3
3 3 3
Coupling here was carried out using 4 mg of M048-D01-hIgG1 in PBS and following the
Sephadex purification the batch was trated by entrifugation and uted.
Protein concentration: 1.53 mg/ml
Drug/mAb Ratio: 2.7
Example 7
H C CH H C
3 3 3 CH3 NH
O 2
AK2B H N
O O N N O
O N N
O O
O CH3 O CH3 O O CH
H C CH CH 3
3 3 3
Coupling here was carried out using 5 mg of M048-D01-hIgG1-b in PBS and following the
Sephadex purification the batch was trated by ultracentrifugation and re-diluted.
Protein concentration: 1.28 mg/ml
Drug/mAb Ratio: 6.1
Example 8
H C CH H C
3 3 3 CH
O 3 N
O H
H N
AK O O N N O
1B N O N N
O O
CH O CH O O H C
3 3 3
O H C CH CH
3 3 3
Coupling here was d out using 5 mg of M048-D01-hIgG1-b in PBS and following the
Sephadex purification the batch was concentrated by ultracentifugation and uted.
Protein concentration: 1.26 mg/ml
Drug/mAb Ratio: 3.5
Example 9
H C CH3 H3C
3 CH N
O 3
H N
AK2B N N O
N N
O O
O CH O CH O O
3 3 CH
H C CH CH 3 H C
3 3 3
Coupling here was carried out using 5 mg of M048-D01-hIgG1-b in PBS and following the
Sephadex purification the batch was concentrated by ultracentifugation and re-diluted.
Protein concentration: 1.28 mg/ml
Drug/mAb Ratio: 6.1
Example 10
H C CH H C
3 3 3 CH N
O 3
O H
H H H N
N N N N O
AK N N N
1B O O
O CH O CH O O
3 3 CH
O H C CH CH 3
3 3 3
Coupling here was d out using 5 mg of M048-D01-hIgG1-b in PBS and following the
Sephadex purification the batch was concentrated by ultracentrifugation and re-diluted.
n concentration: 1.36 mg/ml
Drug/mAb Ratio: 4.4
Example 11
AK1B O
O H C CH H C
3 3 3 CH
3 N
O H
H N
N N N O
N N
O O
O CH O CH O O
3 3 CH
H C CH CH 3 H C
3 3 3 3
Coupling here was carried out using 5 mg of M048-D01-hIgG1-b in PBS and following the
Sephadex purification the batch was concentrated by ultracentrifugation and re-diluted.
Protein concentration: 1.27 mg/ml
Drug/mAb Ratio: 4.8
Example 12
O CH CH
AK1B 3 3
O H C CH H C
3 3 3 CH N
O HN O O 3
H H N
N N O N N O
N N N
H O O
O O CH O CH O CH O O CH
3 3 3
H C CH CH 3
3 3 3
Coupling here was carried out using 5 mg of M048-D01-hIgG1-b in PBS and following the
Sephadex purification the batch was concentrated by ultracentrifugation and re-diluted.
Protein concentration: 1.48 mg/ml
Drug/mAb Ratio: 4.0
Example 13
H C CH H C O
3 3 O 3 CH
3 H N
H N
AK2B N N N
N N
O O
O CH O CH O O CH
3 H C CH 3
3 3 CH
ng here was carried out using 5 mg of M048-D01-hIgG1-b in PBS and following the
Sephadex purification the batch was concentrated by ultracentrifugation and re-diluted.
Protein concentration: 1.21 mg/ml
Drug/mAb Ratio: 1.5
e 14
AK1B 3
O H C CH H C O
3 3 3 CH
O 3 H N
H N
N N N N
N N
O O
O CH O CH O O CH
H C CH 3 3
3 3 CH
ng here was carried out using 5 mg of M048-D01-hIgG1-b in PBS and the batch, following
Sephadex purification, was trated by ultracentrifugation and re-diluted.
Protein concentration: 1.27 mg/ml
Drug/mAb Ratio: 2.7
Example 15
AK CH CH
3 3
1B O
O H C CH H C
3 3 3 CH N
O HN O O 3
H H N
N N O N N O
N N N
H O O
O O CH O CH3 O CH O O
3 3 CH3
H C CH CH
3 3 3
Coupling here was carried out using 5 mg of M048-D01-hIgG1-b in PBS and the batch, following
Sephadex purification, was concentrated by entrifugation and re-diluted with PBS.
Protein concentration: 1.37 mg/ml
Drug/mAb Ratio: 3.9
Example 16
H3C CH H C
3 3 CH
O 3 N
H N
AK2D N N O
N N
O O
O CH O CH3 O O
3 CH
H3C CH CH 3
3 3
H n
Coupling here was carried out using 4 mg of GAL-FR21-mIgG1 in PBS and the batch, following
Sephadex purification, was trated by ultracentrifugation and re-diluted with PBS.
Protein concentration: 1.63 mg/ml
Drug/mAb Ratio: 8.7
Example 17
H C CH3 H3C
3 CH N
O 3
H N
AK2E N N O
N N
O O
O CH O CH3 O O
3 CH
H C CH CH 3
3 3 3
Coupling here was carried out using 4 mg of GAL-FR22-mIgG2a in PBS and the batch, following
Sephadex cation, was trated by ultracentrifugation and re-diluted with PBS.
Protein concentration: 1.60 mg/ml
Drug/mAb Ratio: 8.1
Example 18
N-(6-{[(5S)Aminocarboxypentyl]amino}oxohexyl)-N-methyl-L-valyl-N-[(3R,4S,5S)
{(2S)[(1R,2R){[(2S)(1H-indolyl)(1,2-oxazinanyl)oxopropanyl]amino}
methoxymethyloxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-
L-valinamide trifluoroacetate
H C CH H C
3 3 3 CH
3 N
O H
H H N
H N N N N
2 O
N N
O O
COOH O CH3 O CH O O
3 CH
H C CH CH 3
3 3 3
x H N
H
.5 mg (15 µmol) of Intermediate 210 were taken up in 5 ml of DMF and d with 4.4 mg
(18 µmol) of N2-(tert-butoxycarbonyl)-L-lysine and also 7.7 µL (44 µmol) of N,N-
diisopropylethylamine. The reaction mixture was stirred at RT overnight and then concentrated
under reduced pressure. The residue was subsequently purified by preparative HPLC. This gave
14 mg (81% of theory) of the protected intermediate of the title compound, which was
subsequently taken up in 1 ml of dichloromethane and deprotected with 1 ml of trifluoroacetic
acid. The batch was concentrated and, following lyophilization of the residue from
acetonitrile/water (1:1), 15 mg (97% of ) of the title compound were obtained.
HPLC (Method 12): Rt = 1.8 min;
LC-MS (Method 1): Rt = 0.79 min; MS (ESIpos): m/z = 1083 (M+H)+.
Example 19
N-(6-{[(5S)Aminocarboxypentyl]amino}oxohexyl)-N-methyl-L-valyl-N-[(3R,4S,5S)
2-[(1R,2R){[(1S)carboxy(1H-indolyl)ethyl]amino}methoxymethyl
oxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide
H C CH3 H C
3 3 CH3 OH
O H
H H N
H N N N N
2 O
N N
O O
COOH O CH3 O CH O O
3 CH
H3C CH3 CH 3
40 mg (40 µmol) of ediate 227 were taken up in 5 ml of DMF and admixed with 11.5 mg
(40 µmol) of N2-[(benzyloxy)carbonyl]-L-lysine and also 13 µL (80 µmol) of N,N-
diisopropylethylamine. The reaction mixture was stirred at RT overnight, then concentrated under
reduced pressure and subsequently purified by preparative HPLC. This gave 32.5 mg (70% of
theory) of the ted intermediate of the title compound.
This 32.5 mg of the ediate were dissolved in 10 ml of methanol and, following addition of
2 mg of 10% palladium on activated , were hydrogenated under standard hydrogen pressure
at RT for 30 s. The catalyst was then removed by filtration and the solvent was removed
under reduced pressure. lization of the residue from dioxane/water 1:1 gave 26 mg (99% of
theory) of the title compound.
HPLC (Method 12): Rt = 1.7 min;
LC-MS (Method 1): Rt = 0.76 min; MS (ESIpos): m/z = 1014 (M+H)+.
Example 20
N-[(18S)Aminocarboxyoxo-3,6,9-trioxaazaoctadecyl]-N-methyl-L-valyl-N-
S,5S){(2S)[(1R,2R){[(2S)(1H-indolyl)(1,2-oxazinanyl)oxopropan
yl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxymethyloxoheptan
yl]-N-methyl-L-valinamide trifluoroacetate
H C CH H C
3 3 3 CH3 N
O H
H H N
H2N N O O N N O
O N N
O O
COOH O CH3 O CH O O
3 CH
H3C CH CH3 3
x CF3COOH N
3.5 mg (3 µmol) of Intermediate 202 were taken up in 2 ml of DMF and admixed with 0.8 mg
(3 µmol) of N2-(tert-butoxycarbonyl)-L-lysine and also 1.6 µL (10 µmol) of N,N-
diisopropylethylamine. The reaction mixture was stirred at RT overnight and then concentrated
under reduced pressure. The residue was taken up in acetonitrile/water (1:1), brought to a pH of 2
with trifluoroacetic acid and then purified by preparative HPLC. This gave 1 mg (25% of theory)
2012/075277
of the protected intermediate of the title compound, which was subsequently taken up in 500 µl of
dichloromethane and deprotected with 500 µl of trifluoroacetic acid. The batch was concentrated
and, following lypophilization of the residue from acetonitrile/water (1:1), 1 mg (89% of theory) of
the title compound was obtained.
HPLC (Method 12): Rt = 1.9 min;
LC-MS (Method 1): Rt = 0.82 min; MS (ESIpos): m/z = 1173 (M+H)+.
Example 21
N-(4-{2-[6-(3-{[(2R)Aminocarboxyethyl]sulphanyl}-2,5-dioxopyrrolidinyl)hexanoyl]
hydrazino}oxobutyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)amino
dolyl)oxopropanyl]amino}methoxymethyloxopropyl]pyrrolidinyl}
methoxymethyloxoheptanyl]-N-methyl-L-valinamide
O H C CH H3C
3 3 CH
3 NH2
O O H
H H N
N N N N O
N N N
H O O
O O CH O CH O O
3 3 CH
H C CH CH 3
3 3 3
mg (10 µmol) of Intermediate 157 were taken up in 5.2 ml of DMF and admixed with 2.28 mg
(20 µmol) of L-cysteine. The on e was stirred at RT for 2 hours, then concentrated
under reduced pressure and subsequently purified by preparative HPLC. This gave 5.8 mg (48% of
theory) of the title compound.
HPLC (Method 5): Rt = 1.45 min;
LC-MS (Method 1): Rt = 0.74 min; MS (ESIpos): m/z = 1184 (M+H)+.
Example 22
N-(4-{2-[6-(3-{[(2R)Aminocarboxyethyl]sulphanyl}-2,5-dioxopyrrolidin
yl)hexanoyl]hydrazino}oxobutyl)-N-methyl-L-valyl-N-[(3R,4S,5S){(2S)[(1R,2R)
{[(1S)carboxy(1H-indolyl)ethyl]amino}methoxymethyloxopropyl]pyrrolidin
yl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide
Cys 3
O H C CH3 H C
3 3 CH OH
O O 3 H
H H N
N N N N O
N N N
H O O
O O CH O CH O O
3 3 CH
H C CH3 CH 3
3 3
mg (10 µmol) of Intermediate 113 were taken up in 5.2 ml of DMF and admixed with 2.28 mg
(20 µmol) of eine. The reaction mixture was stirred at RT for 2 hours, then concentrated
under reduced pressure and subsequently purified by preparative HPLC. This gave 6 mg (54% of
theory) of the title compound.
HPLC (Method 5): Rt = 1.5 min;
LC-MS (Method 1): Rt = 0.77 min; MS s): m/z = 1185 .
Example 23
N-[6-(3-{[(2R)Aminocarboxyethyl]sulphanyl}-2,5-dioxopyrrolidinyl)hexyl]-N-methyl-L-
valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(1S)carboxy(1H-indolyl)ethyl]amino}
methoxymethyloxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-
L-valinamide
Cys 3
O H C CH H C
3 3 3 CH
3 OH
O H
H N
N N N O
N N
O O
O CH O CH O O
3 3 CH
H C CH CH 3
3 3 3
mg (10 µmol) of Intermediate 124 were taken up in 4 ml of DMF and admixed with 2.5 mg
(20 µmol) of L-cysteine. The reaction mixture was stirred at RT for 2 hours, then concentrated
under reduced pressure and subsequently purified by preparative HPLC. This gave 7.2 mg (64% of
theory of the title compound.
HPLC (Method 5): Rt = 1.6 min;
LC-MS (Method 1): Rt = 0.8 min; MS (ESIpos): m/z = 1071 (M+H)+.
Example 24
N-[6-(3-{[(2R)Aminocarboxyethyl]sulphanyl}-2,5-dioxopyrrolidinyl)hexyl]-N-methyl-L-
valyl-N-[(3R,4S,5S){(2S)[(1R,2R){[(2S)(1H-indolyl)(1,2-oxazinanyl)
oxopropanyl]amino}methoxymethyloxopropyl]pyrrolidinyl}methoxymethyl
oxoheptanyl]-N-methyl-L-valinamide
Cys 3
O H C CH H C
3 3 3 CH N
O 3
H N
N N N O
N N
O O
O CH O CH O O
3 3 CH
H C CH CH 3
3 3 3
mg (10 µmol) of Intermediate 125 were taken up in 4 ml of DMF and admixed with 2.4 mg
(20 µmol) of L-cysteine. The reaction mixture was stirred at RT for 2 hours, then concentrated
under reduced re and subsequently purified by preparative HPLC. This gave 7.7 mg (69% of
theory of the title compound.
HPLC (Method 5): Rt = 1.7 min;
LC-MS (Method 2): Rt = 1.91 min; MS (ESIpos): m/z = 1140 (M+H)+.
e 25
H C CH H C CH
O 3 3 3 N
O 3
H H N
S N N N O
2B S N N
O O
O CH O CH O O H C
3 3
H C CH CH 3
3 3 3
H n
Coupling here was d out using 5 mg of M048-D01-hIgG1-b in PBS and the batch, following
Sephadex purification, was concentrated by ultracentrifugation and re-diluted.
Protein concentration: 1.27 mg/ml
Drug/mAb Ratio: 1.0
Example 26
H C CH H C
3 3 3 CH
3 N
O H
H N
AK2B N N O
N N
O O
O CH O CH O O
3 3 CH3
H C CH CH3
3 3
Coupling here was carried out using 35 mg of M048-D01-hIgG1-b in PBS and the batch, following
Sephadex cation, was concentrated by ultracentrifugation, re-diluted with PBS and
concentrated again.
Protein concentration: 11.60 mg/ml
Drug/mAb Ratio: 3.7
e 27
AK1B O H C CH H C
3 3 3 CH
3 N
O H
H N
N N N O
N N
O O
O CH O CH O O
3 3 CH
H C CH CH 3
3 3 3
Coupling here was carried out using 35 mg of M048-D01-hIgG1-b in PBS and the batch, following
Sephadex purification, was concentrated by ultracentrifugation, uted with PBS and
concentrated again.
Protein concentration: 11.7 mg/ml
Drug/mAb Ratio: 4.2
Example 28
H C CH H C
3 3 3 CH N
O 3 H
AK2B H N
N N O
N N
O O
O CH O CH O O
3 3 CH
H C CH CH 3
3 3 3
Coupling here was d out using 5 mg of M048-D01-hIgG1-b in PBS and the reaction e,
following Sephadex purification, was concentrated by ultracentrifugation and re-diluted with PBS.
Protein concentration: 1.31 mg/ml
Drug/mAb Ratio: 3.7
Example 29
H C CH H C
3 CH
3 3 N
O 3 H
H N
2B O O N N O
O N N
O O
O CH O CH O O H C
3 3
H CH CH 3
3 3 3
Coupling here was carried out using 5 mg of M048-D01-hIgG1-b in PBS and the reaction mixture,
following Sephadex purification, was concentrated by ultracentrifugation and re-diluted with PBS.
Protein concentration: 1.53 mg/ml
Drug/mAb Ratio: 1.3
Example 30
H C CH H C
3 3 3 CH N
O O O 3
H H N
N N N O
AK N N N
2B O O
3 O CH O CH O O
3 3 CH
H C CH CH 3
3 3 3
H n
Coupling here was carried out using 5 mg of M048-D01-hIgG1-b in PBS and the batch, following
Sephadex purification, was concentrated by ultracentrifugation and re-diluted.
Protein concentration: 1.61 mg/ml
Drug/mAb Ratio: 3.9
Example 31
H C CH H3C O
3 3 CH
O 3 H N
AK2B H N
O O N N N
O N N
O O
O CH3 O CH O O CH
H C CH3 3
3 CH
Coupling here was d out using 5 mg of 01-hIgG1-b in PBS and the reaction mixture,
following Sephadex purification, was concentrated by ultracentrifugation and re-diluted.
Protein concentration: 1.32 mg/ml
Drug/mAb Ratio: 1.7
Example 32
H3C CH H C CH O
3 O 3 3
O H N
H N
O N N
AK1B O N
N O N N
O O
CH O CH3 O O CH3
O H C CH
3 3 CH3
Coupling here was d out using 5 mg of M048-D01-hIgG1-b in PBS and the reaction mixture,
following Sephadex purification, was concentrated by ultracentrifugation and re-diluted.
n concentration: 1.12 mg/ml
Drug/mAb Ratio: 0.2
Example 33
H C CH H C
3 3 3 CH
3 N
O H
AK2B H N
N N O
N N
O O
O CH O CH3 O O
3 CH3
H3C CH CH
3 3
ng here was carried out using 5 mg of M048-D01-hIgG1-b in PBS and the reaction mixture,
following Sephadex purification, was concentrated by ultracentrifugation and re-diluted.
Protein concentration: 1.29 mg/ml
Drug/mAb Ratio: 5.5
Example 34
H C CH H C
3 3 3 CH
O 3
H N
AK N N
N N
O O
O CH O CH O O CH
3 H C CH H3C
3 3 3
Coupling here was carried out using 5 mg of M048-D01-hIgG1-b in PBS and the reaction mixture,
following Sephadex purification, was concentrated by entrifugation and re-diluted.
Protein tration: 1.04 mg/ml
Drug/mAb Ratio: 0.5
Example 35
H C CH H C
3 3 3 CH
3 N
O H
H N
AK2B O O N N O
O N N
O O
O CH O CH O O
3 3 CH
H C CH CH 3
3 3 3
ng here was carried out using 5 mg of M048-D01-hIgG1-b in PBS and the on mixture,
following Sephadex purification, was concentrated by ultracentrifugation and re-diluted.
Protein concentration: 1.66 mg/ml
Drug/mAb-Ratio: 3.4
Example 36
N-(6-{[(5S)Aminocarboxypentyl]amino}oxohexyl)-N-methyl-L-valyl-N-[(3R,4S,5S)
{(2S)[(1R,2R){[(2S)(4-hydroxyphenyl)(1,2-oxazinanyl)oxopropanyl]amino}
ymethyloxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-
valinamide trifluoroacetate
H C CH H C
3 3 3 CH3 N
O H
H H N
H N N N N
2 O
N N
O O
COOH O CH O CH3 O O
3 CH
H C CH CH 3
3 3 3
x H OH
8 mg (8 µmol) of Intermediate 242 were taken up in 3 ml of DMF and admixed with 2.9 mg
(12 µmol) of N2-(tert-butoxycarbonyl)-L-lysine and also 2.7 µL (16 µmol) of N,N-
diisopropylethylamine. The reaction mixture was stirred at RT overnight, then admixed again with
the same amounts of N2-(tert-butoxycarbonyl)-L-lysine and N,N-diisopropylethylamine, and stirred
at RT for a further 4 hours. The batch was subsequently concentrated under reduced pressure. The
residue was then purified by preparative HPLC. Lyophilization from acetonitrile/water gave
6.5 mg (72% of theory) of the protected intermediate of the title compound, which was
subsequently taken up in 5 ml of dichloromethane and deprotected with 0.75 ml of trifluoroacetic
acid. The batch was concentrated, and lyophilization of the e from dioxane/water gave 5 mg
(76% of theory) of the title compound.
HPLC (Method 12): Rt = 1.7 min;
LC-MS (Method 1): Rt = 0.69 min; MS (ESIpos): m/z = 1059 (M+H)+.
Example 37
N-(6-{[(5S)Aminocarboxypentyl]amino}oxohexyl)-N-methyl-L-valyl-N-[(3R,4S,5S)
{(2S)[(1R,2R){[(1S)carboxy(4-hydroxyphenyl)ethyl]amino}methoxymethyl
oxopropyl]pyrrolidinyl}methoxymethyloxoheptanyl]-N-methyl-L-valinamide
trifluoroacetate
H C CH3 H C
3 3 CH3 OH
O H
H H N
H N N N N
2 O
N N
O O
COOH O CH O CH O O
3 3 CH
H3C CH3 CH 3
x CF3COOH OH
38 mg (41 µmol) of Intermediate 248 were first converted into the N-hydroxysuccinimide ester.
72 mg of the crude product obtained were taken up in 5 ml of DMF and admixed with 24 mg
(100 µmol) of N2-(tert-butoxycarbonyl)-L-lysine and 23 µL of isopropylethylamine. The
reaction mixture was stirred at RT overnight, and then d again with 16 mg of N2-(tert-
butoxycarbonyl)-L-lysine and 12 µL of N,N-diisopropylethylamine, and subsequently treated in an
ound bath for a further 2 hours. The batch was then concentrated under reduced pressure and
the residue was purified by preparative HPLC. Lyophilization from acetonitrile/water gave 20 mg
(50% of theory) of the protected intermediate of the title compound.
mg (12 µmol) of this intermediate were subsequently taken up in 3 ml of dichloromethane and
admixed with 1 ml of trifluoroacetic acid. After 40 minutes of stirring at RT, a r 1.5 ml of
oroacetic acid were added and the batch was treated in an ultrasound bath for 1 hour.
Thereafter the batch was concentrated, and lyophilization of the residue from dioxane/water gave
13 mg (90% of ) of the title compound.
HPLC (Method 12): Rt = 1.5 min;
LC-MS (Method 1): Rt = 0.68 min; MS (ESIpos): m/z = 990 (M+H)+.
C: Evaluation of biological activity:
The biological effect of the compounds of the invention was demonstrated by the assays described
below:
C-1. Identification of tumour cells with different FGFR2 levels on the cell surface
To determine the amounts of FGFR2 available for the antibody on the cell surface, the cell binding
of the FGFR2 antibody on different tumour cell lines was analysed in flow cytometry. The cell
lines below were used for the experiments. The information on mutations and copy number of the
FGFR2 comes from the Sanger Center Genome Project:
- SNU-16 human stomach carcinoma cells, FGFR2 gene amplification (copy number 14; ATCC-
CRL-5974, RPMI 1640 rom FG1215) + 10% FCS
- KatoIII human stomach carcinoma cells, FGFR2 gene amplification (copy number 14 ATCCTCP-1008
; Iscove’s (Biochrom FG0465) + 20% FCS
- SUM52-PE human breast cancer cells, FGFR2 gene amplification (copy number 14; Asterand
Lot No.: 1-6004; Ham’s F12 (Biochrom FG0815) + 5% FCS + 10 mM Hepes buffer +
1 µg/ml hydrocortisone + 5 µg/ml insulin
- MFM-223 human breast cancer cells, FGFR2 gene amplification (copy number 14; ECACC-
98050130, MEM Earle rom F0315) + 10% FCS + 2mM glutamine
- NCI-H716 human colorectal oma cells, FGFR2 gene amplification (copy number: 8;
ATCC-CCL-251; RPMI 1640 (Biochrom FG1215) + 10% FCS)
- MDA-MB-231 human breast cancer cells (no FGFR2 gene amplification, copy number 3;
ATCC-HTB-26, DMEM/HAM´s F12 rom FG4815) + 10% FCS
For the experiments, adherent cells were washed twice with PBS (without calcium (Ca2+ ) and
magnesium (Mg2+ ) ions and detached using enzyme-free, PBS-based ce ll dissociation buffer
(Invitrogen). Approximately 1 × 105 cells per well were ded in FACS buffer (PBS without
Ca 2+ and Mg2+ with 3% FCS (Biochrom)), followed by fugation (250 g, 5 min, 4°C), and the
supernatant was ded. The cells were resuspended in antibody dilutions (5 µg/ml in 80 µl) in
FACS buffer, and incubated on ice for 1 hour. Next, the cells were washed once with 100 µl of
cold FACS buffer and 80 µl of 1:150 diluted secondary antibodies (PE-coupled goat anti-mouse
IgG, Jackson Immuno ch #115164 for GAL-FR21-mIgG1 and for GAL-FR22-mIgG2a,
and pled goat anti-human IgG, Dianova #109098 for M048-D01-hIgG1) were added.
Following incubation on ice for 1 hour, the cells were again washed with cold FACS buffer,
resuspended in 100 µl of FACS , and analysed in an FACS array flow cytometer (BD
Biosciences). The s were calculated as the geometric average value of the cell population
detected with FGFR2 dy, minus the background fluorescence, which was measured by
incubating the cell population only with the ary antibody. The values were analysed by the
following system: geometric average value FGFR2 antibody minus geometric average value only
secondary antibody > 10 +, > 100 ++, > 1000 +++, > 10000 ++++, -: no signal. Values in the
vicinity of the category limits are marked with ().
The binding of FGFR2 dies to tumour cells is indicated in Table 4:
Table 4
M048-D01-hIgG1 GAL-FR21-mIgG1 GAL-FR22-mIgG2a
3 +++ +++ +++
SNU-16 ++(+) ++(+) ++
MDA-MB-231 - nd 1) nd1)
1) nd: not ined
The FGFR2 antibodies detect FGFR2 on the cell surface of MFM-223 and SNU-16 cancer cells.
C-2. Determination of the cytotoxic effect of the ADCs directed against FGFR2
The cytotoxic effect of the FGFR2 ADCs was determined on various cell lines with different
expression quantities of FGFR2, as follows:
The cells were cultured according to a standard method, using the growth media indicated under
C-1. For the implementation, the cells were detached with a solution of trypsin (0.05%) and EDTA
(0.02%) in PBS (Biochrom AG #L2143), pelletized, resuspended in culture medium, counted, and
seeded into a 96-well culture plate with a white base (Costar #3610) (at 75 µl/well, following cell
counts per well: SNU-16: 3000; MFM-223: 7000; MDA-MB-231: 4000; SUM52-PE: 3000; NCIH716
: 3000; KatoIII: 3000) and incubated in an incubator at 37°C under 5% carbon dioxide. After
24 hours, the antibody-drug ates in 25 µl of culture medium (four-fold concentration) were
applied to the cells, giving final antibody-drug conjugate concentrations of 3 × 10-7 M to
3 × 10-11 M on the cells (triplicates). The cells were then incubated in an incubator at 37°C and 5%
carbon e. In a parallel plate, the cell vitality at the beginning of drug ent (day 0) was
determined using the Cell Titer Glow Luminescent Cell Viability Assay (Promega #G7573 and
#G7571). For this, 100 µl of the substrate were added per cell batch, and the plates were then
d with aluminium foil, shaken at 180 rpm with a plate shaker for 2 minutes, left to stand on
the laboratory bench for 8 minutes, and then measured using a luminometer r X2, Perkin
Elmer). The substrate detects the ATP content in the living cells, producing a luminescence signal
whose level is directly proportional to the vitality of the cells. After 72 hours of incubation with
the antibody-drug conjugates, the ty was determined in these cells as well, using the Cell
Titer Glow Luminescent Cell Viability Assay as described above. From the data ed, the
IC50 of growth inhibition was calculated in ison to that on day 0, using the laboratory
software MTS (developed by Schering AG and Bayer Business Services 1999-2009) on the basis
of a 4-parameter adaptation.
Table 5 below lists the IC50 values1) of representative working examples from this assay:
Table 5
MDA- SUM52-PE, NCI-H716, KatoIII,
SNU- MFM- MB-231, IC50, 72 hr IC50, 72 hr IC50, 72 hr
16, 223, IC50, 72 [nM] [nM] [nM]
IC50, 72 IC50, 72 hr
Example hr [nM] hr [nM] [nM]
1 0.214 0.0907 > 300
2 1.19 0.86 > 300
3 0.15 0.195 > 300
4 0.567 1.47 > 300
0.496 4.00 > 300
6 0.497 6.85 > 300
7 0.209 0.628 > 300
8 2.06 8.67 256
9 2.05 4.78 230
0.519 10.3 > 300
11 0.614 0.581 80.9
12 0.389 0.145 > 300
13 0.254 0.431 6.61
14 0.914 1.91 67.5
16.6 16.9 > 300
16 < 0.03 0.0788 > 300
17 0.0616 0.278 > 300
26 0.455 na > 248 < 0.097 4.69 na
27 0.159 0.109 > 248 < 0.053 0.517 0.198
28 0.277 na na 0.101 na na
29 1.70 na na 0.106 na na
1.84 9.16 > 248 0.244 na na
31 5.88 na na na na na
32 > 300 na na na na na
33 8.50 na 128 0.104 na 0.920
34 7.41 na > 248 3.37 na na
na na > 248 0.105 na 0.523
1) The activity data reported relate to the working examples described in the present experimental
section, with the drug/mAB ratios indicated. The values may ly deviate for different
drug/mAB ratios.
Working Example 1 inhibited the proliferation of the SNU-16 and 3 cancer cell lines
which expresses FGFR2 at the cell surface, with an IC50 in the omolar concentration range.
Working Example 1 inhibited the proliferation of the MDA-MB-231 cancer cell line which do not
s FGFR2 at the cell surface, with an IC50 of 300 nM. As is apparent from the data, all tested
dy-drug conjugates (Working Examples 1-31, 33-35) selectively inhibit the proliferation of
FGFR2-expressing cancer cell lines 6, MFM-223, SUM52-PE, KatoIII or NCI-H716).
C-3. Determination of the effect on tubulin polymerization
Cancer cells are denatured cells which frequently lead to the formation of tumours also as a result
of sed cell division. Microtubuli form the spindle fibres of the spindle apparatus and are an
essential constituent of the cell cycle. The ted construction and breakdown of microtubuli
allows the precise division of the chromosomes among the daughter cells, and constitutes a
uously dynamic process. Disruption to this dynamic process results in incorrect cell on
and ultimately in cell death. The increased cell division of cancer cells, however, also makes them
particularly sensitive towards spindle fibre poisons, which tute a fixed constituent of
chemotherapy. Spindle fibre poisons such as paclitaxel or epothilone lead to a sharply increased
polymerization rate of the microtubuli, while vinca alkaloids or else monomethylauristatin E
(MMAE) lead to a sharply reduced polymerization rate of the microtubuli. In both cases, the
necessary dynamism of the cell cycle is critically disrupted.
Tubulin polymerization was igated using the "Fluorescence-based Microtubule
Polymerisation Assay Kit" from Cytoskeleton (Denver, Colorado, USA; order number: BK011).
With this assay, GTP is added to unpolymerized tubulin, allowing polymerization to take place
spontaneously. The assay is based on the binding of the fluorophore 4',6-diamidinophenylindole
(DAPI) to tubulin. Free and bound DAPI can be differentiated on the basis of different emission
spectra. Since DAPI exhibits a significantly high affinity for polymerized tubulin in ison to
lymerized tubulin, the tubulin polymerization can be followed via the increase in the
fluorescence of bound DAPI fluorophores.
For the implementation of this assay, the compounds of the invention, in solution in DMSO, were
diluted from their initial concentration of 10 mM to 1 µM in water. In on to the buffer
control, paclitaxel, with a polymerization-increasing effect, and vinblastin, with a polymerization
inhibiting effect, were run additionally as assay controls. Measurement was carried out using 96-
well plates with a half base area. The kinetics of the tubulin polymerization were monitored in a
Fluorimeter at 37°C for 1 hour. The excitation wavelength was 355 nm, and emission was
red at 460 nm. For the region of linear increase within the first 10 minutes, a calculation
was made of the change in fluorescence per minute (∆F/min), which represents the polymerization
rate of the microtubuli. The potency of the test nces was quantified on the basis of their
respective ion of the polymerization rate. Table 6 below gives data for the influence of
representative working examples on tubulin polymerization.
Table 6: de of tubulin polymerization by selected examples of toxophore variants.
Working example Concentration of Tubulin polymerization in the
presence of toxophore in [%].
toxophore
Tubulin polymerization rate at
[µM] 1 µM MMAF set at 100%
MMAF 1 100
MMAF 10 34
MMAF 100 0
18 1 45
18 10 1
19 1 80
19 10 14
1 60
10 0
Working example Concentration of Tubulin polymerization in the
presence of toxophore in [%].
toxophore
Tubulin polymerization rate at
[µM] 1 µM MMAF set at 100%
21 1 88
21 10 25
22 1 109
22 10 27
24 1 121
24 10 35
36 1 88
36 10 21
37 1 90
37 10 17
The MMAF toxophore and the working examples inhibit n polymerization as a function of
their tration. At 100 µM MMAF, the tubulin polymerization is inhibited completely. The
compounds investigated in the context of the present invention result in a d polymerization
rate of the microtubuli. Working Examples 18-21 inhibit the tubulin polymerization at 1 µM to
45-88% of the value measured for 1 µM MMAF.
C-4. In vitro tests for determining cell permeability
The cell permeability of a substance can be investigated by means of in vitro testing in a flux assay
using Caco-2 cells [M.D. Troutman and D.R. Thakker, Pharm. Res. 20 (8), 1210-1224 (2003)]. For
this purpose, the cells were cultured for 15-16 days on 24-well filter plates. For the ination
of permeation, the respective working example was applied in a HEPES buffer to the cells either
apically (A) or y (B) and incubated for 2 hours. After 0 hours and after 2 hours, s
were taken from the cis and trans compartments. The samples were separated by HPLC (Agilent
1200, Böblingen, y) using reverse phase columns. The HPLC system was coupled via a
Turbo Ion Spray Interface to a Triple Quadropol mass spectrometer API 4000 (Applied Biosystems
Applera, Darmstadt, Germany). The bility was evaluated on the basis of a Papp value, which
was ated using the formula published by Schwab et al. [D. Schwab et al., J. Med. Chem. 46,
1716-1725 (2003)].
Of critical importance for toxophores which are released intracellularly is the bility from B
to A [Papp (B-A)]: the lower this permeability, the longer the nce time of the working
example in the cell following intracellular release, and hence also the longer the time available for
interaction with the biochemical target (in this case: tubulin).
Table 7 below sets out permeability data for representative working examples from this assay:
Table 7
Working example Papp (B-A)
[nm/s]
18 2
19 1
21 2
22 2
23 1
36 1.5
37 0.9
The working examples exhibit a low permeability from B to A [Papp (B-A) and therefore have a
long residence time in the CaCo-2 cells. In comparison, monomethylauristatin E (MMAE) and
monomethylauristatin F (MMAF) in this test t a Papp (B-A) value of 73 nm/s, and therefore
have a significantly shorter residence time in the Caco-2 cells.
C-5. In vitro tests for determining the substrate properties for P-glycoprotein (P-gp)
Many tumour cells express transporter proteins for drugs, and this frequently accompanies the
development of ance towards cytostatics. Substances which are not substrates of such
transporter proteins, such as P-glycoprotein (P-gp) or BCRP, for e, could therefore exhibit
an improved activity profile.
The substrate properties of a substance for P-gp ) were determined by means of a flux
assay using LLC-PK1 cells which overexpress P-gp (L-MDR1 cells) [A.H. Schinkel et al., J. Clin.
. 96, 1698-1705 (1995)]. For this purpose, the LLC-PK1 cells or L-MDR1 cells were
cultured on 96-well filter plates for 3-4 days. For determination of the permeation, the respective
test substance, alone or in the ce of an tor (such as Ivermectin or Verapamil, for
example), was applied in a HEPES buffer to the cells either apically (A) or basally (B) and
incubated for 2 hours. After 0 hours and after 2 hours, samples were taken from the cis and trans
compartments. The samples were separated by HPLC using reverse phase columns. The HPLC
system was coupled via a Turbo Ion Spray Interface to a Triple Quadropole mass ometer
API 3000 (Applied Biosystems Applera, Darmstadt, Germany). The permeability was evaluated on
the basis of a Papp value which was calculated using the formula hed by Schwab et al. [D.
Schwab et al., J. Med. Chem. 46, 1716-1725 (2003)].
Of critical importance for toxophores which are released intracellularly is the permeability from B
to A [Papp (B-A)]: the lower this permeability, the longer the residence time of the working
example in the cell following intracellular release, and hence also the longer the time available for
interaction with the biochemical target (in this case: tubulin).
Table 8 below lists permeability data for representative working examples from this assay, which
was carried out in L-MDR1 cells:
Table 8
Working example Papp (B-A)
[nm/s]
18 6
19 4
21 3
22 4
23 4
The working examples t a low permeability from B to A [Papp (B-A) and therefore have a
long residence time in the L-MDR1 cells.
C-6. Pharmacokinetics in the SNU-16 tumour model
Following intravenous administration of various ADCs, the plasma concentrations and tumour
concentrations of ADC and also of potential metabolites are measured and the cokinetic
parameters such as clearance (CL), area under the curve (AUC) and half-life (t1/2 ) are calculated.
Analysis for quantifying the potentially ing metabolites
The measurement of the compounds in plasma and tumour takes place following precipitation of
the proteins with methanol, by means of high-pressure liquid chromatography (HPLC) coupled to a
tandem mass spectrometer (MS).
For the processing of 100 µL of plasma, it is admixed with 400 µL of methanol and 10 µL of
internal standard (ISTD, 50 ng/mL in methanol) and shaken for 10 seconds. After centrifuging for
minutes at 16 000 g, 250 µL of supernatant are transferred to an autosampler vial, which was
made up with 250 µL of ammonium e buffer (AAC, 10 mM, pH 6.8) and shaken again.
For the sing of a tumour, it is admixed with 4 times the amount of methanol. In a Tissuelyser
II (Quiagen), the sample is comminuted at 30 impacts per minute for 6 minutes and then
centrifuged off at 16 000 g for 5 minutes. 50 µL of the supernatant are erred to an
autosampler vial and made up with 50 µL of ammonium acetate buffer (10 mM, pH 6.8) and with
µL of ISTD. After again being shaken, the tumour sample is ready for measurement.
The measurement of both matrix samples takes place, lastly, with the aid of an HPLC-coupled,
atmospheric pressure ionization/tandem mass spectrometer by means of a Turbo Ion Spray
Interface (TISP) on an API4000 instrument from SCIEX.
HPLC/LC-MSMS (TISP) analysis runs on an HP1100 pump (Agilent) with a Gemini column
(5 µm C18 110 A, 50 × 3 mm, enex).
C-7. Activity test in vivo
The activity of the conjugates of the invention was tested in vivo by means for example of
xenograft models. The skilled person knows of methods in the prior art for testing the activity of a
ate of the invention (see, for example, ; Polson et al., Cancer Res. 2009
Mar 15;69(6):2358-64). For this purpose, for example, rodents (e.g. mice) were implanted with a
tumour cell line which expresses the target molecule of the binder. These -carrying rodents
were subsequently administered either a ate of the invention or a control antibody
conjugate, or isotonic salt solution. Administration took place singly or more often. The tumour
growth was ined twice a week by means of a g caliper. After a tumour growth of
several weeks, the tumour size of conjugate-treated animals and the control group was compared.
The conjugate-treated animals showed a significantly lower tumour size.
C-7a. Testing of ADCs in experimental tumours in the mouse
Human tumour cells which express FGFR2 were inoculated subcutaneously into the flank of
immunosuppressed mice, such as nude mice or SCID mice. 1-10 million cells are detached from
the cell culture, centrifuged and resuspended with 100 µl of medium, 50% medium/50% Matrigel
or 100% Matrigel. The cell suspension was injected beneath the skin of the mouse.
Within a few days, a tumour grew. Treatment began no r than at a tumour size of 20-25 mm²
after establishment of a tumour.
Treatment with conjugate took place via the intravenous route into the caudal vein of the mouse.
The conjugate was dissolved in PBS and is administered with a volume of 5-10 ml/kg.
The treatment scheme was governed by the pharmacokinetics of the antibody. As a standard,
treatment took place three times following every fourth day or every seventh day. Treatment,
r, may also be continued further, or a second cycle with three days of treatment may follow
at a later point in time.
As a standard basis, 8 animals were used per treatment group. This number may be higher if
particularly strong fluctuations in tumour growth or after treatment are anticipated. As well as the
groups which e the active substances, one group, as a control group, was treated only with
the buffer, in accordance with the same .
In the course of the experiment, the area of the tumour was measured regularly using a sliding
caliper in two dimensions (length/width). The area of the tumour was calculated by means of the
formula length × width.
At the end of the experiment, the tumours were d and d. The ratio of the average
tumour weights for the therapy group (T) to the control group (C) was expressed as T/C. If l
and treatment groups finished at different times, then the T/C value was ated using the
tumour areas of the last common measurement of all treatment and control groups.
C-7b. g of FGFR2-ADC in the SNU-16 xenograft model in the mouse
Two million SNU-16 stomach carcinoma cells were inoculated subcutaneously into the flank of
female NODscid mice.
Intravenous treatment with the conjugates was commenced at an average tumour size of
-30 mm2. When the control groups had reached the maximum p ermissible size, these groups
were ended. The mental groups treated with FGFR2 conjugates were ended when the
tumours began to grow again. The activity of the conjugates was determined on day 31, the last
point in time at which the vehicle control was still in the experiment. All of the FGFR2 conjugates
tested inhibited tumour growth in a dose-dependent manner. At a dose of 5 mg/kg, Example 1
ed a T/C of 0.08, Example 3 a T/C of 0.06 and Example 26 a T/C of 0.10. For all of the
animals treated, the tumour at this point in time was smaller than at the beginning of treatment
(partial regression of the tumour). At a dose of 2.5 mg/kg, Example 26 achieved a T/C of 0.14. At
this dose, Example 26 led to partial sion in 40% of the animals. At the dose of 1 mg/kg,
Example 1 achieved a T/C of 0.15 and Example 3 of 0.36. At this dose as well, e 1 leads to
partial regression in all of the animals treated, whereas in the case of Example 3 no partial
regressions were obtained. Significant umour effect in comparison to the control was
achieved for all of the conjugates , up to a dose of 1 mg/kg. The corresponding control
antibody-conjugates showed no activity at all in this model at the same doses.
C7c g of FGFR2-ADC in the MFM-223 xenograft model in the mouse
million MFM-223 breast carcinoma cells were inoculated subcutaneously into the flank of
female NMRI nu/nu mice. These mice had been mented beforehand with estradiol pellets.
Intravenous treatment with the conjugates was commenced at an average tumour size of
30-35 mm2. When the control groups had reached the maximum permissible size on day 40, all of
the treatment groups were ended and the tumour weights were ascertained. Example 26, with a
dose of 10 mg/kg, achieved a T/C of 0.09, a T/C of 0.13 at a dose of 5 mg/kg and a T/C of 0.26 at a
dose of 1 mg/kg. Significant anti-tumour effect in comparison to the control was ed for all
three doses tested. The corresponding control antibody conjugate showed a significant non-
specific effect in this model only at the dose of 10 mg/kg.
C7d Testing of FGFR2-2 ADC in the NCI-H716 xenograft model in the mouse
1.5 million NCI-H716 intestinal carcinoma cells were ated aneously into the flank of
female NMRI nu/nu mice.
Intravenous treatment with the conjugates was commenced at an average tumour size of
-30 mm2. When the control groups had reached the maximum sible size on day 36, all of
the treatment groups were ended and the tumour weights were ascertained. Treatment with
Example 26 resulted in a significant ion in tumour weight, achieving a T/C of 0.24 at
mg/kg. At this dose, the corresponding control conjugate had no activity at all in this model.
2012/075277
D. Working examples for pharmaceutical compositions
The compounds of the ion can be converted as follows into pharmaceutical ations:
i.v. Solution:
The compound of the invention is dissolved at a concentration below the saturation solubility in a
physiologically tolerated solvent (e.g. isotonic saline solution, D-PBS, or a formulation with
glycine and sodium chloride in citrate buffer with addition of rbate 80). The solution is
subjected to sterile filtration and dispensed into sterile and pyrogen-free injection containers.
i.v. Solution:
The compounds of the invention can be converted into the administration forms cited. This can be
accomplished in a known way by “mixing with” or “dissolving in” inert, non-toxic,
pharmaceutically suitable excipients (e.g. buffer substances, stabilizers, solubilizers,
preservatives). The following, for example, may be present: amino acids ne, ine,
methionine, arginine, , leucine, isoleucine, ine, glutamic acid, phenylalanine and
others), sugars and related compounds se, saccharose, mannitol, trehalose, sucrose,
mannose, lactose, sorbitol), glycerol, sodium salts, potassium, ammonium salts and calcium salts
(e.g. sodium chloride, ium chloride or disodiumhydrogenphosphate and many others),
e/acetic acid buffer systems, phosphate buffer systems, citric acid and citrate buffer systems,
trometamol (TRIS and TRIS salts), Polysorbates (e.g. Polysorbate 80 and Polysorbate 20),
Poloxamers (e.g. Poloxamer 188 and Poloxamer 171), Macrogols (PEG derivatives, e.g. 3350),
Triton X-100, EDTA salts, glutathione, albumins (e.g. human), urea, benzyl alcohol, phenol,
chlorocresol , metacresol, benzalkonium chloride and many others.
lizate for subsequent conversion into an i.v., s.c. or i.m. solution:
Alternatively the compounds of the invention may be converted into a stable lyophilizate (possibly
with the aid of abovementioned excipients) and, before being administered, reconstituted with a
suitable solvent (e.g. injection-grade water, ic saline solution) and administered.
Claims (36)
1. Binder-drug ates of the general formula (Ia) H C R35 H C 3 CH 3 O 3 H H N N N D AK G L1 B L2 N N O O CH O CH O O CH 3 3 CH 3 H C CH 3 3 3 (Ia), in which n is a number from 1 to 50, AK is a binder which is an antibody or an antigen-binding antibody fragment that binds to FGFR2, the group §-G-L1-B-L2-§§ is a linker, where § marks the linkage site with the group AK and §§ marks the linkage site with the nitrogen atom, G is a carbonyl or a group of the formula O O HO #1 #1 #2 O N H N #2 H #1 N #2 O , OH O or #1 where #1 marks the linkage site with the sulphur atom of the binder, #2 marks the linkage site with the group L1, L1 is a bond, linear (C1-C10)-alkanediyl, or a group of the a ##1 ##2 O m or ##1 L1A B1 L1B ##2 where m is a number from 2 to 6, ## 1 marks the linkage site with the group G, ##2 marks the linkage site with the group B, L1A is linear (C2-C10)-alkanediyl, B1 is a group of the formula O O O ##5 ##6 L5 ##6 N N ##5 N N L6 R29 R30 , R31 R32 or S ##6 ##5 S in which ## 5 marks the linkage site with the group L1A, ## 6 marks the linkage site with the group L1B, L5 is a bond or (C2-C4)-alkanediyl, L6 is a bond or a group of the formula R33 HN HN O O ##8 or ##8 ##7 ##7 R34 O in which ## 7 marks the linkage site with the carbonyl group, ## 8 marks the linkage site with L1B, R33 is hydrogen, (C1-C4)-alkylcarbonyl, tert-butyloxycarbonyl, or benzyloxycarbonyl, R34 is en or methyl, R29 is hydrogen or (C1-C4)-alkyl, R30 is hydrogen or (C1-C4)-alkyl, R29 and R30 together with the atoms to which they are bonded form a 5- or ered heterocycle, R31 is hydrogen or (C1-C4)-alkyl, R32 is hydrogen or (C1-C4)-alkyl, R31 and R32 together with the atoms to which they are bonded form a 5- or 6-membered heterocycle, L1B is linear (C2-C10)-alkanediyl, where 0)-alkanediyl is optionally substituted by 1 to 4 substituents selected independently of one another from the group consisting of methyl, hydroxy and benzyl, where two carbon atoms of the alkanediyl chain in 1,2, 1,3 or 1,4-relation to one r, with inclusion of any carbon atoms situated between them, are optionally bridged to form a (C3-C6)-cycloalkyl ring or a phenyl ring, B is a bond or a group of the formula O O O O * ** L3 ** O ** N N * N N L4 * Q1 R14 R15 R16 R17 O , , , R20 O * P ** * N ** Q2 * ** O , R18 R19 O , R21 R22 , O O R36 O ** ** or N * N O ** H * R23 R24 O R27 , R37 O where * marks the linkage site with L1, ** marks the linkage site with L2, P is O or NH, L3 is a bond or (C2-C4)-alkanediyl, L4 is a bond or a group of the formula R28 HN HN O O **** or *** **** R25 O in which *** marks the linkage site with the carbonyl group, **** marks the linkage site with L2, R25 is en or methyl, R28 is hydrogen, (C1-C4)-alkylcarbonyl, tert-butyloxycarbonyl, or benzyloxycarbonyl, Q1 is a 4- to 7-membered heterocycle, Q2 is a 3- to 7-membered carbocycle or a 4- to ered heterocycle, R14 is en or (C1-C4)-alkyl, R15 is hydrogen or (C1-C4)-alkyl, R14 and R15 together with the atoms to which they are bonded form a 5- or 6- membered heterocycle, R16 is hydrogen or (C1-C4)-alkyl, R17 is hydrogen or (C1-C4)-alkyl, R16 and R17 together with the atoms to which they are bonded form a 5- or 6- membered heterocycle, R18 is hydrogen or (C1-C4)-alkyl, R19 is hydrogen or the side group of a natural α-amino acid or of its homologues or isomers, R20 is hydrogen or (C1-C4)-alkyl, R19 and R20 together with the atoms to which they are bonded form a pyrrolidinyl ring, R21 is hydrogen or )-alkyl, R22 is hydrogen or (C1-C4)-alkyl, R21 and R22 together with the atoms to which they are bonded form a 3- to 7- membered carbocycle, R23 is (C1-C4)-alkyl, R24 is hydrogen or (C1-C4)-alkyl, R27 is hydrogen or (C1-C4)-alkyl, R36 is en, (C1-C4)-alkylcarbonyl, tert-butyloxycarbonyl, or oxycarbonyl R37 is hydrogen or methyl, R36 and R37 together with the atoms to which they are bonded form a pyrrolidine ring, L2 is linear (C2-C10)-alkanediyl or is a group of the formula ##3 ##4 O p where p is a number from 2 to 6, ## 3 marks the linkage site with the group B, ##4 marks the linkage site with the nitrogen atom, where (C2-C10)-alkanediyl is optionally substituted by 1 to 4 substituents selected independently of one another from the group consisting of methyl, hydroxyl, and benzyl, where two carbon atoms of the alkanediyl chain in 1,2-, 1,3- or 1,4-relation to one another, with inclusion of any carbon atoms situated between them, are optionally bridged to form a (C3-C6)-cycloalkyl ring or a phenyl ring, D is a group of the formula O T1 #3 R5 N or #3 R3 R4 O , R26 T2 R1 R2 where #3 marks the linkage site with the nitrogen atom, R1 is hydrogen or methyl, R2 is isopropyl, isobutyl, sec-butyl, tert-butyl, phenyl, benzyl, 1- hydroxyethyl, 4-hydroxybenzyl, 4-hydroxynitrobenzyl, 4-hydroxy enzyl, ylethyl, diphenylmethyl, 1H-imidazolylmethyl, or 1H-indolylmethyl, R1 and R2 er with the carbon atom to which they are bonded form a (1S,2R)phenylcyclopropane-1,1-diyl group of the formula #4 #5 in which #4 marks the linkage site with the adjacent nitrogen atom, #5 marks the linkage site with the carbonyl group, the ring A with the N-O moiety present therein is a mono- or bicyclic, optionally substituted heterocycle of the formula O O O or O N N N N #6 , #6 , #6 #6 in which #6 marks the linkage site with the carbonyl group, R6 is hydrogen, hydroxy, or benzyloxy, R3 is hydrogen or methyl, R4 is isopropyl, isobutyl, sec-butyl, tert-butyl, phenyl, benzyl, 1- yethyl, 4-hydroxybenzyl, 4-hydroxynitrobenzyl, 4-hydroxy aminobenzyl, ylethyl, diphenylmethyl, 1H-imidazolylmethyl, or olylmethyl, R3 and R4 together with the carbon atom to which they are bonded form a (1S,2R)phenylcyclopropane-1,1-diyl group of the formula #7 #8 in which #7 marks the linkage site with the adjacent nitrogen atom, #8 marks the e site with the group T1, T1 is a group of the formula -C(=O)-OR7, -C(=O)-NR8R9, -C(=O)-NH-NHR10 or -CH2-O-R11, in which R7 is en, methyl, ethyl, n-propyl, tert-butyl, benzyl, or adamantylmethyl, R8 is hydrogen or methyl, R9 is hydrogen, methyl, ethyl, n-propyl, or benzyl, R8 and R9 together with the nitrogen atom to which they are bonded form a 4- to ered heterocycle, R10 is benzoyl, R11 is benzyl, which is optionally substituted in the phenyl group by methoxycarbonyl or carboxyl, R5 is hydrogen, methyl or a group of the formula #9 O #9 S , , #9 R13 #9 #9 or R12 R12 , N N in which #9 marks the linkage site with –CHC(R26)-T2, R12 is phenyl which is optionally substituted by methoxycarbonyl, carboxyl, or a group of the formula OH, R13 is phenyl which is optionally substituted by methoxycarbonyl or carboxyl, R26 is hydrogen or hydroxy, T2 is phenyl, benzyl, 1H-indolyl, or 1H-indolylmethyl, R35 is methyl or hydroxy, and also their salts, solvates and solvates of the salts.
2. Binder-drug conjugates of the general formula (Ia) according to Claim 1, in which AK is AK1 or AK2 where AK1 is a binder which is an dy or an antigen-binding antibody fragment that binds to FGFR2 and is bonded via a r atom of the binder to the group G, AK2 is a binder which is an antibody or an antigen-binding antibody fragment that binds to FGFR2 and is bonded via a nitrogen atom of the binder to the group G, G when AK = AK1, is a group of the formula O O HO #1 #1 #2 O N H N #2 H #1 N #2 O , OH O or #1 when AK = AK2, is carbonyl, and also their salts, solvates and solvates of the salts.
3. Binder-drug conjugates of the general formula (Ia) according to Claim 1 or 2, in which n is a number from 1 to 20, AK is AK1 or AK2 where AK1 is a binder which is an antibody or an antigen-binding antibody fragment that binds to FGFR2 and is bonded via the sulphur atom of a ne residue of the binder to the group G, AK2 is a binder which is an antibody or an antigen-binding antibody nt that binds to FGFR2 and is bonded via the NH side group of a lysine residue of the binder to the group G, G when AK = AK1, is a group of the formula N #2 in which #1 marks the linkage site with the cysteine residue of the binder, #2 marks the linkage site with the group L1, when AK = AK2, is carbonyl, L1 is a bond, linear (C2-C6)-alkanediyl, or a group of the formula ##1 ##2 O m or ##1 L1A B1 L1B ##2 where m is a number from 2 to 6, ## 1 marks the linkage site with the group G, ##2 marks the linkage site with the group B, L1A is linear )-alkanediyl, B1 is a group of the formula O O O ##5 ##6 L5 ##6 N N ##5 N N L6 R29 R30 , R31 R32 or S ##6 ##5 S in which ## 5 marks the linkage site with the group L1A, ## 6 marks the linkage site with the group L1B, L5 is a bond, L6 is a bond or a group of the formula R33 HN HN O O ##8 or ##8 ##7 ##7 R34 O in which ## 7 marks the linkage site with the carbonyl group, ## 8 marks the linkage site with L1B, R33 is hydrogen, methylcarbonyl, or tert-butyloxycarbonyl, R34 is en or methyl, R29 is hydrogen, R30 is hydrogen, R31 is hydrogen or methyl, R32 is hydrogen or methyl, L1B is linear (C2-C6)-alkanediyl, where (C2-C6)-alkanediyl is optionally substituted by 1 or 2 methyl tuents, B is a bond or a group of the formula O O O O * ** L3 ** O ** N N * N N L4 * Q1 R14 R15 R16 R17 O , , , R20 O O * N ** ** O ** N * N H H R18 R19 O , R21 R22 , R23 R24 O O R36 ** or * N O ** R37 O where * marks the linkage site with L1, ** marks the linkage site with L2, L3 is a bond or ethane-1,2-diyl, L4 is a bond or a group of the formula R28 HN HN O O **** or *** **** R25 O in which *** marks the linkage site with the carbonyl group, **** marks the linkage site with L2, R25 is hydrogen or methyl, R28 is en, methylcarbonyl, or tert-butyloxycarbonyl, Q1 is a 4- to 7-membered heterocycle, R14 is hydrogen, R15 is hydrogen, R16 is hydrogen or methyl, R17 is hydrogen or methyl, R16 and R17 together with the atoms to which they are bonded form a piperazinyl ring, R18 is hydrogen, R19 is hydrogen, methyl, propanyl, ylpropanyl, or 1- methylpropanyl, R20 is hydrogen or methyl, R19 and R20 together with the atoms to which they are bonded form a pyrrolidinyl ring, R21 is hydrogen or methyl, R22 is hydrogen or methyl, R21 and R22 together with the atoms to which they are bonded form a cyclopropyl ring, R23 is methyl, R24 is hydrogen or methyl, R27 is hydrogen, R36 is hydrogen, methylcarbonyl, or tert-butyloxycarbonyl, R37 is en or methyl, R36 and R37 together with the atoms to which they are bonded form a pyrrolidine ring, L2 is linear (C2-C6)-alkanediyl or is a group of the formula ##3 ##4 O p where p is a number from 2 to 6, ## 3 marks the linkage site with the group B, ##4 marks the linkage site with the nitrogen atom, where (C2-C10)-alkanediyl is optionally substituted by 1 or 2 methyl substituents, D is a group of the formula O #3 T1 #3 R5 N or #3 R3 R4 O , R26 T2 R1 R2 where #3 marks the linkage site with the nitrogen atom, R1 is en, R2 is 1-hydroxyethyl, benzyl, 4-hydroxybenzyl, ylethyl, or 1H-indolylmethyl, R1 and R2 together with the carbon atom to which they are bonded form a (1S,2R)phenylcyclopropane-1,1-diyl group of the formula #4 #5 in which #4 marks the linkage site with the adjacent nitrogen atom, #5 marks the linkage site with the carbonyl group, the ring A with the N-O moiety present therein is a mono- or bicyclic, optionally substituted heterocycle of the formula O O O or O N N N N #6 , #6 , #6 #6 in which #6 marks the linkage site with the carbonyl group, R6 is hydrogen, hydroxy, or benzyloxy, R3 is hydrogen, R4 is 1-hydroxyethyl, benzyl, 4-hydroxybenzyl, 1-phenylethyl, or 1H-indolylmethyl, R3 and R4 together with the carbon atom to which they are bonded form a (1S,2R)phenylcyclopropane-1,1-diyl group of the formula #7 #8 in which #7 marks the linkage site with the nt en atom, #8 marks the linkage site with the group T1, T1 is a group of the a -C(=O)-OR7, -C(=O)-NR8R9, -C(=O)-NH-NHR10 , or -CH2-O-R11, in which R7 is hydrogen, methyl, ethyl, n-propyl, tert-butyl, benzyl, or adamantylmethyl, R8 is en or methyl, R9 is hydrogen, methyl, ethyl, n-propyl or benzyl, R8 and R9 together with the nitrogen atom to which they are bonded form a 4- to 7-membered heterocycle, R10 is l, R11 is benzyl, which is optionally substituted in the phenyl group by methoxycarbonyl or carboxyl, R5 is hydrogen, methyl, or a group of the formula #9 O #9 S , , #9 R13 #9 #9 or R12 R12 , N N in which #9 marks the linkage site with –CHC(R26)-T2, R12 is phenyl which is optionally substituted by methoxycarbonyl, carboxyl, or a group of the formula –S(O)2OH, R13 is phenyl which is optionally substituted by methoxycarbonyl or carboxyl, R26 is hydrogen or hydroxy, T2 is phenyl, benzyl, 1H-indolyl, or 1H-indolylmethyl, and also their salts, es and solvates of the salts.
4. Binder-drug conjugates of the general formula (Ia) ing to any one of Claims 1 to 3, in which n is a number from 1 to 10, AK is AK1 or AK2 where AK1 is a binder which is an antibody or an antigen-binding antibody fragment that binds FGFR2 and is bonded via the sulphur atom of a cysteine residue of the binder to the group G, AK2 is a binder which is an antibody or an antigen-binding antibody nt that binds FGFR2 and is bonded via the NH side group of a lysine residue of the binder to the group G, G when AK = AK1, is a group of the formula N #2 in which #1 marks the linkage site with the cysteine residue of the binder, #2 marks the linkage site with the group L1, when AK = AK2, is carbonyl, L1 is a bond, linear (C2-C6)-alkanediyl, or a group of the formula ##1 ##2 O m where m is a number 2 or 3, ## 1 marks the linkage site with the group G, ##2 marks the linkage site with the group B, where (C2-C6)-alkanediyl is optionally substituted by 1 or 2 methyl tuents, B is a bond or a group of the formula O O O L3 ** O ** * N N L4 * Q1 R16 R17 O , , O O or O * ** ** N * N H H R21 R22 R23 R24 O where * marks the linkage site with L1, ** marks the linkage site with L2, L3 is a bond or ethane-1,2-diyl, L4 is a bond or a group of the a R28 HN HN O O **** or *** **** R25 O in which *** marks the linkage site with the carbonyl group, **** marks the linkage site with L2, R25 is methyl, R28 is hydrogen, methylcarbonyl, or tert-butyloxycarbonyl, Q1 is piperidine-1,4-diyl, R16 is hydrogen or methyl, R17 is hydrogen or methyl, R16 and R17 together with the atoms to which they are bonded form a piperazinyl ring, R21 is hydrogen or methyl, R22 is en or methyl, R21 and R22 together with the atoms to which they are bonded form a cyclopropyl ring, R23 is methyl, R24 is hydrogen, L2 is linear (C2-C6)-alkanediyl or is a group of the formula ##3 ##4 O p where p is a number from 2 to 6, ## 3 marks the linkage site with the group B, ##4 marks the linkage site with the nitrogen atom, D is a group of the formula O T1 #3 R5 N or #3 R3 R4 O , R1 R2 where #3 marks the linkage site with the nitrogen atom, R1 is hydrogen, R2 is 1-hydroxyethyl, benzyl, oxybenzyl, 1-phenylethyl, or 1H-indolylmethyl, R1 and R2 together with the carbon atom to which they are bonded form a (1S,2R)phenylcyclopropane-1,1-diyl group of the formula #4 #5 in which #4 marks the linkage site with the adjacent nitrogen atom, #5 marks the linkage site with the carbonyl group, the ring A with the N-O moiety present therein is a mono- or bicyclic, optionally tuted heterocycle of the a or O O O O N N N N #6 , #6 , #6 #6 in which #6 marks the linkage site with the carbonyl group, R6 is hydrogen, hydroxy, or benzyloxy, R3 is hydrogen, R4 is benzyl, 1-hydroxybenzyl, 1-phenylethyl, or 1H-indolylmethyl, R3 and R4 together with the carbon atom to which they are bonded form a (1S,2R)phenylcyclopropane-1,1-diyl group of the formula #7 #8 in which #7 marks the linkage site with the adjacent nitrogen atom, #8 marks the linkage site with the group T1, T1 is a group of the formula -C(=O)-OR7, -NR8R9, or -CH2-O-R11, in which R7 is hydrogen, methyl, ethyl, n-propyl, tert-butyl, benzyl, or adamantylmethyl, R8 is en or methyl, R9 is en, methyl, ethyl, n-propyl, or benzyl, R11 is benzyl, which is optionally substituted in the phenyl group by methoxycarbonyl or carboxyl, R5 is hydrogen, methyl or a group of the formula #9 R13 #9 #9 or R12 R12 , N N in which #9 marks the linkage site with –CHCH2phenyl, R12 is phenyl which is optionally substituted by methoxycarbonyl, carboxyl or a group of the formula –S(O)2OH, R13 is phenyl which is optionally substituted by methoxycarbonyl or carboxyl, and also their salts, solvates and solvates of the salts.
5. Binder-drug conjugates of the general formula (Ia) according to any one of Claims 1 to 4, in which n is a number from 1 to 10, AK is AK2 where AK2 is a binder which is an antibody or an antigen-binding antibody fragment that binds FGFR2 and is bonded via the NH side group of a lysine residue of the binder to the group G, G is carbonyl, L1 is a bond, B is a bond, L2 is linear (C3-C6)-alkanediyl or is a group of the formula ##3 ##4 O p where p is a number 2 or 3, ## 3 marks the linkage site with the group B, ##4 marks the e site with the nitrogen atom, D is a group of the a O #3 T1 N or #3 R3 R4 R1 R2 where #3 marks the e site with the nitrogen atom, R1 is hydrogen, R2 is benzyl or 1H-indolylmethyl, R1 and R2 together with the carbon atom to which they are bonded form a (1S,2R)phenylcyclopropane-1,1-diyl group of the formula #4 #5 in which #4 marks the linkage site with the adjacent nitrogen atom, #5 marks the linkage site with the carbonyl group, the ring A with the N-O moiety present therein is a mono- or bicyclic, optionally substituted heterocycle of the formula in which #6 marks the linkage site with the carbonyl group, R3 is hydrogen, R4 is benzyl, 4-hydroxybenzyl, or 1H-indolylmethyl, R3 and R4 together with the carbon atom to which they are bonded form a (1S,2R)phenylcyclopropane-1,1-diyl group of the formula #7 #8 in which #7 marks the e site with the adjacent nitrogen atom, #8 marks the linkage site with the group T1, T1 is a group of the formula -C(=O)-OR7 or -C(=O)-NR8R9 in which R7 is hydrogen, methyl, ethyl, n-propyl, utyl, benzyl, or adamantylmethyl, R8 is hydrogen, R9 is hydrogen or benzyl, R35 is methyl, and also their salts, solvates and solvates of the salts.
6. Binder-drug conjugates of the general formula (Ia) ing to any one of Claims 1 to 4, in which n is a number from 1 to 10, AK is AK1 where AK1 is a binder which is an antibody or an antigen-binding antibody nt that binds FGFR2 and is bonded via the sulphur atom of a cysteine residue of the binder to the group G, G is a group of the formula N #2 where #1 marks the linkage site with the cysteine residue of the binder, #2 marks the linkage site with the group L1, L1 is a bond, linear (C3-C5)-alkanediyl, or a group of the formula ##1 ##2 O m where m is a number 2 or 3, ## 1 marks the linkage site with the group G, ##2 marks the linkage site with the group B, where (C3-C5)-alkanediyl is optionally substituted by 1 or 2 methyl substituents, B is a bond or a group of the formula O O L3 ** * N N L4 R16 R17 where * marks the e site with L1, ** marks the linkage site with L2, L3 is a bond or ethane-1,2-diyl, L4 is a bond or a group of the formula O **** R25 O in which *** marks the linkage site with the carbonyl group, **** marks the linkage site with L2, R25 is methyl, R28 is hydrogen, methylcarbonyl, or tert-butyloxycarbonyl, R16 is hydrogen or methyl, R17 is hydrogen or methyl, R16 and R17 together with the atoms to which they are bonded form a piperazinyl ring, L2 is linear (C3-C5)-alkanediyl or is a group of the formula ##3 ##4 O p where p is a number 2 or 3, ## 3 marks the linkage site with the group B, ##4 marks the e site with the nitrogen atom, D is a group of the formula O #3 T1 N or #3 R3 R4 R1 R2 where #3 marks the linkage site with the nitrogen atom, R1 is hydrogen, R2 is benzyl or 1H-indolylmethyl, R1 and R2 together with the carbon atom to which they are bonded form a (1S,2R)phenylcyclopropane-1,1-diyl group of the formula #4 #5 in which #4 marks the linkage site with the nt nitrogen atom, #5 marks the linkage site with the carbonyl group, the ring A with the N-O moiety present therein is a mono- or bicyclic, optionally substituted heterocycle of the formula in which #6 marks the linkage site with the carbonyl group, R3 is hydrogen, R4 is benzyl, 4-hydroxybenzyl or olylmethyl, R3 and R4 together with the carbon atom to which they are bonded form a (1S,2R)phenylcyclopropane-1,1-diyl group of the formula #7 #8 in which #7 marks the linkage site with the nt nitrogen atom, #8 marks the linkage site with the group T1, T1 is a group of the formula -C(=O)-OR7 or -C(=O)-NR8R9, in which R7 is hydrogen, methyl, ethyl, n-propyl, utyl, benzyl, or adamantylmethyl, R8 is hydrogen, R9 is hydrogen or benzyl, R35 is methyl, and also their salts, solvates and solvates of the salts.
7. Binder-drug conjugates of the general formula (Ia) according to claim 1, in which D is a group of the following formula, where * is the linkage site to the nitrogen atom and also their salts, es and solvates of the salts.
8. Compounds of the following formula H C CH H C 3 3 3 CH N O 3 H H N AK N N O N N O O O CH O CH O O 3 3 CH H C CH CH 3 3 3 3 where AK is an antibody or an antigen-binding antibody fragment that binds FGFR2, and n is a number from 1 to 10, and also their salts, solvates and solvates of the salts.
9. Compounds of the following formula H C CH H C 3 3 3 CH O 3 N H N AK N N O N N O O O CH O CH O O 3 3 CH H C CH CH 3 3 3 3 where AK is an antibody or an antigen-binding antibody fragment which binds FGFR2, and n is a number from 1 to 10, and also their salts, solvates and solvates of the salts.
10. Compound of the ing formula H C CH H C 3 3 3 CH O 3 N H N AK2A N N O N N O O O CH O CH O O 3 3 CH H C CH CH 3 3 3 3 where AK2A is M048-D01-hIgG1 and n is a number from 1 to 10, and also their salts, solvates and solvates of the salts.
11. Compound of the following formula H C CH H C 3 3 3 CH N O 3 H H N AK2B N N O N N O O O CH O CH O O 3 3 CH H C CH CH 3 3 3 3 where AK2B is M048-D01-hIgG1-b and n is a number from 1 to 10, and also their salts, solvates and solvates of the salts.
12. Process for preparing the compounds according to any one of Claims 1 to 11, of the general formula (Ia), characterized in that a solution of the binder in a buffer [A] is admixed with a suitable reducing agent ed from the group consisting of dithiothreitol or tris(2-carboxyethyl)phosphine hydrochloride, and is subsequently reacted with a compound of the formula (II) O H C R35 H C 3 CH 3 O 3 H H N N N D N L1 B L2 N N O O CH O CH O O 3 3 CH H C CH CH O 3 3 3 (II), in which D, L1, B, L2, and R35 each have the definitions ted in any one of Claims 1 to 11, to give a nd of the formula (I-A) H C R35 H C O 3 CH 3 O 3 H AK1 H N N N D N L1 B L2 N N O O CH O CH O O 3 3 CH CH 3 O H C CH 3 3 3 (I-A), in which n, AK1, D, L1, B, L2 and R35 each have the definitions indicated in any one of Claims 1 to 11, [B] is reacted with a compound of the formula (III) H C R35 H C O 3 CH 3 O 3 O H O H N N N D N L1 B L2 N N O O CH O CH O O 3 CH O 3 3 H C CH CH 3 3 (III), in which D, L1, B, L2 and R35 each have the definitions indicated in any one of Claims 1 to 11, to give a compound of the formula (I-B) H C R35 H C O 3 CH 3 O 3 H AK2 H N N N D L1 B L2 N N O O CH O CH O O 3 CH 3 3 H C CH CH 3 3 (I-B), in which n, AK2, D, L1, B, L2 and R35 each have the definitions ted in any one of Claims 1 to 11.
13. Compounds prepared by the process in Claim 12, where AK1 and AK2 is an antibody which comprises the six CDR sequences of the antibody M048-D01-hIgG1 or M048- D01-hIgG1-b, the variable light and variable heavy chain of the antibody M048-D01- hIgG1 or M048-D01-hIgG1-b or the light and heavy chain of the antibody M048-D01- hIgG1 or M048-D01-hIgG1-b, and also their salts, solvates and solvates of the salts.
14. Binder-drug conjugate according to any one of Claims 1-11, where the binder binds specifically to FGFR2.
15. Binder-drug conjugate according to any one of claims 1-11 and 13-14, where the binder binds to the extracellular N-terminal epitope SLVEDTTLEPE15) of FGFR2.
16. Binder-drug conjugate or compound according to any one of claims 1-11 and 13-15, where the binder, after binding to FGFR2 on the target cell, is alized by the g of the target cell.
17. Binder-drug conjugate according to any one of claims 1-11 and 13-16, where the binder competes in binding to the cancer target molecule FGFR2 with the GAL-FR21, GALFR22 or M048-D01-hIgG1 antibody.
18. Binder-drug conjugate according to any one of claims 1-11 and 13-17, where the binder comprises the amino acid sequence of the CDR sequences of the variable light and heavy chain of the antibody M048-D01-hIgG1 represented in SEQ ID NO:15 (HCDR1 ), SEQ ID NO:16 (H-CDR2), SEQ ID NO:17 (H-CDR3), SEQ ID NO:18 (LCDR1 ), SEQ ID NO:19 (L-CDR2) and SEQ ID NO:20 (L-CDR3), the amino acid sequence of the variable light and heavy chains of the antibody M048- D01-hIgG1, ented in SEQ ID NO:12 (Vl) and SEQ ID NO:11 (Vh), the amino acid sequence of the variable light and heavy chains of the antibody M048- D01-hIgG1-b, represented in SEQ ID NO:14 (Vl) and SEQ ID NO:13 (Vh), the amino acid sequence of the light and heavy chain of the antibody M048-D01- hIgG1-b represented in SEQ ID NO: 9 (light chain) and SEQ ID NO:10 (heavy chain), the amino acid sequence of the light and heavy chain of the antibody M048-D01- hIgG1 represented in SEQ ID NO: 7 (light chain) and SEQ ID NO:8 (heavy chain), or the amino acid sequence of the variable light and heavy chains of the antibody 1 or GAL-FR22.
19. Binder-drug conjugate or compounds according to any one of Claims 1-11 and 13-18 for the ent and/or prophylaxis of illnesses.
20. Binder-drug conjugate or a nd according to any of Claims 1-11 and 13-19 for use in a method for the treatment and/or prophylaxis of hyperproliferative and/or angiogenic diseases.
21. Binder-drug conjugate according to any of Claims 1-11 and 13-20 for producing a medicament for the treatment and/or prophylaxis of hyperproliferative and/or angiogenic diseases.
22. Medicament comprising a binder-drug conjugate or a compound according to any of Claims 1-11 and 13-21, in combination with an inert, non-toxic, pharmaceutically suitable excipient.
23. Medicament comprising a binder-drug conjugate or a nd according to any of Claims 1-11 and 13-21, in combination with one or more yperproliferative, cytostatic or cytotoxic substances.
24. ment according to Claim 22 or 23 for the treatment and/or prophylaxis of hyperproliferative and/or angiogenic diseases.
25. Use of at least one binder-drug conjugate or a compound according to any of Claims 1- 11 and 13-21 in the manufacture of a medicament for the treatment and/or prophylaxis of hyperproliferative and/or angiogenic es in humans and animals.
26. A binder-drug conjugate according to claim 1 substantially as herein described or exemplified.
27. A binder-drug conjugate according to claim 7 substantially as herein described or exemplified.
28. A compound according to claim 8 substantially as herein described or exemplified.
29. A compound according to claim 9 ntially as herein described or exemplified.
30. A nd according to claim 10 ntially as herein described or exemplified.
31. A compound according to claim 11 substantially as herein described or exemplified.
32. A process according to claim 12 substantially as herein described or exemplified.
33. A compound according to claim 13 substantially as herein described or exemplified.
34. A medicament according to claim 22 substantially as herein described or exemplified.
35. A ment according to claim 23 substantially as herein described or exemplified.
36. A use according to claim 25 substantially as herein described or exemplified. WO 87716 -
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11193617.5 | 2011-12-14 | ||
EP11193617 | 2011-12-14 | ||
EP12189467.9 | 2012-10-22 | ||
EP12189467 | 2012-10-22 | ||
PCT/EP2012/075277 WO2013087716A2 (en) | 2011-12-14 | 2012-12-12 | New antibody drug conjugates (adcs) and the use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ625745A NZ625745A (en) | 2016-07-29 |
NZ625745B2 true NZ625745B2 (en) | 2016-11-01 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2017203928B2 (en) | Novel binder-drug conjugates (ADCs) and their use | |
US20150023989A1 (en) | New antibody drug conjugates (adcs) and the use thereof | |
US10744205B2 (en) | Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with anti-CD123-antibodies | |
US20180318438A1 (en) | Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-tweakr-antibodies | |
NZ625745B2 (en) | FGFR antibody drug conjugates (ADCs) and the use thereof | |
NZ615839B2 (en) | Novel binder-drug conjugates (adcs) and their use | |
TW201339175A (en) | New binder-drug conjugates (ADCs) and use thereof | |
TW201302799A (en) | New binder-drug conjugates (ADCs) and use thereof |